0001387131-22-004477.txt : 20220331 0001387131-22-004477.hdr.sgml : 20220331 20220331161352 ACCESSION NUMBER: 0001387131-22-004477 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 80 CONFORMED PERIOD OF REPORT: 20211231 FILED AS OF DATE: 20220331 DATE AS OF CHANGE: 20220331 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NANOPHASE TECHNOLOGIES Corp CENTRAL INDEX KEY: 0000883107 STANDARD INDUSTRIAL CLASSIFICATION: MISCELLANEOUS PRIMARY METAL PRODUCTS [3390] IRS NUMBER: 363687863 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-22333 FILM NUMBER: 22792655 BUSINESS ADDRESS: STREET 1: 1319 MARQUETTE DRIVE CITY: ROMEOVILLE STATE: IL ZIP: 60446 BUSINESS PHONE: 6303231200 MAIL ADDRESS: STREET 1: 1319 MARQUETTE DRIVE CITY: ROMEOVILLE STATE: IL ZIP: 60446 FORMER COMPANY: FORMER CONFORMED NAME: NANOPHASE TECHNOLOGIES CORPORATION DATE OF NAME CHANGE: 19970305 10-K 1 nanx-10k_123121.htm ANNUAL REPORT
0000883107 false FY --12-31 2021 P0Y8M12D P1Y4M24D P2Y10M25D P3Y P3Y P7Y P7Y P5Y1M6D P4Y4M24D 0000883107 2021-01-01 2021-12-31 0000883107 2021-06-30 0000883107 2022-03-31 0000883107 2021-12-31 0000883107 2020-12-31 0000883107 2020-01-01 2020-12-31 0000883107 us-gaap:ProductMember 2021-01-01 2021-12-31 0000883107 us-gaap:ProductMember 2020-01-01 2020-12-31 0000883107 us-gaap:ProductAndServiceOtherMember 2021-01-01 2021-12-31 0000883107 us-gaap:ProductAndServiceOtherMember 2020-01-01 2020-12-31 0000883107 us-gaap:PreferredStockMember 2019-12-31 0000883107 us-gaap:CommonStockMember 2019-12-31 0000883107 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000883107 us-gaap:RetainedEarningsMember 2019-12-31 0000883107 2019-12-31 0000883107 us-gaap:PreferredStockMember 2020-12-31 0000883107 us-gaap:CommonStockMember 2020-12-31 0000883107 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000883107 us-gaap:RetainedEarningsMember 2020-12-31 0000883107 us-gaap:PreferredStockMember 2020-01-01 2020-12-31 0000883107 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0000883107 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0000883107 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0000883107 us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0000883107 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0000883107 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0000883107 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0000883107 us-gaap:PreferredStockMember 2021-12-31 0000883107 us-gaap:CommonStockMember 2021-12-31 0000883107 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000883107 us-gaap:RetainedEarningsMember 2021-12-31 0000883107 us-gaap:EquipmentMember srt:MinimumMember 2021-01-01 2021-12-31 0000883107 us-gaap:EquipmentMember srt:MaximumMember 2021-01-01 2021-12-31 0000883107 us-gaap:LeaseholdImprovementsMember srt:MinimumMember 2021-01-01 2021-12-31 0000883107 us-gaap:LeaseholdImprovementsMember srt:MaximumMember 2021-01-01 2021-12-31 0000883107 us-gaap:OtherCapitalizedPropertyPlantAndEquipmentMember srt:MinimumMember 2021-01-01 2021-12-31 0000883107 us-gaap:OtherCapitalizedPropertyPlantAndEquipmentMember srt:MaximumMember 2021-01-01 2021-12-31 0000883107 nanx:Year2021Member 2021-12-31 0000883107 nanx:Year2022Member 2021-12-31 0000883107 nanx:Year2023Member 2021-12-31 0000883107 nanx:LibertyvilleBankAndTrustMember 2021-01-01 2021-12-31 0000883107 nanx:LibertyvilleBankAndTrustMember 2021-12-31 0000883107 nanx:LibertyvilleBankAndTrustMember 2020-12-31 0000883107 nanx:LibertyvilleBankAndTrustOneMember 2021-01-01 2021-12-31 0000883107 nanx:LibertyvilleBankAndTrustOneMember 2020-12-31 0000883107 nanx:LibertyvilleBankAndTrustTwoMember 2021-01-01 2021-12-31 0000883107 nanx:LibertyvilleBankAndTrustTwoMember 2021-12-31 0000883107 nanx:BeachcorpLLCMember 2021-01-01 2021-12-31 0000883107 nanx:BeachcorpLLCMember 2021-12-31 0000883107 nanx:BeachcorpLLCMember 2020-12-31 0000883107 nanx:BeachcorpLLCOneMember 2021-01-01 2021-12-31 0000883107 nanx:BeachcorpLLCOneMember 2021-12-31 0000883107 nanx:BeachcorpLLCOneMember 2020-12-31 0000883107 nanx:SecuredConvertiblePromissoryNoteMember 2021-01-01 2021-12-31 0000883107 nanx:SecuredConvertiblePromissoryNoteMember 2020-12-31 0000883107 nanx:PPPLoanLibertyvillePromissoryNoteMember 2021-01-01 2021-12-31 0000883107 nanx:PPPLoanLibertyvillePromissoryNoteMember 2020-12-31 0000883107 nanx:BeachcorpLLCThreeMember 2021-01-01 2021-12-31 0000883107 nanx:BeachcorpLLCFourMember 2021-01-01 2021-12-31 0000883107 nanx:StrandlerLLCMember 2021-01-01 2021-12-31 0000883107 us-gaap:LetterOfCreditMember 2014-07-31 0000883107 us-gaap:LetterOfCreditMember 2014-07-01 2014-07-31 0000883107 nanx:CreditAgreementMember 2021-12-31 0000883107 us-gaap:LetterOfCreditMember nanx:NewBusinessLoanAgreementMember 2021-01-01 2021-12-31 0000883107 nanx:BusinessLoanAgreementMember nanx:TermLoanMember nanx:BeachcorpLLCMember 2018-11-16 0000883107 nanx:BusinessLoanAgreementMember nanx:TermLoanMember nanx:BeachcorpLLCMember 2018-11-15 2018-11-16 0000883107 nanx:BusinessLoanAgreementMember us-gaap:RevolvingCreditFacilityMember nanx:BeachcorpLLCMember 2018-11-16 0000883107 nanx:BusinessLoanAgreementMember us-gaap:RevolvingCreditFacilityMember nanx:BeachcorpLLCMember 2018-11-15 2018-11-16 0000883107 nanx:BusinessLoanAgreementMember us-gaap:RevolvingCreditFacilityMember nanx:BeachcorpLLCMember srt:MinimumMember 2018-11-16 0000883107 nanx:FirstAmendmentMember nanx:TermLoanAndTheRevolverFacilityMember nanx:BeachcorpLLCMember 2020-03-21 2020-03-23 0000883107 nanx:SecondAmendmentMember us-gaap:RevolvingCreditFacilityMember nanx:BeachcorpLLCMember 2020-09-08 0000883107 nanx:ThirdAmendmentMember us-gaap:RevolvingCreditFacilityMember nanx:BeachcorpLLCMember 2020-12-23 0000883107 nanx:FirstAmendmentMember nanx:TermLoanAndTheRevolverFacilityMember nanx:BeachcorpLLCMember 2020-12-22 2020-12-23 0000883107 nanx:FourthAmendmentMember us-gaap:RevolvingCreditFacilityMember nanx:BeachcorpLLCMember 2021-04-21 0000883107 nanx:FourthAmendmentMember us-gaap:RevolvingCreditFacilityMember nanx:BeachcorpLLCMember 2021-04-20 2021-04-21 0000883107 nanx:FourthAmendmentMember nanx:TermLoanMember nanx:BeachcorpLLCMember 2021-04-21 0000883107 nanx:FourthAmendmentMember nanx:TermLoanMember nanx:BeachcorpLLCMember 2021-04-20 2021-04-21 0000883107 nanx:SecuredConvertiblePromissoryNoteMember nanx:BradfordTWhitmoreMember 2019-11-20 0000883107 nanx:SecuredConvertiblePromissoryNoteMember nanx:BradfordTWhitmoreMember 2019-11-18 2019-11-20 0000883107 nanx:RelatedPartyCreditFacilitiesMember 2021-01-01 2021-12-31 0000883107 nanx:WhitmoreMember 2021-05-06 2021-05-07 0000883107 nanx:WhitmoreMember 2021-05-07 0000883107 nanx:PromissoryNoteMember nanx:LibertyvilleMember 2020-04-17 0000883107 nanx:PromissoryNoteMember 2021-12-31 0000883107 nanx:BusinessLoanAgreementMember nanx:BeachcorpLLCMember 2022-01-27 2022-01-28 0000883107 nanx:AAndRLoanAgreementMember nanx:BeachcorpLLCMember us-gaap:RevolvingCreditFacilityMember 2022-01-27 2022-01-28 0000883107 nanx:AAndRLoanAgreementMember nanx:StrandlerLLCMember us-gaap:RevolvingCreditFacilityMember 2022-01-27 2022-01-28 0000883107 nanx:RelatedPartyTransactionMember 2021-12-31 0000883107 nanx:RelatedPartyTransactionMember 2020-12-31 0000883107 nanx:SecuredConvertiblePromissoryNotesMember 2021-12-31 0000883107 nanx:SecuredConvertiblePromissoryNotesMember 2020-12-31 0000883107 us-gaap:MachineryAndEquipmentMember 2021-12-31 0000883107 us-gaap:MachineryAndEquipmentMember 2020-12-31 0000883107 us-gaap:OfficeEquipmentMember 2021-12-31 0000883107 us-gaap:OfficeEquipmentMember 2020-12-31 0000883107 us-gaap:FurnitureAndFixturesMember 2021-12-31 0000883107 us-gaap:FurnitureAndFixturesMember 2020-12-31 0000883107 us-gaap:LeaseholdImprovementsMember 2021-12-31 0000883107 us-gaap:LeaseholdImprovementsMember 2020-12-31 0000883107 us-gaap:ConstructionInProgressMember 2021-12-31 0000883107 us-gaap:ConstructionInProgressMember 2020-12-31 0000883107 us-gaap:DomesticCountryMember 2021-01-01 2021-12-31 0000883107 nanx:ExpiringOperatingLossCarryforwardsMember 2021-12-31 0000883107 us-gaap:TaxYear2012Member 2021-12-31 0000883107 nanx:PlanMember 2021-12-31 0000883107 nanx:EquityCompensationPlan2019Member 2021-01-01 2021-12-31 0000883107 nanx:EquityCompensationPlan2010Member 2021-01-01 2021-12-31 0000883107 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0000883107 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0000883107 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember nanx:CustomerOneMember 2021-01-01 2021-12-31 0000883107 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember nanx:CustomerOneMember 2020-01-01 2020-12-31 0000883107 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember nanx:CustomerTwoMember 2021-01-01 2021-12-31 0000883107 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember nanx:CustomerTwoMember 2020-01-01 2020-12-31 0000883107 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember nanx:CustomerThreeMember 2021-01-01 2021-12-31 0000883107 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember nanx:CustomerThreeMember 2020-01-01 2020-12-31 0000883107 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember nanx:CustomerFourMember 2021-01-01 2021-12-31 0000883107 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember nanx:CustomerFourMember 2020-01-01 2020-12-31 0000883107 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember nanx:CustomerFiveMember 2021-01-01 2021-12-31 0000883107 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember nanx:CustomerFiveMember 2020-01-01 2020-12-31 0000883107 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember nanx:CustomersOneThroughFiveMember 2021-01-01 2021-12-31 0000883107 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember nanx:CustomersOneThroughFiveMember 2020-01-01 2020-12-31 0000883107 nanx:CustomerOneMember 2021-12-31 0000883107 nanx:CustomerOneMember 2020-12-31 0000883107 nanx:CustomerTwoMember 2021-12-31 0000883107 nanx:CustomerTwoMember 2020-12-31 0000883107 nanx:CustomerThreeMember 2021-12-31 0000883107 nanx:CustomerThreeMember 2020-12-31 0000883107 nanx:CustomerFourMember 2021-12-31 0000883107 nanx:CustomerFourMember 2020-12-31 0000883107 nanx:CustomerFiveMember 2020-12-31 0000883107 us-gaap:SupplyCommitmentMember 2021-12-31 0000883107 us-gaap:NonUsMember 2021-01-01 2021-12-31 0000883107 us-gaap:NonUsMember 2020-01-01 2020-12-31 0000883107 nanx:PersonalCareIngredientsMember 2021-01-01 2021-12-31 0000883107 nanx:PersonalCareIngredientsMember 2020-01-01 2020-12-31 0000883107 nanx:AdvancedMaterialsMember 2021-01-01 2021-12-31 0000883107 nanx:AdvancedMaterialsMember 2020-01-01 2020-12-31 0000883107 nanx:SolesenceMember 2021-01-01 2021-12-31 0000883107 nanx:SolesenceMember 2020-01-01 2020-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

 

 

UNITED STATES  

SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549

 

FORM 10-K

 

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended December 31, 2021 

or

 

☐  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

FOR THE TRANSITION PERIOD FROM_____ TO_____

 

COMMISSION FILE NUMBER 000-22333 

 

NANOPHASE TECHNOLOGIES CORPORATION  

(Exact name of registrant as specified in its charter)  

 

Delaware 36-3687863
(State or other jurisdiction (I.R.S. Employer Identification No.)
of incorporation or organization)  

 

1319 Marquette Drive, Romeoville, Illinois 60446  

(Address of principal executive offices) (zip code)

 

Registrant’s telephone number, including area code: (630) 771-6708

 

Securities registered pursuant to Section 12(b) of the Act: None

 

Securities registered pursuant to Section 12(g) of the Act: 

Common Stock, par value $.01 per share

 

Indicate by check mark whether the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒

 

Indicate by check mark if the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes ☐ No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer ☐ Smaller reporting company ☒
  Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

The aggregate market value of the registrant’s voting stock held by non-affiliates of the registrant based upon the last reported sale price of the registrant’s common stock on June 30, 2021 was $27,240,325 as of such date.

 

The number of shares outstanding of the registrant’s common stock, par value $.01, as of March 31, 2022 was 48,893,573.

 

DOCUMENTS INCORPORATED BY REFERENCE

 

None.

 

 

 

 

 

 

PART I

  
Item 1.  General 2
  Company Background 2
  Solésence Beauty Science Business 2
  Advanced Materials Business 3
  Personal Care Ingredients Business 3
  Sources and Availability of Raw Materials 3
  Markets and Distribution 4
  Research and Development 4
  Competitive Advantage 5
  Manufacturing Operations 5
  Intellectual Property and Proprietary Rights 5
  Competition 6
  Governmental Regulations, Including Climate Change 6
  Employees 7
  Backlog 7
  Business Segment and Geographical Information 7
  Key Customers 7
  Forward-Looking Statements 7
  Investor Information 8
Item 1A. Risk Factors 8
Item 1B. Unresolved Staff Comments 8
Item 2. Properties 8
Item 3. Legal Proceedings 9
Item 4. Mine Safety Disclosures 9
     
  PART II  
     
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 9
Item 6. Selected Financial Data 9
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations 10
Item 7A. Quantitative and Qualitative Disclosures About Market Risk 15
Item 8. Financial Statements and Supplementary Data 15
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 15
Item 9A. Controls and Procedures 15
Item 9B. Other Information 16
     
  PART III  
     
Item 10. Directors, Executive Officers and Corporate Governance 17
Item 11. Executive Compensation 19
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 23
Item 13. Certain Relationships and Related Transactions, and Director Independence 24
Item 14. Principal Accounting Fees and Services 25
     
  PART IV  
     
Item 15. Exhibits and Financial Statement Schedules 26
Item 16. Form 10-K Summary 26

1

 

 

 PART I

 

Item 1. General

 

Company Background

 

Nanophase Technologies Corporation (“Nanophase,” “Company,” “we,” “our,” or “us”), along with its wholly owned subsidiary, Solésence, LLC (our “Solésence beauty science subsidiary”), is a leading innovator in minerals-based and scientifically-driven health care solutions across beauty and life science categories, protecting skin from environmental aggressors and aiding in medical diagnostics. Skin health and medical diagnostics combined currently make up the great majority of our business and drive our forward growth strategy, with additional revenue being generated from other legacy advanced materials applications. The Company was incorporated in Illinois on November 25, 1989 and became a Delaware corporation during November 1997. Our common stock trades on the OTCQB marketplace under the symbol NANX. We have development and application laboratories and manufacturing capacity in two locations in the Chicago, Illinois area.

 

Leveraging a platform of integrated patented and proprietary technologies, we create products with unique performance to enhance end-consumers’ health and well-being. We offer soup-to-nuts production, from engineered materials, formulation development, and finished product development, to commercial manufacturing and packaging capabilities. Our expertise in materials engineering allows us to effectively coat and disperse materials on a nano and “non-nano” scale for use in a variety of markets in skin health, including for use in sunscreens as Active Pharmaceutical Ingredients (“APIs”) and as fully developed prestige skin care products, marketed and sold through our Solésence beauty science subsidiary.  We believe that we have developed technological advantages with respect to our APIs sold for use as ingredients, while our Solésence beauty science technologies lead to enhanced efficacy and aesthetics in our finished products, which have received broad acceptance in the marketplace. Due to the enhanced efficacy and aesthetic qualities offered by our proprietary technology platform, Solésence finished products satisfy growing consumer demands around “clean” and inclusive beauty. Solésence beauty science also benefits from the Company’s vertical integration with each product’s key active ingredient that delivers its point-of-difference. This vertical integration helps us to improve efficiency and avoid potential major supply chain challenges while also addressing ongoing sustainability efforts.  

 

We have seen recent conditions significantly increase demand for our medical diagnostics materials. Polymerase Chain Reaction (“PCR”) testing for various viruses, most notably SARS-CoV-2 (“COVID-19”), has become a critical use of our technology in the life science space. While we saw reduced demand for these materials in 2021, when compared to 2020, it is difficult to predict whether the increased demand for our medical diagnostic materials used in COVID-19 testing will expand to establish a new “floor” as we continue through the currently unprecedented period of testing and awareness of the way viruses impact all of us. We believe that our deep expertise in materials science has created advantages that enable performance in certain tests that may not be achievable through other materials. Outside of life science, we continue to sell advanced materials for use in legacy applications, all of which, along with medical diagnostics, currently fall into the advanced materials product category. 

   

Given our technological position, in addition to the historical market acceptance of our APIs for use in skin health products and sunscreens, rapidly growing sales for our suite of Solésence® finished products, and the expanded use of our diagnostic materials in aiding the fight to curb the spread of COVID-19 and other viruses, in 2021 we announced that we reoriented our Company strategy. We continue to see unprecedented demand in both beauty science and life science areas. The markets for both have shown an appetite for what we are producing, and management believes that this growth is happening now due to a confluence of our technology, market conditions that favor what we produce, and our expanded expertise in these areas.  

 

Nanophase, and Solésence, is now focusing our combined business-, ingredient-, and product-development capabilities on products with unique performance that enhance consumers’ wellbeing through beauty science and life science applications — in skin health and medical diagnostics, respectively. While we will continue to produce and sell materials to our other advanced materials customers, it is not our strategic focus. We may develop additional technologies, or find unique applications outside of our core markets in the future, but to maximize the use of our resources today, we plan on expanding efforts in areas where we have proven we can deliver innovation and growth.

 

Solésence Beauty Science Business

 

In 2020, Solésence beauty science surpassed our personal care ingredients business in terms of total revenue, and in 2021, Solésence beauty science more than doubled our revenue from personal care ingredients. We believe that Solésence offers the greatest growth potential of any group of products in any market in the Company’s history. Our volumes are continuing to grow, limited mainly by our capacity. We expect our Solésence volume, based on 2022 shipments and customer orders in-hand, to exceed full year 2021 volume.  

 

The extent to which we grow will be dependent upon our ability to effectively expand our capabilities during the first two quarters of 2022. As a result, we have made significant investments in facilities and equipment as well as in human resources, both in Q4 2021 and so far in Q1 2022. We are prioritizing facilities expansion, human resources, and capital investment in this business to allow for continued, profitable growth.  

 

2

 

 

During 2015 we were granted a patent on a new type of particle surface treatment (coating) — now called Active Stress Defense™ Technology — which has become the cornerstone of our new product development in our Solésence business, with first revenue recognized during 2017. We now offer a suite of three technologies under our Active Stress Defense™ platform, each of which offers a distinct market advantage in terms of performance, aesthetics, and/or “clean” positioning in UV and environmental protection, with flexible formulas that allow for adoption by a range of brands with different market positions. We continue to develop and expand our in-house formulating capability, through which we have created, and now sold, more than 250 SKUs of fully formulated finished cosmetics products in markets focused on skin health, with the majority in prestige beauty. Products developed and sold by our Solésence beauty science subsidiary are all produced under the requirements of current Good Manufacturing Standards (“cGMP”), as enforced by the U.S. Food and Drug Administration (“FDA”), which enables us to leverage the expertise we developed in the manufacture of personal care ingredients. Although our Solésence products are fully formulated for consumer use, we do not sell directly to consumers or distribute products to consumers under the Solésence® brand through intermediaries or resellers. Instead, we sell our Solésence® products to brand partners as market-ready products, as customized white label products, or as custom-developed products, in each case, for sale or distribution to consumers under our customers’ brand names. In early 2022, Solésence (through Nanophase, as its parent company) was granted site clearance by Australia’s Therapeutic Goods Administration (“TGA”) for the full finished product manufacture of creams, lotions, sprays, sticks and all topical sunscreen forms. TGA site clearance is legally required for brands to market Solésence-made products as primary sunscreens in Australia. Our initial focus will be on establishing a footprint with both new and existing Solésence brand partners, to enable the sale of our patented skin health products as primary sunscreens.

 

Personal Care Ingredients Business

 

Historically, our largest line of business has been the manufacture and sale of APIs in the skin health and sun care markets, which we deliver to customers through strategic partnerships. We manufacture and supply hundreds of metric tons of surface engineered zinc oxide and titanium dioxide to our customers annually, and these are used by major global consumer products companies for sunscreens and skin health-focused personal care products. We produce these products using proprietary coating and dispersion technologies that comply with the requirements of cGMP and are classified as Active Pharmaceutical Ingredients, or APIs, by the FDA. We believe we have strong opportunities for growth in API sales in 2022.

 

Advanced Materials Business

 

Our third line of business has been the manufacture and sale of advanced nanoparticle materials, including a material used in life science applications to enhance the performance of PCR test methods. Given the high level of demand for our medical diagnostics material, this now composes the majority of our advanced materials business. We continue to service other profitable markets where we have had a degree of success in the past, including applications in food packaging, coatings and optical polishing, but our strategic focus and related future development is in the area of life science and any related applications that may be created as we work to develop future materials to satisfy this growing area.

 

Sources and Availability of Raw Materials

 

Most of the raw materials we use are readily commercially available. In some cases, we rely on sole-source processors of materials that utilize an array of worldwide sources for the raw materials that they process to our specifications. However, we require very high purity zinc for our personal care applications that have occasionally seen shortages in prior years. Although we currently believe we have developed adequate commercial relationships to supply the necessary raw materials for our business which are not readily commercially available, our business is subject to the pricing and availability of certain raw materials.

 

Some of the raw materials that are critical to the production of our products and parts that are critical to the operation of our equipment are sourced from single suppliers, suppliers from China and Korea, and in some cases, a single supplier from China. In December 2019, a novel strain of coronavirus (SARS-CoV-2) emerged in Wuhan, Hubei Province, China, which was proclaimed by the World Health Organization to have been the cause of a global pandemic (COVID-19).   Although operations of our third-party suppliers were disrupted to a certain extent in 2020 from the pandemic, particularly related to receiving packaging for our Solésence products on a timely basis, by mid-2021, we saw less impact from COVID-19 supply chain issues on our suppliers.  As of this writing, parts of China appear to be having delays in shipping exports. We have not yet experienced any feedback from these potential activities through our chain of supply. Given the Russian invasion of Ukraine, we do not anticipate any directly related supply disruptions as we do not knowingly source any materials directly from either country. Beginning in late 2021, and for the near future, we expect labor shortages to be another risk in this regard over which we have limited control. Additionally, we could be disrupted by conditions unrelated to our business operations or that are beyond our control, including but not limited to international trade restrictions and conditions related to COVID-19 or other epidemics. We typically maintain no less than one month’s supply of raw materials and parts that are sourced from sole suppliers and make efforts to identify additional suppliers who may be able to provide such raw materials or parts.

 

3

 

 

Markets and Distribution

 

Solésence Beauty Science Business

 

We develop and manufacture beauty products for our brand partners on a global basis. These products are fully-formulated solutions built around proprietary Solésence technologies, which are aligned with consumer demand for “clean” and inclusive beauty products that enhance skin health. Solésence clients, or brand partners, are positioned in skin care, makeup/cosmetics, and sun care markets, with the majority of our partners operating in the prestige beauty segment with retail, direct-to-consumer, and/or omnichannel strategies. This represents a move downstream from our previous position — one of providing ingredients to manufacturers — to offering finished products that we believe offer a clear and distinct market advantage relative both aesthetics and performance. With our first Solésence beauty science product revenue recognized during 2017, we had our first material amounts of Solésence product revenue in 2018, and saw significant expansion in these sales during 2020 and 2021. Solésence brand partners have experienced strong growth as our products have seen broad acceptance from retailers, adoption by consumers, and recognition by third-party media outlets through awards and accolades. We expect our Solésence beauty science business to enhance both our degree of control of the business development cycle, and to further enable our ability to grow rapidly.  

 

Personal Care Ingredients Business

 

In addition to serving strategic partners in diverse markets and geographic locations, we will continue to devote significant resources to maintaining and growing our relationship with BASF Corporation (“BASF”), the largest customer in our personal care ingredients line of business. This has been a successful relationship that we expect will contribute to our future growth. BASF, which describes itself as the world’s leading chemical company with annual revenue of approximately $77 billion, is a “globally leading supplier of sustainable high-performance ingredients for the personal care industry,” with recognized brands, significant revenue, and a broad sales network. BASF is primarily responsible for the business development cycle and maintains the direct customer relationships. We have a long-term exclusive relationship with BASF, primarily to provide nano-scale zinc oxide-based products to be used in personal care cosmetics, with sunscreens and daily wear products being the dominant applications.  

 

Advanced Materials Business

 

Our technologies for engineering and manufacturing life science materials and other nanomaterials, and our understanding of how to make nano and other advanced materials exhibit desirable performance characteristics in various media, have resulted in commercial materials solutions that we believe offer superior performance in many applications. Medical diagnostics, which we view as being a life science application, was the largest market for our materials in 2020 and 2021, and we expect this to be true for the foreseeable future. This is a key area of focus in advanced materials in terms of new business development.  Our legacy markets for advanced materials include architectural coatings, surface treatment (polishing), plastics additives, textiles applications, and others. As advanced materials markets continue to develop and grow, we believe that customers’ preferred delivery formats will often be dispersed and/or coated nanomaterials for life science applications. We believe we are well-positioned with our platform of integrated commercial nanomaterial technologies to respond to this demand, although outside of life science areas, we are currently not actively developing new business in this area.

 

Research and Development

 

Most of our research and development over the past few years has been directly related to Solésence beauty science product and personal care ingredient applications development. In 2020 and 2021, we increased development of our medical diagnostics materials as market demand has expanded.  We endeavor to either meet specific customer needs or to develop applications solutions to address unmet needs in a particular market where we believe our materials will offer a distinct performance advantage. Our efforts in research and development, cosmetic formulating, process engineering and advanced engineering groups are focused in three major areas: 1) application development for our products; 2) creating or obtaining additional core materials technologies and/or materials that have the capability to serve multiple beauty or life science markets; and 3) continuing to improve our core technologies to improve manufacturing operations and reduce costs.

 

Our total research and development expense, which includes all expenses relating to our technology and advanced engineering groups, during the years ended December 31, 2021 and 2020, was $2.2 million and $1.6 million, respectively. This represents our share of these expenses only and does not take into account amounts spent by any of our customers in support of new product development. Our future success will depend in large part upon our ability to develop products which bring a high degree of value to our customers’ products. Through the three-year period ended December 31, 2021, we had cumulative research and development expenses of approximately $5.7 million and cumulative expenditures on equipment and leasehold improvements of approximately $0.3 million.

 

4

 

 

Competitive Advantage

 

In our Solésence beauty science business, our Active Stress Defense ™ platform of proprietary technologies offers unique performance-related and aesthetic advantages in environmental protection skin health products, including in UVA/UVB, pollution and HEV (blue) light protection. By combining our proprietary dispersion capabilities and formulation know-how, our Solésence products enable our brand partners to expand the range of products within skin care and color cosmetics categories that can include sun and environmental protection, and their products consequently fill a unique market segment which drives the growing demand for our Solésence products.

 

In our personal care ingredients business, we believe that targeted collaborations with our long-standing customers in the ingredients space will enable them to have a competitive advantage which will sustain and/or grow their market share in the sunscreen API market. Both the Solesence® beauty science business and the personal care ingredients business have been positively impacted by the growing interest among consumers for mineral-based sunscreens, which management sees as a validation of the Company strategy.

 

In our advanced materials business, we have created an integrated platform of commercial nanomaterial technologies that are patented, patent-pending or proprietary, and result in products that see end use in a variety of applications, including use in enhancing the performance of PCR testing for various viruses, including COVID-19. These technologies revolve around our two distinct manufacturing process (PVS – Plasma Vapor Synthesis and NAS – NanoArc® Synthesis) and are designed to deliver nano- and advanced-materials solutions for a targeted market or a specific customer application. Our platform provides flexibility and capability to engineer nanomaterials that meet a customer’s performance requirements and delivers our nanomaterial solutions in a readily usable format. Our technologies are scalable and robust, having allowed us to produce up to several hundred metric tons in this segment annually.

 

Manufacturing Operations  

 

We currently have manufacturing capacity based in two locations in the Chicago area. At each of these facilities, we are able to develop and supply engineered materials and bulk finished goods in quantities ranging from grams to metric tons. Our two existing facilities are registered under the ISO 9001, American National Standard, Quality Management System Requirements, and ISO 14001, American National Standard, Environmental Management System Requirements.  We are compliant with cGMP for products under U.S. Food and Drug Administration (“FDA”) regulation, applying to the manufacture of APIs and OTC Finished Dosage Form materials (primarily used in sun protection). We have registered some of the chemicals we ship to customers in Europe pursuant to the European Chemical Agency’s regulations issued to date pertaining to Registration Evaluation and Authorization of Chemicals (“REACH”). Currently, we have registered Zinc Oxide, Aluminum Oxide, Iron Oxide and Octyltrimethoxysilane under REACH. We leased a third facility, also in the Chicago area, in late 2021 to be built out for additional manufacturing and warehouse space in 2022 in response to growing demand. Over time, we expect this facility to have similar capabilities and registrations as those in our two current manufacturing facilities.

 

Our operations employ a cellular, team-based manufacturing approach, where workers operate in work “cells,” under a lean manufacturing environment to continuously advance and improve production capabilities. We have also developed a highly flexible workforce that has been cross trained to allow it to be employed broadly across our manufacturing processes. Beginning in late 2019, we also began to employ a significant number of temporary operators to assist us in supporting the production of our Solésence products.  Our manufacturing approach, targeted engineering actions, and capital investment have resulted in continuing process innovations and improvements that have reduced the variable manufacturing cost significantly over the past several years, while increasing our capacity to meet demand.

 

We are committed to a Lean Six Sigma manufacturing approach, to the extent possible given a certain measure of irregular demand, where we are able to reduce excess labor and manage the lowest practical inventory and supply levels in order to minimize working capital demands. This approach complements two of our major operational goals - (1) to increase output without adding unnecessarily to existing equipment and (2) to continually reduce production costs while consistently producing high quality products.

 

Intellectual Property and Proprietary Rights

 

We rely on a combination of patent, trademark, copyright, trade secret and other intellectual property laws, nondisclosure agreements and other protective measures to protect our intellectual property. In addition to obtaining patent and trademarks based on our inventions and products, we may also license certain third-party patents from time-to-time to expand our technology base.

 

As of the date of this filing, we own 10 U.S. patents and 8 pending U.S. patent applications. We also own 43 foreign patents and patent applications consisting of 33 issued or allowed foreign patents and 10 pending foreign patent applications. All of the pending and owned foreign patents are counterparts to domestic filings covering our platform of nanotechnologies and surface treatments.

 

5

 

 

Competition

 

Within each of our targeted markets and product applications, we face potential competition from contract manufacturers and developers, advanced materials and chemical companies, and suppliers of traditional materials. In many markets, the actual or potential competitors are larger and more diversified than we are; however, we believe we focus on market segments and opportunities where our materials and related technologies are superior to those of our competitors, often due to our abilities to produce highly engineered ingredients to meet specific performance requirements, develop advanced material solutions for customers’ specific applications, and in the case of Solésence, finished products that impart the benefits of minerals-based products with superior tactile, visual, and performance characteristics. 

 

With respect to traditional suppliers, we may compete against lower priced traditional materials for certain customer applications. In some product or process applications the benefits of using advanced materials do not always justify a process change or outweigh their frequently higher costs. 

 

We believe that our material technologies and manufacturing platforms are strong. We believe we are well-positioned with our platform of integrated commercial materials technologies and track record of technology improvement and evolution.

 

In addition to competition in the advanced materials and related markets, our Solésence beauty science subsidiary faces competition from a wide variety of offerings in the field of skin care. Our Solésence products compete with existing solutions as well as new solutions from various sources, including other product developers and manufacturers who seek to serve skin care brands and integrated brands who also manufacture their own products in-house, and we must differentiate our value proposition in order to gain traction in this marketplace. The complexities of sunscreen regulation and the nuances of the development and manufacture of sunscreen products present a barrier for brands with integrated manufacturing in other skin care and cosmetics areas. Still, several Solésence customers have internal development and manufacturing capabilities that are similar to the capabilities of Solésence, and can serve as indirect competition to our products and services. We believe that our Solésence beauty science technology and our expertise in the nuances of formulating products that contain UV protection, coupled with our expanding capability to produce novel formats, will allow us to become a competitive player in this market on a sustainable basis. 

 

Governmental Regulations, Including Climate Change

 

The manufacture and use of certain of the products that contain Active Pharmaceutical Ingredients are subject to governmental regulations. As a result, we are required to adhere to the cGMP requirements of the FDA and similar regulations that include testing, control and documentation requirements enforced by periodic inspections. We also comply with the European Chemical Agency’s regulations issued to date pertaining to the chemicals we have registered under REACH. In early 2022, we were granted site clearance by Australia’s TGA for the full finished product manufacture of creams, lotions, sprays, sticks and all topical sunscreen forms. TGA site clearance is legally required for brands to market Solésence-made products as primary sunscreens in Australia. Our initial focus will be on establishing a footprint with both new and existing Solésence brand partners, to enable the sale of our patented skin health products as primary sunscreens.

 

We are committed to environmental health and safety (“EH&S”). We believe we comply with all applicable exposure limit standards issued by the United States Department of Labor’s Occupational Health and Safety Administration (“OSHA”). Because nanotechnology remains an emerging and evolving science, there are no currently accepted standards, measurements or personal protective equipment available that are specific to nanoparticle safety. Accordingly, we rely on general chemical safety and process safety practices to identify safe personal protective equipment and appropriate handling protocols. We believe that we have taken a leadership position on EH&S in our operations and have internal and external review and monitoring of our practices.

 

In addition, our facilities and operations are subject to the plant and laboratory safety requirements of various environmental and occupational safety and health laws. We believe we are in compliance with all such laws and regulations, and to date, those regulations have not materially restricted or impeded operations. Further, we believe our processes to be highly efficient, generating very low levels of waste and emissions. For this reason, we do not view issues surrounding climate change and any currently foreseeable related regulations as materially impacting our business and financial statements, beyond any inestimable impact on the macro-economic environment. 

 

We have taken a responsible, proactive approach to EH&S by implementing appropriate procedures and processes to have our facilities registered under ISO 14001, American National Standard, Environmental Management System Requirements. We are also involved with leading industry groups that are defining nanomaterial standards and protocols. These currently include the ASTM International Committee on Nanotechnology, and the US TAG to ISO TC 229 Nanotechnology committee managed by the American National Standards Institute committee (ANSI). We also participate in FDA reviews relative to cosmetic and applicable drug applications. We have a full-time, advanced degreed professional who spends a significant amount of time managing governmental regulation compliance and EH&S. We believe that our Company has an exemplary safety record.

6

 

 

Employees

 

On December 31, 2021, we had a total of 58 full-time employees, 6 of whom hold advanced degrees. Additionally, we have a number of temporary, and temporary-to-permanent employees, typically 90 to 110 on a rotating basis, and a number of contractors with specific industry experience that have become a part of our talent pool. We have no collective bargaining agreements and believe that we have a strong relationship with our employees, whom management believes represent the strength of our Company.

 

Backlog

 

We do not believe that a backlog as of any particular date is indicative of future results. Our sales are primarily pursuant to purchase orders for delivery of our Solésence formulated products, personal care ingredients, and advanced materials. We have some agreements that give customers the right to purchase a specific quantity of ingredients during a specified time period. These agreements, however, do not obligate the customers to purchase any minimum quantity of such ingredients. The quantities actually purchased by the customer, as well as the shipment schedules, are frequently revised during the agreement term to reflect changes in the customer’s needs. For these reasons we do not believe that such agreements are meaningful for determining backlog amounts.

 

Business Segment and Geographical Information

 

Our operations comprise a single business segment and all of our long-lived assets are located within the United States. See Note 13 to the accompanying Financial Statements for additional information.

 

Key Customers

 

A limited number of key customers account for a substantial portion of our commercial revenue, and aside from our largest customer, and our medical diagnostics customer, we are seeing the composition of these key customers change with the growth we are experiencing within our Solésence beauty science subsidiary, which has grown to exceed Personal Care Ingredients and Advanced Materials combined.  For 2021, total Solésence revenue amounted to $18.2M or 62% of total revenue compared to $6.7M, or 39% for 2020.  In particular, revenue from five customers across all business areas, our largest customer in personal care applications (BASF), three of our Solésence customers, and, within our advanced materials business, our medical diagnostics application customer, constituted approximately 26%, 19%, 15%, 10%, and 8%, respectively, of our 2021 total revenue.

 

As our Solésence products continue to represent more of our total revenues, we expect to see a number of smaller (sub-10% of revenue) customers represent a more significant portion of our total revenue. We have experienced this in 2021 and expect it to continue in 2022 and beyond. Many of our customers are significantly larger than we are and, therefore, may be able to exert a high degree of influence over us. While our agreements with BASF are long-term agreements, they may be terminated by BASF under certain circumstances with reasonable notice and do not provide any guarantees that BASF will buy our products. The loss of one of our largest customers or the failure to attract new customers could have a material adverse effect on our business, results of operations and financial condition. To reduce the impact of having a high concentration of sales to a limited number of customers, we have aggressively pursued new customers through our market focused business model, and particularly through our Solésence beauty science subsidiary. To the extent we are successful in both adding a large number of customers through this model, and maintaining or expanding our existing partners, we believe we will be able to best manage the risks associated with customer concentration.

 

Forward-Looking Statements

 

We want to provide investors with more meaningful and useful information. As a result, this Annual Report on Form 10-K (the “Form 10-K”) contains certain “forward-looking statements”, as defined in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements reflect our current expectations of the future results of our operations, performance and achievements. Forward-looking statements are covered under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We have tried, wherever possible, to identify these statements by using words such as “anticipates”, “believes”, “estimates”, “expects”, “plans”, “intends” and similar expressions. These statements reflect management’s current beliefs and are based on information now available to it. Accordingly, these statements are subject to certain risks, uncertainties and contingencies that could cause our actual results, performance or achievements in 2022 and beyond to differ materially from those expressed in, or implied by, such statements. These risks, uncertainties and factors include, without limitation: our ability to be consistently profitable despite the losses we have incurred since our incorporation; a decision by a customer to cancel a purchase order or supply agreement in light of our dependence on a limited number of key customers; the terms of our supply agreements with BASF which could trigger a requirement to transfer technology and/or sell equipment to that customer; our potential inability to obtain working capital when needed on acceptable terms or at all; our ability to obtain materials at costs we can pass through to our customers, including high purity zinc, and other items impacted by supply chain pressures; uncertain demand for, and acceptance of, our Solésence products, and our advanced materials; our manufacturing capacity and product mix flexibility in light of customer demand; our limited marketing experience, including with our suite of Solésence products; changes in development and distribution relationships; the impact of competitive products and technologies; our dependence on patents and protection of proprietary information; our ability to maintain an appropriate electronic trading venue for our securities; the impact of any potential new governmental regulations, especially any new governmental regulations focusing on the processing, handling, storage or sale of nanomaterials, that could be difficult to respond to or costly to comply with; business interruptions due to unexpected events or public health crises, including viral pandemics such as COVID-19; and the resolution of litigation or other legal proceedings in which we may become involved. In addition, our forward-looking statements could be affected by general industry and market conditions and growth rates. Readers of this Form 10-K should not place undue reliance on any forward-looking statements. Except as required by federal securities laws, we undertake no obligation to update or revise these forward-looking statements to reflect new events or uncertainties.

 

7

 

Investor Information

 

We are subject to the informational requirements of the Exchange Act and, accordingly, file periodic reports, proxy statements and other information with the Securities and Exchange Commission (the “SEC”). Such reports, proxy statements and other information may be obtained by visiting the Public Reference Room of the SEC at 100 F Street, N.E., Washington, DC 20549 or by calling the SEC at 1-800-SEC-0330. In addition, the SEC maintains an Internet site (http://www.sec.gov) that contains reports, proxy and information statements and other information regarding issuers that file electronically.

 

Financial and other information may also be accessed at our website. The address is www.nanophase.com. We make available, free of charge, copies of our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after filing such material electronically with, or otherwise furnishing it to, the SEC, and intend to make all such reports and amendments to reports available free of charge on our website. We have included our website address throughout this Form 10-K as textual references only. The information contained on, or accessible through, our website is not incorporated into this Form 10-K.

 

Item 1A. Risk Factors

 

Not required for a smaller reporting company.

 

Item 1B. Unresolved Staff Comments

 

Not required for a smaller reporting company.

 

Item 2. Properties

 

We have traditionally operated two facilities in the Chicago suburbs - a 36,000 square-foot production, research and headquarters facility in Romeoville, Illinois and a 20,000 square-foot production facility in Burr Ridge, Illinois. We also lease a 20,000 square-foot offsite warehouse in the vicinity of the Romeoville facility. At the end of 2021, we leased an additional production facility of 260,000 square-feet in Bolingbrook, Illinois.

 

Our manufacturing operations in Burr Ridge are registered under ISO 9001, and we believe that our manufacturing operations are within the cGMP requirements of the FDA for products that require such compliance. This facility is also registered under ISO 14001 which is the international standard for environmental management.

 

The Romeoville facility houses our headquarters, advanced engineering, manufacturing (including nanoparticle coating, nanoparticle dispersion and pilot-scale manufacturing), filling and assembly of our Solésence® products, and research and development with three applications development and formulating laboratories. The Romeoville facility has a quality control laboratory designed for the dual purposes of validating operations to cGMP and ISO standards and production process control. This laboratory is equipped to handle many routine analytical and in-process techniques that are currently required. All Romeoville manufacturing processes are registered under ISO 9001 and ISO 14001, and we believe that the particle coating processes used for our ingredients and fully formulated sunscreens and cosmetic products for personal care are in compliance with the cGMP requirements of the FDA.

 

We lease our Romeoville and Burr Ridge facilities. During October 2016 we entered into an amendment to our Industrial Lease Agreement for the facility in Romeoville, Illinois, which, among other things, extended the term of such lease through December 31, 2024. On March 14, 2017, we entered into a new Building Lease for the Burr Ridge facility that began in September 2017, and was extended for one year to end during September 2022, with our option to further extend this lease by two additional one-year periods. We exercised the first lease extension for the Burr Ridge facility in February, 2021.  On August 6, 2019 we entered into a new warehouse lease for a different property in Romeoville that began in September 2019 and will end in September 2022, with our option to extend this lease for one additional year. 

 

During December 2021, we entered into a Standard Form Industrial Lease for a new facility in Bolingbrook, Illinois, which, among other things, will end in May of 2032, with options to extend this lease at market rent for each of three concurrent five-year periods.

 

8

 

With the addition of our new Bolingbrook space, we believe that our leased facilities will provide sufficient capacity to fulfill current known customer demand as well as allow for the creation of substantial additional space to enable expansion of key production processes. We believe we will be able to expand certain operations, and consolidate others, to support additional growth in an economically efficient manner. We believe that our capital expenditures made in 2021, and projected for 2022, will support currently anticipated demand from existing and expected customers through 2022 and in to 2023. Management will spend considerable time in 2022 determining how best to optimize our facilities to maximize growth over the next few years. Our actual future capacity requirements will depend on many factors, including new and potential customer acceptance of our current and potential engineered materials, applications and products, both expected and currently unplanned growth from existing customers, continued progress in our research and development activities and product testing programs and the magnitude of these activities and programs.

 

Item 3. Legal Proceedings

 

We are not a party to any pending legal proceedings or claims that we believe will result in a material adverse effect on our business, financial condition, or operating results.

 

Item 4. Mine Safety Disclosures

 

Not applicable. 

PART II

 

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

 

Market Information; Holders; Dividends

 

Our common stock is traded under the symbol “NANX” on the OTCQB marketplace, operated by OTC Markets Group. The following table sets forth, for the periods indicated, the range of high and low sale prices for our common stock on the OTCQB marketplace:

 

    High     Low  
Fiscal year ended December 31, 2021:                
First Quarter   $ 1.26     $ 0.74  
Second Quarter     1.76       1.15  
Third Quarter     2.77       1.52  
Fourth Quarter     4.45       2.46  
Fiscal year ended December 31, 2020:                
First Quarter   $ 0.49     $ 0.21  
Second Quarter     0.56       0.17  
Third Quarter     0.65       0.32  
Fourth Quarter     0.95       0.55  

 

On March 25, 2022, the last reported sale price of our common stock was $3.12 per share, and there were 120 holders of record of our common stock.

 

We have never declared or paid any cash dividends on our common stock and do not currently anticipate paying any cash dividends or other distributions on our common stock in the foreseeable future. We intend instead to retain any future earnings for reinvestment in our business. Any future determination to pay cash dividends will be at the discretion of our Board of Directors and will be dependent upon our financial condition, results of operations, capital requirements and such other factors deemed relevant by our Board of Directors. Our Business Loan Agreements with Beachcorp, LLC (“Beachcorp”), Strandler, LLC (“Strandler”), and Libertyville Bank and Trust Company (“Libertyville”), dated as of November 19, 2018, January 28, 2022, and December 21, 2021 respectively, require us to obtain the written consent of the lender prior to paying any cash dividends on our common stock. 

 

Item 6. Selected Financial Data

 

Not required for a smaller reporting company.

 

9

 

   

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

The following discussion and analysis should be read in conjunction with risks discussed in the financial statements and related notes thereto appearing elsewhere in this Form 10-K. When used in the following discussions, the words “anticipates,” “believes,” “estimates,” “expects,” “plans,” “intends” and similar expressions are intended to identify forward-looking statements. Such statements are subject to certain risks, uncertainties and contingencies that could cause actual results, performance or achievements to differ materially from those expressed in, or implied by, such statements. See the “Forward Looking Statements” section in Part 1, Item 1, of this Form 10-K.

 

Overview

 

Nanophase is a health-oriented, science-driven company, which, along with its wholly owned subsidiary, Solésence, LLC (our “Solésence beauty science subsidiary”), is focused in various beauty- and life-science markets. Our primary skin health products are fully developed prestige skin care formulations with mineral-based UV protection, marketed and sold through our Solésence beauty science subsidiary, enabled by our proprietary Active Pharmaceutical Ingredients (“APIs”) which are also marketed as APIs for sale to manufacturers of other types of skin health products, including sunscreens and daily care products.  In terms of the balance of our life sciences focus, we have seen current conditions significantly increase demand for our medical diagnostics ingredients, which are used in testing for various viruses, most notably COVID-19.  Additionally, we continue to sell products in legacy markets including architectural coatings, industrial coating applications, abrasion-resistant additives, plastics additives, and surface finishing technologies (polishing) applications— all of which, along with medical diagnostics, currently fall into the advanced materials product category.  

 

Critical Accounting Estimates

 

We review long-lived assets for impairment whenever events or changes in circumstances indicate that the asset’s carrying amount may not be recoverable. We conduct long-lived asset impairment analyses in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 360-10-15, Impairment or Disposal of Long-Lived Assets. ASC 360-10-15 requires us to group assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities and evaluate the asset group against the sum of the undiscounted future cash flows. If the undiscounted cash flows do not indicate the carrying amount of the asset is recoverable, an impairment charge is measured as the amount by which the carrying amount of the asset group exceeds its fair value based on discounted cash flow analysis or appraisals.

 

Other critical estimates include the allowance for doubtful accounts applied against our receivables balance as well as an inventory reserve. In the determination of a reserve to apply toward receivables, management considered provisions in FASB ASC 450-20-25 regarding the recognition of loss contingencies and applied a reserve balance against gross receivables to arrive at the net reported balance. Under the guidance referenced above, management judgmentally applied an estimate of the portion of gross receivables for which loss is both probable and can be reasonably estimated and accrued a loss contingency by a charge to income. A $60,000 and $9,000 bad debt reserve was applied to gross receivables for 2021 and 2020, respectively. Particularly with respect to customers of our Solésence beauty science subsidiary, it can be difficult to estimate collectability. We frequently require significant deposits from customers before ordering materials and scheduling production. This serves as a good indicator of the customer’s wherewithal to pay for the balance of the product when shipped. In cases where it is difficult to establish creditworthiness, we require payment of the full amount before we ship. Notwithstanding these credit security measures, we frequently find that pay cycles get extended for reasons that can be outside of our control. The nature of the business is that there are many product launches, often by smaller or start-up companies, that may not result in initial commercial success. This has resulted in extensions of payment terms, but collectability has ultimately occurred in most cases. As our Solésence beauty science subsidiary grows, we will monitor this closely and adjust estimates as necessary.

 

Management also monitors the value of inventory for the effects of aging, obsolescence, and seasonality. Consistent with the provisions in FASB ASC 330-10-35, we adjust inventory valuation upon management’s determination that the net realizable value of our inventory, which applies the average cost method, is lower than its historic cost. In the application of this policy in 2021, management deemed a portion of inventory will likely experience such an impairment and elected to apply a $406,000 inventory reserve in anticipation. Some of the materials in question are nearing expiration and therefore more difficult to sell, some represent soon-to-be obsolete products, and some are raw materials that we no longer use regularly.

 

Certain assumptions are necessary to assess the impact of risks and uncertainties on the financial information, such as cash flow projections, availability of capital if needed to support the ongoing operations of the business, and our expected compliance with contractual commitments. Any changes in those plans or assumptions could have a material impact on our liquidity and financial condition. While we have seen costs increase on an inflationary basis as we enter 2022, it is our belief that we will be able to offset much of this cost as we gain greater production efficiencies and seek to increase our pricing where possible. 

 

10

 

Results of Operations

 

Years Ended December 31, 2021 and 2020

 

Total revenue increased to $29,475,000 in 2021, compared to $17,123,000 in 2020. A substantial majority of our revenue for each year is from our largest customers, in particular, sales to our largest customer in skin care and sunscreen applications, finished skin health products marketed through our Solésence beauty science subsidiary, and medical diagnostics. Product revenue, the primary component of our total revenue, increased to $29,325,000 in 2021, compared to $16,422,000 in 2020. This increase was due to rapid growth in the adoption of our Solésence® products, and growth in 2021 sales to our largest customer in our personal care ingredients business, offset by a decrease in revenue from our medical diagnostics materials customer (within our advanced materials business). 

 

Current Significant Customers

 

    2021   2020
Largest Personal Care Customer   26 %   30 %  
Solésence Customer - 1   19 %   14 %  
Solésence Customer - 2   15 %   11 %  
Solésence Customer - 3   10 %   5 %  
Medical Diagnostics Customer   8 %   20 %  
Significant Customer Total   78 %   80 %  

 

Cost of revenue generally includes costs associated with commercial production and customer development arrangements. Cost of revenue increased to $20,785,000 in 2021, compared to $11,133,000 in 2020. The increase in cost of revenue was primarily driven by the rapid increases in product revenue volume, with attendant inefficiencies caused by hitting capacity limits in various critical processes. Lower-then-expected volume in the fourth quarter of 2021, write-downs of obsolete inventory, reduction in contract revenue (which generally has little direct cost associated with it), and changes in product mix added to relative increases in cost of revenue. While gross margin dollars increased by approximately $2,700,000, all of these factors contributed to a reduction of overall gross margin percentage by 6% when compared to 2020. We expect to continue new materials development and dispersion technologies for personal care applications and for our formulated Solésence products during 2022 and beyond, as part of our business model. At current revenue levels we have generated a positive gross margin, though margins can be impeded by the cyclicality of our demand, often leading to the Company not having enough revenue to efficiently absorb manufacturing overhead that is required to work with current customers and expected future customers. We believe that our current fixed manufacturing cost structure is sufficient to support higher levels of revenue volume. The extent to which margins grow, as a percentage of total revenue, will be dependent upon revenue mix, revenue volume, our ability to cut costs and pass commodity market-driven raw materials increases on to customers, and the speed and efficiency with which we are able to scale up production for our Solésence products. We expect that, as product revenue volume increases, our fixed manufacturing costs will be more efficiently absorbed, which should lead to increased margins as we grow. We expect to continue to focus on reducing controllable variable product manufacturing costs, with potential variability related to the commodity metals markets and cost and wage inflation, but may or may not realize gross margin percentage growth through 2022 and beyond, dependent upon the factors discussed above.

 

Research and development expense, which includes all expenses relating to the technology and advanced engineering groups, primarily consists of costs associated with the development or acquisition of new finished product formulations for skin care, new product applications for our skin care ingredients, advancement of our medical diagnostics ingredient knowledge, and the cost of enhancing our manufacturing processes. As an example, we are currently focusing the bulk of our resources on developing new product formulations, and related new technologies, as we expand marketing and sales efforts relating to our Solésence products. This work has led to several new products and additional potential new products. Our efforts in research and development, cosmetic formulating, process engineering and advanced engineering groups are focused in three major areas: 1) application development for our products; 2) creating or obtaining additional core materials technologies and/or materials that have the capability to serve multiple skin health-related markets; and 3) continuing to improve our core technologies to improve manufacturing operations and reduce costs.

 

Research and development expense increased to $2,235,000 in 2021, compared to $1,571,000 in 2020. The primary reasons for this were increases in compensation expense and headcount, outside testing, and materials charges associated with the development and launch of our Solésence line of personal care products and related capabilities. We expect expenses for research and development to expand 50% or more, depending on both growth in our Solésence line of products, and related technologies. This expense growth will be dependent upon the success we have in developing new products, which adds significantly to outside testing fees to both enhance product development and comply with regulatory requirements.

 

11

 

Selling, general and administrative expense increased to $3,896,000 in 2021, compared to $2,934,000 in 2020. The net increase was primarily attributed to an increase in compensation expense and headcount, including consultants, and increases in marketing and trade show expense, which began again in late 2021. We expect 2022 expenses in this area to be higher, potentially as much as 30% to 35%, if growth continues as planned.  We will be expanding our selling and marketing efforts, and parts of our administrative functions, including related staffing additions.  The extent to which this increase occurs will be dependent upon growth.

 

Interest expense was $1,154,000 in 2021, compared to $496,000 in 2020, due largely to the remaining discount-related interest expense, amounting to $814,000, taken on an accelerated basis in May 2021 at the early conversion of our $2,000,000 Convertible Note. The balance of interest expense for 2020 and 2021 related to interest paid relating to our revolving line of credit for working capital funding, and finance leases and term loans supporting some of our equipment.

 

In Company-wide operations, we believe inflation has not had a material effect on our operations or financial position for 2021, although we have seen increases in our costs broadly, beginning in the fourth quarter. We expect supplier price increases and wage and benefit inflation, both of which represent a significant component of our costs of operations, may have a material effect on our operations and financial position in 2022 and beyond. We will apply our best efforts to pass through any significant cost increases to our customers. If we are unable to pass through any increases due to contractual limitations or conditions in our markets specifically, this could reduce margins and net income.

 

Liquidity and Capital Resources

 

Cash, cash proceeds and use of cash for 2021 and 2020 were:

 

For the year ended December 31,
  2021       2020  
Total cash $ 657,000     $ 957,000  
Cash provided by (used in) operating activities   2,321,000       (2,061,000 )
Net cash (used in) investing activities   (1,874,000 )     (878,000 )
Net cash (used in) provided by financing activities   (747,000 )     2,702,000  

 

The $4,382,000 year-over-year increase in cash provided by operating activities for the year ended December 31, 2021 was mainly due to the Company generating $2,320,000 in net income in 2021 compared to $989,000 in 2020. Cash capital expenditures amounted to approximately $1,874,000 and $878,000 for the years ended December 31, 2021 and 2020, respectively. We did not dispose of or sell any assets during 2021 or 2020.

 

On April 17, 2020, we received a loan of $952,000 from the Libertyville Bank and Trust Company (“Libertyville”) under the Paycheck Protection Program (the “PPP”).  This loan was forgiven by the Small Business Administration (“SBA”) in February 2021. These funds specifically were used to absorb a portion of the Company’s salary and benefit costs.

 

The Company maintains a credit agreement with Libertyville which most recently served the primary purpose of insuring that it met its cash balance requirements at quarter end relating to a contract with the Company’s largest customer. Outstanding borrowings were $500,000 on this line of credit as of December 31, 2020. On December 21, 2021, this facility was converted for use support our obligations under our newly leased manufacturing and warehouse space in Bolingbrook, Illinois. This credit agreement has a maturity of December 22, 2022.

 

On November 16, 2018, we entered into a Business Loan Agreement (the “Master Agreement”) with Beachcorp, LLC. The Master Agreement relates to two loan facilities, each evidenced by a separate promissory note dated as of November 16, 2018: a term loan to the Company of up to $500,000 to be disbursed in a single advance (the “Term Loan”) with a fixed annual interest rate of 8.25%, payable quarterly, and with principal due on December 31, 2020; and an asset-based revolving loan facility for the Company of up to $2,000,000 (the “A/R Revolver Facility”), with floating interest accruing at the prime rate plus 3% (8.25% minimum) per year, with a borrowing base consisting of qualified accounts receivable of the Company, and a maturity of March 31, 2020, as amended. On March 23, 2020, the Company and Beachcorp, LLC executed the First Amendment to our Master Agreement that extended the maturities of both the Term Loan and the A/R Revolver Facility to March 31, 2021. Effective September 8, 2020, the Company and Beachcorp, LLC executed the Second Amendment to our Master Agreement that expanded the limit on the A/R Revolver Facility from $2,000,000 to $2,750,000.  On December 23, 2020, the Company and Beachcorp, LLC executed the Third Amendment to our Master Agreement that expanded the limit on the A/R Revolver Facility from $2,750,000 to $4,000,000 and extended the maturities of both the Term Loan and the A/R Revolver Facility to March 31, 2022. Effective April 21, 2021 the Company and Beachcorp, LLC executed the Fourth Amendment to our Master Agreement that expanded the limit on the A/R Revolver Facility from $4,000,000 to $6,000,000, changed the interest rate to fully floating and reduced the rate to the prime rate plus 2%, also extending the maturity of the A/R Revolver Facility to March 31, 2023. This amendment also increased the amount of the Term Loan from $500,000 to $1,000,000, changed the interest rate to fully floating and reduced the rate to the prime rate plus 2%. The maturity of the Term Loan remained March 31, 2022.

 

12

 

The Term Loan and A/R Revolver Facility are secured by all the unencumbered assets of the Company and subordinated to Libertyville’s secured interest under the New Business Loan Credit Agreement. The Master Agreement substantially restricted the Company’s ability to incur additional indebtedness during the terms of the Term Loan, the Revolver Facility, and the Convertible Promissory Note.

 

In November 2019, we entered in to a 2% Convertible Promissory Note in the original principal amount of $2,000,000. The maturity date of this note was May 15, 2024, and was payable to our investor at that time in cash, or through conversion of the rights to purchase up to 10,000,000 unregistered shares of the Company’s common stock at $0.20 per share.  Our investor chose to exercise his conversion rights effective May 7, 2021. 

 

On December 31, 2021, the balances on the Term Loan and the Convertible Promissory Note were $1,000,000 and $0, respectively, and the balance on the Revolver Facility was $1,351,000. On December 31, 2020, the balances on the Term Loan and the Convertible Promissory Note were $500,000 and $2,000,000, respectively, and the balance on the A/R Revolver Facility was $2,155,000.

 

On April 17, 2020, we received a loan of $952,000 from Libertyville under the PPP.  Under the PPP, the Company could apply for forgiveness of the amount due on the loan in an amount equal to the sum of the following costs incurred during the 24-week period beginning on the date of the first disbursement of the Loan: (a) payroll costs, (b) any payment of interest on a covered obligation (which shall not include any prepayment of or payment of principal on a covered mortgage obligation), (c) any payment on a covered rent obligation, and (d) any covered utility payment, calculated in accordance with the terms of the CARES Act. The principal amount of the PPP Note would have accrued interest at the rate of 1.00% per year. Management applied for loan forgiveness in February 2021 and the loan was forgiven shortly thereafter during the first quarter of 2021. Under the terms of the PPP loan, it could be subject to audit for six years from the date of forgiveness. If any portion of the PPP loan were to be deemed ineligible, the Company could be required to repay the funds. On December 31, 2021, the balance under the PPP note was $0.

 

On January 28, 2022, to support the working capital demands created by the commercial growth of the Company and its wholly owned subsidiary, Solésence, LLC, the Company entered into (i) an Amended and Restated Business Loan Agreement (the “A&R Loan Agreement”), which amends and restates the Master Agreement, (ii) a Business Loan Agreement (the “New Term Loan Agreement”) with Strandler, LLC, (iii) a Business Loan Agreement (the “New Revolving Loan Agreement” and together with the A&R Loan Agreement and the New Term Loan Agreement, the “Loan Agreements”) with Beachcorp, LLC, and (iv) three promissory notes in order to evidence the loans pursuant to the Loan Agreements (the “Notes”). Beachcorp, LLC and Strandler, LLC are affiliates of Mr. Bradford T. Whitmore, who beneficially owns a majority of the Company’s common stock and is the brother of Ms. R. Janet Whitmore, a director of the Company and the chair of the Company’s board of directors.

 

The Loan Agreements change the terms of both the Company’s asset-based revolving loan facility (the “A/R Revolver Facility”) and the secured advance (the “Term Loan”, which was assigned from Beachcorp, LLC to Strandler, LLC) under the Master Agreement and provide a new asset-based revolving loan facility based on inventory (the “Inventory Facility”). The maximum borrowing amount under the A/R Revolver Facility increases from $6,000,000 to $8,000,000, with a borrowing base consisting of qualified accounts receivable of the Company. The maximum borrowing amount under the Inventory Facility is $4,000,000, with a borrowing base consisting of up to 50% of the value of qualified inventory of the Company. The Loan Agreements also extend the date for which all principal and accrued interest under the A&R Revolver Facility and the Term Loan are due from March 31, 2023 and March 31, 2022, respectively, to March 31, 2024, which is also the maturity date for the Inventory Facility. The Loan Agreements reduce interest on outstanding borrowings under the A/R Revolver Facility and the Term Loan from the prime rate plus 2% and 5.25% per year, to a floating rate equal to the prime rate plus 0.75%, which is also the interest rate for borrowings under the Inventory Facility. The amount of the Term Loan remains $1,000,000. The A/R Revolver Facility, the Inventory Facility and the Term Loan are all secured by all the unencumbered assets of the Company and subordinated to the Company’s revolving line of credit with Libertyville Bank & Trust. 

 

For more information regarding the New Business Loan Agreement, see Note 3 to our Financial Statements referred to in Part II, Item 8 of this Annual Report on Form 10-K. 

 

Our supply agreements with our largest customer, BASF, contain certain financial covenants which could potentially impact our liquidity. The most restrictive financial covenants under these agreements required that we maintain a minimum of $1,000,000 in certain current assets; which may be composed of no less than $500,000 cash, cash equivalents, and certain investments, no more than a combined $500,000 of certain related inventory, of which no more than $250,000 could be raw material, and certain receivables, and that we not have the acceleration of any debt maturity having a principal amount of more than $10 million, in order to avoid triggering the customer’s potential right to transfer certain technology and equipment to that customer at a contractually-defined price.  We were in compliance with these covenants at December 31, 2020. This financial trigger was removed when the Company achieved cumulative net earnings in excess of $1.5 million, as defined, during the second quarter of 2021. This supply agreement and its covenants are more fully described in Note 12, and our line of credit is more fully described in Note 3, to our Financial Statements referred to in Part II, Item 8, of this Annual Report on Form 10-K.

 

13

 

Our actual future capital requirements in 2022 and beyond will depend on many factors, including customer acceptance of our current and potential finished Solésence  products, APIs sold as ingredients in to the skin health markets, medical diagnostics ingredients, and other engineered materials, applications, and products, continued progress in research and development activities and product testing programs, the magnitude of these activities and programs, and the costs necessary to increase and expand our manufacturing capabilities and to market and sell these products and ingredients. Other important issues that will drive future capital requirements will be the development of new markets and new customers as well as the potential for significant unplanned growth with existing customers. Depending on the success of certain projects, we expect that capital spending relating to currently known capital needs for 2022 will be between $4 million and $8 million, to be funded by profit from operations, our existing loans and lines of credit, and possible new debt financing. If those projects are delayed or ultimately prove unsuccessful, or if we fail to be able to support the additional cost of funding them in the near term, we expect our capital expenditures may fall below the lower end of the range. Similarly, substantial success in business development projects may cause the actual 2022 capital investment to exceed the top of this range.

 

The Company currently has two areas within its strategic plan that will result in material cash requirements that could have an impact on operations. We have several operating leases (see note 6 to the financial statements) for our facilities that require us to increase our cash outlays for facilities expenses significantly beginning in 2022. The new 260,000 square foot facility we leased in December 2021 exceeds our current needs for space considerably. We are growing rapidly and continue to expect significant growth going forward. We will also consolidate some of our facilities to mitigate costs. Our view was that a lack of space would have hindered our ability to continue to grow, as well as making it difficult to satisfy existing customer demands on a timely basis if we couldn’t expand our production footprint. We have estimated our future growth through a combination of industry experience, customer feedback, market intelligence, and our successful history in commercializing new products. Sales of our Solésence products have roughly tripled between 2019 and 2021, and tripled again in 2021 to have reached $18 million annually. We expect this growth to continue, albeit at less than a multiple of each year’s sales going forward. Many of these estimates are qualitative in nature, but are informed by experience. If we were to not grow more than incrementally in 2022 and 2023, we would need to re-evaluate our expansion strategy in light of the increases in our facilities costs that extend for as much as ten years in to the future. Similarly, our capital spending plan for 2022 will amount to between $4 million and $8 million. We expect our capital spending to increase further in 2023 and 2024. At December 31, 2021, our commitments to equipment suppliers relate mainly to the $1.1 million of construction in progress, much of which reflects deposits on to-be-delivered equipment. We estimate the unpaid committed capital relating to capital spending to be less than $1 million as of December 31, 2021.

 

 We have federal net operating loss carryforwards for tax purposes of approximately $62 million on December 31, 2021. Because the Company may experience “ownership changes” within the meaning of the U.S. Internal Revenue Code (“IRC”) in connection with any future equity offerings, future utilization of this carryforward may be subject to certain limitations as defined by the IRC. If not utilized, $57 million of this loss carryforward will expire between 2022 and 2037. Given changes to the IRC, net operating loss carryforwards generated after January 1, 2018 do not expire, therefore, $5 million in net operating losses generated since January 1, 2018 do not expire. We have Illinois net loss deduction carryforwards for tax purposes of approximately $21 million on December 31, 2021. Due to the provisions of Illinois Public Act 102-0669 signed November 16, 2021, Illinois net loss deductions expire between 2029 and 2039.

 

As a result of the annual limitation and uncertainty as to the amount of future taxable income that will be earned prior to the expiration of the carryforward, we have concluded that it is likely that some portion of this carryforward will expire before ultimately becoming available to reduce income tax liabilities.

 

14

 

Item 7A. Quantitative and Qualitative Disclosures About Market Risk

 

Not required for a smaller reporting company.

 

Item 8. Financial Statements and Supplementary Data

 

The financial statements, with the report of independent auditors, listed in Item 15 appear on pages F-1 through F-20 of this Form 10-K.

 

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

 

None.

 

Item 9A. Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures. We are responsible for establishing and maintaining disclosure controls and procedures that are designed to ensure that information required to be disclosed by us in the reports filed by us under the Exchange Act is: (a) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms; and (b) accumulated and communicated to our management, including our principal executive and principal financial officer, to allow timely decisions regarding required disclosures. It should be noted that in designing and evaluating our disclosure controls and procedures, we recognize that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and that our management necessarily was required to apply its judgment regarding the design of our disclosure controls and procedures. As of the end of the period covered by this report, we conducted an evaluation, under the supervision (and with the participation) of our management, including our Chief Executive Officer (our principal executive officer) and our Chief Financial Officer (our principal financial officer), of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rules 13a-15(e) and 15d-15(e) of the Exchange Act.

 

Through the course of our evaluation of our internal control over financial reporting, we advised our Board of Directors that we had identified a material weakness as defined under standards established by the Public Company Accounting Oversight Board (United States). A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis. The material weakness we identified is discussed in “Internal Control Over Financial Reporting” below. Our Chief Executive Officer, Chief Financial Officer (which roles are currently filled by the same person), and Chief Operating Officer have concluded that as a result of the material weakness, as of the end of the period covered by this Annual Report on Form 10-K, our Disclosure Controls were not effective.

 

Notwithstanding such material weakness in internal control over financial reporting, our management concluded that our consolidated financial statements in this Annual Report on Form 10-K present fairly, in all material respects, the Company’s financial position, results of operations and cash flows as of the dates, and for the periods presented, in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”), and include certain amounts based on management’s judgment and best estimates. Other financial information presented is consistent with the financial statements.

 

Management’s Annual Report on Internal Control Over Financial Reporting. Management is responsible for the preparation, integrity and fair presentation of the financial statements and Notes to the financial statements. Management is also responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934. The Company’s internal control over financial reporting is designed under the supervision of the Company’s principal executive officer and principal financial officer in order to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. The Company’s internal control over financial reporting includes those policies and procedures that:

 

  (i) Pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of assets of the Company;
  (ii) Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and
  (iii) Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company’s assets that could have a material effect on the financial statements.

15

 

 

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

 

Management assessed the effectiveness of the Company’s internal control over financial reporting as of December 31, 2021. In making this assessment, management used the criteria established in Internal Control–Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”). Because of the material weakness described above, management concluded that, as of December 31, 2021 our internal control over financial reporting was not effective based on the criteria established in Internal Control-Integrated Framework issued by COSO.

 

Based on our assessment, and those criteria, our management, including our Chief Executive Officer (our principal executive officer) and our Chief Financial Officer (our principal financial officer) (which roles are currently filled by the same person), and our Chief Operating Officer, concluded that there is a material weakness in our internal control over financial reporting. The above material weakness identified did not result in a material misstatement of our previously issued financial statements, nor does management believe that it had any effect on the accuracy of the Company’s financial statements for the current reporting period, however, it could result in a misstatement of our account balances or disclosures that would result in a material misstatement of our annual or interim financial statements that would not be prevented or detected.

 

Management has identified a material weakness in the way the Company tracks and accounts for its inventory. Controls were not effectively designed, documented, and maintained to verify that the existence of all inventories subject to physical inventory counts were correctly counted, and our process for compiling and communicating inventory data to ensure accurate reporting in our financial statements was not effective, including inadequate verification for completeness and accuracy of key reports used to review and monitor inventory balances. A consequence of this was that the process of conducting a full physical inventory required an inordinate amount of time to establish an accurate valuation.

 

Remediation Activities.  In order to address the material weakness in internal control over financial reporting described above, management, with direction from the Audit Committee, has begun the process of remediation to address control deficiencies that led to the material weakness. Specifically, management will:

 

●Continue discussions with third party experts, then engage one of them to assist management in completing a comprehensive risk assessment to identify, design and implement best practices for its supply chain and inventory control policies; and

 

●Begin reviewing and enhancing business policies, procedures, and related internal controls to standardize business processes throughout the organization.

 

Changes in Internal Control over Financial Reporting. The Company’s management, including the Chief Executive Officer (our principal executive officer) and Chief Financial Officer (our principal financial officer), confirm that there was no change in the Company’s internal control over financial reporting during the quarter ended December 31, 2021 that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

 

This annual report does not include an attestation report of the Company’s registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by the Company’s registered public accounting firm pursuant to the rules of the Securities and Exchange Commission that permit the Company to provide only management’s report in this Form 10-K.

16

 

 

Item 9B. Other Information

 

PART III

 

Item 10. Directors, Executive Officers and Corporate Governance

 

DIRECTORS

 

Set forth below is certain information regarding the directors of the Company.

 

Name   Age   Position with Company   Director Since   Term Expires   Class
R. Janet Whitmore   67   Chair of the Board of Directors   2003   2022   I
Laura M. Beres   38   Director   2020   2022   I

Richard W. Siegel, Ph.D.

  

84 

  

Director 

  

1989

  

2023 

  

II 

Jess A. Jankowski   56   President, Chief Executive Officer, Chief Financial Officer, and Director   2009   2024   III

  

Ms. Whitmore joined the board in November 2003. She is a former director of Silverleaf Resorts, Inc., where she served as Chair of the Compensation Committee and as a member of the Audit Committee. She is also a former director of Epoch Biosciences, a supplier of proprietary products used to accelerate genomic analysis. Ms. Whitmore is Founder of Benton Consulting, LLC, which specializes in business development and processes. From 1976 through 1999, Ms. Whitmore held numerous engineering and finance positions at Mobil Corporation, including Mobil’s Chief Financial Analyst and Controller of Mobil’s Global Petrochemicals Division. Ms. Whitmore holds a B.S. degree in Chemical Engineering from Purdue University and an M.B.A. from Lewis University. We believe that Ms. Whitmore’s combination of global financial, engineering, and management expertise makes her a valuable member of our Board of Directors. Ms. Whitmore is the sister of Bradford T. Whitmore, and herself beneficially owned approximately 3% of the outstanding shares of our common stock as of March 31, 2022. Mr. Whitmore, together with his affiliates Strandler, LLC, Grace Brothers, Ltd. and Grace Investments, Ltd., beneficially owned approximately 62% of the outstanding shares of our common stock as of March 31, 2022. He is also the manager of Beachcorp, LLC.  The Company has entered into loan agreements with both Beachcorp, LLC, and Strandler, LLC.

 

Ms. Beres has served as a director of the Company since October 2020. She has spent her career in corporate strategy and operations in retail and consumer industries, transforming programs and building new organizational and market-facing capabilities. Ms. Beres currently serves as Vice President, Enterprise Transformation at Ulta Beauty, where she leads the company’s investment portfolio, aimed at accelerating growth and the company’s strategic goals. She established and led the Conscious Beauty program, a holistic project that offers enhanced transparency and choice around clean ingredients and sustainability. Previously, she has worked at Deloitte Consulting, advising primarily on growth and transformation strategies in Consumer-Packaged Goods, with additional leadership roles in the CMO practice, developing and executing strategies on large global accounts. Ms. Beres started her career working in the financial services, focused on small and middle market companies, with responsibilities including commercial lending and credit evaluation, and credit transaction negotiation. She earned her M.B.A. from The University of Chicago Booth School of Business, and has a B.S. in Finance and B.A. in Oboe Performance from Butler University. Ms. Beres has also served on Associate and Auxiliary Boards for non-profit organizations in Chicago, as well as the Board of Directors for Chicago Youth Symphony Orchestras. We believe that Ms. Beres’ broad strategic experience in CPG, and specific experience with cosmetics, along with her strong financial background makes her a valuable member of our Board of Directors.

 

Dr. Siegel is a co-founder of the Company and has served as a director of the Company since 1989. Dr. Siegel served as a consultant to the Company from 1990 to 2002 with regard to the application and commercialization of nanomaterials. Dr. Siegel is an internationally recognized scientist in the field of nanomaterials. During his tenure on the research staff at Argonne National Laboratory from July 1974 to May 1995, he was the principal scientist engaged in research with the laboratory-scale synthesis process that was the progenitor of the Company’s physical-vapor-synthesis production system. Dr. Siegel was the Robert W. Hunt Professor in Materials Science and Engineering at Rensselaer Polytechnic Institute from June 1995 until his retirement from RPI at the end of 2021, and served as Department Head from 1995 to 2000. Dr. Siegel was the founding Director of both the Rensselaer Nanotechnology Center (2001-2015) and the U.S. National Science Foundation funded Nanoscale Science and Engineering Center for Directed Assembly of Nanostructures (2001-2013). During the period from 1995 until 1998, he was also a visiting professor at the Max Planck Institute for Microstructure Physics in Germany on an Alexander von Humboldt Research Prize received in 1994. During the period from 2003 until 2004 he was a visiting professor in Japan on a RIKEN Eminent Scientist Award. He chaired the World Technology Evaluation Center worldwide study of nanostructure science and technology for the U.S. government, has served on the Council of the Materials Research Society and as Chairman of the International Committee on Nanostructured Materials. He also served on the Committee on Materials with Sub-Micron Sized Microstructures of the National Materials Advisory Board and was the co-chairman of the Study Panel on Clusters and Cluster-Assembled Materials for the U.S. Department of Energy. He served on the Nanotechnology Technical Advisory Group to the U.S. President’s Council of Advisors on Science and Technology during 2003-2009. Dr. Siegel was named a Fellow of the Materials Research Society in 2010, the American Institute of Medical and Biological Engineering in 2015, and the National Academy of Inventors in 2017. Dr. Siegel holds an A.B. degree in physics from Williams College and an M.S. degree and Ph.D. from the University of Illinois at Urbana-Champaign. We believe that Dr. Siegel’s value to our Board of Directors, as co-founder of the Company and inventor of our initial base technology, is self-explanatory. 

 

17

 

 Mr. Jankowski joined the board in February 2009. He has served as the Company’s President and Chief Executive Officer since that time. He is currently serving as the Company’s Chief Financial Officer, in addition to his existing role. After joining the Company in 1995, Mr. Jankowski held offices including Vice President of Finance, Chief Financial Officer, Secretary, Treasurer and Controller. From 1990-1995 he served as Controller for two building and public works contractors in the Chicago area, during which time he had significant business development responsibilities. Mr. Jankowski holds a B.S. from Northern Illinois University and an M.B.A. from Loyola University. He served on the TechAmerica Midwest Board from 2008 to 2012 and was a past member of the TechAmerica Midwest CFO Committee. He was appointed to the Advisory Board of the Nanobusiness Commercialization Association in 2009. Mr. Jankowski was also appointed to the Romeoville Economic Development Commission and served from 2004 to 2010. He has also served on the advisory board of NITECH (Formerly WESTEC), an Illinois Technology Enterprise Center focusing on the commercialization of advanced manufacturing technologies from 2003 to 2008. From 2009 to 2018, Mr. Jankowski was appointed to the board of directors of the Northern Illinois Technology Foundation, an economic development and technology transfer entity that is part of Northern Illinois University. From 2011 to 2015, he served as a subject matter expert for the Invest Illinois Venture Fund. We believe that Mr. Jankowski’s long-term and intimate experience with Nanophase operations, the markets in which it competes, along with his financial and management expertise, makes him a valuable member of our Board of Directors.

 

 Meetings of the Board and Committees During the year ended December 31, 2021, the Board of Directors (“BOD”) held eleven meetings.  All directors attended all meetings of the BOD and related committee meetings in 2021.

 

Committees of the Board of Directors -- The Board of Directors has established an Audit and Finance Committee, Compensation Committee and Nominating and Corporate Governance Committee. Each operates in accordance with its charter (available on our website www.nanophase.com under the “Investor Relations” section). The current members of the Audit and Finance Committee are Ms. Whitmore (Chair), Ms. Beres, and Dr. Siegel The members of the Compensation Committee are Ms. Whitmore (Chair), Ms. Beres, and Dr. Siegel. The members of the Nominating and Corporate Governance Committee are Ms. Whitmore (Chair), Ms. Beres, and Dr. Siegel.

 

The Audit and Finance Committee generally has responsibility for retaining the Company’s independent public auditors, reviewing the plan and scope of the accountants’ annual audit, reviewing the Company’s internal control functions and financial management policies, reviewing and approving all related party transactions, and reporting to the Board of Directors regarding all of the foregoing. The Audit and Finance Committee held six meetings during 2021. The Board of Directors has determined that Ms. Whitmore is an “audit committee financial expert” as described in applicable SEC rules.   The Board of Directors has not determined affirmatively that Ms. Whitmore is independent under the Nasdaq Stock Market rules, but such rules are inapplicable to the Company because the Company is no longer listed on Nasdaq.

 

The Compensation Committee generally has responsibility for establishing executive officer and key employee compensation, reviewing, and establishing the Company’s executive compensation, evaluating our Outside Director compensation, and reporting to the Board of Directors regarding the foregoing. The Compensation Committee also has responsibility for administering the 2019 Equity Compensation Plan (the “2019 Equity Plan”), determining the number of options, if any, to be granted to the Company’s employees and consultants pursuant to the 2019 Equity Plan, and reporting to the Board of Directors regarding the foregoing. Regarding most compensation matters, including executive compensation, our management provides recommendations to the Compensation Committee; however, the Compensation Committee does not delegate any of its functions to others in setting compensation. The Compensation Committee does not currently utilize external consultants in executive or director compensation matters. The Compensation Committee held four meetings during 2021. Each member of the Compensation Committee is a “non-employee director” as defined in Rule 16b-3 under the Exchange Act and is an “Outside Director” as defined by the regulations under Section 162(m) of the Internal Revenue Code.

 

The Nominating and Corporate Governance Committee generally has responsibility for evaluating and nominating candidates to serve on the Board of Directors, and for establishing and reviewing our Corporate Governance Principles. The Nominating and Corporate Governance Committee held two meetings during 2021.

 

The Board of Directors considers its role in risk oversight to focus primarily on evaluating risk at the entity and strategic levels, with management primarily responsible for managing day-to-day risk factors and presenting summary materials for those positions to the Board of Directors. Consistent with this philosophy, the Board of Directors has no formal policy as to whether the roles of Chief Executive Officer and board Chair should be segregated or combined. The Board of Directors considers the circumstances of the Company and makes a determination as to the appropriate leadership structure for the Company at that time. As of the time of this filing, the positions of CEO and Board Chair are held by two individuals – Ms. Whitmore serves as Chair and Mr. Jankowski serves as CEO. Ms. Whitmore brings extensive experience in corporate leadership from her own working experience and from a number of boards on which she has served in the past, and Mr. Jankowski is expected to benefit from that experience. The Board of Directors believes this to be the most appropriate structure for the Company at this time. Under our Corporate Governance Principles, in the event that the Chair of the Board is not an Outside Director, the Board will elect a lead independent director, who will have the responsibility to schedule and prepare agendas for meetings of the Outside Directors, communicate with the CEO, disseminate information to the rest of the Board and raise issues with management on behalf of the Outside Directors when appropriate. The Board evaluates its leadership structure on an ongoing basis and may change it as circumstances warrant.

 

18

 

 

The Board of Directors does not have a stated policy regarding diversity, although pursuant to our Corporate Governance Principles, diversity is one factor that the Nominating and Corporate Governance Committee considers when recommending directors for stockholder approval. The Board seeks experienced individuals for service who bring extensive experience in leadership, operations, finance, and engineering, particularly in areas directly applicable to the Company or its intended future endeavors.

 

EXECUTIVE OFFICERS

 

Set forth below is certain information regarding the executive officers of the Company as of the date of this Form 10-K who are not identified above as directors.

 

Name   Age   Position
Kevin Cureton   60   Chief Operating Officer

 

Mr. Cureton joined the Company in November 2012 as Vice President of Sales, Marketing and Business Development. Effective January 1, 2018, Mr. Cureton was named Chief Commercial Officer, and became the Company’s Chief Operating Officer in December 2019. His chemical industry experience has spanned more than twenty years, the majority of which has been in the personal care industry, including twelve years at AMCOL International Corporation, where he served as the founder and Managing Director of its skin care and dermatology technology business. Prior to AMCOL, he made significant contributions at Air Products, Borden, and other entities. Mr. Cureton holds a Bachelor of Science in chemical engineering from Carnegie Mellon University and an M.B.A. from the University of Chicago Booth School of Business.

 

The Board of Directors elects executive officers and such executive officers, subject to the terms of their employment agreements, serve at the discretion of the Board of Directors. Messrs. Jankowski and Cureton each have employment agreements with the Company. See Item 11 below. There are no family relationships among any of the directors or officers of the Company.

 

CODE OF ETHICS

 

We have adopted a Code of Business Conduct and Ethics (“Code of Ethics”) that applies to, among others, our principal executive officer, principal financial officer and principal accounting officer or controller, or persons performing similar functions. The Code of Ethics is posted on our Internet website www.nanophase.com under the “Investor Relations” section. In the event that we make any amendment to, or grant any waiver from, a provision of the Code of Ethics that requires disclosure under applicable SEC rules, we intend to disclose such amendment or waiver on our website. 

 

 Item 11. Executive Compensation

 

SUMMARY COMPENSATION TABLE

 

The following table sets forth a summary of the compensation for each of our named executive officers in U.S. dollars for the years ended December 31, 2021 and 2020.

 

Name and Principal Position   Year     Salary
($)		     Bonus
($) (1)		     Option
Awards
($) (2)		     Non-Equity
Incentive Plan Compensation
($) (3)		     All
Other Compensation
($) (4)		     Total
($)		  
Jess Jankowski     2021     $ 319,410     $ —     $ 234,580     $ —     $ 30,321     $ 584,311  
Chief Executive Officer     2020     $ 319,250     $ 79,813     $ 24,876     $ —     $ 18,147     $ 442,086  
Kevin Cureton     2021     $ 269,325     $ —     $ 234,580     $ —     $ 20,109     $ 524,014  
Chief Operating Officer     2020     $ 247,500     $ 60,750     $ 24,876     $ —     $ 11,846     $ 344,972  

 

(1) Any amounts earned during 2021 and 2020 would typically have been paid in early-to-mid 2022 and 2021, respectively. Bonus compensation is driven by Company performance against its goals as ultimately determined by the Compensation Committee of the Board of Directors (“Compensation Committee”). A set of Company-level objectives is created at the beginning of the year, focusing on total revenue, revenue growth, particular sources of revenue growth, business development achievements, cash flows and related targets, as well as a small discretionary component designed to capture items not specifically listed. Each measure has varying levels of achievement, which is reflected in the aggregate bonus measurement. The resulting bonus calculation is then applied to each individual’s bonus potential as a percentage of salary. Management met a number of its performance milestones in 2021, which will be fully evaluated by the Compensation Committee and paid, to whatever extent is deemed appropriate, during the second quarter of 2022.    Although the Solésence business achieved many critical milestones in 2020, the Compensation Committee felt that 2020 performance goals could not be judged properly until first quarter 2021 performance was complete.  The bonuses for 2020 performance were paid during the second quarter of 2021.

 

19

 

 

(2) The amounts in this column represent the aggregate grant date fair value of awards granted in 2021 and 2020 in accordance with FASB ASC Topic 718. See Note 11 of the notes to our financial statements contained elsewhere in this Form 10-K for a discussion of all assumptions made by us in determining the FASB ASC Topic 718 values.
(3) None.
(4) The amounts in this column represent 401(k) match (total for executive officers of $15,242 during 2021 and $4,305 during 2020), and the value of the Company portion of the health and life insurance. Health insurance benefits are the same for all employees. Life insurance is provided to all employees in the amount of the employee’s annual base salary, capped at a maximum of $150,000.
   

Employment Agreements

 

Effective as of August 12, 2009, we entered into an employment agreement with Jess Jankowski in connection with his services as President and Chief Executive Officer. No term has been assigned to Mr. Jankowski’s employment agreement.

 

Pursuant to the terms of his employment agreement, Mr. Jankowski will receive an annual base salary of not less than $275,000. In addition, Mr. Jankowski will be eligible for discretionary bonuses for services to be performed as an executive officer of the Company based on performance and achieving milestones approved by our Board of Directors (the “Board”).

 

Mr. Jankowski will be eligible for such stock options and other equity compensation as the Board deems appropriate, subject to the provisions of the 2019 Equity Compensation Plan. Mr. Jankowski will also be entitled to the employee benefits made available by us generally to all of our other executive officers, subject to the terms and conditions of our employee benefit plan in effect from time to time.

 

In the event Mr. Jankowski’s employment is terminated other than for “cause” (as such term is defined in the employment agreement), Mr. Jankowski will receive a sum equal to Mr. Jankowski’s base salary in effect at the time of termination for 52 full weeks after the effective date of termination, payable in proportionate amounts on our regular pay cycle for professional employees, provided that Mr. Jankowski signs, without subsequent revocation, a separation agreement and release in a form acceptable to us. In addition, all stock options granted to Mr. Jankowski prior to termination will become fully vested and exercisable in accordance with the applicable option grant agreement and the 2019 Equity Compensation. If he is terminated for cause, or if he resigns as an employee of the Company, Mr. Jankowski will not be entitled to any severance or other benefits accruing after the term of the employment agreement and such rights will be forfeited immediately upon the end of such term.

 

If, within two years after the occurrence of a change in control, as defined in his employment agreement, Mr. Jankowski’s employment is terminated other than for cause, his responsibilities or annual compensation are materially reduced without his prior consent, or we cease to be publicly held (each, a “Trigger”), then, subject to Mr. Jankowski signing, without subsequently revoking, a separation agreement and release in a form acceptable to us, Mr. Jankowski will receive a sum equal to his base salary for 104 full weeks after the date the Trigger occurs. In addition, all stock options granted to Mr. Jankowski prior to the Trigger will become fully vested and exercisable in accordance with the applicable option grant agreement and the 2019 Equity Compensation Plan. 

 

 Effective as of November 28, 2012, we entered into an employment agreement with Mr. Kevin Cureton providing for an annual base salary of not less than $190,000. No term has been assigned to Mr. Cureton’s employment agreement. If Mr. Cureton is terminated other than for “cause” (as such term is defined in Mr. Cureton’s employment agreement), then, subject to Mr. Cureton signing, without revoking, a separation agreement and release in a form acceptable to us, Mr. Cureton will receive severance benefits in an amount equal to Mr. Cureton’s base salary for 26 weeks. In addition, all stock options granted to Mr. Cureton prior to termination will become fully vested and exercisable in connection with the applicable option grant agreement and the 2019 Equity Compensation Plan. A signing bonus of $25,000 was paid upon Mr. Cureton’s acceptance of employment.

 

20

 

OUTSTANDING EQUITY AWARDS AT FISCAL YEAR-END

 

The following table sets forth information regarding each unexercised option held by each of our named executive officers as of December 31, 2021.

 

    Option Awards      Stock Awards  
Name   Number of Securities Underlying Unexercised Options (#) Exercisable     Number of Securities Underlying Unexercised Options (#) Unexercisable     Option Exercise Price ($)     Option Expiration Date     Number
of Shares of
Stock
That Have
Not
Vested
(#)		     Market Value of Shares of Stock That Have Not Vested ($)  
Jess Jankowski                                      
    98,000     -0-     $ 0.30     08/07/22              
    90,000     -0-     $ 0.42     02/14/23              
    90,000     -0-     $ 0.52     02/13/24              
    81,000     -0-     $ 0.44     02/18/25              
    69,000     -0-     $ 0.42     02/23/26              
    81,000     -0-     $ 0.68     02/21/27              
    90,000     -0-     $ 0.82     05/23/28              
    11,000     5,500 (1)    $ 0.51     05/22/29              
    30,000     60,000 (2)    $ 0.45     06/18/27              
    -0-     90,000 (3)    $ 4.17     12/28/28     —     —  
Kevin Cureton                                      
    25,000     -0-     $ 0.52     02/13/24              
    50,000     -0-     $ 0.44     02/18/25              
    43,500     -0-     $ 0.42     02/23/26              
    50,000     -0-     $ 0.68     02/21/27              
    80,000     -0-     $ 0.82     05/23/28              
    11,000     5,500 (1)    $ 0.51     05/22/29              
    30,000     60,000 (2)    $ 0.45     06/18/27              
    -0-     90,000 (3)    $ 4.17     12/28/28     —     —  

 

(1)These grants expiring May 22, 2029 vest in three equal installments on May 22, 2020, 2021, and 2022.
(2)These grants expiring June 18, 2027 vest in three equal installments on June 18, 2021, 2022, and 2023.
(3)These grants expiring December 28, 2028 vest in three equal installments on December 28, 2022, 2023, and 2024.

 

POTENTIAL PAYMENT UPON TERMINATION OR CHANGE IN CONTROL

 

Severance Benefits. Please see discussion of severance benefits under “Employment Agreements” above.

 

Change in Control. Upon a change in control, the 2019 Equity Compensation Plan provides that: (1) vesting under all outstanding stock options will automatically accelerate and each option will become fully exercisable; (2) the restrictions and conditions on all outstanding restricted shares shall immediately lapse; and (3) the holders of performance shares will receive a payment in settlement of the performance shares, in an amount determined by the Compensation Committee, based on the target payment for the performance period and the portion of the performance period that precedes the change in control. If the Company is not the surviving entity, the successor is required to assume all unexercised options.

 

21

 

Payments. The following table quantifies the estimated payments that would be made in each covered circumstance to the following named executive officers:

 

 Name   Termination By Company Without
Cause (1)(4)		     Change In
Control (2)(4)		     Involuntary
Termination In Connection With
or
Following a
Change In
Control (3)(4)		  
Jess Jankowski   $ 319,250     $ 279,095     $ 917,595  
Kevin Cureton   $ 135,000     $ 279,095     $ 414,095  

 

  (1) This amount represents the severance benefits that would be received under the executive officer’s employment agreement as described had the executive officer been terminated by the Company without cause on December 31, 2021, including the value of any stock options that would have accelerated vesting in connection with such termination.

 

  (2) This amount represents an estimate of the value that would have been received under the 2019 Equity Compensation Plan had a change in control occurred as of December 31, 2021, and the executive officers benefited from an acceleration of vesting in the 2019 Equity Compensation Plan awards, as described above.

 

  (3)

This amount represents an estimate of the payments and value (including acceleration of vesting of equity-based awards) that would have been received by the executive officers had the executive officers been terminated by the Company without cause on December 31, 2021 in connection with a change in control on this date.

 

 

 

 (4) In all three columns, for purposes of calculating the value of the acceleration of vesting of equity-based awards relating to a change in control on December 31, 2021, the closing price of our common stock as of December 31, 2021, was used. The amount represents the difference between the exercise price of any unvested options and $4.40.

 

DIRECTOR COMPENSATION

 

Upon first being elected to the Board of Directors, each director of the Company who is not an employee or consultant of the Company (an “Outside Director”) is granted stock options to purchase shares of common stock at the closing price as of the date of issuance (the fair market value). This initial option grant to an Outside Director typically vests over three years, though may accelerate upon termination from the Board of Directors.

 

In 2021, we paid quarterly compensation to the Chairman of the Board of Directors, for an annual total of $24,000. Our other three Outside Directors, Ms. Beres, Dr. Siegel, and Mr. Vincent were each paid quarterly compensation for an annual total of $18,000. This compensation was made solely for services performed by each in their capacities as directors. Dr. Siegel also served on a Scientific Advisory Board, with two other non-employee scientists, for which he was paid $4,500 in 2021. These meetings are held on an ad-hoc basis and remuneration is currently made to all three non-employee members at $1,000 per meeting attended.

 

During the fourth quarter of 2021, we granted our then Outside Directors stock options totaling 50,000 shares under the 2019 Equity Plan, as follows: the Chairman of the Board of Directors received stock options to purchase 20,000 shares of our common stock, while the other two of the then Outside Directors received stock options to purchase 15,000 shares of our common stock. Our current Outside Directors had the following shares of our common stock underlying stock options (both vested and unvested) outstanding as of December 31, 2021: Ms. Whitmore: 131,100 shares; Ms. Beres 25,000 shares; and Dr. Siegel: 121,100 shares.

 

In 2005, we adopted, and our stockholders approved, the 2005 Non-Employee Director Restricted Stock Plan (the “Director Restricted Stock Plan”) which reserved 150,000 shares of our common stock to be issued to Outside Directors in the form of restricted shares. In 2005, no awards were made under the Director Restricted Stock Plan. In 2005, we also adopted the Non-Employee Director Deferred Compensation Plan (the “Director Deferred Compensation Plan”) which permits an Outside Director to defer the receipt of director fees until separation from service or the Company undergoes a change in control. We amended the Director Restricted Stock Plan in 2005 to permit an Outside Director to defer receipt of restricted stock granted under it. The deferred restricted shares are accounted for under the Director Deferred Compensation Plan and issued upon separation from service or the Company’s change in control. Under the Director Deferred Compensation Plan, the deferred fees that would have been paid in cash are deemed invested in 5-year U.S. Treasury Bonds during the deferral period. The accumulated hypothetical earnings are paid following the Outside Director’s separation from service or the Company’s change in control. The deferred fees that would have been paid as restricted shares are deemed invested in our common stock during the deferral period. The Director Deferred Compensation Plan is an unfunded, nonqualified deferred compensation arrangement. In 2009, all Outside Directors elected to defer receipts of all of the restricted shares they became entitled to under the Director Restricted Stock Plan, which was consolidated into the 2010 Equity Plan. In November 2019, the 2010 Equity Plan was consolidated in to the 2019 Equity Compensation Plan.

 

22

 

All Outside Directors are reimbursed for their reasonable out-of-pocket expenses incurred in attending board and committee meetings. 

 

    2021 Outside Director Compensation  
Name    Fees Earned
or Paid in
Cash
($)		     Option Awards ($) (1)     Total ($)  
R. Janet Whitmore   $ 24,000     $ 52,129     $ 76,129  
Laura M. Beres   $ 18,000     $ 39,097     $ 57,097  
Dr. Richard Siegel   $ 18,000     $ 39,097     $ 57,097  
George A. Vincent III   $ 18,000     $ —     $ 18,000  

 

  (1) The amounts in this column represent the aggregate grant date fair value of awards granted in fiscal 2021 in accordance with FASB ASC Topic 718. See Note 11 of the notes to our financial statements contained elsewhere in this Form 10-K for a discussion of all assumptions made by us in determining the FASB ASC Topic 718 values.

 

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

 

SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLAN

 

The following table gives information about our common stock that may be issued upon the exercise of options and rights under our 2019 Equity Compensation Plan (the “2019 Equity Plan”) and our 2010 Equity Compensation Plan (the “2010 Equity Plan”) on December 31, 2021. The 2019 Equity Plan replaced the 2010 Equity Plan.

 

   (a)   (b)    (c) 
Plan Category   Number of securities to be issued upon exercise of outstanding options, warrants and rights    Weighted - average exercise price of outstanding options, warrants and rights   Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) 
Plans Approved by Shareholders   3,193,000   $1.18    1,888,000 
Plans Not Approved by Shareholders   None   $—    None 

  

SECURITY OWNERSHIP OF MANAGEMENT 

AND PRINCIPAL STOCKHOLDERS

 

The following table sets forth, as of March 31, 2022 certain information with respect to the beneficial ownership of our common stock by (1) each person known by us to own beneficially more than 5% of the outstanding shares of common stock, (2) each of our directors, (3) each of our named executive officers and (4) all of our named executive officers and directors as a group. There were 48,893,573 shares of common stock outstanding as of March 31, 2022.

 

Name   Number of
Shares
Beneficially Owned (1)		     Percent of
Shares Beneficially Owned 		 
Bradford T. Whitmore     30,278,154  (2)     61.93 %
R Janet Whitmore     1,564,821  (3)     3.19 %
Jess A. Jankowski     705,500  (4)     1.42 %
Richard W. Siegel, Ph.D.     485,938  (5)        *
Kevin Cureton     345,821  (6)        *
Beres, Laura M     3,333  (7)        *
All current executive officers and directors as a group (5 persons)     3,105,413  (8)     6.21 %

 

*Denotes beneficial ownership of less than one percent.

 

23

 

Unless otherwise indicated below, the person’s address is the same as the address for the Company.

 

  (1) Beneficial ownership is determined in accordance with the rules of the SEC. Unless otherwise indicated below, the persons in the above table have sole voting and investment power with respect to all shares of common stock shown as beneficially owned by them.

 

  (2) Includes 601,410 shares of common stock held by Grace Investments, Ltd., 7,731,573 shares held by Strandler, LLC, and 21,893,717 shares held by Bradford T. Whitmore, as well as 51,454 shares held by his daughter.  Mr. Whitmore is a general partner of Grace Investments, Ltd.,and manager of Strandler, LLC.  In such capacities, Mr. Whitmore shares voting and investment power with respect to the shares of common stock held by the Grace Investments, Ltd., and Strandler, LLC.  This information is based on information reported on a Form 4 filed on December 23, 2021 with the SEC. The address of the stockholder is 1603 Orrington Avenue, Suite 900, Evanston, Illinois 60201.

   

  (3) Includes Ms. Whitmore’s 97,766 shares of common stock issuable upon exercise of options exercisable currently or within 60 days of March 31, 2022.

 

  (4) Includes Mr. Jankowski’s 645,500 shares of common stock issuable upon exercise of options exercisable currently or within 60 days of March 31, 2022, as well as 1,000 shares held by his spouse.

 

  (5) Includes Dr. Siegel’s 96,100 shares of common stock issuable upon exercise of options exercisable currently or within 60 days of March 31, 2022.  

 

  (6) Includes Mr. Cureton’s 295,000 shares of common stock issuable upon exercise of options exercisable currently or within 60 days of March 31, 2022.

 

  (7) Includes Ms. Beres’ 3,333 shares of common stock issuable upon exercise of options exercisable currently or within 60 days of March 31, 2022.

 

  (8) Includes all current executive officers and directors as a group’s 1,137,699 shares of common stock issuable upon exercise of options exercisable currently or within 60 days of March 31, 2022.

 

Item 13. Certain Relationships and Related Transactions, and Director Independence

 

We have engaged in a series of debt transactions with Bradford T. Whitmore since January 1, 2020. One of these was for debt with a conversion provision that resulted in the issuance of common shares in May, 2021. Together with his affiliates Grace Brothers, Ltd., Grace Investments, Ltd. and Strandler, LLC, Mr. Whitmore beneficially owned approximately 62% of the outstanding shares of our common stock as of March 31, 2022. Mr. Whitmore is the brother of R. Janet Whitmore, who has been the Chair of the Board of Directors since November 19, 2019 and one of our directors since 2003, and who is also a stockholder. Through his affiliate Beachcorp, LLC, Mr. Whitmore is also a substantial lender to the Company under the Business Loan Agreement, dated November 16, 2018 (see Note 3 to our financial statements included in this Annual Report on Form 10-K).

 

On November 13, 2019, we entered into a Securities Purchase Agreement (the “SPA”) with Mr. Whitmore pursuant to which he agreed to purchase a Convertible Note (see below) from the Company for $2,000,000 and otherwise including representations, warranties and covenants which are customary for similar transactions. The transactions contemplated by the SPA closed on November 20, 2019. At the closing of the SPA on November 20, 2019, the Company sold to Mr. Whitmore, and Mr. Whitmore purchased from the Company, a 2% Secured Convertible Promissory Note in the original principal amount of $2,000,000 (the “Convertible Note”), the principal amount of which is payable to the order of Mr. Whitmore and his registered assigns and successors in a single payment on May 15, 2024 (the “Maturity Date”). The principal amount of the Convertible Note accrues interest at the rate of 2.0% per year, which interest is payable semi-annually on the 15th day of May and November, commencing on May 15, 2020. The principal amount and, at the holder’s option, accrued interest under the Convertible Note is convertible at the holder’s option into additional shares of the Company’s common stock in whole or in part and from time to time up to the Maturity Date at a conversion price of $0.20 per share. The obligations under the Convertible Note were secured by a security interest in all of the Company’s personal property pursuant to a Commercial Security Agreement among Mr. Whitmore, the Company and Solésence, LLC, the Company’s sole subsidiary. The SPA also amended the Common Stock Purchase Agreement, dated May 13, 2019, between the Company and Mr. Whitmore to add the shares of common stock issuable upon conversion of the Convertible Note to the registration rights granted therein. Mr. Whitmore chose to exercise his conversion rights effective May 7, 2021, requesting that any accrued interest be paid him in the form of shares. In addition to the 10,000,000 shares issued upon conversion, the Company issued 95,555 shares of additional stock to Mr. Whitmore in lieu of cash for the $19,000 in accrued interest owed at May 7, 2021.

 

24

 

 Director Independence. The Board of Directors has determined that the following Company directors are “independent” as that term is defined in the rules and regulations of the SEC and the Nasdaq Stock Market: Ms. Beres and Dr. Siegel. Though we are no longer listed on Nasdaq, our Board of Directors used the Nasdaq listing standards in making its independence determinations. Under the Nasdaq Stock Market rules, the Company would qualify as a “controlled company” because of the direct and indirect ownership of Bradford T. Whitmore. As a controlled company, the Company would be exempt from the requirements under those rules to have a majority of independent directors, to have an independent compensation committee, or to have independent director oversight of director nominations.

 

The Board of Directors has established an Audit and Finance Committee, Compensation Committee and Nominating and Corporate Governance Committee (the “Standing Committees”). Ms. Whitmore, Ms. Beres, and Dr. Siegel are members of the Standing Committees, and Ms. Whitmore serves as Chair of each committee.

 

Item 14. Principal Accounting Fees and Services

 

Audit Fees. The aggregate amount billed by our principal accountant, RSM US LLP (“RSM”), for audit services performed for the fiscal years ended December 31, 2021 and 2020 was approximately $253,000 and $169,000, respectively. Audit services include the auditing of financial statements and quarterly reviews.

 

 Audit Related Fees. There were $13,000 and $0 in audit related fees billed by RSM for the years ended December 31, 2021 and 2020, respectively, which may include costs incurred for reviews of registration statements, assistance with Staff comment letters, and consultation on various accounting matters in support of our financial statements.

 

Our independent registered public accounting firm is RSM US LLP, Chicago, IL, Auditor ID: 49

 

 Tax Fees. There were no fees billed by our principal accountant for tax related services for the fiscal years ended December 31, 2021 and 2020.

 

All Other Fees. Other than those fees described above, during the fiscal years ended December 31, 2021 and 2020, there were no other fees billed for services performed by our principal accountant.

 

All of the fees described above were approved by our Audit and Finance Committee.

 

Audit and Finance Committee Pre-Approval Policies and Procedures. Our Audit and Finance Committee pre-approves the audit and non-audit services performed by RSM, our principal accountants, in order to assure that the provision of such services does not impair RSM’s independence. Unless a type of service to be provided by RSM has received general pre-approval, it will require specific pre-approval by the Audit and Finance Committee. In addition, any proposed services exceeding pre-approval cost levels or budgeted amounts will require specific pre-approval by the Audit and Finance Committee.

 

The term of any pre-approval is 12 months from the date of pre-approval, unless the Audit and Finance Committee specifically provides for a different period. The Audit and Finance Committee will periodically revise the list of pre-approved services, based on subsequent determinations, and has delegated pre-approval authority to the Chairman of the Audit and Finance Committee. In the event the Chairman exercises such delegated authority, he shall report such pre-approval decisions to the Audit and Finance Committee at its next scheduled meeting. The Audit and Finance Committee does not delegate its responsibilities to pre-approve services performed by the independent auditor to management.

 

25

 

PART IV

 

Item 15. Exhibits and Financial Statement Schedules

 

(a) The following documents are filed as part of this Form 10-K:

 

  1. The following financial statements of the Company, with the report of independent registered public accounting firm, are filed as part of this Form 10-K:

 

Report of Independent Registered Public Accounting Firm
Consolidated Balance Sheets as of December 31, 2021 and 2020
Consolidated Statements of Operations for the Years Ended December 31, 2021 and 2020
Consolidated Statements of Stockholders’ Equity for the Years Ended December 31, 2021 and 2020
Consolidated Statements of Cash Flows for the Years Ended December 31, 2021 and 2020

 

Notes to Consolidated Financial Statements

 

  2. A list of exhibits required to be filed as part of this Form 10-K is set forth in the Exhibit Index beginning on page E-1 of this Form 10-K, and is incorporated herein by reference.


 

Item 16. Form 10-K Summary

 

NONE. 

 

26

 

 NANOPHASE TECHNOLOGIES CORPORATION

 

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

 

  Page
   
Report of Independent Registered Public Accounting Firm F-2
   
Consolidated Balance Sheets as of December 31, 2021 and 2020 F-4
   
Consolidated Statements of Operations for the years ended December 31, 2021 and 2020 F-5
   
Consolidated Statements of Stockholders’ Equity for the years ended December 31, 2021 and 2020 F-6
   
Consolidated Statements of Cash Flows for the years ended December 31, 2021 and 2020 F-7
   
Notes to the Consolidated Financial Statements F-8

  

F-1

 

 

Report of Independent Registered Public Accounting Firm

 

 

Shareholders and the Board of Directors

Nanophase Technologies Corporation

 

 

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Nanophase Technologies Corporation (the Company) as of December 31, 2021 and 2020, the related consolidated statements of operations, stockholders’ equity and cash flows for the years then ended, and the related notes to the consolidated financial statements (collectively, the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.

 

Basis for Opinion

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

Critical Audit Matter

The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of a critical audit matter does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing separate opinions on the critical audit matter or on the accounts or disclosures to which they relate.

 

F-1

 

Going Concern

The Company believes that cash from operations and cash on hand, in addition to unused borrowing capacity, will be adequate to fund operating plans and required debt repayments within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable), therefore there is not substantial doubt regarding the Company’s ability to continue as a going concern.

 

We identified the evaluation of the Company’s ability to continue as a going concern as a critical audit matter because of certain significant assumptions management makes when estimating future cash flows. These estimates are subject to significant estimation and execution uncertainty regarding the Company’s future cash flows and the risk of bias in management’s judgements and assumptions in estimating these cash flows. Auditing these assumptions involved a high degree of auditor judgment and an increase in audit effort due to the impact of these assumptions on the determination of the degree of doubt regarding the ability of the entity to continue as a going concern.

 

Our audit procedures related to testing management’s assessment of the ability of the Company to continue as a going concern included the following, among others:

 

·We evaluated the forecasted revenues and operating expenses, as well as management’s assumptions related to sources and uses of cash for reasonableness. This testing included:

 

oEvaluating the impact of the Company’s existing financing arrangements on their ability to continue as a going concern, including inspecting amendments to financing arrangements subsequent to December 31, 2021, but prior to the issuance of the financial statements.
oDeveloping an understanding of management’s expectations for future changes in revenue and expenses through discussions with management and review of budgets.
oComparing forecasted revenues and expenses to historical results.

 

·We evaluated that the disclosures included in the Form 10-K were complete and accurate and in accordance with generally accepted accounting principles in the United States of America.

 

 

 

/s/ RSM US LLP

Firm id: 49

We have served as the Company’s auditor since 2001.

 

Chicago, Illinois

March 31, 2022

 

F-2

 

 

NANOPHASE TECHNOLOGIES CORPORATION

 

CONSOLIDATED BALANCE SHEETS

 

             
   As of December 31, 
   2021   2020 
   (in thousands except share and
per share data)		 
ASSETS        
Current assets:          
Cash  $657   $957 
Trade accounts receivable, less allowance for doubtful accounts of $60 for December 31, 2021, and $9 for 2020   3,937    2,932 
Inventories, net   6,095    4,340 
Prepaid expenses and other current assets   910    606 
Total current assets   11,599    8,835 
           
Equipment and leasehold improvements, net   4,712    2,868 
Operating leases, right of use   12,075    1,827 
Other assets, net   8    10 
 Total Current Assets  $28,394   $13,540 
LIABILITIES AND STOCKHOLDERS’ EQUITY          
           
Current liabilities:          
Line of credit, bank  $—   $500 
Line of credit, related party   1,351    2,155 
Current portion of long-term debt, related party   —    500 
Current portion of finance lease obligations   105    177 
Current portion of operating lease obligations   1,983    431 
Accounts payable   3,566    2,126 
Current portion of deferred revenue   783    411 
Accrued expenses   946    484 
Total current liabilities   8,734    6,784 
           
Long-term portion of finance lease obligations   6    110 
Long-term portion of operating lease obligations   10,306    1,651 
Long-term debt, related party   1,000    — 
Long-term convertible loan, related party   —    1,097 
PPP Loan (SBA)   —    952 
Long-term portion of deferred revenue   661    — 
Asset retirement obligations   222    214 
Total long-term liabilities   12,195    4,024 
           
Contingent liabilities   —    — 
Stockholders’ equity:          
Preferred stock, $.01 par value, 24,088 shares authorized, and no shares issued and outstanding   —    — 
Common stock, $.01 par value, 55,000,000 shares authorized; 48,893,573 and 38,221,292 shares issued and outstanding on December 31, 2021 and December 31, 2020, respectively   489    382 
Additional paid-in capital   104,423    102,117 
Accumulated deficit   (97,447)   (99,767)
Total stockholders’ equity   7,465    2,732 
Total liabilities and shareholder’s equity  $28,394   $13,540 

 

(See accompanying Notes to Consolidated Financial Statements)

 

F-3

 

 

NANOPHASE TECHNOLOGIES CORPORATION

 

CONSOLIDATED STATEMENTS OF OPERATIONS

 

             
   Years ended December 31, 
   2021   2020 
   (in thousands except share and
per share data)		 
Revenue:        
Product revenue  $29,325   $16,422 
Other revenue   150    701 
Total revenue   29,475    17,123 
           
Operating expense:          
Cost of revenue   20,785    11,133 
Gross profit   8,690    5,990 
           
Research and development expense   2,235    1,571 
Selling, general and administrative expense   3,896    2,934 
Income from operations   2,559    1,485 
Interest expense   (1,154)   (496)
Other income, net   952    — 
Income before provision for income taxes   2,357    989 
Provision for income taxes   37    — 
           
Net income  $2,320   $989 
           
Net income per share-basic  $0.05   $0.03 
           
Weighted average number of basic common shares outstanding   45,021,173    38,158,586 
           
Net income per share-diluted  $0.05   $0.03 
           
Weighted average number of diluted common shares outstanding   47,039,173    38,545,586 

 

(See accompanying Notes to Consolidated Financial Statements)

 

F-4

 

 

NANOPHASE TECHNOLOGIES CORPORATION

 

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY 

 (in thousands except share data)

 

                                     
   Preferred Stock   Common Stock   Additional         
                   Paid-in   Accumulated     
Description  Shares   Amount   Shares   Amount   Capital   Deficit   Total 
Balance on December 31, 2019   —   $—    38,136,792   $381   $101,886   $(100,756)  $1,511 
Stock option exercises   —    —    84,500   $1    36    —    37 
Stock-based compensation   —    —    —    —    195    —    195 
Net income for the year ended   December 31, 2020   —    —    —    —    —    989    989 
Balance on December 31, 2020   —   $—    38,221,292   $382   $102,117   $(99,767)  $2,732 
Issuances of shares and stock option exercises   —    —    576,726   $6   $228    —    234 
Exercise of conversion rights – convertible loan, related party   —    —    10,095,555    101    1,918    —    2,019 
Stock-based compensation   —    —    —    —    160    —    160 
Net income for the year ended December 31, 2021   —    —    —    —    —    2,320    2,320 
Balance on December 31, 2021   —   $—    48,893,573   $489   $104,423   $(97,447)  $7,465 

 

 

(See accompanying Notes to Consolidated Financial Statements)

 

F-5

 

 

 NANOPHASE TECHNOLOGIES CORPORATION

 

CONSOLIDATED STATEMENTS OF CASH FLOWS

 

             
   Years ended December 31, 
   2021   2020 
   (in thousands) 
Operating activities:          
Net Income  $2,320   $989 
Adjustments to reconcile net income to cash provided by (used in) operating activities:          
Depreciation and amortization   454    358 
Gain on forgiveness of PPP loan   (952)   — 
Amortization of debt discount   903    267 
Share-based compensation   160    195 
Changes in assets and liabilities related to operations:          
Trade accounts receivable   (1,005)   (1,962)
Inventories   (1,755)   (1,786)
Prepaid expenses and other assets   (304)   (339)
Accounts payable   1,026    295 
Deferred Revenue   1,033    (164)
Accrued expenses   481    113 
Other long-term assets and liabilities   (40)   (27)
Net cash used in operating activities   2,321    (2,061)
           
Investing activities:          
Acquisition of equipment and leasehold improvements   (1,874)   (878)
Net cash used in investing activities   (1,874)   (878)
           
Financing activities:          
Principal payment on finance leases   (177)   (218)
Proceeds from line of credit, bank   500    2,000 
Payments to the line of credit, bank   (1,000)   (2,000)
Proceeds from PPP / SBA loan   —    952 
Proceeds from line of credit, Beachcorp LLC   24,750    14,515 
Payments to line of credit, Beachcorp LLC   (25,554)   (12,584)
Proceeds from related party term loan   500    — 
Proceeds from exercise of stock options   234    37 
Net cash (used in) provided by financing activities   (747)   2,702 
Decrease in cash   (300)   (237)
Cash at beginning of period   957    1,194 
Cash at end of period  $657   $957 
           
Supplemental cash flow information:          
Interest paid  $218   $178 
           
Supplemental non-cash investing and financing activities:          
Accounts payable incurred for the purchase of equipment and leasehold improvements  $414   $83 
Conversion of $2M convertible loan, related party   2,000    — 
Interest paid via stock issuance, convertible loan, related party   19    — 
Right of use asset acquired through operating lease   10,505    — 

 

(See accompanying Notes to Consolidated Financial Statements)

 

F-6

 

NANOPHASE TECHNOLOGIES CORPORATION

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

(In thousands, except share and per share data or as otherwise noted herein)

 

 

(1) Description of Business

 

Nanophase Technologies Corporation (“Nanophase,” “Company,” “we,” “our,” or “us”) is a science-driven company which, along with its wholly owned subsidiary, Solésence, LLC (our “Solésence beauty science subsidiary”), is focused in various beauty- and life-science markets.  Using consumer health as our end-goal and science and innovation to guide the path, skin health and medical diagnostics combined currently make up the great majority of our business and drive our forward growth strategy.  We offer engineered materials, formulation development and commercial manufacturing through an integrated family of technologies. Our expertise in materials engineering allows us to effectively coat and disperse particles on a nano and “non-nano” scale for use in a variety of skin health markets, including for use in sunscreens as active ingredients and as fully developed prestige skin care and cosmetics products, marketed and sold through our Solésence beauty science subsidiary.  In terms of our life sciences focus, we have seen current conditions significantly increase demand for our medical diagnostics ingredients, as testing for various viruses, most notably COVID-19, has become a critical use of our technology.  Additionally, we continue to sell products in legacy markets, including architectural coatings, industrial coating applications, abrasion-resistant additives, plastics additives, and surface finishing technologies (polishing) applications, all of which, along with medical diagnostics, fall into the advanced materials product category. 

 

 We target markets, primarily related to skin health products and ingredients, as well as diagnostic life sciences ingredients where we believe our materials and products offer practical and competitive minerals-based solutions. We traditionally work closely with current customers in these target markets to identify their material and performance requirements. We market our materials to various end-use applications manufacturers, and our Solésence® products to cosmetics and skin care brands.

 

Recently developed technologies have made certain new products possible and opened potential new markets. During 2015 we were granted a patent on a new type of particle surface treatment (coating) — now called Active Stress Defense ™ Technology — which became the cornerstone of our new product development in personal care, with first revenue recognized during 2016. Active Stress Defense™ now refers to a suite of three proprietary technologies — Original Active Stress Defense™, Kleair™, and Bloom™ — all three of which either utilize a unique and proprietary, mineral-based technology or work synergistically with one of our unique and proprietary, mineral-based technologies to improve performance and/or aesthetics. Our ongoing innovation efforts include new IP in areas that advance environmental protection, align with market needs, and complement our existing technologies Through the creation of our Solésence beauty science subsidiary, we utilize our technology suite to manufacture and sell fully developed solutions to targeted customers in the skin care industry, typically in prestige skin care and cosmetics markets, in addition to the ingredients we have traditionally sold in the personal care area. 

 

Although our primary strategic focus has been the North American market, we currently sell materials to customers overseas and have been working to expand our reach within foreign markets. Our common stock trades on the OTCQB marketplace under the symbol NANX. 

 

While product sales comprise the majority of our revenue, we also recognize revenue from other sources from time to time. These activities are not expected to drive the long-term growth of the business. For this reason, we classify such revenue as “other revenue” in our Consolidated Statements of Operations, as it does not represent revenue directly from the sale of our products. 

 

 The Company has recorded positive net income and positive cash flow from operations in 2021. We have also significantly improved our borrowing flexibility and capacity in early 2022, as discussed in Note 3. Based upon our financial performance, as well as our current liquidity and available borrowing capacity, there is not substantial doubt regarding the Company's ability to continue as a going concern.

 

 

(2) Summary of Significant Accounting Policies

 

Use of Estimates and Risks and Uncertainties

 

The preparation of financial statements requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. Certain assumptions are also necessary to assess the impact of risks and uncertainties on the financial statements, such as cash flow projections, availability of capital if needed to support the ongoing operations of the business, and our expected compliance with contractual commitments. These risks and uncertainties are further discussed in Note 12. Any changes in these assumptions or business plans could have a material impact on the financial statements.

 

F-7

 

 

Cash

 

The Cash balance on December 31, 2021 consists of funds borrowed from our Revolving Line of Credit, which is facilitated by Beachcorp, LLC. Our ability to access cash from our credit facility solely depends on carrying an Accounts Receivable balance greater than the outstanding loan balance in the Revolving Line of Credit. As part of the agreement, we are required to have a bank account in place to act as a depository account for our customers. This account is referred to as the Control Account. Furthermore, there is an Account Control Agreement in place which provides Beachcorp, LLC the ability to exercise control over the account via approval of requested transfers. According to our agreements with Beachcorp, LLC, Nanophase is to be the party initiating any transfers, whether to Nanophase or to Beachcorp, LLC, and approval to access any monies within this account can only be withheld by Beachcorp, LLC if the borrowing base falls below the Company’s qualified receivables, or if we are in arrears with respect to interest payments due Beachcorp, LLC. The failure of Nanophase to remedy the previously mentioned conditions could lead to Beachcorp, LLC gaining the right, through a “springing” feature administered by Libertyville Bank and Trust, a Wintrust Community Bank (“Libertyville”), to transfer funds to itself without direct approval from Nanophase.  Cash is held at a federally insured institution, but our cash balances at times exceed insured limits. The Company has not experienced any losses related to these statutory limits.

 

 Trade Accounts Receivable

 

Trade accounts receivable are carried at original invoice amount less an estimate made for doubtful receivables based on a review of all outstanding amounts on a monthly basis. We determine the allowance for doubtful accounts by identifying troubled accounts and by using historical experience applied to an aging of accounts. Trade accounts receivable are written off when deemed uncollectible. Recoveries of trade accounts receivable previously written off are recorded when received. Our typical credit terms are between thirty and sixty days from shipment and invoicing.

 

Inventories

 

Inventories are stated at the lower of cost, maintained on an average cost basis, or net realizable value. We have recorded allowances to reduce inventory relating to excess quantities of certain materials. Write-downs of inventories establish a new cost basis, which is not increased for future increases in market value of inventories or changes in estimated excess quantities.

 

Equipment and Leasehold Improvements

 

Equipment is stated at cost and is being depreciated over its estimated useful life (3-20 years) using the straight-line method. Leasehold improvements are stated at cost and are being amortized using the straight-line method over the shorter of the useful life of the asset or the term of the lease (3-7 years). Depreciation expense for leased assets is included with depreciation expense for owned assets. From time to time we have self-constructed assets. These assets are stated at cost plus the capitalization of labor and are depreciated over an estimated useful life (7-10 years) using the straight-line method.

 

Long Lived Assets

 

We review long-lived assets for impairment whenever events or changes in circumstances indicate that the asset’s carrying amount may not be recoverable. We conduct long-lived asset impairment analyses in accordance with ASC 360-10-15, Impairment or Disposal of Long-Lived Assets. ASC 360-10-15 requires us to group assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities and evaluate the asset group against the sum of the undiscounted future cash flows. If the undiscounted cash flows do not indicate the carrying amount of the asset is recoverable, an impairment charge is measured as the amount by which the carrying amount of the asset group exceeds its fair value based on discounted cash flow analysis or appraisals. Based upon our analysis, there were no impairment charges recognized in either period presented.

 

Deferred Revenue

 

The Company records a contract liability for development projects due to the contractual billing of these projects not always aligning with revenue recognition. In addition, it is now the Company’s policy to frequently require deposits relating to the initial production of our Solésence products. Of the total $1,444 in deferred revenue reported in 2021, approximately 70% is comprised of prepayment received from our medical diagnostics application customer for purchase orders to be filled in 2022 and 2023, 25% related to prepayments received from new customers as per Company policy, and the remaining 5% related to prepayments from a product development agreement with a personal care ingredient customer.

 

F-8

 

 

Asset Retirement Obligations

 

In connection with our leased facilities, we are required to remove certain leasehold improvements upon termination of our occupancy. We follow the provisions of the FASB issued ASC 410-20, Asset Retirement Obligations, under which we recognize a liability for the fair value of these asset retirement obligations. The fair value of that liability is measured based on an expected cash flow approach and accretion expense is recognized each period to recognize increases to the fair value of the liability due to the passage of time. Increases to the fair value of the liability, except for accretion, are added to the carrying value of the long-lived asset. Those increases are then reported in amortization expense over the estimated useful life of the long-lived asset.

 

        Activity in the asset retirement obligation account for the years ended December 31, is as follows:

 

   2021   2020 
Balance, beginning  $214   $206 
Accretion of liability due to passage of time   8    8 
Amortization of asset due to passage of time   —    — 
Balance, ending  $222   $214 

 

 

Financial Instruments

 

We follow ASC Topic 820, Fair Value Measurements and Disclosures, which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. The fair value framework requires the categorization of assets and liabilities into three levels based upon the assumptions (inputs) used to price the assets or liabilities. Level 1 provides the most reliable measure of fair value, whereas Level 3 generally requires significant management judgment.

 

Our financial instruments include cash, any cash equivalents, accounts receivable, accounts payable and accrued expenses, along with any short term and long-term borrowings as described in Note 3. There were no financial instruments adjusted to fair value on December 31, 2021 and 2020.

 

Product Revenue

 

Revenues are recognized when control of the promised goods is transferred to customers, in an amount that reflects the consideration we expect to receive in exchange for those goods. When our ingredients and finished products are shipped, with control being transferred at the shipping point almost universally, is the point in time at which we recognize the related revenue.

 

We generally expense sales commissions when incurred because the amortization period would have been one year or less. These costs are recorded within selling, general and administrative expenses. Customers’ deposits, deferred revenue and other receipts are deferred and recognized when the revenue is realized and earned. Cash payments to customers are classified as reductions of revenue in our statements of operations.

 

Contract balances for the year 2021 and 2020

Contract balances for the year ended December 31, 2021 is as follows:

 

   Accounts
Receivable,
net		   Contract
Assets		   Contract
Liabilities		 
Balance, beginning  $2,932   $—   $411 
Balance, ending   3,937    —    1,444 

 

Contract balances for the year ended December 31, 2020 is as follows:

 

   Accounts
Receivable,
net		   Contract
Assets		   Contract
Liabilities		 
Balance, beginning  $970   $—   $575 
Balance, ending   2,932    —    411 

 

F-9

 

 

Revenue recognized in the reporting period that was included in the contract liability balance at the beginning of the period was $260 and $468 for the years ended December 31, 2021 and 2020, respectively.

 

Other Revenue

 

Other revenue may include revenue from technology license fees and paid development projects. Technology license fees and paid development projects are recognized over time when the obligations under the agreed upon contractual arrangements are performed on our part.  Revenue recognized over time was $150 and $701 for the years ended December 31, 2021 and 2020, respectively.

 

Research and Development Expenses

 

Research and development expenses are recognized as expense when incurred.

 

Income Taxes

 

We account for income taxes using the liability method. As such, deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Deferred tax assets and liabilities are calculated using the enacted tax rates and laws that are expected to be in effect when the anticipated reversal of these differences is scheduled to occur. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some or all of the deferred tax assets will not be realized.

 

When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured, as described above, is reflected as a liability for uncertain tax benefits in the accompanying balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination.

 

We have not recorded a reserve for any tax positions for which the ultimate deductibility is highly certain but for which there is uncertainty about the timing of such deductibility. We file tax returns in all appropriate jurisdictions, which includes a federal tax return and Illinois state tax return. When and if applicable, potential interest and penalty costs are accrued as incurred, with expenses recognized in selling, general and administrative expenses in the statements of operations. As of December 31, 2021, and 2020, we had no liability for unrecognized tax benefits.

 

Earnings Per Share

 

Options to purchase approximately 2,018,000 shares of common stock that were outstanding as of December 31, 2021 were included in the computation of earnings per share for the year ended December 31, 2021.  Options to purchase approximately 387,000 shares of common stock that were outstanding as of December 31, 2020 were included in the computation of earnings per share for the year ended December 31, 2020.

 

Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows:

 

               
   Years Ended December 31, 
   2021   2020 
Numerator: (in Thousands)        
Net income  $2,320   $989 
           
Denominator:          
Weighted average number of basic common shares outstanding   45,021,173    38,158,586 
Weighted average additional shares assuming conversion of in-the-money stock options to common shares   2,018,000    387,000 
Weighted average number of diluted common shares outstanding   47,039,173    38,545,586 
           

Basic earnings per common share:

          
Net income per share – basic  $0.05   $0.03 
Diluted earnings per common share:          
Net income per share – diluted  $0.05   $0.03 

 

 

F-10

 

 

New Accounting Pronouncements

 

 In June 2016, the FASB issued ASU 2016-13, “Measurement of Credit Losses on Financial Instruments,” which replaces existing incurred loss impairment guidance and establishes a single allowance framework for financial assets carried at amortized cost. The effective date for our adoption (as amended) of this updated Standard will be January 1, 2023. The Company is currently evaluating the impact of the adoption of this standard on the consolidated financial statements.

 

 

 

(3) Notes and Lines of Credit

 

Notes and lines of credit consist of the following:

 

         As of December 31, 
        2021   2020 
   Rate    Available   Outstanding
Balance		   Available   Outstanding
Balance		 
Libertyville Bank & Trust (1)    4.25%    $30   $—   $30   $— 
Libertyville Bank & Trust (2)   4.25%     n/a    n/a    500    500 
Libertyville Bank & Trust (2)   4.25%     500    —    n/a    n/a 
Beachcorp, LLC (3)   5.25%     3,467    1,351    2,776    2,155 
Beachcorp, LLC (3)   5.25%    $1,000   $1,000   $500   $500 
Secured convertible promissory note (4)   2.00%     —    —    2,000    1,097 
PPP Loan / Libertyville promissory note (5)   1.00%     —    —    952    952 
Beachcorp, LLC (6)   4.00%     n/a    n/a    n/a    n/a 
Beachcorp, LLC (7)   4.00%     n/a    n/a    n/a    n/a 
Strandler, LLC (8)   4.00%     n/a    n/a    n/a    n/a 

 

1)Since July 2014, we have maintained a bank-issued letter of credit for up to $30 in borrowings, with interest at the prime rate plus 1%, to support our obligations under our Romeoville, Illinois facility lease agreement. No borrowings have been incurred under this promissory note. It is our intention to renew this note annually. Because there were no amounts outstanding on the note at any time during 2021 or 2020, we have recorded no related liability on our balance sheet.

 

F-11

 

 

2)The Company maintains a credit agreement with Libertyville which most recently served the primary purpose of insuring that it met its cash balance requirements at quarter end relating to a contract with the Company’s largest customer. Outstanding borrowings were $500 on this line of credit as of December 31, 2020. Interest on drawn balances was at the prime rate plus 1%. On December 21, 2021, the existing credit agreement with Libertyville was converted for use to support our obligations under our newly leased manufacturing and warehouse space in Bolingbrook, Illinois. Interest on drawn balances will be at the prime rate plus 1%. This credit agreement has a maturity of December 22, 2022. We expect to renew this agreement annually, as the lease requires. This credit agreement is secured by all the unencumbered assets of the Company, and has superior collateral rights to those credit facilities with Beachcorp, LLC and Strandler, LLC.

 

3)On November 16, 2018, we entered into a Business Loan Agreement (the “Master Agreement”) with Beachcorp, LLC. The Master Agreement relates to two loan facilities, each evidenced by a separate promissory note dated as of November 16, 2018: a term loan to the Company of up to $500 to be disbursed in a single advance (the “Term Loan”) with a fixed annual interest rate of 8.25%, payable quarterly, and with principal due on December 31, 2020; and an asset-based revolving loan facility for the Company of up to $2,000 (the “A/R Revolver Facility”), with floating interest accruing at the prime rate plus 3% (8.25% minimum) per year, with a borrowing base consisting of qualified accounts receivable of the Company, and a maturity of March 31, 2020, as amended. On March 23, 2020, the Company and Beachcorp, LLC executed the First Amendment to our Master Agreement that extended the maturities of both the Term Loan and the A/R Revolver Facility to March 31, 2021. Effective September 8, 2020, the Company and Beachcorp, LLC executed the Second Amendment to our Master Agreement that expanded the limit on the A/R Revolver Facility from $2,000 to $2,750.  On December 23, 2020, the Company and Beachcorp, LLC executed the Third Amendment to our Master Agreement that expanded the limit on the A/R Revolver Facility from $2,750 to $4,000 and extended the maturities of both the Term Loan and the A/R Revolver Facility to March 31, 2022. Effective April 21, 2021 the Company and Beachcorp, LLC executed the Fourth Amendment to our Master Agreement that expanded the limit on the A/R Revolver Facility from $4,000 to $6,000, changed the interest rate to fully floating and reduced the rate to the prime rate plus 2%, also extending the maturity of the A/R Revolver Facility to March 31, 2023. This amendment also increased the amount of the Term Loan from $500 to $1,000, changed the interest rate to fully floating and reduced the rate to the prime rate plus 2%. The maturity of the Term Loan remained March 31, 2022. The Term Loan and A/R Revolver Facility are secured by all the unencumbered assets of the Company and subordinated to Libertyville’s secured interest under the New Business Loan Credit Agreement. The Master Agreement substantially restricts the Company’s ability to incur additional indebtedness during the terms of both the Term Loan and the A/R Revolver Facility.

 

4)On November 20, 2019, we entered into a 2% Secured Convertible Promissory Note with Bradford T. Whitmore in the principal amount of $2,000 (the “Convertible Note”). The principal amount was payable in a single payment on May 15, 2024 (the “Maturity Date”). The principal amount of the Convertible Note accrued interest at the rate of 2.0% per year, which interest was payable semi-annually on the 15th day of May and November, commencing on May 15, 2020. The principal amount and, at the holder’s option, accrued interest under the Convertible Note was convertible at the holder’s option into additional shares of the Company’s common stock in whole or in part and from time to time up to the Maturity Date at a conversion price of $0.20 per share. The convertible note contained a beneficial conversion feature since the Company’s stock was trading at $0.32 per share on the date the Company entered into the agreement. The intrinsic value of the beneficial conversion feature was $1.2 million on November 20, 2019 and was recorded as a discount on the convertible note. The discount was to be accreted to the convertible note over the life of the note using the straight-line method. The offset to these discounts was interest expense. The Company recognized amortized interest expense relating to this discount of $267 in 2020. Upon exercise of the conversion right in 2021, the acceleration of the remaining discount, in addition to the amortization of interest in 2021 prior to the conversion, amounted to $903, all of which was recognized as interest expense. Mr. Whitmore chose to exercise his conversion rights effective May 7, 2021, with any interest to be paid in the form of shares, as allowed in the Convertible Note. In addition to the 10,000,000 shares issued upon conversion, the Company issued 95,555 shares of additional stock to Mr. Whitmore in lieu of cash for the $19 in accrued interest owed at May 7, 2021. The note and related interest obligations were paid in full and cancelled in May, 2021 via conversion.

 

5)On April 17, 2020, we entered into a Promissory Note (the “PPP Note”), dated as of April 16, 2020, in favor of Libertyville in the principal amount of $952 for our loan under the Paycheck Protection Program (“PPP”). The Company was allowed to apply for forgiveness of the amount due on the PPP Note in an amount equal to the sum of the following costs incurred during the 24-week period beginning on the date of the first disbursement of the loan: (a) payroll costs, (b) any payment of interest on a covered obligation (which shall not include any prepayment of or payment of principal on a covered mortgage obligation), (c) any payment on a covered rent obligation, and (d) any covered utility payment, calculated in accordance with the terms of the CARES Act. The principal amount of the PPP Note would have accrued interest at the rate of 1.00% per year. The Company applied for, and received, PPP forgiveness during the first quarter of 2021. Under the terms of the PPP loan, it is subject to audit for six years from the date of forgiveness. If any portion of the PPP loan were to be deemed ineligible, the Company could be required to repay the funds. On December 31, 2021, the balance under the PPP note was $0.

 

F-12

 

 

6)On January 28, 2022 the Company entered into an Amended and Restated Business Loan Agreement (the “A&R Loan Agreement”), which amends and restates the Master Agreement between the Company and Beachcorp, LLC, and a new promissory note in order to evidence the A/R Revolver facility, including an amendment to expand the limit on the A/R Revolver Facility from $6,000 to $8,000, reduce the interest rate to the prime rate plus 0.75%, and extend the maturity of the A/R Revolver Facility to March 31, 2024.

 

7)On January 28, 2022 the Company entered into the A&R Loan Agreement and a new revolving loan agreement (“Inventory Facility”) with Beachcorp, LLC, and a new promissory note in order to evidence the Inventory Facility. The maximum borrowing amount under the Inventory Facility is $4,000, with a borrowing base consisting of up to 50% of the value of qualified inventory of the Company. The interest rate for the Inventory Revolver is at the prime rate plus 0.75%, and it matures on March 31, 2024.

 

8)On January 28, 2022 the Company entered into an additional Business Loan Agreement (the “New Term Loan Agreement”) with Strandler, LLC, which effectively transferred or assigned the Term Loan to Strandler, LLC from Beachcorp, LLC. Interest on the New Term Loan is at the prime rate plus 0.75%, and it matures on March 31, 2024. Strandler, LLC is also an affiliate of Bradford T. Whitmore.

 

 

Related party interest expense consists of the following:

 

         
   Twelve Months Ended December 31, 
   2021   2020 
Interest expense, related parties  $1,129   $452 

 

Accrued interest consists of the following:

 

         
   As of December 31, 
   2021   2020 
Accrued interest expense, related parties  $13   $20 

 

Outstanding balances associated with related parties are as follows:

 

   As of December 31, 
   2021   2020 
Beachcorp, LLC  $2,351   $2,655 
Secured convertible promissory note   —    1,097 
Strandler, LLC   n/a    n/a 

 

Beachcorp, LLC and Strandler, LLC are affiliates of Mr. Bradford T. Whitmore, who beneficially owns a majority of the Company’s common stock and is the brother of Ms. R. Janet Whitmore, a director of the Company and the chair of the Company’s board of directors. The A/R Revolver Facility, the Inventory Facility and the New Term Loan are all secured by all the unencumbered assets of the Company and subordinated to the Company’s credit facility with Libertyville Bank & Trust. 

 

 

(4) Inventories  

 

Inventories consist of the following:

 

               
   As of December 31, 
   2021   2020 
Raw materials  $4,819   $2,825 
Finished goods   1,682    1,545 
 Inventories, gross   6,501    4,370 
Allowance for excess quantities   (406)   (30)
 Inventories, net  $6,095   $4,340 

 

 

 

 

(5)

Equipment and Leasehold Improvements

 

Equipment and leasehold improvements consist of the following: 

 

   As of December 31, 
   2021   2020 
Machinery and equipment  $18,289   $16,758 
Office equipment   961    870 
Office furniture   110    110 
Leasehold improvements   4,900    4,850 
Construction in progress   1,062    445 
    25,322    23,033 
Less: Accumulated depreciation and amortization   (20,610)   (20,165)
   $4,712   $2,868 

 

Depreciation expense was $444 and $348, for the years ended December 31, 2021 and 2020, respectively.

 

F-13

 

 

 

(6) Lease Commitments

 

The Company’s operating lease portfolio is comprised of operating leases for office, warehouse space and equipment. Certain of the Company’s leases include one or more options to renew or terminate the lease at the Company’s discretion. The Company regularly evaluates the renewal and termination options and when they are reasonably certain of exercise, includes the renewal or termination option in our lease term. During the first seven months of the term of our newly leased building, we have subleased a portion of the unused floorspace on a temporary basis. This sublease may convert to a month-to-month lease upon expiration.

 

As of December 31, 2021, the ROU asset had a balance of $12,075 which is included in the “Operating lease right-of-use assets” line item of these consolidated financial statements and current and non-current lease liabilities related to the ROU asset of $1,983 and $10,306, respectively.  As of December 31, 2020, the ROU asset had a balance of $1,827 which is included in the “Operating lease right-of-use assets” line item of these consolidated financial statements and current and non-current lease liabilities related to the ROU asset of $431 and $1,651, respectively.  These amounts are included in the “Current portion of operating lease obligations” and “Long-term portion of operating lease obligations” line items of these consolidated financial statements. The discount rates used for leases accounted for under ASC 842 are based on an interest rate yield curve developed for the leases in the Company’s portfolio.

 

The office leases contain variable lease payments which consist primarily of rent escalations based on an established index or rate and taxes, insurance, and common area or other maintenance costs, which are paid based on actual costs incurred by the lessor. The Company has elected to utilize the available practical expedient to not separate lease and non-lease components.

 

Quantitative information regarding the Company’s leases is as follows:

 

         
   Twelve Months Ended December 31, 2021   Twelve Months Ended December 31, 2020 
Components of lease cost          
Finance lease cost components:          
Amortization of finance lease assets  $52   $70 
Interest on finance lease liabilities   18    36 
Total finance lease costs   70    106 
Operating lease cost components:          
Operating lease cost   554    565 
Variable lease cost   134    146 
Short-term lease cost   49    33 
Total operating lease costs   737    744 
Total lease cost:  $807   $850 

 

Supplemental cash flow information related to leases is as follows for the years ended December 31, 2021 and 2020:

 

   2021   2020 
Cash paid for amounts included in the measurement of lease liabilities:          
Operating cash outflow from operating leases  $741   $690 
           
Lease liabilities arising from obtaining right-of-use assets   10,505    — 
Weighted-average remaining lease term-finance leases (in years)   0.7    1.4 
Weighted-average remaining lease term-operating leases (in years)   9.5    3.2 
Weighted-average discount rate-finance leases   9.3%   9.3%
Weighted-average discount rate-operating leases   7.5%   14.3%

 

F-14

 

 

The future maturities of the Company’s finance and operating leases as of December 31, 2021 are as follows:

 

    Finance
Leases		   Operating
Leases		   Total 
2022   $109   $1,456   $1,565 
2023    6    2,099    2,105 
2024    —    2,025    2,025 
2025    —    1,470    1,470 
2026    —    1,468    1,468 
Thereafter    —    8,668    8,668 
Total payments   $115   $17,186   $17,301 
Less amounts representing interest    (4)   (4,897)   (4,901)
Total minimum payments required   $111   $12,289   $12,400 

 

The future maturities of the Company’s finance and operating leases as of December 31, 2020 were as follows:

 

    Finance
Leases		   Operating
Leases		   Total 
2021   $196   $701   $897 
2022    109    720    829 
2023    5    705    710 
2024    —    595    595 
2025    —    1    1 
Thereafter    —    —    — 
Total payments   $310   $2,722   $3,032 
Less amounts representing interest    (23)   (640)   (663)
Total minimum payments required   $287   $2,082   $2,369 

 

 

 

(7) Accrued Expenses

 

Accrued expenses consist of the following:

 

               
   As of December 31, 
   2021   2020 
Accrued payroll and related expenses  $471   $315 
Accrued accounts payable   320    122 
Tenant Security Deposit / Advance Rent   122    — 
Other   33    47 
 Total  $946   $484 

 

 

(8)Income Taxes

 

Our net income tax provision, including both current and deferred, related to U.S. federal and state income taxes, is $37. This is due to a change in law for the state of Illinois limiting the use of net loss deductions to $100 each year for tax years ending on or after December 31, 2021, and before December 31, 2024. Our current federal and deferred tax expenses are zero.

 

F-15

 

 

A reconciliation of income tax expense to the amount computed by applying the Federal income tax rate to loss before provision for income taxes as of December 31, 2021 and 2020 is as follows:

 

   2021   2020 
Income tax credit at statutory rates  $495   $208 
Nondeductible expenses   —    5 
Tax Exempt Income - PPP Loan   (271)   — 
Permanent Tax Deduction Stock Options Exercised   (63)   — 
State income tax, net of federal benefits   177    74 
Expiration of NOL & Credits   899    2,543 
Tax basis in excess of book Convertible Debt   —    — 
Expiration of Stock Options   92    122 
Other   2    (7)
Change in valuation allowance   (1,294)   (2,945)
 TOTAL  $37    — 

 

Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred income taxes consist of the following:

 

               
   As of December 31, 
   2021   2020 
Deferred tax liabilities:          
  Excess tax basis convertible debt  $—    (257)
     Total deferred tax liabilities   —    (257)
           
Deferred tax assets:          
  Net operating loss carryforwards  $14,566   $15,597 
  Inventory and other allowances   148    23 
  Charitable contribution & other carryforwards   —    9 
  Excess (tax) book depreciation   31    375 
  Excess (tax) book amortization   63    61 
  Share-based compensation   308    624 
  Other accrued costs   161    138 
     Total deferred tax assets   15,277    16,827 
           
  Less:  Valuation allowance   (15,277)   (16,570)
Deferred income taxes  $—   $— 

 

The valuation allowance decreased approximately $1.3 million and $6.4 million for the years ended December 31, 2021 and 2020, respectively (net of approximately $1 million and $6.3 million for the years ended December 31, 2021 and 2020, respectively, for expiring net operating loss carryforwards and credits) due principally to the change in the net operating loss carryforward and uncertainty as to whether future taxable income will be generated prior to the expiration of the carryforward period. Under the Internal Revenue Code, certain ownership changes, including the prior issuance of preferred stock and our public offering of common stock, may subject us to annual limitations on the utilization of our net operating loss carryforward. As of December 31, 2021, it has been determined that we are not subject to annual limitations on the utilization of our net operating loss carryforward.

 

We have federal net operating loss carryforwards for tax purposes of approximately $62 million on December 31, 2021. $57 million expire between 2022 and 2037. All net operating loss carryforwards generated after January 1, 2018 do not expire. Therefore, $5 million in net operating losses generated since January 1, 2018 do not expire. We have Illinois net loss deduction carryforwards for tax purposes of approximately $21 million on December 31, 2021. Due to the provisions of Illinois Public Act 102-0669 signed November 16, 2021, Illinois net loss deductions expire between 2029 and 2039.

 

F-16

 

 

 

(9)

Capital Stock

 

As of December 31, 2021, and 2020, we had 24,088 authorized but unissued shares of preferred stock. In addition, as of December 31, 2020, we had 10,000,000 authorized but unissued shares of common stock reserved to meet the conversion requirement of the Convertible Note discussed in Note 3. These shares were issued at the conversion of this note in May of 2021.

 

 

(10) Stock Options and Stock Grants

 

We have entered into stock option agreements with certain officers, employees and directors. The stock options granted prior to the adoption of the 2019 Equity Compensation Plan (the “2019 Plan”) on November 19, 2019 generally expire ten years from the date of grant. Future options to be granted under the 2019 Plan will expire seven years from the date of grant.

 

Employee Stock Options

 

We follow ASC Topic 718, Share-Based Payments, in which compensation expense is recognized only for share-based payments expected to vest. 

 

               
   Years ended
December 31,		 
   2021   2020 
Share-based compensation expense  $160   $195 
Remaining unrecognized compensation expense   $1,581      
Remaining weighted average-period, expense recognition (years)   2.9      

 

 

We use the Black-Scholes option pricing model to determine the fair value of stock-based compensation. The Black-Scholes model requires us to make several assumptions, including the estimated length of time employees will retain their vested stock options before exercising them (“expected term”), the estimated volatility of our common stock price over the expected term, and estimated forfeitures. Expected price volatility is based on the daily market rate changes of our stock. The active shares granted prior to fiscal 2020 had a contractual life of 10 years as dictated by the 2010 Plan. The Black-Scholes model also requires a risk-free interest rate, which is based on the U.S. Treasury yield curve in effect at the time of the grant, and the dividend yield on our common stock, which is assumed to be zero since we do not pay dividends and have no current plans to do so in the future. Changes in these assumptions can materially affect the estimate of fair value of stock-based compensation and consequently, the related expense recognized on the statement of operations. We recognize stock-based compensation expense on a straight-line basis over the requisite service period. 

 

The following table illustrates the various assumptions used to calculate the Black-Scholes option pricing model for options granted for all years presented:

 

   Years Ended
December 31,		 
    2021   2020 
Weighted-average risk-free interest rates:   1.4%   0.5%
           
Dividend yield:   0%   0%
           
Weighted-average expected life (years) of the option:   5    5 
           
Weighted-average expected stock price volatility:   115%   95%
           
Weighted-average fair value of the options granted:  $2.59   $0.28 

  

F-17

 

 

Additional disclosures for options granted for all years presented:

 

   Years Ended
December 31,		 
    2021   2020 
Vesting period (years) of shares granted in period   3    3 
           
Contractual life (years) of shares granted in period   7    7 
           
Estimated forfeitures   4%   4%

 

The following table summarizes the option activity for our employees and directors during the year ended December 31, 2021:

 

Options  Shares
(Rounded)		   Weighted
Average
Exercise
Price
per Share		   Weighted
Average
Remaining
Contractual
Term (Years)		   Aggregate
Intrinsic
Value
(000s)		 
Outstanding on January 1, 2021   3,412,686   $0.57    —    — 
                     
Granted   567,500   $4.14    —    — 
Exercised   (535,100)  $0.44    —    — 
Forfeited or expired   (251,870)  $1.09    —    — 
                     
Outstanding on December 31, 2021   3,193,216   $1.18    5.1   $10,267 
Exercisable on December 31, 2021   2,189,378   $0.56    4.4   $8,405 
                     
Shares available for grant   1,887,500                

 

The aggregate intrinsic value in the table above is based on our closing stock price of $4.40 on the last business day for the year ended December 31, 2021.

 

             
   Years ended
December 31,		 
   2021   2020 
Shares exercised   535,100    84,500 
Total intrinsic value  $1,169   $10 
Cash received  $234   $37 

 

Based on our election of the “with and without” approach, no realized tax benefits from stock options were recognized for the years ended December 31, 2021 and 2020.

 

 

(11) 401(k) Profit-Sharing Plan

 

We have a 401(k) profit-sharing plan covering substantially all employees who meet defined service requirements. During 2020, we maintained a Company contribution program, in which 10% of the first 8% of any employee’s was matched (for a match of up to 0.8% of a participant’s salary). In 2021, we implemented a new Company match program, in which the Company matches the first 3% of eligible pay that any employee contributes on a dollar-for-dollar basis. Contributions made in 2021 and 2020 aggregated to $107 and $21, respectively.

 

F-18

 

 

 

(12) Significant Customers and Contingencies

 

We had five significant customers for the year ended December 31, 2021.

 

      For the years ended
December 31,		 
Customer #  Product Category  2021   2020 
1  Personal Care Ingredients   26%   30%
2  Solésence®   19%   14%
3  Solésence®   15%   11%
4  Solésence®   10%   5%
5  Advanced Materials (Medical Diagnostics customer)   8%   20%
   Total   78%   80%


 

 Accounts receivable balances for these five customers were approximately:

 

     

For the years ended

December 31,

 
Customer #  Product Category  2021   2020 
1  Personal Care Ingredients  $641   $381 
2  Solésence®   534    342 
3  Solésence®   1,048    116 
4  Solésence®   239    863 
5  Advanced Materials (Medical Diagnostics customer)   -0-    735 
   Total  $2,462   $2,437 

 

We currently have exclusive supply agreements with BASF Corporation (“BASF”), our largest customer, that have contingencies outlined which could potentially result in the license of technology and/or the sale of production equipment from the Company to the customer intended to provide capacity sufficient to meet the customer’s production needs. This outcome may occur if we fail to meet certain performance requirements. Our supply agreements with BASF also “trigger” a technology transfer right in the event of our insolvency, as further defined within the agreements. In the event of an equipment sale, upon incurring a triggering event, the equipment would be sold to the customer at either 115% of the equipment’s net book value or the greater of 30% of the original book value of such equipment, and any associated upgrades to it, or 115% of the equipment’s net book value, depending on the equipment and related products.

 

If a triggering event were to occur and BASF elected to proceed with the license and related equipment sale mentioned above, we would receive royalty payments from this customer for products sold using our technology; however, we would lose both significant revenue and the ability to generate significant revenue to replace that which was lost in the near term. Replacement of necessary equipment that could be purchased and removed by the customer pursuant to this triggering event could take in excess of twelve months. Any additional capital outlays required to rebuild capacity would probably be greater than the proceeds from the purchase of the assets as dictated by our agreement with the customer. Similar consequences would occur if we were determined to have materially breached certain other provisions of the supply agreement with BASF. Any such event would also likely result in the loss of many of our key staff and line employees due to economic realities. We believe that our employees are a critical component of our success, and it could be difficult to replace them quickly. Given the occurrence of any such event, we might not be able to hire and retain skilled employees given the stigma relating to such an event and its impact on us.

 

F-19

 

 

 

(13) Business Segmentation and Geographical Distribution

 

Revenue from international sources approximated $3,236 and $3,714 for the years ended December 31, 2021 and 2020, respectively. As part of our revenue from international sources, we recognized approximately $2,335 and $3,450 in product revenue from German companies, in the aggregate, for the years ended December 31, 2021 and 2020, respectively.

 

Our Operations comprise a single business segment and all of our long-lived assets are located within the United States. We categorize our revenue stream into three main product categories, Personal Care Ingredients, Advanced Materials and Solésence. The revenues for 2021 and 2020 by category are as follows:

 

  

For the years ended  

December 31 

 
Product Category  2021   2020 
Solésence  $18,175   $6,737 
Personal Care Ingredients   7,739    5,536 
Advanced Materials   3,561    4,850 
Total Sales  $29,475   $17,123 

 

  

 

(14) Contingencies 

 

In December 2019, a novel strain of coronavirus (SARS-CoV-2) emerged in Wuhan, Hubei Province, China, which was proclaimed by the World Health Organization to have been the cause of a global pandemic (COVID-19).   COVID-19 has been followed by a series of variants that have also impacted our operations, but to a lesser extent than the initial strain.. Some of the raw materials that are critical to the production of our products and parts that are critical to the operation of our equipment are sourced from single suppliers, suppliers from China and Korea, and in some cases, a single supplier from China. Although operations of our third-party suppliers were disrupted to a certain extent in 2020 from the pandemic, particularly related to receiving packaging for our Solésence products on a timely basis, we are currently seeing a more limited impact relating to COVID-19 on our suppliers. The biggest challenge in 2021 and during the beginning of 2022 related to the pandemic is now slowdowns in production and shipping due to capacity limitations which seems to be a function of company’s inability to keep up with renewed market demand. We typically maintain no less than one month’s supply of raw materials and parts that are sourced from sole suppliers and make efforts to identify additional suppliers who may be able to provide such raw materials or parts. During 2021, shortages of labor, which may have been related to COVID-19, created challenges to the Company as we navigated a rapidly growing business under these conditions.

 

The Company is aware that such changes in its business as a result of COVID-19-related changes to our economy could occur, but is uncertain of the impacts of those changes on its consolidated statements of position, operations, or cash flows. The Company’s management believes any resulting cessations, reductions, and disruptions in its customers’ and suppliers’ operations would probably be temporary; however, the Company’s management also believes the duration and, hence, the potential impact of such cessations, reductions, and disruptions is currently unknowable. As a result, we are unable to estimate the potential impact on our business as of the date of this filing.

 

F-20

 

 

EXHIBIT INDEX

 

Exhibit
Number

 

2.1 Plan and Agreement of Merger dated as of November 25, 1997 by and between the Company and its Illinois predecessor, incorporated by reference to Exhibit 2 to the Company’s Annual Report on Form 10-K for the year ended December 31, 1997 (the “1997 10-K”), SEC File No. 000-22333.

 

3(i).1 Certificate of Incorporation of the Company, incorporated by reference to Exhibit 3.1 to the 1997 10-K, SEC File No. 000-22333.

 

3(i).2 First Amendment to the Certificate of Incorporation of the Company dated July 27, 2006, incorporated by reference to Exhibit 99.3 to the Company’s Current Report on Form 8-K filed July 27, 2006, SEC File No. 000-22333.

   

3(i).3 Second Amendment to the Certificate of Incorporation of the Company dated August 23, 2010, incorporated by reference to Exhibit A of the Company’s Definitive Proxy Statement on Schedule 14A filed July 9, 2010, SEC File No. 000-22333.

 

3(i).4 Third Amendment to the Certificate of Incorporation of the Company, incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed August 29, 2016.

 

3(i).5 Fourth Amendment to the Certificate of Incorporation of the Company, incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed November 22, 2019.

 

3(i).6 Sixth Amendment to the Certificate of Incorporation of the Company.

 

3(ii).1 By-Laws of the Company, incorporated by reference to Exhibit 3.2 to the 1997 10-K, SEC File No. 000-22333.

 

4.1 Specimen stock certificate representing common stock, incorporated by reference to Exhibit 4.1 to the Company’s Registration Statement on Form S-1/A filed November 4, 1997 (File No. 333-36937) (the “Form S-1/A”).

 

4.2 Form of Warrants, incorporated by reference to Exhibit 4.2 to the Company’s Registration Statement on Form S-1 filed October 1, 1997 (File No. 333-36937) (the “IPO S-1”).

 

4.3 Certificate of Designations of Series A Junior Participating Preferred Stock, incorporated by reference to Exhibit 4.4 to the Company’s Annual Report on Form 10-K for the year ended December 31, 1998, SEC File No. 000-22333.

 

4.4 Stock Purchase Agreement dated August 25, 2006 between the Company and Rohm and Haas Electronic Materials CMP Holdings, Inc., incorporated by reference to Exhibit 99.1 to the Company’s Current Report on Form 8-K filed August 28, 2006, SEC File No. 000-22333.

 

4.5 Registration Rights Agreement dated August 25, 2006 between the Company and Rohm and Haas Electronic Materials CMP Holdings, Inc., incorporated by reference to Exhibit 99.2 to the Company’s Current Report on Form 8-K filed August 28, 2006, SEC File No. 000-22333.

 

4.6 Common Stock Purchase Agreement, dated February 10, 2016, between the Company and Bradford T. Whitmore, incorporated by reference to Exhibit 4.1 of the Company’s Current Report on Form 8-K filed February 10, 2016.

 

4.7 Common Stock Purchase Agreement, dated December 19, 2017, between the Company and Bradford T. Whitmore, incorporated by reference to Exhibit 4.1 of the Company’s Current Report on Form 8-K filed December 21, 2017.

 

4.8 Common Stock Purchase Agreement, dated May 13, 2019, between the Company and Bradford T. Whitmore, incorporated by reference to Exhibit 4.1 of the Company’s Quarterly Report on Form 10-Q filed May 15, 2019

 

4.9 Securities Purchase Agreement, dated November 13, 2019, between the Company and Bradford T. Whitmore, incorporated by reference to Exhibit 4.1 of the Company’s Quarterly Report on Form 10-Q filed November 14, 2019.

 

4.10 Commercial Security Agreement, dated November 20, 2019, between the Company, Solésence, LLC and Bradford T. Whitmore, incorporated by reference to Exhibit 4.2 of the Company’s Quarterly Report on Form 10-Q filed November 14, 2019.

 

E-1

 

 

4.11 2% Second Secured Convertible Note, dated November 20, 2019, made by the Company and payable to the order of Bradford T. Whitmore, incorporated by reference to Exhibit 4.3 of the Company’s Quarterly Report on Form 10-Q filed November 14, 2019.

 

10.1 Industrial Building Lease dated September 15, 2004 between the Company and the Village of Burr Ridge, incorporated by reference to Exhibit 10.32 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2004 (the “2004 10-K”), SEC File No. 000- 22333.

 

10.2 Industrial Building Lease Agreement between Centerpoint Properties Trust (formerly CP Financing Trust) and the Company, dated June 15, 2000, incorporated by reference to Exhibit 10.23 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2000 (the “2000 10-K”), SEC File No. 000-22333.

 

10.3 Lease Amendment effective October 1, 2005 between the Company and Centerpoint Properties Trust, incorporated by reference to Exhibit 99.1 to the Company’s Current Report on Form 8-K filed October 20, 2005, SEC File No. 000-22333.

 

10.4 Second Amendment to Industrial Lease Agreement, dated as of November 13, 2014 between the Company and MLRP 1319 Marquette LLC, successor-in-interest to Centerpoint Properties Trust, incorporated by reference to Exhibit 10.4 to the Company’s Annual Report on Form 10- K for the year ended December 31, 2014.

 

10.5 Third Amendment to Industrial Lease Agreement, entered into on October 17, 2016 and effective October 1, 2016, by and between the Company and 1319 Marquette, LLC, incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed October 19, 2016.

 

10.6 Mutual Cooperation Agreement entered into on January 17, 2012, by and among the Company, C.I. Kasei Co., Ltd. and CIK NanoTek Corporation, incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed January 20, 2012, SEC File No. 000-22333.

 

10.7 Trademark Ownership Assignment Agreement, dated March 31, 2012, between the Company and CIK NanoTek Corporation, incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed April 4, 2012, SEC File No 000-22333.

 

10.8 Memorandum on the Payment of Royalty, dated March 31, 2012, between the Company and CIK NanoTek Corporation, incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed April 4, 2012, SEC File No 000-22333.

 

10.9 Supply Agreement between the Company and Schering-Plough HealthCare Products, Inc. dated as of March 15, 1997, incorporated by reference to Exhibit 10.17 to the Form S-1/A.

 

10.10* Zinc Oxide Supply Agreement dated as of September 16, 1999 between the Company and BASF Corporation, as assignee, incorporated by reference to Exhibit 10.22 to the Company’s Annual Report on Form 10-K for the year ended December 31, 1999, SEC File No. 000-22333.

 

10.11* Amendment No. 1 to Zinc Oxide Supply Agreement dated as of January, 2001 between the Company and BASF Corporation, incorporated by reference to Exhibit 10.24 to the 2000 10-K, SEC File No. 000-22333.

 

10.12 Amendment No. 2. to Zinc Oxide Supply Agreement dated as of March 17, 2003 between the Company and BASF Corporation, incorporated by reference to Exhibit 10.26 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2002 (the “2002 10-K”), SEC File No. 000-22333.

 

10.13* Amendment No. 3 to Zinc Oxide Supply Agreement entered into on December 12, 2012, between the Company and BASF Corporation, incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed December 6, 2012, SEC File No. 000-22333.

 

10.14*

Amendment No. 4 to Zinc Oxide Supply Agreement, dated as of January 1, 2019 and entered into on March 11, 2019, between the Company and BASF Corporation, incorporated by reference to Exhibit 10.1 of the Company’s Quarterly Report on Form 10-Q filed May 15, 2019.

 

E-2

 

 

10.15 Z-COTE HP-2 Brand Supply Agreement dated May 15, 2006 between the Company and BASF Corporation, incorporated by reference to Exhibit 99.1 to the Company’s Current Report on Form 8-K filed June 20, 2006, SEC File No. 000-22333.

 

10.16* Amended and Restated Cooperation Agreement dated August 25, 2006 between the Company and Rohm and Haas Electronic Materials CMP Inc., incorporated by reference to Exhibit 99.3 to the Company’s Current Report on Form 8-K filed August 28, 2006, SEC File No. 000- 22333.

 

10.17 Supply Agreement effective as of March 23, 2009, between the Company and Rohm and Haas Electronic Materials CMP Inc., incorporated by reference to Exhibit 10.56 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2008, SEC File No. 000-22333.

 

10.18* Distributor Agreement dated October 24, 2005 between Johnson Matthey Catalog Company, Inc., d/b/a ALFA AESAR and the Company, incorporated by reference to Exhibit 99.1 to the Company’s Current Report on Form 8-K filed November 1, 2005, SEC File No. 000-22333.

 

10.19* Supply Agreement dated March 3, 2006 between Roche Diagnostics GmbH and the Company, incorporated by reference to Exhibit 99.1 to the Company’s Current Report on Form 8-K filed March 9, 2006, SEC File No. 000-22333.

 

10.20* First Amendment to the Supply Agreement entered into on November 19, 2014 between the Company and Roche Diagnostics GmbH, incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed November 25, 2014.

 

10.21* Second Amendment to the Supply Agreement, entered into on November 21, 2016, between the Company and Roche Diagnostics GmbH, incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed November 28, 2016.

 

10.22 Joint Development Agreement dated March 23, 2004 between the Company and Altana Chemie AG, incorporated by reference to Exhibit 10.29 to the 2003 10-K, SEC File No. 000-22333.

 

10.23* Agreement dated July 7, 2008 between the Company and Altana Chemie GmbH, incorporated by reference to Exhibit 99.1 to the Company’s Current Report on Form 8-K filed July 18, 2008, SEC File No. 000-22333.

 

10.24* Settlement and Termination Agreement, dated August 20, 2010, between the Company and Altana Chemie GmbH, incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed August 25, 2010, SEC File No. 000-22333.

 

10.25* Supply Agreement, dated as of March 31, 2016, between the Company and Ester Solutions Company, incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed April 6, 2016.

 

10.26 First Amendment to Supply Agreement, dated May 21, 2018, by and between Nanophase Technologies Corporation and Hallstar Ester Solutions Corporation (formerly known as Ester Solutions Company), incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed May 25, 2018.

 

10.27 Joint Development Agreement, dated as of July 31, 2019, between the Company and Sumitomo Corporation of Americas, incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed August 2, 2019.

 

10.28 Joint Development & Supply Agreement, dated December 12, 2016, by and between Solésence, LLC and Colorescience Inc., incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed May 24, 2018.

 

10.29 Amended and Restated Joint Development & Supply Agreement, executed by Solésence, LLC on May 18, 2018, by and between Solésence, LLC and Colorescience Inc., incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed May 24, 2018.

 

 10.30

Promissory Note, dated March 4, 2015, granted by the Company in favor of Libertyville Bank and Trust Company, incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed March 10, 2015.

 

E-3

 

 

10.31

Commercial Security Agreement, dated March 4, 2015, between the Company and Libertyville Bank and Trust Company, incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K filed March 10, 2015.

 

10.32

 

Change in Terms Agreement, dated March 4, 2016, between the Company and Libertyville Bank and Trust Company, incorporated by reference to Exhibit 10.2 of the Current Report on Form 8-K filed March 10, 2016.

 

10.33 Change in Terms Agreement, dated February 14, 2017, between the Company and Libertyville Bank and Trust Company, incorporated by reference to Exhibit 10.32 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2016.

 

10.34 Promissory Note, executed by the Company on March 26, 2018, granted by the Company in favor of Libertyville Bank and Trust Company, incorporated by reference to Exhibit 10.34 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2017.

 

10.35 Commercial Security Agreement, executed by the Company on March 26, 2018, between the Company and Libertyville Bank and Trust Company, incorporated by reference to Exhibit 10.35 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2017.

 

10.36 Business Loan Agreement, executed by the Company on March 22, 2019, between the Company and Libertyville Bank and Trust Company, incorporated by reference to the Exhibit 10.32 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2018.

 

10.37 Change in Terms Agreement, executed by the Company on March 22, 2019, between the Company and Libertyville Bank and Trust Company, incorporated by reference to the Exhibit 10.33 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2018.

 

10.38 Business Loan Agreement, dated November 16, 2018, between the Company and Beachcorp, LLC, incorporated by reference to the Company’s Quarterly Report on Form 10-Q filed November 19, 2018.

 

10.39 Promissory Note, dated November 19, 2018, made by the Company and payable to the order of Beachcorp, LLC to evidence a term loan in the original principal amount of up to $500,000, incorporated by reference to the Company’s Quarterly Report on Form 10-Q filed November 19, 2018.

 

10.40 Promissory Note, dated November 19, 2018, made by the Company and payable to the order of Beachcorp, LLC to evidence revolving borrowings in a principal amount of up to $2,000,000, incorporated by reference to the Company’s Quarterly Report on Form 10-Q filed November 19, 2018.

 

10.41 First Amendment to Business Loan Agreement, dated March 23, 2020, between the Company and Beachcorp, LLC, incorporated by reference to the Company’s Annual Report on Form 10-K filed March 30, 2020.

 

10.42 Fourth Amendment to Business Loan Agreement, dated April 21, 2021, between the Company and Beachcorp, LLC, incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed April 21, 2021.

 

10.43 Business Loan Agreement, dated January 28, 2022, between the Company and Beachcorp, LLC, incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed February 2, 2022.

 

10.44 Business Loan Agreement, dated January 28, 2022, between the Company and Strandler, LLC, incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed February 2, 2022.

 

10.45 Amended and Restated Business Loan Agreement, dated January 28, 2022, between the Company and Beachcorp, LLC, incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K filed February 2, 2022.

 

10.46

Replacement Promissory Note, dated January 28, 2022, made by the Company and payable to the order of Beachcorp, LLC to evidence revolving borrowings in a principal amount of up to $8,000,000, incorporated by reference to Exhibit 10.4 to the Company’s Current Report on Form 8-K filed February 2, 2022. 

 

E-4

 

 

10.47 Promissory Note, dated January 28, 2022, made by the Company and payable to the order of Strandler, LLC to evidence a term loan in the original principal amount of up to $1,000,000, incorporated by reference to Exhibit 10.5 to the Company’s Current Report on Form 8-K filed February 2, 2022.

 

10.48 Promissory Note, dated January 28, 2022, made by the Company and payable to the order of Beachcorp, LLC to evidence revolving borrowings in a principal amount of up to $4,000,000, incorporated by reference to Exhibit 10.6 to the Company’s Current Report on Form 8-K filed February 2, 2022.

 

10.49 Employment Agreement effective August 12, 2009 between the Company and Jess Jankowski, incorporated by reference to Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2009, SEC File No. 000-22333. +

 

10.50

Employment Agreement dated November 28, 2012, between the Company and Kevin Cureton, incorporated by reference to Exhibit 10.36 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2012, SEC File No. 000-22333. +

 

10.51 Nanophase Technologies Corporation 2004 Equity Compensation Plan (“2004 Equity Plan”), incorporated by reference to Exhibit 4 to the Company’s Registration Statement on Form S-8 (File No. 333-119466). +

 

10.52 2008 Long-Term Cash Incentive Plan, incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed July 25, 2008, SEC File No. 000-22333.+

 

10.53 Nanophase Technologies Corporation 2010 Equity Compensation Plan, as amended, incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed August 29, 2016.+

 

10.54 Form of Stock Option Award Agreement under the 2010 Equity Compensation Plan, incorporated by reference to Exhibit 10.47 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2013.+

 

10.55 Nanophase Technologies Corporation 2019 Equity Compensation Plan, incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed November 22, 2019.+

 

10.56 Building Lease, dated as of September 15, 2010, between the Company and the Village of Burr Ridge, incorporated by reference to Exhibit 10.50 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2016.

 

10.57 Building Lease, dated as of March 13, 2017, between the Company and the Village of Burr Ridge, incorporated by reference to Exhibit 10.51 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2016.

 

10.58* Know-How License Agreement, executed by the Company on June 26, 2017, between the Company and Eminess Technologies, Inc., incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed June 29, 2017.

 

10.59* Exclusive Supply Agreement, executed by the Company on June 26, 2017, between the Company and Eminess Technologies, Inc., incorporated by reference to Exhibit 10.2 of the Current Report on Form 8-K filed June 29, 2017.

 

10.60 Technology Development Agreement, executed by the Company on June 26, 2017, between the Company and Eminess Technologies, Inc., incorporated by reference to Exhibit 10.3 of the Current Report on Form 8-K filed June 29, 2017.

 

10.61* Exclusive Supply Agreement, effective April 1, 2021, between Solesence, LLC and Ilia Beauty, Inc., incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed June 14, 2021.

 

10.62* Lease, effective December 1, 2021, between the Company and FR JH 10, LLC, incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed December 9, 2021.

 

21.1

Subsidiary of the Company. 

 

E-5

 

 

23.1 Consent of RSM US LLP. (filed herewith)

 

31.1 Certification of the Chief Executive Officer (principal executive officer) pursuant to Rules 13a-14(a) and 15d-14(a) under the Exchange Act. (filed herewith)

 

31.2 Certification of the Chief Financial Officer (principal financial officer) pursuant to Rules 13a-14(a) and 15d-14(a) under the Exchange Act. (filed herewith)

 

32 Certification of the Chief Executive Officer (principal executive officer) and Chief Financial Officer (principal financial officer) pursuant to 18 U.S.C. Section 1350. (filed herewith)

 

101 The following materials from the Company’s Annual Report on Form 10-K for the year ended December 31, 2017, formatted in XBRL (Extensible Business Reporting Language): (1) the Balance Sheets, (2) the Statements of Operations, (3) the Statements of Cash Flows, (4) the Statements of Stockholders’ Equity, and (5) the Notes to the Financial Statements.

 

* Confidentiality previously granted for portions of this agreement.

 

+ Indicates management contracts or compensatory plans or arrangements.

 

E-6

 

  

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on the 31st day of March, 2022.

 

  NANOPHASE TECHNOLOGIES CORPORATION
       
    By: /s/ Jess A. Jankowski
      Jess A. Jankowski
      President and Chief Executive Officer

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the registrant and in the capacities indicated on the 31st day of March, 2022.

 

Signature   Title
     
/s/ Jess A. Jankowski   President, Chief Executive Officer (principal executive officer,
Jess A. Jankowski   principal financial officer, and principal accounting officer) and Director
     
/s/ R. Janet Whitmore   Chair of the Board of Directors
R. Janet Whitmore    
     
/s/ Laura M. Beres   Director
Laura M. Beres    
     
/s/ Richard W. Siegel   Director
Richard W. Siegel    

 

 EX-21.1 2 ex21-1.htm SUBSIDIARY OF THE COMPANY

 

 

NANOPHASE TECHNOLOGIES CORPORATION 10-K

Exhibit 21.1

 

SUBSIDIARY OF NANOPHASE TECHNOLOGIES CORPORATION

 

(as of December 31, 2021)

 

  Name Jurisdiction of Formation
     
  Solésence, LLC Delaware

 

 

 EX-23.1 3 ex23-1.htm CONSENT OF RSM US LLP

 

 

NANOPHASE TECHNOLOGIES CORPORATION 10-K

Exhibit 23.1

 

Consent of Independent Registered Public Accounting Firm

 

We consent to the incorporation by reference in the Registration Statements (No.’s 333-53445, No. 333-74170, No. 333-119466, No. 333-150765, No. 333-187649, and No. 333-255357) on Form S-8 and Registration Statements (No. 333-90326, No. 333-112130, No. 333-116224, No. 333-140461, No. 333-143153, and No. 333-163363) on Form S-3 of Nanophase Technologies Corporation of our report dated March 31, 2022, relating to the consolidated financial statements of Nanophase Technologies Corporation, appearing in this Annual Report on Form 10-K of Nanophase Technologies Corporation for the year ended December 31, 2021.

 

/s/ RSM US LLP

 

Chicago, Illinois

March 31, 2022

 

 

 EX-31.1 4 ex31-1.htm CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER

 

 

NANOPHASE TECHNOLOGIES CORPORATION 10-K

Exhibit 31.1

 

Certification of the Chief Executive Officer
Pursuant to

Rules 13a-14(a) and 15d-14(a) under the Exchange Act

 

I, Jess A. Jankowski, certify that:

 

1.        I have reviewed this annual report on Form 10-K of Nanophase Technologies Corporation;

 

2.        Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.        Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.        The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15(d)-15(f)) for the registrant and have:

 

(a)       Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)       Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c)       Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d)       Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.        The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):

 

(a)       All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b)      Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: March 31, 2022    
     
  /s/ JESS A. JANKOWSKI  
       Jess A. Jankowski  
       President and Chief Executive Officer  
       (Principal Executive Officer)  

 

  

 EX-31.2 5 ex31-2.htm CERTIFICATION OF THE CHIEF FINANCIAL OFFICER

 

NANOPHASE TECHNOLOGIES CORPORATION 10-K

Exhibit 31.2

 

Certification of the Chief Financial Officer
Pursuant to  

Rules 13a-14(a) and 15d-14(a) under the Exchange Act

 

I, Jess Jankowski, certify that:

 

1.        I have reviewed this annual report on Form 10-K of Nanophase Technologies Corporation;

 

2.        Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.        Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.        The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15(d)-15(f)) for the registrant and have:

 

(a)        Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)        Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c)        Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d)       Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.        The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):

 

(a)        All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b)        Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: March 31, 2022  
   
  /s/ JESS A. JANKOWSKI  
  Jess A. Jankowski
  President, Chief Executive Officer, and Chief Financial Officer
 

(Principal Financial Officer)

 

 

 EX-32 6 ex32.htm CERTIFICATION OF THE CEO AND CFO

 

 

NANOPHASE TECHNOLOGIES CORPORATION 10-K

Exhibit 32

 

Certification Pursuant to 18 U.S.C. Section 1350 

(as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002)

 

In connection with this annual report of Nanophase Technologies Corporation (the “Company”) on Form 10-K for the year ending December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jess A. Jankowski, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

 

1.             The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2.             The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

Date: March 31, 2022  
   
  /s/ JESS A. JANKOWSKI  
  Jess A. Jankowski
  President, Chief Executive Officer, and Chief Financial Officer

 

 

 EX-101.SCH 7 nanx-20211231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Description of Business link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Notes and Lines of Credit link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Equipment and Leasehold Improvements link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Lease Commitments link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Capital Stock link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Stock Options and Stock Grants link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - 401(k) Profit-Sharing Plan link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Significant Customers and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Business Segmentation and Geographical Distribution link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Contingencies link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Notes and Lines of Credit (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Equipment and Leasehold Improvements (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Lease Commitments (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Stock Options and Stock Grants (Tables) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Significant Customers and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Business Segmentation and Geographical Distribution (Tables) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Activity in the asset retirement obligation account for the years ended December 31, is as follows: (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Contract balances for the year 2021 and 2020 (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows: (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Notes and lines of credit consist of the following: (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Schedule of Related Parties (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Inventories consist of the following: (Details) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Equipment and leasehold improvements consist of the following: (Details) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Equipment and Leasehold Improvements (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Quantitative information regarding the Company’s leases is as follows: (Details) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Supplemental cash flow information related to leases is as follows for the years ended December 31, 2021 and 2020: (Details) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - The future maturities of the Company’s finance and operating leases as of December 31, 2021 are as follows: (Details) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - Lease Commitments (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - Accrued expenses consist of the following: (Details) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - A reconciliation of income tax expense to the amount computed by applying the Federal income tax rate to loss before provision for income taxes as of December 31, 2021 and 2020 is as follows: (Details) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - Significant components of our deferred income taxes consist of the following: (Details) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - Income Taxes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000050 - Disclosure - Capital Stock (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000051 - Disclosure - We follow ASC Topic 718, Share-Based Payments, in which compensation expense is recognized only for share-based payments expected to vest. (Details) link:presentationLink link:calculationLink link:definitionLink 00000052 - Disclosure - Schedule of assumptions used to calculate Black-Scholes option pricing model for options granted (Details) link:presentationLink link:calculationLink link:definitionLink 00000053 - Disclosure - Additional disclosures for options granted for all years presented: (Details) link:presentationLink link:calculationLink link:definitionLink 00000054 - Disclosure - Schedule of option activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000055 - Disclosure - The aggregate intrinsic value in the table above is based on our closing stock price of $4.40 on the last business day for the year ended December 31, 2021. (Details) link:presentationLink link:calculationLink link:definitionLink 00000056 - Disclosure - Stock Options and Stock Grants (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000057 - Disclosure - 401(k) Profit-Sharing Plan (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000058 - Disclosure - We had five significant customers for the year ended December 31, 2021. (Details) link:presentationLink link:calculationLink link:definitionLink 00000059 - Disclosure - Accounts receivable balances for these five customers were approximately: (Details) link:presentationLink link:calculationLink link:definitionLink 00000060 - Disclosure - Significant Customers and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000061 - Disclosure - The revenues for 2021 and 2020 by category are as follows: (Details) link:presentationLink link:calculationLink link:definitionLink 00000062 - Disclosure - Business Segmentation and Geographical Distribution (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 nanx-20211231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 nanx-20211231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 nanx-20211231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Product and Service [Axis] Product [Member] Product and Service, Other [Member] Equity Components [Axis] Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Long-Lived Tangible Asset [Axis] Equipment [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Leasehold Improvements [Member] Other Capitalized Property Plant and Equipment [Member] Tax Period [Axis] Year 2021 [Member] Year 2022 [Member] Year 2023 [Member] Credit Facility [Axis] Libertyville Bank And Trust [Member] Libertyville Bank And Trust One [Member] Libertyville Bank And Trust Two [Member] Beachcorp, LLC [Member] Beachcorp LLC One [Member] 2% Secured Convertible Promissory Note Due on May 15, 2024 [Member] PPP Loan Libertyville Promissory Note [Member] Beachcorp LLC Three [Member] Beachcorp LLC Four [Member] Strandler LLC [Member] Short-term Debt, Type [Axis] Letter of Credit [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Credit Agreement [Member] New Business Loan Agreement [Member] Business Loan Agreement [Member] Term Loan [Member] Counterparty Name [Axis] Revolving Credit Facility [Member] First Amendment [Member] Term Loan and The Revolver Facility [Member] Second Amendment [Member] Third Amendment [Member] Fourth Amendment [Member] Long-term Debt, Type [Axis] Related Party [Axis] Bradford T. Whitmore [Member] Related Party Credit Facilities [Member] Whitmore [Member] Promissory Note (PPP) [Member] Libertyville [Member] A And R Loan Agreement [Member] Related Party Transaction [Axis] Related Party Transaction [Member] Secured Convertible Promissory Note [Member] Machinery and Equipment [Member] Office Equipment [Member] Furniture and Fixtures [Member] Construction in Progress [Member] Income Tax Authority [Axis] Domestic Tax Authority [Member] Valuation Allowance by Deferred Tax Asset [Axis] Expiring Operating Loss Carry forwards [Member] Tax Year 2012 [Member] Plan Name [Axis] Plan [Member] :Equity Compensation Plan 2019 [Member] Equity Compensation Plan 2010 [Member] Award Type [Axis] Share-based Payment Arrangement, Option [Member] Concentration Risk Type [Axis] Customer Concentration Risk [Member] Concentration Risk Benchmark [Axis] Revenue Benchmark [Member] Customer [Axis] Customer One - Personal Care Ingredients [Member] Customer Two - Solesence [Member] Customer Three - Solesence [Member] Customer Four - Solesence [Member] Customer Five - Medical Diagnostics [Member] Customers One through Five [Member] Supply Commitment [Axis] Supply Commitment [Member] Geographical [Axis] Non-US [Member] Personal Care Ingredients [Member] Advanced Materials [Member] Solesence [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Auditor Name Auditor Firm ID Auditor Location Statement of Financial Position [Abstract] ASSETS Current assets: Cash Trade accounts receivable, less allowance for doubtful accounts of $60 for December 31, 2021, and $9 for 2020 Inventories, net Prepaid expenses and other current assets Total current assets Equipment and leasehold improvements, net Operating leases, right of use Other assets, net  Total Current Assets LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Line of credit, bank Line of credit, related party Current portion of long-term debt, related party Current portion of finance lease obligations Current portion of operating lease obligations Accounts payable Current portion of deferred revenue Accrued expenses Total current liabilities Long-term portion of finance lease obligations Long-term portion of operating lease obligations Long-term debt, related party Long-term convertible loan, related party PPP Loan (SBA) Long-term portion of deferred revenue Asset retirement obligations Total long-term liabilities Contingent liabilities Stockholders’ equity: Preferred stock, $.01 par value, 24,088 shares authorized, and no shares issued and outstanding Common stock, $.01 par value, 55,000,000 shares authorized; 48,893,573 and 38,221,292 shares issued and outstanding on December 31, 2021 and December 31, 2020, respectively Additional paid-in capital Accumulated deficit Total stockholders’ equity Total liabilities and shareholder’s equity Allowance for doubtful accounts Preferred stock, par value (in dollars per share) Preferred stock, authorized Preferred stock, issued Preferred stock, outstanding Common stock, par value (in dollars per share) Common stock, authorized Common stock, issued Common stock, outstanding Statement [Table] Statement [Line Items] Revenue: Total revenue Operating expense: Cost of revenue Gross profit Research and development expense Selling, general and administrative expense Income from operations Interest expense Other income, net Income before provision for income taxes Provision for income taxes Net income Net income per share-basic Weighted average number of basic common shares outstanding Net income per share-diluted Weighted average number of diluted common shares outstanding Balance at beginning Balance at beginning (in shares) Stock option exercises Stock option exercises (in shares) Stock-based compensation Net income Issuances of shares and stock option exercises Issuances of shares and stock option exercises (in shares) Exercise of conversion rights – convertible loan, related party Exercise of conversion rights convertible loan, related party (in shares) Balance at ending Balance at ending (in shares) Statement of Cash Flows [Abstract] Operating activities: Net Income Adjustments to reconcile net income to cash provided by (used in) operating activities: Depreciation and amortization Gain on forgiveness of PPP loan Amortization of debt discount Share-based compensation Changes in assets and liabilities related to operations: Trade accounts receivable Inventories Prepaid expenses and other assets Accounts payable Deferred Revenue Accrued expenses Other long-term assets and liabilities Net cash used in operating activities Investing activities: Acquisition of equipment and leasehold improvements Net cash used in investing activities Financing activities: Principal payment on finance leases Proceeds from line of credit, bank Payments to the line of credit, bank Proceeds from PPP / SBA loan Proceeds from line of credit, Beachcorp LLC Payments to line of credit, Beachcorp LLC Proceeds from related party term loan Proceeds from exercise of stock options Net cash (used in) provided by financing activities Decrease in cash Cash at beginning of period Cash at end of period Supplemental cash flow information: Interest paid Supplemental non-cash investing and financing activities: Accounts payable incurred for the purchase of equipment and leasehold improvements Conversion of $2M convertible loan, related party Interest paid via stock issuance, convertible loan, related party Right of use asset acquired through operating lease Conversion of convertible loan, related party Organization, Consolidation and Presentation of Financial Statements [Abstract] Description of Business Accounting Policies [Abstract] Summary of Significant Accounting Policies Debt Disclosure [Abstract] Notes and Lines of Credit Inventory Disclosure [Abstract] Inventories Property, Plant and Equipment [Abstract] Equipment and Leasehold Improvements Leases [Abstract] Lease Commitments Payables and Accruals [Abstract] Accrued Expenses Income Tax Disclosure [Abstract] Income Taxes Equity [Abstract] Capital Stock Share-based Payment Arrangement [Abstract] Stock Options and Stock Grants Retirement Benefits [Abstract] 401(k) Profit-Sharing Plan Risks and Uncertainties [Abstract] Significant Customers and Contingencies Segment Reporting [Abstract] Business Segmentation and Geographical Distribution Commitments and Contingencies Disclosure [Abstract] Contingencies Use of Estimates and Risks and Uncertainties Cash Trade Accounts Receivable Inventories Equipment and Leasehold Improvements Long Lived Assets Deferred Revenue Asset Retirement Obligations Financial Instruments Product Revenue Other Revenue Research and Development Expenses Income Taxes Earnings Per Share New Accounting Pronouncements Activity in the asset retirement obligation account for the years ended December 31, is as follows: Contract balances for the year 2021 and 2020 Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows: Notes and lines of credit consist of the following: Schedule of Related Parties Inventories consist of the following: Equipment and leasehold improvements consist of the following: Quantitative information regarding the Company’s leases is as follows: Supplemental cash flow information related to leases is as follows for the years ended December 31, 2021 and 2020: The future maturities of the Company’s finance and operating leases as of December 31, 2021 are as follows: Accrued expenses consist of the following: A reconciliation of income tax expense to the amount computed by applying the Federal income tax rate to loss before provision for income taxes as of December 31, 2021 and 2020 is as follows: Significant components of our deferred income taxes consist of the following: We follow ASC Topic 718, Share-Based Payments, in which compensation expense is recognized only for share-based payments expected to vest. Schedule of assumptions used to calculate Black-Scholes option pricing model for options granted Additional disclosures for options granted for all years presented: Schedule of option activity The aggregate intrinsic value in the table above is based on our closing stock price of $4.40 on the last business day for the year ended December 31, 2021. We had five significant customers for the year ended December 31, 2021. Accounts receivable balances for these five customers were approximately: The revenues for 2021 and 2020 by category are as follows: Balance, beginning Accretion of liability due to passage of time Amortization of asset due to passage of time Balance, ending Accounts receivable net Contract liability Numerator: (in Thousands) Denominator: Weighted average additional shares assuming conversion of in-the-money stock options to common shares Weighted average number of diluted common shares outstanding Basic earnings per common share: Net income per share – basic Diluted earnings per common share: Net income per share – diluted Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Equipment leasehold improvements and leased assets useful life Deferred revenue Percentage of prepayments Revenue from contract with customer excluding assessed tax Revenue Tax rate reconciliation and settlement Options included in computation of earnings per share Schedule of Long-term Debt Instruments [Table] Debt Instrument [Line Items] Line of credit facility, description Line of Credit Facility, Commitment Fee Percentage Available Outsanding balance Short-term Debt Debt Instrument, Description of Variable Rate Basis Debt Instrument, Basis Spread on Variable Rate Debt Instrument, Interest Rate, Stated Percentage Debt Instrument, Maturity Date Line of Credit Facility, Expiration Date Debt Instrument, Face Amount Debt Instrument, Interest Rate Terms Debt Instrument, Date of First Required Payment Debt Instrument, Convertible, Conversion Price Share Price Debt Instrument, Unamortized Discount Interest Expense Conversion of Stock, Shares Issued Stock Issued During Period, Shares, New Issues Cash Long-term Debt Line of Credit Facility, Borrowing Capacity, Description Line of Credit Facility [Table] Line of Credit Facility [Line Items] Interest expense, related parties Accrued interest expense, related parties Due to Related Parties Raw materials Finished goods  Inventories, gross Allowance for excess quantities  Inventories, net Property plant and equipment,gross Less: Accumulated depreciation and amortization Property, Plant and Equipment, Net, Total Depreciation expense Components of lease cost Finance lease cost components: Amortization of finance lease assets Interest on finance lease liabilities Total finance lease costs Operating lease cost components: Operating lease cost Variable lease cost Short-term lease cost Total operating lease costs Total lease cost: Operating cash outflow from operating leases Lease liabilities arising from obtaining right-of-use assets Weighted-average remaining lease term-finance leases (in years) Weighted-average remaining lease term-operating leases (in years) Weighted-average discount rate-finance leases Weighted-average discount rate-operating leases Finance Leases, Year 1 Operating Leases, Year 1 Total, Year 1 Finance Leases, Year 2 Operating Leases, Year 2 Total, Year 2 Finance Leases, Year 3 Operating Leases, Year 3 Total, Year 3 Operating Leases, Year 4 Total, Year 4 Operating Leases, Year 5 Total, Year 5 Operating Leases, thereafter Total, thereafter Finance Lease, Liability, Payment, Due Lessee, Operating Lease, Liability, to be Paid Total payments Finance Lease, Liability, Undiscounted Excess Amount Lessee, Operating Lease, Liability, Undiscounted Excess Amount Less amounts representing interest Finance Leases, Total minimum payments required: Operating Leases, Total minimum payments required: Total, Total minimum payments required: Accrued payroll and related expenses Accrued accounts payable Tenant Security Deposit / Advance Rent Other  Total Income tax credit at statutory rates Nondeductible expenses Tax Exempt Income - PPP Loan Permanent Tax Deduction Stock Options Exercised State income tax, net of federal benefits Expiration of NOL & Credits Tax basis in excess of book Convertible Debt Expiration of Stock Options Other Change in valuation allowance  TOTAL Deferred tax liabilities:   Excess tax basis convertible debt      Total deferred tax liabilities Deferred tax assets:   Net operating loss carryforwards   Inventory and other allowances   Charitable contribution & other carryforwards   Excess (tax) book depreciation   Excess (tax) book amortization   Share-based compensation   Other accrued costs      Total deferred tax assets   Less:  Valuation allowance Deferred income taxes Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Line Items] Increase (decrease) in valuation allowance Net operating loss carryforwards Net operating loss carryforwards Deferred Tax Assets, Tax Credit Carryforwards Capital loss carryforwards expiration period start Capital loss carryforwards expiration period end Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Preferred stock, shares authorized Authorized, unissued shares of common stock Share-based compensation expense Remaining unrecognized compensation expense  Remaining weighted average-period, expense recognition (years) Weighted-average risk-free interest rates Dividend yield Weighted-average expected life (years) of the option Weighted-average expected stock price volatility Weighted-average fair value of the options granted Vesting period (years) of shares granted in period Contractual life (years) of shares granted in period Estimated forfeitures Shares Outstanding, Beginning Shares Outstanding Beginning, (per share) Granted Granted (per share) Exercised Exercised (per share) Forfeited or expired Forfeited or expired (per share) Shares Outstanding, Beginning Shares Outstanding Ending, (per share) Shares Outstanding (years) Shares Outstanding (Intrinsic value) Shares Exercisable Shares Exercisable, (per share) Shares Exercisable (years) Shares Exercisable (Intrinsic value) Shares for grants Shares exercised Total intrinsic value Cash received Shares based compensation payment award expiration period Employer's matching contribution percentage Percentage of employee's matching contribution Participant salary percentage matched Defined Contribution Plan, Cost Concentration Risk [Table] Concentration Risk [Line Items] Revenue from customers Total Supply Commitment [Table] Supply Commitment [Line Items] Equipment sale - net book value Equipment sale- original book value Revenue from External Customers by Products and Services [Table] Revenue from External Customer [Line Items] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Revenues from External Customers and Long-Lived Assets [Line Items] Revenues This element represents text block fact value Tabular disclosure of future maturities of finance and opertaing lease. This element represents a monetary value. This element represents a monetary value. This element represents a time fact value. This element represents a time fact value. This element represents a member fact value. This element is a member fact value. This element represents a monetary value. Customer one. Customer two. Customer three. Customer four. Customer five. Customers One through Five. Personal Care Ingredients. Advanced Materials. Solesence. The cash inflow from a Paycheck Protection Program Loan by the SBA. This element represents a monetary fact value. This element represents a monetary fact value. This element reprsents a monetary fact value. This element represents a monetary fact value. This element represents a monetary fact value. Percentage of equipment's net book value to be sold to customer after a triggering event as stated in the supply agreement. Percentage of equipment's original value, including upgrades; to be sold to customer after a triggering event as stated in the supply agreement. This element represents a member fact value. This element represents a member fact value. This element represents a table text block fact value. This element represents a percentage fact value. This element represents a duration fact value. This element represents a table text block fact value. Business loan agreement. Term loan. Beachcorp LLC. First amendment. Term Loan and The Revolver Facility. Second amendment. Third amendment. Fourth amendment. Secured Convertible Promissory Note. Bradford T Whitmore. Whit more member. Related Party Credit Facilities. Promissory note. Libertyville. This element represents member fact value. This element represents member fact value. This element represents member fact value. This element represents member fact value. This element represents a abstract fact value. This element represents a abstract fact value. Amount of finance lease costs recognized by lessee for lease contract. Amount of lessee's undiscounted obligation for lease payments due in second fiscal year following latest fiscal year. Amount of lessee's undiscounted obligation for lease payments due in third fiscal year following latest fiscal year. Amount of lessee's undiscounted obligation for lease payments due in fourth fiscal year following latest fiscal year. Amount of lessee's undiscounted obligation for lease payments due in fifth fiscal year following latest fiscal year. Amount of lessee's undiscounted obligation for lease payments due after fifth fiscal year following latest fiscal year. Amount of lessee's undiscounted obligation for lease payments. Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for leases. Present value of lessee's discounted obligation for lease payments. This element represents member fact value. This element represents member fact value. This element represents member fact value. This element represents member fact value. This element represents member fact value. This element represents member fact value. This element represents member fact value. This element represents member fact value. This element represents member fact value. This element represents a monetary fact value. This element represents a table text block fact value. This element represents a member fact value. This element represents a table text block fact value. Amount of lessee's undiscounted obligation for lease payments due in remainder of fiscal year following latest fiscal year ended. Secured Convertible Promissory Note Type of related party transaction. Assets, Current Liabilities, Current Liabilities, Noncurrent Liabilities and Equity Gross Profit Operating Income (Loss) Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Shares, Outstanding Gain On Forgiveness Of Ppp Loan Increase (Decrease) in Accounts Receivable Increase (Decrease) in Inventories Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Accounts Payable Increase (Decrease) in Accrued Liabilities Increase (Decrease) in Other Noncurrent Assets and Liabilities, Net Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment Net Cash Provided by (Used in) Investing Activities Finance Lease, Principal Payments Repayments of Lines of Credit Repayments of Related Party Debt Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Inventory, Policy [Policy Text Block] Property, Plant and Equipment, Policy [Policy Text Block] Revenue from Contract with Customer [Policy Text Block] Income Tax, Policy [Policy Text Block] Cash [Default Label] Inventory, Gross Inventory Valuation Reserves Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Total finance lease costs Operating Lease, Expense Lease, Cost Finance Lease, Liability, Payment, Due Lessee, Operating Lease, Liability, to be Paid Total payments Finance Lease, Liability, Undiscounted Excess Amount Lessee, Operating Lease, Liability, Undiscounted Excess Amount Less amounts representing interest Effective Income Tax Rate Reconciliation, Tax Exempt Income, Amount Effective Income Tax Rate Reconciliation, Noncontrolling Interest Income (Loss), Amount Effective Income Tax Rate Reconciliation, Other Adjustments, Amount Deferred Tax Liabilities, Financing Arrangements Deferred Tax Liabilities, Net Deferred Tax Assets, Valuation Allowance Operating Loss Carryforwards Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price EX-101.PRE 11 nanx-20211231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 12 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Cover - USD ($)
 12 Months Ended
Dec. 31, 2021
Mar. 31, 2022
Jun. 30, 2021
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Dec. 31, 2021    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2021    
Current Fiscal Year End Date --12-31    
Entity File Number 000-22333    
Entity Registrant Name NANOPHASE TECHNOLOGIES CORPORATION    
Entity Central Index Key 0000883107    
Entity Tax Identification Number 36-3687863    
Entity Incorporation, State or Country Code DE    
Entity Address, Address Line One 1319 Marquette Drive    
Entity Address, City or Town Romeoville    
Entity Address, State or Province IL    
Entity Address, Postal Zip Code 60446    
City Area Code 630    
Local Phone Number 771-6708    
Title of 12(b) Security Common Stock, par value $.01 per share    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Public Float     $ 27,240,325
Entity Common Stock, Shares Outstanding   48,893,573  
Auditor Name RSM US LLP    
Auditor Firm ID 49    
Auditor Location Chicago, Illinois    
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.22.1
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Current assets:    
Cash $ 657 $ 957
Trade accounts receivable, less allowance for doubtful accounts of $60 for December 31, 2021, and $9 for 2020 3,937 2,932
Inventories, net 6,095 4,340
Prepaid expenses and other current assets 910 606
Total current assets 11,599 8,835
Equipment and leasehold improvements, net 4,712 2,868
Operating leases, right of use 12,075 1,827
Other assets, net 8 10
 Total Current Assets 28,394 13,540
Current liabilities:    
Line of credit, bank 500
Line of credit, related party 1,351 2,155
Current portion of long-term debt, related party 500
Current portion of finance lease obligations 105 177
Current portion of operating lease obligations 1,983 431
Accounts payable 3,566 2,126
Current portion of deferred revenue 783 411
Accrued expenses 946 484
Total current liabilities 8,734 6,784
Long-term portion of finance lease obligations 6 110
Long-term portion of operating lease obligations 10,306 1,651
Long-term debt, related party 1,000
Long-term convertible loan, related party 1,097
PPP Loan (SBA) 952
Long-term portion of deferred revenue 661
Asset retirement obligations 222 214
Total long-term liabilities 12,195 4,024
Contingent liabilities
Stockholders’ equity:    
Preferred stock, $.01 par value, 24,088 shares authorized, and no shares issued and outstanding
Common stock, $.01 par value, 55,000,000 shares authorized; 48,893,573 and 38,221,292 shares issued and outstanding on December 31, 2021 and December 31, 2020, respectively 489 382
Additional paid-in capital 104,423 102,117
Accumulated deficit (97,447) (99,767)
Total stockholders’ equity 7,465 2,732
Total liabilities and shareholder’s equity $ 28,394 $ 13,540
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.22.1
CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Statement of Financial Position [Abstract]    
Allowance for doubtful accounts $ 60 $ 9
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, authorized 24,088 24,088
Preferred stock, issued 0 0
Preferred stock, outstanding 0 0
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, authorized 55,000,000 55,000,000
Common stock, issued 48,893,573 38,221,292
Common stock, outstanding 48,893,573 38,221,292
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.22.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Revenue:    
Total revenue $ 29,475 $ 17,123
Operating expense:    
Cost of revenue 20,785 11,133
Gross profit 8,690 5,990
Research and development expense 2,235 1,571
Selling, general and administrative expense 3,896 2,934
Income from operations 2,559 1,485
Interest expense (1,154) (496)
Other income, net 952
Income before provision for income taxes 2,357 989
Provision for income taxes 37
Net income $ 2,320 $ 989
Net income per share-basic $ 0.05 $ 0.03
Weighted average number of basic common shares outstanding 45,021,173 38,158,586
Net income per share-diluted $ 0.05 $ 0.03
Weighted average number of diluted common shares outstanding 47,039,173 38,545,586
Product [Member]    
Revenue:    
Total revenue $ 29,325 $ 16,422
Product and Service, Other [Member]    
Revenue:    
Total revenue $ 150 $ 701
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.22.1
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Balance at beginning at Dec. 31, 2019 $ 381 $ 101,886 $ (100,756) $ 1,511
Balance at beginning (in shares) at Dec. 31, 2019 38,136,792      
Stock option exercises $ 1 36 37
Stock option exercises (in shares)   84,500      
Stock-based compensation 195 195
Net income 989 989
Balance at ending at Dec. 31, 2020 $ 382 102,117 (99,767) $ 2,732
Balance at ending (in shares) at Dec. 31, 2020 38,221,292      
Stock option exercises (in shares)         535,100
Stock-based compensation 160 $ 160
Net income 2,320 2,320
Issuances of shares and stock option exercises $ 6 228 234
Issuances of shares and stock option exercises (in shares)   576,726      
Exercise of conversion rights – convertible loan, related party $ 101 1,918 2,019
Exercise of conversion rights convertible loan, related party (in shares)   10,095,555      
Balance at ending at Dec. 31, 2021 $ 489 $ 104,423 $ (97,447) $ 7,465
Balance at ending (in shares) at Dec. 31, 2021 48,893,573      
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.22.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Operating activities:    
Net Income $ 2,320 $ 989
Adjustments to reconcile net income to cash provided by (used in) operating activities:    
Depreciation and amortization 454 358
Gain on forgiveness of PPP loan (952)
Amortization of debt discount 903 267
Share-based compensation 160 195
Changes in assets and liabilities related to operations:    
Trade accounts receivable (1,005) (1,962)
Inventories (1,755) (1,786)
Prepaid expenses and other assets (304) (339)
Accounts payable 1,026 295
Deferred Revenue 1,033 (164)
Accrued expenses 481 113
Other long-term assets and liabilities (40) (27)
Net cash used in operating activities 2,321 (2,061)
Investing activities:    
Acquisition of equipment and leasehold improvements (1,874) (878)
Net cash used in investing activities (1,874) (878)
Financing activities:    
Principal payment on finance leases (177) (218)
Proceeds from line of credit, bank 500 2,000
Payments to the line of credit, bank (1,000) (2,000)
Proceeds from PPP / SBA loan 952
Proceeds from line of credit, Beachcorp LLC 24,750 14,515
Payments to line of credit, Beachcorp LLC (25,554) (12,584)
Proceeds from related party term loan 500
Proceeds from exercise of stock options 234 37
Net cash (used in) provided by financing activities (747) 2,702
Decrease in cash (300) (237)
Cash at beginning of period 957 1,194
Cash at end of period 657 957
Supplemental cash flow information:    
Interest paid 218 178
Supplemental non-cash investing and financing activities:    
Accounts payable incurred for the purchase of equipment and leasehold improvements 414 83
Conversion of $2M convertible loan, related party 2,000
Interest paid via stock issuance, convertible loan, related party 19
Right of use asset acquired through operating lease $ 10,505
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.22.1
CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)
 12 Months Ended
Dec. 31, 2021
USD ($)
Statement of Cash Flows [Abstract]  
Conversion of convertible loan, related party $ 2,000,000
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.22.1
Description of Business
 12 Months Ended
Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Description of Business

 

(1) Description of Business

 

Nanophase Technologies Corporation (“Nanophase,” “Company,” “we,” “our,” or “us”) is a science-driven company which, along with its wholly owned subsidiary, Solésence, LLC (our “Solésence beauty science subsidiary”), is focused in various beauty- and life-science markets.  Using consumer health as our end-goal and science and innovation to guide the path, skin health and medical diagnostics combined currently make up the great majority of our business and drive our forward growth strategy.  We offer engineered materials, formulation development and commercial manufacturing through an integrated family of technologies. Our expertise in materials engineering allows us to effectively coat and disperse particles on a nano and “non-nano” scale for use in a variety of skin health markets, including for use in sunscreens as active ingredients and as fully developed prestige skin care and cosmetics products, marketed and sold through our Solésence beauty science subsidiary.  In terms of our life sciences focus, we have seen current conditions significantly increase demand for our medical diagnostics ingredients, as testing for various viruses, most notably COVID-19, has become a critical use of our technology.  Additionally, we continue to sell products in legacy markets, including architectural coatings, industrial coating applications, abrasion-resistant additives, plastics additives, and surface finishing technologies (polishing) applications, all of which, along with medical diagnostics, fall into the advanced materials product category. 

 

 We target markets, primarily related to skin health products and ingredients, as well as diagnostic life sciences ingredients where we believe our materials and products offer practical and competitive minerals-based solutions. We traditionally work closely with current customers in these target markets to identify their material and performance requirements. We market our materials to various end-use applications manufacturers, and our Solésence® products to cosmetics and skin care brands.

 

Recently developed technologies have made certain new products possible and opened potential new markets. During 2015 we were granted a patent on a new type of particle surface treatment (coating) — now called Active Stress Defense ™ Technology — which became the cornerstone of our new product development in personal care, with first revenue recognized during 2016. Active Stress Defense™ now refers to a suite of three proprietary technologies — Original Active Stress Defense™, Kleair™, and Bloom™ — all three of which either utilize a unique and proprietary, mineral-based technology or work synergistically with one of our unique and proprietary, mineral-based technologies to improve performance and/or aesthetics. Our ongoing innovation efforts include new IP in areas that advance environmental protection, align with market needs, and complement our existing technologies Through the creation of our Solésence beauty science subsidiary, we utilize our technology suite to manufacture and sell fully developed solutions to targeted customers in the skin care industry, typically in prestige skin care and cosmetics markets, in addition to the ingredients we have traditionally sold in the personal care area. 

 

Although our primary strategic focus has been the North American market, we currently sell materials to customers overseas and have been working to expand our reach within foreign markets. Our common stock trades on the OTCQB marketplace under the symbol NANX. 

 

While product sales comprise the majority of our revenue, we also recognize revenue from other sources from time to time. These activities are not expected to drive the long-term growth of the business. For this reason, we classify such revenue as “other revenue” in our Consolidated Statements of Operations, as it does not represent revenue directly from the sale of our products. 

 

 The Company has recorded positive net income and positive cash flow from operations in 2021. We have also significantly improved our borrowing flexibility and capacity in early 2022, as discussed in Note 3. Based upon our financial performance, as well as our current liquidity and available borrowing capacity, there is not substantial doubt regarding the Company's ability to continue as a going concern.
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.22.1
Summary of Significant Accounting Policies
 12 Months Ended
Dec. 31, 2021
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

 

(2) Summary of Significant Accounting Policies

 

Use of Estimates and Risks and Uncertainties

 

The preparation of financial statements requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. Certain assumptions are also necessary to assess the impact of risks and uncertainties on the financial statements, such as cash flow projections, availability of capital if needed to support the ongoing operations of the business, and our expected compliance with contractual commitments. These risks and uncertainties are further discussed in Note 12. Any changes in these assumptions or business plans could have a material impact on the financial statements.

 

 

Cash

 

The Cash balance on December 31, 2021 consists of funds borrowed from our Revolving Line of Credit, which is facilitated by Beachcorp, LLC. Our ability to access cash from our credit facility solely depends on carrying an Accounts Receivable balance greater than the outstanding loan balance in the Revolving Line of Credit. As part of the agreement, we are required to have a bank account in place to act as a depository account for our customers. This account is referred to as the Control Account. Furthermore, there is an Account Control Agreement in place which provides Beachcorp, LLC the ability to exercise control over the account via approval of requested transfers. According to our agreements with Beachcorp, LLC, Nanophase is to be the party initiating any transfers, whether to Nanophase or to Beachcorp, LLC, and approval to access any monies within this account can only be withheld by Beachcorp, LLC if the borrowing base falls below the Company’s qualified receivables, or if we are in arrears with respect to interest payments due Beachcorp, LLC. The failure of Nanophase to remedy the previously mentioned conditions could lead to Beachcorp, LLC gaining the right, through a “springing” feature administered by Libertyville Bank and Trust, a Wintrust Community Bank (“Libertyville”), to transfer funds to itself without direct approval from Nanophase.  Cash is held at a federally insured institution, but our cash balances at times exceed insured limits. The Company has not experienced any losses related to these statutory limits.

 

 Trade Accounts Receivable

 

Trade accounts receivable are carried at original invoice amount less an estimate made for doubtful receivables based on a review of all outstanding amounts on a monthly basis. We determine the allowance for doubtful accounts by identifying troubled accounts and by using historical experience applied to an aging of accounts. Trade accounts receivable are written off when deemed uncollectible. Recoveries of trade accounts receivable previously written off are recorded when received. Our typical credit terms are between thirty and sixty days from shipment and invoicing.

 

Inventories

 

Inventories are stated at the lower of cost, maintained on an average cost basis, or net realizable value. We have recorded allowances to reduce inventory relating to excess quantities of certain materials. Write-downs of inventories establish a new cost basis, which is not increased for future increases in market value of inventories or changes in estimated excess quantities.

 

Equipment and Leasehold Improvements

 

Equipment is stated at cost and is being depreciated over its estimated useful life (3-20 years) using the straight-line method. Leasehold improvements are stated at cost and are being amortized using the straight-line method over the shorter of the useful life of the asset or the term of the lease (3-7 years). Depreciation expense for leased assets is included with depreciation expense for owned assets. From time to time we have self-constructed assets. These assets are stated at cost plus the capitalization of labor and are depreciated over an estimated useful life (7-10 years) using the straight-line method.

 

Long Lived Assets

 

We review long-lived assets for impairment whenever events or changes in circumstances indicate that the asset’s carrying amount may not be recoverable. We conduct long-lived asset impairment analyses in accordance with ASC 360-10-15, Impairment or Disposal of Long-Lived Assets. ASC 360-10-15 requires us to group assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities and evaluate the asset group against the sum of the undiscounted future cash flows. If the undiscounted cash flows do not indicate the carrying amount of the asset is recoverable, an impairment charge is measured as the amount by which the carrying amount of the asset group exceeds its fair value based on discounted cash flow analysis or appraisals. Based upon our analysis, there were no impairment charges recognized in either period presented.

 

Deferred Revenue

 

The Company records a contract liability for development projects due to the contractual billing of these projects not always aligning with revenue recognition. In addition, it is now the Company’s policy to frequently require deposits relating to the initial production of our Solésence products. Of the total $1,444 in deferred revenue reported in 2021, approximately 70% is comprised of prepayment received from our medical diagnostics application customer for purchase orders to be filled in 2022 and 2023, 25% related to prepayments received from new customers as per Company policy, and the remaining 5% related to prepayments from a product development agreement with a personal care ingredient customer.

 

 

Asset Retirement Obligations

 

In connection with our leased facilities, we are required to remove certain leasehold improvements upon termination of our occupancy. We follow the provisions of the FASB issued ASC 410-20, Asset Retirement Obligations, under which we recognize a liability for the fair value of these asset retirement obligations. The fair value of that liability is measured based on an expected cash flow approach and accretion expense is recognized each period to recognize increases to the fair value of the liability due to the passage of time. Increases to the fair value of the liability, except for accretion, are added to the carrying value of the long-lived asset. Those increases are then reported in amortization expense over the estimated useful life of the long-lived asset.

 

        Activity in the asset retirement obligation account for the years ended December 31, is as follows:

 

   2021   2020 
Balance, beginning  $214   $206 
Accretion of liability due to passage of time   8    8 
Amortization of asset due to passage of time   —    — 
Balance, ending  $222   $214 

 

 

Financial Instruments

 

We follow ASC Topic 820, Fair Value Measurements and Disclosures, which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. The fair value framework requires the categorization of assets and liabilities into three levels based upon the assumptions (inputs) used to price the assets or liabilities. Level 1 provides the most reliable measure of fair value, whereas Level 3 generally requires significant management judgment.

 

Our financial instruments include cash, any cash equivalents, accounts receivable, accounts payable and accrued expenses, along with any short term and long-term borrowings as described in Note 3. There were no financial instruments adjusted to fair value on December 31, 2021 and 2020.

 

Product Revenue

 

Revenues are recognized when control of the promised goods is transferred to customers, in an amount that reflects the consideration we expect to receive in exchange for those goods. When our ingredients and finished products are shipped, with control being transferred at the shipping point almost universally, is the point in time at which we recognize the related revenue.

 

We generally expense sales commissions when incurred because the amortization period would have been one year or less. These costs are recorded within selling, general and administrative expenses. Customers’ deposits, deferred revenue and other receipts are deferred and recognized when the revenue is realized and earned. Cash payments to customers are classified as reductions of revenue in our statements of operations.

 

Contract balances for the year 2021 and 2020

Contract balances for the year ended December 31, 2021 is as follows:

 

   Accounts
Receivable,
net		   Contract
Assets		   Contract
Liabilities		 
Balance, beginning  $2,932   $—   $411 
Balance, ending   3,937    —    1,444 

 

Contract balances for the year ended December 31, 2020 is as follows:

 

   Accounts
Receivable,
net		   Contract
Assets		   Contract
Liabilities		 
Balance, beginning  $970   $—   $575 
Balance, ending   2,932    —    411 

 

 

Revenue recognized in the reporting period that was included in the contract liability balance at the beginning of the period was $260 and $468 for the years ended December 31, 2021 and 2020, respectively.

 

Other Revenue

 

Other revenue may include revenue from technology license fees and paid development projects. Technology license fees and paid development projects are recognized over time when the obligations under the agreed upon contractual arrangements are performed on our part.  Revenue recognized over time was $150 and $701 for the years ended December 31, 2021 and 2020, respectively.

 

Research and Development Expenses

 

Research and development expenses are recognized as expense when incurred.

 

Income Taxes

 

We account for income taxes using the liability method. As such, deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Deferred tax assets and liabilities are calculated using the enacted tax rates and laws that are expected to be in effect when the anticipated reversal of these differences is scheduled to occur. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some or all of the deferred tax assets will not be realized.

 

When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured, as described above, is reflected as a liability for uncertain tax benefits in the accompanying balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination.

 

We have not recorded a reserve for any tax positions for which the ultimate deductibility is highly certain but for which there is uncertainty about the timing of such deductibility. We file tax returns in all appropriate jurisdictions, which includes a federal tax return and Illinois state tax return. When and if applicable, potential interest and penalty costs are accrued as incurred, with expenses recognized in selling, general and administrative expenses in the statements of operations. As of December 31, 2021, and 2020, we had no liability for unrecognized tax benefits.

 

Earnings Per Share

 

Options to purchase approximately 2,018,000 shares of common stock that were outstanding as of December 31, 2021 were included in the computation of earnings per share for the year ended December 31, 2021.  Options to purchase approximately 387,000 shares of common stock that were outstanding as of December 31, 2020 were included in the computation of earnings per share for the year ended December 31, 2020.

 

Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows:

 

               
   Years Ended December 31, 
   2021   2020 
Numerator: (in Thousands)        
Net income  $2,320   $989 
           
Denominator:          
Weighted average number of basic common shares outstanding   45,021,173    38,158,586 
Weighted average additional shares assuming conversion of in-the-money stock options to common shares   2,018,000    387,000 
Weighted average number of diluted common shares outstanding   47,039,173    38,545,586 
           

Basic earnings per common share:

          
Net income per share – basic  $0.05   $0.03 
Diluted earnings per common share:          
Net income per share – diluted  $0.05   $0.03 

 

 

 

New Accounting Pronouncements

 

 In June 2016, the FASB issued ASU 2016-13, “Measurement of Credit Losses on Financial Instruments,” which replaces existing incurred loss impairment guidance and establishes a single allowance framework for financial assets carried at amortized cost. The effective date for our adoption (as amended) of this updated Standard will be January 1, 2023. The Company is currently evaluating the impact of the adoption of this standard on the consolidated financial statements.

 
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.22.1
Notes and Lines of Credit
 12 Months Ended
Dec. 31, 2021
Debt Disclosure [Abstract]  
Notes and Lines of Credit

 

(3) Notes and Lines of Credit

 

Notes and lines of credit consist of the following:

 

         As of December 31, 
        2021   2020 
   Rate    Available   Outstanding
Balance		   Available   Outstanding
Balance		 
Libertyville Bank & Trust (1)    4.25%    $30   $—   $30   $— 
Libertyville Bank & Trust (2)   4.25%     n/a    n/a    500    500 
Libertyville Bank & Trust (2)   4.25%     500    —    n/a    n/a 
Beachcorp, LLC (3)   5.25%     3,467    1,351    2,776    2,155 
Beachcorp, LLC (3)   5.25%    $1,000   $1,000   $500   $500 
Secured convertible promissory note (4)   2.00%     —    —    2,000    1,097 
PPP Loan / Libertyville promissory note (5)   1.00%     —    —    952    952 
Beachcorp, LLC (6)   4.00%     n/a    n/a    n/a    n/a 
Beachcorp, LLC (7)   4.00%     n/a    n/a    n/a    n/a 
Strandler, LLC (8)   4.00%     n/a    n/a    n/a    n/a 

 

1)Since July 2014, we have maintained a bank-issued letter of credit for up to $30 in borrowings, with interest at the prime rate plus 1%, to support our obligations under our Romeoville, Illinois facility lease agreement. No borrowings have been incurred under this promissory note. It is our intention to renew this note annually. Because there were no amounts outstanding on the note at any time during 2021 or 2020, we have recorded no related liability on our balance sheet.

 

 

2)The Company maintains a credit agreement with Libertyville which most recently served the primary purpose of insuring that it met its cash balance requirements at quarter end relating to a contract with the Company’s largest customer. Outstanding borrowings were $500 on this line of credit as of December 31, 2020. Interest on drawn balances was at the prime rate plus 1%. On December 21, 2021, the existing credit agreement with Libertyville was converted for use to support our obligations under our newly leased manufacturing and warehouse space in Bolingbrook, Illinois. Interest on drawn balances will be at the prime rate plus 1%. This credit agreement has a maturity of December 22, 2022. We expect to renew this agreement annually, as the lease requires. This credit agreement is secured by all the unencumbered assets of the Company, and has superior collateral rights to those credit facilities with Beachcorp, LLC and Strandler, LLC.

 

3)On November 16, 2018, we entered into a Business Loan Agreement (the “Master Agreement”) with Beachcorp, LLC. The Master Agreement relates to two loan facilities, each evidenced by a separate promissory note dated as of November 16, 2018: a term loan to the Company of up to $500 to be disbursed in a single advance (the “Term Loan”) with a fixed annual interest rate of 8.25%, payable quarterly, and with principal due on December 31, 2020; and an asset-based revolving loan facility for the Company of up to $2,000 (the “A/R Revolver Facility”), with floating interest accruing at the prime rate plus 3% (8.25% minimum) per year, with a borrowing base consisting of qualified accounts receivable of the Company, and a maturity of March 31, 2020, as amended. On March 23, 2020, the Company and Beachcorp, LLC executed the First Amendment to our Master Agreement that extended the maturities of both the Term Loan and the A/R Revolver Facility to March 31, 2021. Effective September 8, 2020, the Company and Beachcorp, LLC executed the Second Amendment to our Master Agreement that expanded the limit on the A/R Revolver Facility from $2,000 to $2,750.  On December 23, 2020, the Company and Beachcorp, LLC executed the Third Amendment to our Master Agreement that expanded the limit on the A/R Revolver Facility from $2,750 to $4,000 and extended the maturities of both the Term Loan and the A/R Revolver Facility to March 31, 2022. Effective April 21, 2021 the Company and Beachcorp, LLC executed the Fourth Amendment to our Master Agreement that expanded the limit on the A/R Revolver Facility from $4,000 to $6,000, changed the interest rate to fully floating and reduced the rate to the prime rate plus 2%, also extending the maturity of the A/R Revolver Facility to March 31, 2023. This amendment also increased the amount of the Term Loan from $500 to $1,000, changed the interest rate to fully floating and reduced the rate to the prime rate plus 2%. The maturity of the Term Loan remained March 31, 2022. The Term Loan and A/R Revolver Facility are secured by all the unencumbered assets of the Company and subordinated to Libertyville’s secured interest under the New Business Loan Credit Agreement. The Master Agreement substantially restricts the Company’s ability to incur additional indebtedness during the terms of both the Term Loan and the A/R Revolver Facility.

 

4)On November 20, 2019, we entered into a 2% Secured Convertible Promissory Note with Bradford T. Whitmore in the principal amount of $2,000 (the “Convertible Note”). The principal amount was payable in a single payment on May 15, 2024 (the “Maturity Date”). The principal amount of the Convertible Note accrued interest at the rate of 2.0% per year, which interest was payable semi-annually on the 15th day of May and November, commencing on May 15, 2020. The principal amount and, at the holder’s option, accrued interest under the Convertible Note was convertible at the holder’s option into additional shares of the Company’s common stock in whole or in part and from time to time up to the Maturity Date at a conversion price of $0.20 per share. The convertible note contained a beneficial conversion feature since the Company’s stock was trading at $0.32 per share on the date the Company entered into the agreement. The intrinsic value of the beneficial conversion feature was $1.2 million on November 20, 2019 and was recorded as a discount on the convertible note. The discount was to be accreted to the convertible note over the life of the note using the straight-line method. The offset to these discounts was interest expense. The Company recognized amortized interest expense relating to this discount of $267 in 2020. Upon exercise of the conversion right in 2021, the acceleration of the remaining discount, in addition to the amortization of interest in 2021 prior to the conversion, amounted to $903, all of which was recognized as interest expense. Mr. Whitmore chose to exercise his conversion rights effective May 7, 2021, with any interest to be paid in the form of shares, as allowed in the Convertible Note. In addition to the 10,000,000 shares issued upon conversion, the Company issued 95,555 shares of additional stock to Mr. Whitmore in lieu of cash for the $19 in accrued interest owed at May 7, 2021. The note and related interest obligations were paid in full and cancelled in May, 2021 via conversion.

 

5)On April 17, 2020, we entered into a Promissory Note (the “PPP Note”), dated as of April 16, 2020, in favor of Libertyville in the principal amount of $952 for our loan under the Paycheck Protection Program (“PPP”). The Company was allowed to apply for forgiveness of the amount due on the PPP Note in an amount equal to the sum of the following costs incurred during the 24-week period beginning on the date of the first disbursement of the loan: (a) payroll costs, (b) any payment of interest on a covered obligation (which shall not include any prepayment of or payment of principal on a covered mortgage obligation), (c) any payment on a covered rent obligation, and (d) any covered utility payment, calculated in accordance with the terms of the CARES Act. The principal amount of the PPP Note would have accrued interest at the rate of 1.00% per year. The Company applied for, and received, PPP forgiveness during the first quarter of 2021. Under the terms of the PPP loan, it is subject to audit for six years from the date of forgiveness. If any portion of the PPP loan were to be deemed ineligible, the Company could be required to repay the funds. On December 31, 2021, the balance under the PPP note was $0.

 

 

6)On January 28, 2022 the Company entered into an Amended and Restated Business Loan Agreement (the “A&R Loan Agreement”), which amends and restates the Master Agreement between the Company and Beachcorp, LLC, and a new promissory note in order to evidence the A/R Revolver facility, including an amendment to expand the limit on the A/R Revolver Facility from $6,000 to $8,000, reduce the interest rate to the prime rate plus 0.75%, and extend the maturity of the A/R Revolver Facility to March 31, 2024.

 

7)On January 28, 2022 the Company entered into the A&R Loan Agreement and a new revolving loan agreement (“Inventory Facility”) with Beachcorp, LLC, and a new promissory note in order to evidence the Inventory Facility. The maximum borrowing amount under the Inventory Facility is $4,000, with a borrowing base consisting of up to 50% of the value of qualified inventory of the Company. The interest rate for the Inventory Revolver is at the prime rate plus 0.75%, and it matures on March 31, 2024.

 

8)On January 28, 2022 the Company entered into an additional Business Loan Agreement (the “New Term Loan Agreement”) with Strandler, LLC, which effectively transferred or assigned the Term Loan to Strandler, LLC from Beachcorp, LLC. Interest on the New Term Loan is at the prime rate plus 0.75%, and it matures on March 31, 2024. Strandler, LLC is also an affiliate of Bradford T. Whitmore.

 

 

Related party interest expense consists of the following:

 

         
   Twelve Months Ended December 31, 
   2021   2020 
Interest expense, related parties  $1,129   $452 

 

Accrued interest consists of the following:

 

         
   As of December 31, 
   2021   2020 
Accrued interest expense, related parties  $13   $20 

 

Outstanding balances associated with related parties are as follows:

 

   As of December 31, 
   2021   2020 
Beachcorp, LLC  $2,351   $2,655 
Secured convertible promissory note   —    1,097 
Strandler, LLC   n/a    n/a 

 

Beachcorp, LLC and Strandler, LLC are affiliates of Mr. Bradford T. Whitmore, who beneficially owns a majority of the Company’s common stock and is the brother of Ms. R. Janet Whitmore, a director of the Company and the chair of the Company’s board of directors. The A/R Revolver Facility, the Inventory Facility and the New Term Loan are all secured by all the unencumbered assets of the Company and subordinated to the Company’s credit facility with Libertyville Bank & Trust. 
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.22.1
Inventories
 12 Months Ended
Dec. 31, 2021
Inventory Disclosure [Abstract]  
Inventories

 

(4) Inventories  

 

Inventories consist of the following:

 

               
   As of December 31, 
   2021   2020 
Raw materials  $4,819   $2,825 
Finished goods   1,682    1,545 
 Inventories, gross   6,501    4,370 
Allowance for excess quantities   (406)   (30)
 Inventories, net  $6,095   $4,340 

 

 
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.22.1
Equipment and Leasehold Improvements
 12 Months Ended
Dec. 31, 2021
Property, Plant and Equipment [Abstract]  
Equipment and Leasehold Improvements

 

(5)

Equipment and Leasehold Improvements

 

Equipment and leasehold improvements consist of the following: 

 

   As of December 31, 
   2021   2020 
Machinery and equipment  $18,289   $16,758 
Office equipment   961    870 
Office furniture   110    110 
Leasehold improvements   4,900    4,850 
Construction in progress   1,062    445 
    25,322    23,033 
Less: Accumulated depreciation and amortization   (20,610)   (20,165)
   $4,712   $2,868 

 

Depreciation expense was $444 and $348, for the years ended December 31, 2021 and 2020, respectively.
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.22.1
Lease Commitments
 12 Months Ended
Dec. 31, 2021
Leases [Abstract]  
Lease Commitments

 

(6) Lease Commitments

 

The Company’s operating lease portfolio is comprised of operating leases for office, warehouse space and equipment. Certain of the Company’s leases include one or more options to renew or terminate the lease at the Company’s discretion. The Company regularly evaluates the renewal and termination options and when they are reasonably certain of exercise, includes the renewal or termination option in our lease term. During the first seven months of the term of our newly leased building, we have subleased a portion of the unused floorspace on a temporary basis. This sublease may convert to a month-to-month lease upon expiration.

 

As of December 31, 2021, the ROU asset had a balance of $12,075 which is included in the “Operating lease right-of-use assets” line item of these consolidated financial statements and current and non-current lease liabilities related to the ROU asset of $1,983 and $10,306, respectively.  As of December 31, 2020, the ROU asset had a balance of $1,827 which is included in the “Operating lease right-of-use assets” line item of these consolidated financial statements and current and non-current lease liabilities related to the ROU asset of $431 and $1,651, respectively.  These amounts are included in the “Current portion of operating lease obligations” and “Long-term portion of operating lease obligations” line items of these consolidated financial statements. The discount rates used for leases accounted for under ASC 842 are based on an interest rate yield curve developed for the leases in the Company’s portfolio.

 

The office leases contain variable lease payments which consist primarily of rent escalations based on an established index or rate and taxes, insurance, and common area or other maintenance costs, which are paid based on actual costs incurred by the lessor. The Company has elected to utilize the available practical expedient to not separate lease and non-lease components.

 

Quantitative information regarding the Company’s leases is as follows:

 

         
   Twelve Months Ended December 31, 2021   Twelve Months Ended December 31, 2020 
Components of lease cost          
Finance lease cost components:          
Amortization of finance lease assets  $52   $70 
Interest on finance lease liabilities   18    36 
Total finance lease costs   70    106 
Operating lease cost components:          
Operating lease cost   554    565 
Variable lease cost   134    146 
Short-term lease cost   49    33 
Total operating lease costs   737    744 
Total lease cost:  $807   $850 

 

Supplemental cash flow information related to leases is as follows for the years ended December 31, 2021 and 2020:

 

   2021   2020 
Cash paid for amounts included in the measurement of lease liabilities:          
Operating cash outflow from operating leases  $741   $690 
           
Lease liabilities arising from obtaining right-of-use assets   10,505    — 
Weighted-average remaining lease term-finance leases (in years)   0.7    1.4 
Weighted-average remaining lease term-operating leases (in years)   9.5    3.2 
Weighted-average discount rate-finance leases   9.3%   9.3%
Weighted-average discount rate-operating leases   7.5%   14.3%

 

 

The future maturities of the Company’s finance and operating leases as of December 31, 2021 are as follows:

 

    Finance
Leases		   Operating
Leases		   Total 
2022   $109   $1,456   $1,565 
2023    6    2,099    2,105 
2024    —    2,025    2,025 
2025    —    1,470    1,470 
2026    —    1,468    1,468 
Thereafter    —    8,668    8,668 
Total payments   $115   $17,186   $17,301 
Less amounts representing interest    (4)   (4,897)   (4,901)
Total minimum payments required   $111   $12,289   $12,400 

 

The future maturities of the Company’s finance and operating leases as of December 31, 2020 were as follows:

 

    Finance
Leases		   Operating
Leases		   Total 
2021   $196   $701   $897 
2022    109    720    829 
2023    5    705    710 
2024    —    595    595 
2025    —    1    1 
Thereafter    —    —    — 
Total payments   $310   $2,722   $3,032 
Less amounts representing interest    (23)   (640)   (663)
Total minimum payments required   $287   $2,082   $2,369 

 
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.22.1
Accrued Expenses
 12 Months Ended
Dec. 31, 2021
Payables and Accruals [Abstract]  
Accrued Expenses

 

(7) Accrued Expenses

 

Accrued expenses consist of the following:

 

               
   As of December 31, 
   2021   2020 
Accrued payroll and related expenses  $471   $315 
Accrued accounts payable   320    122 
Tenant Security Deposit / Advance Rent   122    — 
Other   33    47 
 Total  $946   $484 

 
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.22.1
Income Taxes
 12 Months Ended
Dec. 31, 2021
Income Tax Disclosure [Abstract]  
Income Taxes

(8)Income Taxes

 

Our net income tax provision, including both current and deferred, related to U.S. federal and state income taxes, is $37. This is due to a change in law for the state of Illinois limiting the use of net loss deductions to $100 each year for tax years ending on or after December 31, 2021, and before December 31, 2024. Our current federal and deferred tax expenses are zero.

 

 

A reconciliation of income tax expense to the amount computed by applying the Federal income tax rate to loss before provision for income taxes as of December 31, 2021 and 2020 is as follows:

 

   2021   2020 
Income tax credit at statutory rates  $495   $208 
Nondeductible expenses   —    5 
Tax Exempt Income - PPP Loan   (271)   — 
Permanent Tax Deduction Stock Options Exercised   (63)   — 
State income tax, net of federal benefits   177    74 
Expiration of NOL & Credits   899    2,543 
Tax basis in excess of book Convertible Debt   —    — 
Expiration of Stock Options   92    122 
Other   2    (7)
Change in valuation allowance   (1,294)   (2,945)
 TOTAL  $37    — 

 

Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred income taxes consist of the following:

 

               
   As of December 31, 
   2021   2020 
Deferred tax liabilities:          
  Excess tax basis convertible debt  $—    (257)
     Total deferred tax liabilities   —    (257)
           
Deferred tax assets:          
  Net operating loss carryforwards  $14,566   $15,597 
  Inventory and other allowances   148    23 
  Charitable contribution & other carryforwards   —    9 
  Excess (tax) book depreciation   31    375 
  Excess (tax) book amortization   63    61 
  Share-based compensation   308    624 
  Other accrued costs   161    138 
     Total deferred tax assets   15,277    16,827 
           
  Less:  Valuation allowance   (15,277)   (16,570)
Deferred income taxes  $—   $— 

 

The valuation allowance decreased approximately $1.3 million and $6.4 million for the years ended December 31, 2021 and 2020, respectively (net of approximately $1 million and $6.3 million for the years ended December 31, 2021 and 2020, respectively, for expiring net operating loss carryforwards and credits) due principally to the change in the net operating loss carryforward and uncertainty as to whether future taxable income will be generated prior to the expiration of the carryforward period. Under the Internal Revenue Code, certain ownership changes, including the prior issuance of preferred stock and our public offering of common stock, may subject us to annual limitations on the utilization of our net operating loss carryforward. As of December 31, 2021, it has been determined that we are not subject to annual limitations on the utilization of our net operating loss carryforward.

 

We have federal net operating loss carryforwards for tax purposes of approximately $62 million on December 31, 2021. $57 million expire between 2022 and 2037. All net operating loss carryforwards generated after January 1, 2018 do not expire. Therefore, $5 million in net operating losses generated since January 1, 2018 do not expire. We have Illinois net loss deduction carryforwards for tax purposes of approximately $21 million on December 31, 2021. Due to the provisions of Illinois Public Act 102-0669 signed November 16, 2021, Illinois net loss deductions expire between 2029 and 2039.
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.22.1
Capital Stock
 12 Months Ended
Dec. 31, 2021
Equity [Abstract]  
Capital Stock

 

(9)

Capital Stock

 

As of December 31, 2021, and 2020, we had 24,088 authorized but unissued shares of preferred stock. In addition, as of December 31, 2020, we had 10,000,000 authorized but unissued shares of common stock reserved to meet the conversion requirement of the Convertible Note discussed in Note 3. These shares were issued at the conversion of this note in May of 2021.
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.22.1
Stock Options and Stock Grants
 12 Months Ended
Dec. 31, 2021
Share-based Payment Arrangement [Abstract]  
Stock Options and Stock Grants

 

(10) Stock Options and Stock Grants

 

We have entered into stock option agreements with certain officers, employees and directors. The stock options granted prior to the adoption of the 2019 Equity Compensation Plan (the “2019 Plan”) on November 19, 2019 generally expire ten years from the date of grant. Future options to be granted under the 2019 Plan will expire seven years from the date of grant.

 

Employee Stock Options

 

We follow ASC Topic 718, Share-Based Payments, in which compensation expense is recognized only for share-based payments expected to vest. 

 

               
   Years ended
December 31,		 
   2021   2020 
Share-based compensation expense  $160   $195 
Remaining unrecognized compensation expense   $1,581      
Remaining weighted average-period, expense recognition (years)   2.9      

 

 

We use the Black-Scholes option pricing model to determine the fair value of stock-based compensation. The Black-Scholes model requires us to make several assumptions, including the estimated length of time employees will retain their vested stock options before exercising them (“expected term”), the estimated volatility of our common stock price over the expected term, and estimated forfeitures. Expected price volatility is based on the daily market rate changes of our stock. The active shares granted prior to fiscal 2020 had a contractual life of 10 years as dictated by the 2010 Plan. The Black-Scholes model also requires a risk-free interest rate, which is based on the U.S. Treasury yield curve in effect at the time of the grant, and the dividend yield on our common stock, which is assumed to be zero since we do not pay dividends and have no current plans to do so in the future. Changes in these assumptions can materially affect the estimate of fair value of stock-based compensation and consequently, the related expense recognized on the statement of operations. We recognize stock-based compensation expense on a straight-line basis over the requisite service period. 

 

The following table illustrates the various assumptions used to calculate the Black-Scholes option pricing model for options granted for all years presented:

 

   Years Ended
December 31,		 
    2021   2020 
Weighted-average risk-free interest rates:   1.4%   0.5%
           
Dividend yield:   0%   0%
           
Weighted-average expected life (years) of the option:   5    5 
           
Weighted-average expected stock price volatility:   115%   95%
           
Weighted-average fair value of the options granted:  $2.59   $0.28 

  

 

Additional disclosures for options granted for all years presented:

 

   Years Ended
December 31,		 
    2021   2020 
Vesting period (years) of shares granted in period   3    3 
           
Contractual life (years) of shares granted in period   7    7 
           
Estimated forfeitures   4%   4%

 

The following table summarizes the option activity for our employees and directors during the year ended December 31, 2021:

 

Options  Shares
(Rounded)		   Weighted
Average
Exercise
Price
per Share		   Weighted
Average
Remaining
Contractual
Term (Years)		   Aggregate
Intrinsic
Value
(000s)		 
Outstanding on January 1, 2021   3,412,686   $0.57    —    — 
                     
Granted   567,500   $4.14    —    — 
Exercised   (535,100)  $0.44    —    — 
Forfeited or expired   (251,870)  $1.09    —    — 
                     
Outstanding on December 31, 2021   3,193,216   $1.18    5.1   $10,267 
Exercisable on December 31, 2021   2,189,378   $0.56    4.4   $8,405 
                     
Shares available for grant   1,887,500                

 

The aggregate intrinsic value in the table above is based on our closing stock price of $4.40 on the last business day for the year ended December 31, 2021.

 

             
   Years ended
December 31,		 
   2021   2020 
Shares exercised   535,100    84,500 
Total intrinsic value  $1,169   $10 
Cash received  $234   $37 

 

Based on our election of the “with and without” approach, no realized tax benefits from stock options were recognized for the years ended December 31, 2021 and 2020.
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.22.1
401(k) Profit-Sharing Plan
 12 Months Ended
Dec. 31, 2021
Retirement Benefits [Abstract]  
401(k) Profit-Sharing Plan

 

(11) 401(k) Profit-Sharing Plan

 

We have a 401(k) profit-sharing plan covering substantially all employees who meet defined service requirements. During 2020, we maintained a Company contribution program, in which 10% of the first 8% of any employee’s was matched (for a match of up to 0.8% of a participant’s salary). In 2021, we implemented a new Company match program, in which the Company matches the first 3% of eligible pay that any employee contributes on a dollar-for-dollar basis. Contributions made in 2021 and 2020 aggregated to $107 and $21, respectively.
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.22.1
Significant Customers and Contingencies
 12 Months Ended
Dec. 31, 2021
Risks and Uncertainties [Abstract]  
Significant Customers and Contingencies

 

(12) Significant Customers and Contingencies

 

We had five significant customers for the year ended December 31, 2021.

 

      For the years ended
December 31,		 
Customer #  Product Category  2021   2020 
1  Personal Care Ingredients   26%   30%
2  Solésence®   19%   14%
3  Solésence®   15%   11%
4  Solésence®   10%   5%
5  Advanced Materials (Medical Diagnostics customer)   8%   20%
   Total   78%   80%


 

 Accounts receivable balances for these five customers were approximately:

 

     

For the years ended

December 31,

 
Customer #  Product Category  2021   2020 
1  Personal Care Ingredients  $641   $381 
2  Solésence®   534    342 
3  Solésence®   1,048    116 
4  Solésence®   239    863 
5  Advanced Materials (Medical Diagnostics customer)   -0-    735 
   Total  $2,462   $2,437 

 

We currently have exclusive supply agreements with BASF Corporation (“BASF”), our largest customer, that have contingencies outlined which could potentially result in the license of technology and/or the sale of production equipment from the Company to the customer intended to provide capacity sufficient to meet the customer’s production needs. This outcome may occur if we fail to meet certain performance requirements. Our supply agreements with BASF also “trigger” a technology transfer right in the event of our insolvency, as further defined within the agreements. In the event of an equipment sale, upon incurring a triggering event, the equipment would be sold to the customer at either 115% of the equipment’s net book value or the greater of 30% of the original book value of such equipment, and any associated upgrades to it, or 115% of the equipment’s net book value, depending on the equipment and related products.

 

If a triggering event were to occur and BASF elected to proceed with the license and related equipment sale mentioned above, we would receive royalty payments from this customer for products sold using our technology; however, we would lose both significant revenue and the ability to generate significant revenue to replace that which was lost in the near term. Replacement of necessary equipment that could be purchased and removed by the customer pursuant to this triggering event could take in excess of twelve months. Any additional capital outlays required to rebuild capacity would probably be greater than the proceeds from the purchase of the assets as dictated by our agreement with the customer. Similar consequences would occur if we were determined to have materially breached certain other provisions of the supply agreement with BASF. Any such event would also likely result in the loss of many of our key staff and line employees due to economic realities. We believe that our employees are a critical component of our success, and it could be difficult to replace them quickly. Given the occurrence of any such event, we might not be able to hire and retain skilled employees given the stigma relating to such an event and its impact on us.
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.22.1
Business Segmentation and Geographical Distribution
 12 Months Ended
Dec. 31, 2021
Segment Reporting [Abstract]  
Business Segmentation and Geographical Distribution

 

(13) Business Segmentation and Geographical Distribution

 

Revenue from international sources approximated $3,236 and $3,714 for the years ended December 31, 2021 and 2020, respectively. As part of our revenue from international sources, we recognized approximately $2,335 and $3,450 in product revenue from German companies, in the aggregate, for the years ended December 31, 2021 and 2020, respectively.

 

Our Operations comprise a single business segment and all of our long-lived assets are located within the United States. We categorize our revenue stream into three main product categories, Personal Care Ingredients, Advanced Materials and Solésence. The revenues for 2021 and 2020 by category are as follows:

 

  

For the years ended  

December 31 

 
Product Category  2021   2020 
Solésence  $18,175   $6,737 
Personal Care Ingredients   7,739    5,536 
Advanced Materials   3,561    4,850 
Total Sales  $29,475   $17,123 

 
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.22.1
Contingencies
 12 Months Ended
Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]  
Contingencies

 

(14) Contingencies 

 

In December 2019, a novel strain of coronavirus (SARS-CoV-2) emerged in Wuhan, Hubei Province, China, which was proclaimed by the World Health Organization to have been the cause of a global pandemic (COVID-19).   COVID-19 has been followed by a series of variants that have also impacted our operations, but to a lesser extent than the initial strain.. Some of the raw materials that are critical to the production of our products and parts that are critical to the operation of our equipment are sourced from single suppliers, suppliers from China and Korea, and in some cases, a single supplier from China. Although operations of our third-party suppliers were disrupted to a certain extent in 2020 from the pandemic, particularly related to receiving packaging for our Solésence products on a timely basis, we are currently seeing a more limited impact relating to COVID-19 on our suppliers. The biggest challenge in 2021 and during the beginning of 2022 related to the pandemic is now slowdowns in production and shipping due to capacity limitations which seems to be a function of company’s inability to keep up with renewed market demand. We typically maintain no less than one month’s supply of raw materials and parts that are sourced from sole suppliers and make efforts to identify additional suppliers who may be able to provide such raw materials or parts. During 2021, shortages of labor, which may have been related to COVID-19, created challenges to the Company as we navigated a rapidly growing business under these conditions.

 

The Company is aware that such changes in its business as a result of COVID-19-related changes to our economy could occur, but is uncertain of the impacts of those changes on its consolidated statements of position, operations, or cash flows. The Company’s management believes any resulting cessations, reductions, and disruptions in its customers’ and suppliers’ operations would probably be temporary; however, the Company’s management also believes the duration and, hence, the potential impact of such cessations, reductions, and disruptions is currently unknowable. As a result, we are unable to estimate the potential impact on our business as of the date of this filing.
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.22.1
Summary of Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2021
Accounting Policies [Abstract]  
Use of Estimates and Risks and Uncertainties

Use of Estimates and Risks and Uncertainties

 

The preparation of financial statements requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. Certain assumptions are also necessary to assess the impact of risks and uncertainties on the financial statements, such as cash flow projections, availability of capital if needed to support the ongoing operations of the business, and our expected compliance with contractual commitments. These risks and uncertainties are further discussed in Note 12. Any changes in these assumptions or business plans could have a material impact on the financial statements.
Cash

Cash

 

The Cash balance on December 31, 2021 consists of funds borrowed from our Revolving Line of Credit, which is facilitated by Beachcorp, LLC. Our ability to access cash from our credit facility solely depends on carrying an Accounts Receivable balance greater than the outstanding loan balance in the Revolving Line of Credit. As part of the agreement, we are required to have a bank account in place to act as a depository account for our customers. This account is referred to as the Control Account. Furthermore, there is an Account Control Agreement in place which provides Beachcorp, LLC the ability to exercise control over the account via approval of requested transfers. According to our agreements with Beachcorp, LLC, Nanophase is to be the party initiating any transfers, whether to Nanophase or to Beachcorp, LLC, and approval to access any monies within this account can only be withheld by Beachcorp, LLC if the borrowing base falls below the Company’s qualified receivables, or if we are in arrears with respect to interest payments due Beachcorp, LLC. The failure of Nanophase to remedy the previously mentioned conditions could lead to Beachcorp, LLC gaining the right, through a “springing” feature administered by Libertyville Bank and Trust, a Wintrust Community Bank (“Libertyville”), to transfer funds to itself without direct approval from Nanophase.  Cash is held at a federally insured institution, but our cash balances at times exceed insured limits. The Company has not experienced any losses related to these statutory limits.
Trade Accounts Receivable

 Trade Accounts Receivable

 

Trade accounts receivable are carried at original invoice amount less an estimate made for doubtful receivables based on a review of all outstanding amounts on a monthly basis. We determine the allowance for doubtful accounts by identifying troubled accounts and by using historical experience applied to an aging of accounts. Trade accounts receivable are written off when deemed uncollectible. Recoveries of trade accounts receivable previously written off are recorded when received. Our typical credit terms are between thirty and sixty days from shipment and invoicing.
Inventories

Inventories

 

Inventories are stated at the lower of cost, maintained on an average cost basis, or net realizable value. We have recorded allowances to reduce inventory relating to excess quantities of certain materials. Write-downs of inventories establish a new cost basis, which is not increased for future increases in market value of inventories or changes in estimated excess quantities.
Equipment and Leasehold Improvements

Equipment and Leasehold Improvements

 

Equipment is stated at cost and is being depreciated over its estimated useful life (3-20 years) using the straight-line method. Leasehold improvements are stated at cost and are being amortized using the straight-line method over the shorter of the useful life of the asset or the term of the lease (3-7 years). Depreciation expense for leased assets is included with depreciation expense for owned assets. From time to time we have self-constructed assets. These assets are stated at cost plus the capitalization of labor and are depreciated over an estimated useful life (7-10 years) using the straight-line method.
Long Lived Assets

Long Lived Assets

 

We review long-lived assets for impairment whenever events or changes in circumstances indicate that the asset’s carrying amount may not be recoverable. We conduct long-lived asset impairment analyses in accordance with ASC 360-10-15, Impairment or Disposal of Long-Lived Assets. ASC 360-10-15 requires us to group assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities and evaluate the asset group against the sum of the undiscounted future cash flows. If the undiscounted cash flows do not indicate the carrying amount of the asset is recoverable, an impairment charge is measured as the amount by which the carrying amount of the asset group exceeds its fair value based on discounted cash flow analysis or appraisals. Based upon our analysis, there were no impairment charges recognized in either period presented.
Deferred Revenue

Deferred Revenue

 

The Company records a contract liability for development projects due to the contractual billing of these projects not always aligning with revenue recognition. In addition, it is now the Company’s policy to frequently require deposits relating to the initial production of our Solésence products. Of the total $1,444 in deferred revenue reported in 2021, approximately 70% is comprised of prepayment received from our medical diagnostics application customer for purchase orders to be filled in 2022 and 2023, 25% related to prepayments received from new customers as per Company policy, and the remaining 5% related to prepayments from a product development agreement with a personal care ingredient customer.
Asset Retirement Obligations

Asset Retirement Obligations

 

In connection with our leased facilities, we are required to remove certain leasehold improvements upon termination of our occupancy. We follow the provisions of the FASB issued ASC 410-20, Asset Retirement Obligations, under which we recognize a liability for the fair value of these asset retirement obligations. The fair value of that liability is measured based on an expected cash flow approach and accretion expense is recognized each period to recognize increases to the fair value of the liability due to the passage of time. Increases to the fair value of the liability, except for accretion, are added to the carrying value of the long-lived asset. Those increases are then reported in amortization expense over the estimated useful life of the long-lived asset.

 

        Activity in the asset retirement obligation account for the years ended December 31, is as follows:

 

   2021   2020 
Balance, beginning  $214   $206 
Accretion of liability due to passage of time   8    8 
Amortization of asset due to passage of time   —    — 
Balance, ending  $222   $214 

 
Financial Instruments

Financial Instruments

 

We follow ASC Topic 820, Fair Value Measurements and Disclosures, which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. The fair value framework requires the categorization of assets and liabilities into three levels based upon the assumptions (inputs) used to price the assets or liabilities. Level 1 provides the most reliable measure of fair value, whereas Level 3 generally requires significant management judgment.

 

Our financial instruments include cash, any cash equivalents, accounts receivable, accounts payable and accrued expenses, along with any short term and long-term borrowings as described in Note 3. There were no financial instruments adjusted to fair value on December 31, 2021 and 2020.
Product Revenue

Product Revenue

 

Revenues are recognized when control of the promised goods is transferred to customers, in an amount that reflects the consideration we expect to receive in exchange for those goods. When our ingredients and finished products are shipped, with control being transferred at the shipping point almost universally, is the point in time at which we recognize the related revenue.

 

We generally expense sales commissions when incurred because the amortization period would have been one year or less. These costs are recorded within selling, general and administrative expenses. Customers’ deposits, deferred revenue and other receipts are deferred and recognized when the revenue is realized and earned. Cash payments to customers are classified as reductions of revenue in our statements of operations.

 

Contract balances for the year 2021 and 2020

Contract balances for the year ended December 31, 2021 is as follows:

 

   Accounts
Receivable,
net		   Contract
Assets		   Contract
Liabilities		 
Balance, beginning  $2,932   $—   $411 
Balance, ending   3,937    —    1,444 

 

Contract balances for the year ended December 31, 2020 is as follows:

 

   Accounts
Receivable,
net		   Contract
Assets		   Contract
Liabilities		 
Balance, beginning  $970   $—   $575 
Balance, ending   2,932    —    411 

 

 

Revenue recognized in the reporting period that was included in the contract liability balance at the beginning of the period was $260 and $468 for the years ended December 31, 2021 and 2020, respectively.
Other Revenue

Other Revenue

 

Other revenue may include revenue from technology license fees and paid development projects. Technology license fees and paid development projects are recognized over time when the obligations under the agreed upon contractual arrangements are performed on our part.  Revenue recognized over time was $150 and $701 for the years ended December 31, 2021 and 2020, respectively.
Research and Development Expenses

Research and Development Expenses

 

Research and development expenses are recognized as expense when incurred.
Income Taxes

Income Taxes

 

We account for income taxes using the liability method. As such, deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Deferred tax assets and liabilities are calculated using the enacted tax rates and laws that are expected to be in effect when the anticipated reversal of these differences is scheduled to occur. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some or all of the deferred tax assets will not be realized.

 

When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured, as described above, is reflected as a liability for uncertain tax benefits in the accompanying balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination.

 

We have not recorded a reserve for any tax positions for which the ultimate deductibility is highly certain but for which there is uncertainty about the timing of such deductibility. We file tax returns in all appropriate jurisdictions, which includes a federal tax return and Illinois state tax return. When and if applicable, potential interest and penalty costs are accrued as incurred, with expenses recognized in selling, general and administrative expenses in the statements of operations. As of December 31, 2021, and 2020, we had no liability for unrecognized tax benefits.
Earnings Per Share

Earnings Per Share

 

Options to purchase approximately 2,018,000 shares of common stock that were outstanding as of December 31, 2021 were included in the computation of earnings per share for the year ended December 31, 2021.  Options to purchase approximately 387,000 shares of common stock that were outstanding as of December 31, 2020 were included in the computation of earnings per share for the year ended December 31, 2020.

 

Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows:

 

               
   Years Ended December 31, 
   2021   2020 
Numerator: (in Thousands)        
Net income  $2,320   $989 
           
Denominator:          
Weighted average number of basic common shares outstanding   45,021,173    38,158,586 
Weighted average additional shares assuming conversion of in-the-money stock options to common shares   2,018,000    387,000 
Weighted average number of diluted common shares outstanding   47,039,173    38,545,586 
           

Basic earnings per common share:

          
Net income per share – basic  $0.05   $0.03 
Diluted earnings per common share:          
Net income per share – diluted  $0.05   $0.03 

 
New Accounting Pronouncements

New Accounting Pronouncements

 

 In June 2016, the FASB issued ASU 2016-13, “Measurement of Credit Losses on Financial Instruments,” which replaces existing incurred loss impairment guidance and establishes a single allowance framework for financial assets carried at amortized cost. The effective date for our adoption (as amended) of this updated Standard will be January 1, 2023. The Company is currently evaluating the impact of the adoption of this standard on the consolidated financial statements.
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.22.1
Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2021
Accounting Policies [Abstract]  
Activity in the asset retirement obligation account for the years ended December 31, is as follows:

        Activity in the asset retirement obligation account for the years ended December 31, is as follows:

 

   2021   2020 
Balance, beginning  $214   $206 
Accretion of liability due to passage of time   8    8 
Amortization of asset due to passage of time   —    — 
Balance, ending  $222   $214 
Contract balances for the year 2021 and 2020

Contract balances for the year 2021 and 2020

Contract balances for the year ended December 31, 2021 is as follows:

 

   Accounts
Receivable,
net		   Contract
Assets		   Contract
Liabilities		 
Balance, beginning  $2,932   $—   $411 
Balance, ending   3,937    —    1,444 

 

Contract balances for the year ended December 31, 2020 is as follows:

 

   Accounts
Receivable,
net		   Contract
Assets		   Contract
Liabilities		 
Balance, beginning  $970   $—   $575 
Balance, ending   2,932    —    411 
Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows:

Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows:

 

               
   Years Ended December 31, 
   2021   2020 
Numerator: (in Thousands)        
Net income  $2,320   $989 
           
Denominator:          
Weighted average number of basic common shares outstanding   45,021,173    38,158,586 
Weighted average additional shares assuming conversion of in-the-money stock options to common shares   2,018,000    387,000 
Weighted average number of diluted common shares outstanding   47,039,173    38,545,586 
           

Basic earnings per common share:

          
Net income per share – basic  $0.05   $0.03 
Diluted earnings per common share:          
Net income per share – diluted  $0.05   $0.03 
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.22.1
Notes and Lines of Credit (Tables)
 12 Months Ended
Dec. 31, 2021
Debt Disclosure [Abstract]  
Notes and lines of credit consist of the following:

Notes and lines of credit consist of the following:

 

         As of December 31, 
        2021   2020 
   Rate    Available   Outstanding
Balance		   Available   Outstanding
Balance		 
Libertyville Bank & Trust (1)    4.25%    $30   $—   $30   $— 
Libertyville Bank & Trust (2)   4.25%     n/a    n/a    500    500 
Libertyville Bank & Trust (2)   4.25%     500    —    n/a    n/a 
Beachcorp, LLC (3)   5.25%     3,467    1,351    2,776    2,155 
Beachcorp, LLC (3)   5.25%    $1,000   $1,000   $500   $500 
Secured convertible promissory note (4)   2.00%     —    —    2,000    1,097 
PPP Loan / Libertyville promissory note (5)   1.00%     —    —    952    952 
Beachcorp, LLC (6)   4.00%     n/a    n/a    n/a    n/a 
Beachcorp, LLC (7)   4.00%     n/a    n/a    n/a    n/a 
Strandler, LLC (8)   4.00%     n/a    n/a    n/a    n/a 

 

1)Since July 2014, we have maintained a bank-issued letter of credit for up to $30 in borrowings, with interest at the prime rate plus 1%, to support our obligations under our Romeoville, Illinois facility lease agreement. No borrowings have been incurred under this promissory note. It is our intention to renew this note annually. Because there were no amounts outstanding on the note at any time during 2021 or 2020, we have recorded no related liability on our balance sheet.

 

 

2)The Company maintains a credit agreement with Libertyville which most recently served the primary purpose of insuring that it met its cash balance requirements at quarter end relating to a contract with the Company’s largest customer. Outstanding borrowings were $500 on this line of credit as of December 31, 2020. Interest on drawn balances was at the prime rate plus 1%. On December 21, 2021, the existing credit agreement with Libertyville was converted for use to support our obligations under our newly leased manufacturing and warehouse space in Bolingbrook, Illinois. Interest on drawn balances will be at the prime rate plus 1%. This credit agreement has a maturity of December 22, 2022. We expect to renew this agreement annually, as the lease requires. This credit agreement is secured by all the unencumbered assets of the Company, and has superior collateral rights to those credit facilities with Beachcorp, LLC and Strandler, LLC.

 

3)On November 16, 2018, we entered into a Business Loan Agreement (the “Master Agreement”) with Beachcorp, LLC. The Master Agreement relates to two loan facilities, each evidenced by a separate promissory note dated as of November 16, 2018: a term loan to the Company of up to $500 to be disbursed in a single advance (the “Term Loan”) with a fixed annual interest rate of 8.25%, payable quarterly, and with principal due on December 31, 2020; and an asset-based revolving loan facility for the Company of up to $2,000 (the “A/R Revolver Facility”), with floating interest accruing at the prime rate plus 3% (8.25% minimum) per year, with a borrowing base consisting of qualified accounts receivable of the Company, and a maturity of March 31, 2020, as amended. On March 23, 2020, the Company and Beachcorp, LLC executed the First Amendment to our Master Agreement that extended the maturities of both the Term Loan and the A/R Revolver Facility to March 31, 2021. Effective September 8, 2020, the Company and Beachcorp, LLC executed the Second Amendment to our Master Agreement that expanded the limit on the A/R Revolver Facility from $2,000 to $2,750.  On December 23, 2020, the Company and Beachcorp, LLC executed the Third Amendment to our Master Agreement that expanded the limit on the A/R Revolver Facility from $2,750 to $4,000 and extended the maturities of both the Term Loan and the A/R Revolver Facility to March 31, 2022. Effective April 21, 2021 the Company and Beachcorp, LLC executed the Fourth Amendment to our Master Agreement that expanded the limit on the A/R Revolver Facility from $4,000 to $6,000, changed the interest rate to fully floating and reduced the rate to the prime rate plus 2%, also extending the maturity of the A/R Revolver Facility to March 31, 2023. This amendment also increased the amount of the Term Loan from $500 to $1,000, changed the interest rate to fully floating and reduced the rate to the prime rate plus 2%. The maturity of the Term Loan remained March 31, 2022. The Term Loan and A/R Revolver Facility are secured by all the unencumbered assets of the Company and subordinated to Libertyville’s secured interest under the New Business Loan Credit Agreement. The Master Agreement substantially restricts the Company’s ability to incur additional indebtedness during the terms of both the Term Loan and the A/R Revolver Facility.

 

4)On November 20, 2019, we entered into a 2% Secured Convertible Promissory Note with Bradford T. Whitmore in the principal amount of $2,000 (the “Convertible Note”). The principal amount was payable in a single payment on May 15, 2024 (the “Maturity Date”). The principal amount of the Convertible Note accrued interest at the rate of 2.0% per year, which interest was payable semi-annually on the 15th day of May and November, commencing on May 15, 2020. The principal amount and, at the holder’s option, accrued interest under the Convertible Note was convertible at the holder’s option into additional shares of the Company’s common stock in whole or in part and from time to time up to the Maturity Date at a conversion price of $0.20 per share. The convertible note contained a beneficial conversion feature since the Company’s stock was trading at $0.32 per share on the date the Company entered into the agreement. The intrinsic value of the beneficial conversion feature was $1.2 million on November 20, 2019 and was recorded as a discount on the convertible note. The discount was to be accreted to the convertible note over the life of the note using the straight-line method. The offset to these discounts was interest expense. The Company recognized amortized interest expense relating to this discount of $267 in 2020. Upon exercise of the conversion right in 2021, the acceleration of the remaining discount, in addition to the amortization of interest in 2021 prior to the conversion, amounted to $903, all of which was recognized as interest expense. Mr. Whitmore chose to exercise his conversion rights effective May 7, 2021, with any interest to be paid in the form of shares, as allowed in the Convertible Note. In addition to the 10,000,000 shares issued upon conversion, the Company issued 95,555 shares of additional stock to Mr. Whitmore in lieu of cash for the $19 in accrued interest owed at May 7, 2021. The note and related interest obligations were paid in full and cancelled in May, 2021 via conversion.

 

5)On April 17, 2020, we entered into a Promissory Note (the “PPP Note”), dated as of April 16, 2020, in favor of Libertyville in the principal amount of $952 for our loan under the Paycheck Protection Program (“PPP”). The Company was allowed to apply for forgiveness of the amount due on the PPP Note in an amount equal to the sum of the following costs incurred during the 24-week period beginning on the date of the first disbursement of the loan: (a) payroll costs, (b) any payment of interest on a covered obligation (which shall not include any prepayment of or payment of principal on a covered mortgage obligation), (c) any payment on a covered rent obligation, and (d) any covered utility payment, calculated in accordance with the terms of the CARES Act. The principal amount of the PPP Note would have accrued interest at the rate of 1.00% per year. The Company applied for, and received, PPP forgiveness during the first quarter of 2021. Under the terms of the PPP loan, it is subject to audit for six years from the date of forgiveness. If any portion of the PPP loan were to be deemed ineligible, the Company could be required to repay the funds. On December 31, 2021, the balance under the PPP note was $0.

 

 

6)On January 28, 2022 the Company entered into an Amended and Restated Business Loan Agreement (the “A&R Loan Agreement”), which amends and restates the Master Agreement between the Company and Beachcorp, LLC, and a new promissory note in order to evidence the A/R Revolver facility, including an amendment to expand the limit on the A/R Revolver Facility from $6,000 to $8,000, reduce the interest rate to the prime rate plus 0.75%, and extend the maturity of the A/R Revolver Facility to March 31, 2024.

 

7)On January 28, 2022 the Company entered into the A&R Loan Agreement and a new revolving loan agreement (“Inventory Facility”) with Beachcorp, LLC, and a new promissory note in order to evidence the Inventory Facility. The maximum borrowing amount under the Inventory Facility is $4,000, with a borrowing base consisting of up to 50% of the value of qualified inventory of the Company. The interest rate for the Inventory Revolver is at the prime rate plus 0.75%, and it matures on March 31, 2024.

 

8)On January 28, 2022 the Company entered into an additional Business Loan Agreement (the “New Term Loan Agreement”) with Strandler, LLC, which effectively transferred or assigned the Term Loan to Strandler, LLC from Beachcorp, LLC. Interest on the New Term Loan is at the prime rate plus 0.75%, and it matures on March 31, 2024. Strandler, LLC is also an affiliate of Bradford T. Whitmore.
Schedule of Related Parties

Related party interest expense consists of the following:

 

         
   Twelve Months Ended December 31, 
   2021   2020 
Interest expense, related parties  $1,129   $452 

 

Accrued interest consists of the following:

 

         
   As of December 31, 
   2021   2020 
Accrued interest expense, related parties  $13   $20 

 

Outstanding balances associated with related parties are as follows:

 

   As of December 31, 
   2021   2020 
Beachcorp, LLC  $2,351   $2,655 
Secured convertible promissory note   —    1,097 
Strandler, LLC   n/a    n/a 
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.22.1
Inventories (Tables)
 12 Months Ended
Dec. 31, 2021
Inventory Disclosure [Abstract]  
Inventories consist of the following:

Inventories consist of the following:

 

               
   As of December 31, 
   2021   2020 
Raw materials  $4,819   $2,825 
Finished goods   1,682    1,545 
 Inventories, gross   6,501    4,370 
Allowance for excess quantities   (406)   (30)
 Inventories, net  $6,095   $4,340 

 
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.22.1
Equipment and Leasehold Improvements (Tables)
 12 Months Ended
Dec. 31, 2021
Property, Plant and Equipment [Abstract]  
Equipment and leasehold improvements consist of the following:

Equipment and leasehold improvements consist of the following: 

 

   As of December 31, 
   2021   2020 
Machinery and equipment  $18,289   $16,758 
Office equipment   961    870 
Office furniture   110    110 
Leasehold improvements   4,900    4,850 
Construction in progress   1,062    445 
    25,322    23,033 
Less: Accumulated depreciation and amortization   (20,610)   (20,165)
   $4,712   $2,868 
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.22.1
Lease Commitments (Tables)
 12 Months Ended
Dec. 31, 2021
Leases [Abstract]  
Quantitative information regarding the Company’s leases is as follows:

Quantitative information regarding the Company’s leases is as follows:

 

         
   Twelve Months Ended December 31, 2021   Twelve Months Ended December 31, 2020 
Components of lease cost          
Finance lease cost components:          
Amortization of finance lease assets  $52   $70 
Interest on finance lease liabilities   18    36 
Total finance lease costs   70    106 
Operating lease cost components:          
Operating lease cost   554    565 
Variable lease cost   134    146 
Short-term lease cost   49    33 
Total operating lease costs   737    744 
Total lease cost:  $807   $850 
Supplemental cash flow information related to leases is as follows for the years ended December 31, 2021 and 2020:

Supplemental cash flow information related to leases is as follows for the years ended December 31, 2021 and 2020:

 

   2021   2020 
Cash paid for amounts included in the measurement of lease liabilities:          
Operating cash outflow from operating leases  $741   $690 
           
Lease liabilities arising from obtaining right-of-use assets   10,505    — 
Weighted-average remaining lease term-finance leases (in years)   0.7    1.4 
Weighted-average remaining lease term-operating leases (in years)   9.5    3.2 
Weighted-average discount rate-finance leases   9.3%   9.3%
Weighted-average discount rate-operating leases   7.5%   14.3%
The future maturities of the Company’s finance and operating leases as of December 31, 2021 are as follows:

The future maturities of the Company’s finance and operating leases as of December 31, 2021 are as follows:

 

    Finance
Leases		   Operating
Leases		   Total 
2022   $109   $1,456   $1,565 
2023    6    2,099    2,105 
2024    —    2,025    2,025 
2025    —    1,470    1,470 
2026    —    1,468    1,468 
Thereafter    —    8,668    8,668 
Total payments   $115   $17,186   $17,301 
Less amounts representing interest    (4)   (4,897)   (4,901)
Total minimum payments required   $111   $12,289   $12,400 

 

The future maturities of the Company’s finance and operating leases as of December 31, 2020 were as follows:

 

    Finance
Leases		   Operating
Leases		   Total 
2021   $196   $701   $897 
2022    109    720    829 
2023    5    705    710 
2024    —    595    595 
2025    —    1    1 
Thereafter    —    —    — 
Total payments   $310   $2,722   $3,032 
Less amounts representing interest    (23)   (640)   (663)
Total minimum payments required   $287   $2,082   $2,369 
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.22.1
Accrued Expenses (Tables)
 12 Months Ended
Dec. 31, 2021
Payables and Accruals [Abstract]  
Accrued expenses consist of the following:

Accrued expenses consist of the following:

 

               
   As of December 31, 
   2021   2020 
Accrued payroll and related expenses  $471   $315 
Accrued accounts payable   320    122 
Tenant Security Deposit / Advance Rent   122    — 
Other   33    47 
 Total  $946   $484 
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.22.1
Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2021
Income Tax Disclosure [Abstract]  
A reconciliation of income tax expense to the amount computed by applying the Federal income tax rate to loss before provision for income taxes as of December 31, 2021 and 2020 is as follows:

A reconciliation of income tax expense to the amount computed by applying the Federal income tax rate to loss before provision for income taxes as of December 31, 2021 and 2020 is as follows:

 

   2021   2020 
Income tax credit at statutory rates  $495   $208 
Nondeductible expenses   —    5 
Tax Exempt Income - PPP Loan   (271)   — 
Permanent Tax Deduction Stock Options Exercised   (63)   — 
State income tax, net of federal benefits   177    74 
Expiration of NOL & Credits   899    2,543 
Tax basis in excess of book Convertible Debt   —    — 
Expiration of Stock Options   92    122 
Other   2    (7)
Change in valuation allowance   (1,294)   (2,945)
 TOTAL  $37    — 
Significant components of our deferred income taxes consist of the following:

Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred income taxes consist of the following:

 

               
   As of December 31, 
   2021   2020 
Deferred tax liabilities:          
  Excess tax basis convertible debt  $—    (257)
     Total deferred tax liabilities   —    (257)
           
Deferred tax assets:          
  Net operating loss carryforwards  $14,566   $15,597 
  Inventory and other allowances   148    23 
  Charitable contribution & other carryforwards   —    9 
  Excess (tax) book depreciation   31    375 
  Excess (tax) book amortization   63    61 
  Share-based compensation   308    624 
  Other accrued costs   161    138 
     Total deferred tax assets   15,277    16,827 
           
  Less:  Valuation allowance   (15,277)   (16,570)
Deferred income taxes  $—   $— 
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.22.1
Stock Options and Stock Grants (Tables)
 12 Months Ended
Dec. 31, 2021
Share-based Payment Arrangement [Abstract]  
We follow ASC Topic 718, Share-Based Payments, in which compensation expense is recognized only for share-based payments expected to vest.

We follow ASC Topic 718, Share-Based Payments, in which compensation expense is recognized only for share-based payments expected to vest. 

 

               
   Years ended
December 31,		 
   2021   2020 
Share-based compensation expense  $160   $195 
Remaining unrecognized compensation expense   $1,581      
Remaining weighted average-period, expense recognition (years)   2.9      

 
Schedule of assumptions used to calculate Black-Scholes option pricing model for options granted

The following table illustrates the various assumptions used to calculate the Black-Scholes option pricing model for options granted for all years presented:

 

   Years Ended
December 31,		 
    2021   2020 
Weighted-average risk-free interest rates:   1.4%   0.5%
           
Dividend yield:   0%   0%
           
Weighted-average expected life (years) of the option:   5    5 
           
Weighted-average expected stock price volatility:   115%   95%
           
Weighted-average fair value of the options granted:  $2.59   $0.28 
Additional disclosures for options granted for all years presented:

Additional disclosures for options granted for all years presented:

 

   Years Ended
December 31,		 
    2021   2020 
Vesting period (years) of shares granted in period   3    3 
           
Contractual life (years) of shares granted in period   7    7 
           
Estimated forfeitures   4%   4%
Schedule of option activity

The following table summarizes the option activity for our employees and directors during the year ended December 31, 2021:

 

Options  Shares
(Rounded)		   Weighted
Average
Exercise
Price
per Share		   Weighted
Average
Remaining
Contractual
Term (Years)		   Aggregate
Intrinsic
Value
(000s)		 
Outstanding on January 1, 2021   3,412,686   $0.57    —    — 
                     
Granted   567,500   $4.14    —    — 
Exercised   (535,100)  $0.44    —    — 
Forfeited or expired   (251,870)  $1.09    —    — 
                     
Outstanding on December 31, 2021   3,193,216   $1.18    5.1   $10,267 
Exercisable on December 31, 2021   2,189,378   $0.56    4.4   $8,405 
                     
Shares available for grant   1,887,500                
The aggregate intrinsic value in the table above is based on our closing stock price of $4.40 on the last business day for the year ended December 31, 2021.

The aggregate intrinsic value in the table above is based on our closing stock price of $4.40 on the last business day for the year ended December 31, 2021.

 

             
   Years ended
December 31,		 
   2021   2020 
Shares exercised   535,100    84,500 
Total intrinsic value  $1,169   $10 
Cash received  $234   $37 
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.22.1
Significant Customers and Contingencies (Tables)
 12 Months Ended
Dec. 31, 2021
Risks and Uncertainties [Abstract]  
We had five significant customers for the year ended December 31, 2021.

We had five significant customers for the year ended December 31, 2021.

 

      For the years ended
December 31,		 
Customer #  Product Category  2021   2020 
1  Personal Care Ingredients   26%   30%
2  Solésence®   19%   14%
3  Solésence®   15%   11%
4  Solésence®   10%   5%
5  Advanced Materials (Medical Diagnostics customer)   8%   20%
   Total   78%   80%
Accounts receivable balances for these five customers were approximately:

 Accounts receivable balances for these five customers were approximately:

 

     

For the years ended

December 31,

 
Customer #  Product Category  2021   2020 
1  Personal Care Ingredients  $641   $381 
2  Solésence®   534    342 
3  Solésence®   1,048    116 
4  Solésence®   239    863 
5  Advanced Materials (Medical Diagnostics customer)   -0-    735 
   Total  $2,462   $2,437 
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.22.1
Business Segmentation and Geographical Distribution (Tables)
 12 Months Ended
Dec. 31, 2021
Segment Reporting [Abstract]  
The revenues for 2021 and 2020 by category are as follows:

Our Operations comprise a single business segment and all of our long-lived assets are located within the United States. We categorize our revenue stream into three main product categories, Personal Care Ingredients, Advanced Materials and Solésence. The revenues for 2021 and 2020 by category are as follows:

 

  

For the years ended  

December 31 

 
Product Category  2021   2020 
Solésence  $18,175   $6,737 
Personal Care Ingredients   7,739    5,536 
Advanced Materials   3,561    4,850 
Total Sales  $29,475   $17,123 
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.22.1
Activity in the asset retirement obligation account for the years ended December 31, is as follows: (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Accounting Policies [Abstract]    
Balance, beginning $ 214 $ 206
Accretion of liability due to passage of time 8 8
Amortization of asset due to passage of time
Balance, ending $ 222 $ 214
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.22.1
Contract balances for the year 2021 and 2020 (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Accounting Policies [Abstract]      
Accounts receivable net $ 3,937 $ 2,932 $ 970
Contract liability $ 1,444 $ 411 $ 575
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.22.1
Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows: (Details) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Numerator: (in Thousands)    
Net income $ 2,320 $ 989
Denominator:    
Weighted average number of basic common shares outstanding 45,021,173 38,158,586
Weighted average additional shares assuming conversion of in-the-money stock options to common shares 2,018,000 387,000
Weighted average number of diluted common shares outstanding 47,039,173 38,545,586
Basic earnings per common share:    
Net income per share – basic $ 0.05 $ 0.03
Diluted earnings per common share:    
Net income per share – diluted $ 0.05 $ 0.03
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.22.1
Summary of Significant Accounting Policies (Details Narrative) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Property, Plant and Equipment [Line Items]    
Deferred revenue $ 1,444  
Revenue from contract with customer excluding assessed tax 260 $ 468
Revenue $ 29,475 $ 17,123
Tax rate reconciliation and settlement 50.00%  
Options included in computation of earnings per share 2,018,000 387,000
Product and Service, Other [Member]    
Property, Plant and Equipment [Line Items]    
Revenue $ 150 $ 701
Year 2021 [Member]    
Property, Plant and Equipment [Line Items]    
Percentage of prepayments 70.00%  
Year 2022 [Member]    
Property, Plant and Equipment [Line Items]    
Percentage of prepayments 25.00%  
Year 2023 [Member]    
Property, Plant and Equipment [Line Items]    
Percentage of prepayments 5.00%  
Equipment [Member] | Minimum [Member]    
Property, Plant and Equipment [Line Items]    
Equipment leasehold improvements and leased assets useful life 3 years  
Equipment [Member] | Maximum [Member]    
Property, Plant and Equipment [Line Items]    
Equipment leasehold improvements and leased assets useful life 20 years  
Leasehold Improvements [Member] | Minimum [Member]    
Property, Plant and Equipment [Line Items]    
Equipment leasehold improvements and leased assets useful life 3 years  
Leasehold Improvements [Member] | Maximum [Member]    
Property, Plant and Equipment [Line Items]    
Equipment leasehold improvements and leased assets useful life 7 years  
Other Capitalized Property Plant and Equipment [Member] | Minimum [Member]    
Property, Plant and Equipment [Line Items]    
Equipment leasehold improvements and leased assets useful life 7 years  
Other Capitalized Property Plant and Equipment [Member] | Maximum [Member]    
Property, Plant and Equipment [Line Items]    
Equipment leasehold improvements and leased assets useful life 10 years  
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.22.1
Notes and lines of credit consist of the following: (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 1 Months Ended 12 Months Ended
Jan. 28, 2022
May 07, 2021
Apr. 21, 2021
Dec. 23, 2020
Mar. 23, 2020
Nov. 20, 2019
Nov. 16, 2018
Jul. 31, 2014
Dec. 31, 2021
Dec. 31, 2020
Sep. 08, 2020
Apr. 17, 2020
Debt Instrument [Line Items]                        
Interest Expense                 $ 1,154 $ 496    
Whitmore [Member]                        
Debt Instrument [Line Items]                        
Conversion of Stock, Shares Issued   10,000,000                    
Stock Issued During Period, Shares, New Issues   95,555                    
Cash   $ 19                    
2% Secured Convertible Promissory Note Due on May 15, 2024 [Member] | Bradford T. Whitmore [Member]                        
Debt Instrument [Line Items]                        
Debt Instrument, Interest Rate, Stated Percentage           2.00%            
Debt Instrument, Face Amount           $ 2,000            
Debt Instrument, Interest Rate Terms           interest was payable semi-annually            
Debt Instrument, Date of First Required Payment           May 15, 2020            
Debt Instrument, Convertible, Conversion Price           $ 0.20            
Share Price           $ 0.32            
Debt Instrument, Unamortized Discount           $ 1,200,000            
Promissory Note (PPP) [Member]                        
Debt Instrument [Line Items]                        
Long-term Debt                 0      
Promissory Note (PPP) [Member] | Libertyville [Member]                        
Debt Instrument [Line Items]                        
Debt Instrument, Interest Rate, Stated Percentage                       1.00%
Debt Instrument, Face Amount                       $ 952
Credit Agreement [Member]                        
Debt Instrument [Line Items]                        
Outsanding balance                 $ 500      
Business Loan Agreement [Member] | Beachcorp, LLC [Member]                        
Debt Instrument [Line Items]                        
Line of Credit Facility, Borrowing Capacity, Description the Company entered into an Amended and Restated Business Loan Agreement (the “A&R Loan Agreement”), which amends and restates the Master Agreement between the Company and Beachcorp, LLC, and a new promissory note in order to evidence the A/R Revolver facility, including an amendment to expand the limit on the A/R Revolver Facility from $6,000 to $8,000, reduce the interest rate to the prime rate plus 0.75%, and extend the maturity of the A/R Revolver Facility to March 31, 2024.                      
Letter of Credit [Member]                        
Debt Instrument [Line Items]                        
Short-term Debt               $ 30        
Debt Instrument, Description of Variable Rate Basis               prime rate        
Debt Instrument, Basis Spread on Variable Rate               1.00%        
Letter of Credit [Member] | New Business Loan Agreement [Member]                        
Debt Instrument [Line Items]                        
Debt Instrument, Description of Variable Rate Basis                 prime rate      
Debt Instrument, Basis Spread on Variable Rate                 1.00%      
Libertyville Bank And Trust [Member]                        
Debt Instrument [Line Items]                        
Line of credit facility, description                 Libertyville Bank & Trust      
Line of Credit Facility, Commitment Fee Percentage                 4.25%      
Available                 $ 30 30    
Outsanding balance                    
Libertyville Bank And Trust One [Member]                        
Debt Instrument [Line Items]                        
Line of credit facility, description                 Libertyville Bank & Trust      
Line of Credit Facility, Commitment Fee Percentage                 4.25%      
Available                   500    
Outsanding balance                   500    
Libertyville Bank And Trust Two [Member]                        
Debt Instrument [Line Items]                        
Line of credit facility, description                 Libertyville Bank & Trust      
Line of Credit Facility, Commitment Fee Percentage                 4.25%      
Available                 $ 500      
Outsanding balance                      
Beachcorp, LLC [Member]                        
Debt Instrument [Line Items]                        
Line of credit facility, description                 Beachcorp, LLC      
Line of Credit Facility, Commitment Fee Percentage                 5.25%      
Available                 $ 3,467 2,776    
Outsanding balance                 $ 1,351 2,155    
Beachcorp LLC One [Member]                        
Debt Instrument [Line Items]                        
Line of credit facility, description                 Beachcorp      
Line of Credit Facility, Commitment Fee Percentage                 5.25%      
Available                 $ 1,000 500    
Outsanding balance                 $ 1,000 500    
2% Secured Convertible Promissory Note Due on May 15, 2024 [Member]                        
Debt Instrument [Line Items]                        
Line of credit facility, description                 Secured convertible promissory note      
Line of Credit Facility, Commitment Fee Percentage                 2.00%      
Available                   2,000    
Outsanding balance                   1,097    
PPP Loan Libertyville Promissory Note [Member]                        
Debt Instrument [Line Items]                        
Line of credit facility, description                 PPP Loan / Libertyville promissory note      
Line of Credit Facility, Commitment Fee Percentage                 1.00%      
Available                   952    
Outsanding balance                   $ 952    
Beachcorp LLC Three [Member]                        
Debt Instrument [Line Items]                        
Line of credit facility, description                 Beachcorp      
Line of Credit Facility, Commitment Fee Percentage                 4.00%      
Beachcorp LLC Four [Member]                        
Debt Instrument [Line Items]                        
Line of credit facility, description                 Beachcorp      
Line of Credit Facility, Commitment Fee Percentage                 4.00%      
Strandler LLC [Member]                        
Debt Instrument [Line Items]                        
Line of credit facility, description                 Strandler      
Line of Credit Facility, Commitment Fee Percentage                 4.00%      
Term Loan [Member] | Business Loan Agreement [Member] | Beachcorp, LLC [Member]                        
Debt Instrument [Line Items]                        
Outsanding balance             $ 500          
Debt Instrument, Interest Rate, Stated Percentage             8.25%          
Debt Instrument, Maturity Date             Dec. 31, 2020          
Term Loan [Member] | Fourth Amendment [Member] | Beachcorp, LLC [Member]                        
Debt Instrument [Line Items]                        
Outsanding balance     $ 1,000                  
Debt Instrument, Maturity Date     Mar. 31, 2022                  
Revolving Credit Facility [Member] | Business Loan Agreement [Member] | Beachcorp, LLC [Member]                        
Debt Instrument [Line Items]                        
Outsanding balance             $ 2,000          
Debt Instrument, Description of Variable Rate Basis             prime rate          
Debt Instrument, Basis Spread on Variable Rate             3.00%          
Line of Credit Facility, Expiration Date             Mar. 31, 2020          
Revolving Credit Facility [Member] | Business Loan Agreement [Member] | Beachcorp, LLC [Member] | Minimum [Member]                        
Debt Instrument [Line Items]                        
Debt Instrument, Interest Rate, Stated Percentage             8.25%          
Revolving Credit Facility [Member] | Second Amendment [Member] | Beachcorp, LLC [Member]                        
Debt Instrument [Line Items]                        
Outsanding balance                     $ 2,750  
Revolving Credit Facility [Member] | Third Amendment [Member] | Beachcorp, LLC [Member]                        
Debt Instrument [Line Items]                        
Outsanding balance       $ 4,000                
Revolving Credit Facility [Member] | Fourth Amendment [Member] | Beachcorp, LLC [Member]                        
Debt Instrument [Line Items]                        
Outsanding balance     $ 6,000                  
Debt Instrument, Description of Variable Rate Basis     prime rate                  
Debt Instrument, Basis Spread on Variable Rate     2.00%                  
Line of Credit Facility, Expiration Date     Mar. 31, 2023                  
Revolving Credit Facility [Member] | A And R Loan Agreement [Member] | Beachcorp, LLC [Member]                        
Debt Instrument [Line Items]                        
Line of Credit Facility, Borrowing Capacity, Description the Company entered into the A&R Loan Agreement and a new revolving loan agreement (“Inventory Facility”) with Beachcorp, LLC, and a new promissory note in order to evidence the Inventory Facility. The maximum borrowing amount under the Inventory Facility is $4,000, with a borrowing base consisting of up to 50% of the value of qualified inventory of the Company. The interest rate for the Inventory Revolver is at the prime rate plus 0.75%, and it matures on March 31, 2024.                      
Revolving Credit Facility [Member] | A And R Loan Agreement [Member] | Strandler LLC [Member]                        
Debt Instrument [Line Items]                        
Line of Credit Facility, Borrowing Capacity, Description the Company entered into an additional Business Loan Agreement (the “New Term Loan Agreement”) with Strandler, LLC, which effectively transferred or assigned the Term Loan to Strandler, LLC from Beachcorp, LLC. Interest on the New Term Loan is at the prime rate plus 0.75%, and it matures on March 31, 2024. Strandler, LLC is also an affiliate of Bradford T. Whitmore.                      
Term Loan and The Revolver Facility [Member] | First Amendment [Member] | Beachcorp, LLC [Member]                        
Debt Instrument [Line Items]                        
Debt Instrument, Maturity Date       Mar. 31, 2022 Mar. 31, 2021              
Related Party Credit Facilities [Member]                        
Debt Instrument [Line Items]                        
Interest Expense                 $ 903      
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Related Parties (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Line of Credit Facility [Line Items]    
Interest expense, related parties $ 1,129 $ 452
Secured Convertible Promissory Note [Member]    
Line of Credit Facility [Line Items]    
Due to Related Parties 0 1,097
Beachcorp, LLC [Member]    
Line of Credit Facility [Line Items]    
Due to Related Parties 2,351 2,655
Related Party Transaction [Member]    
Line of Credit Facility [Line Items]    
Accrued interest expense, related parties $ 13 $ 20
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.22.1
Inventories consist of the following: (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Inventory Disclosure [Abstract]    
Raw materials $ 4,819 $ 2,825
Finished goods 1,682 1,545
 Inventories, gross 6,501 4,370
Allowance for excess quantities (406) (30)
 Inventories, net $ 6,095 $ 4,340
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.22.1
Equipment and leasehold improvements consist of the following: (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Property, Plant and Equipment [Line Items]    
Property plant and equipment,gross $ 25,322 $ 23,033
Less: Accumulated depreciation and amortization (20,610) (20,165)
Property, Plant and Equipment, Net, Total 4,712 2,868
Machinery and Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Property plant and equipment,gross 18,289 16,758
Office Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Property plant and equipment,gross 961 870
Furniture and Fixtures [Member]    
Property, Plant and Equipment [Line Items]    
Property plant and equipment,gross 110 110
Leasehold Improvements [Member]    
Property, Plant and Equipment [Line Items]    
Property plant and equipment,gross 4,900 4,850
Construction in Progress [Member]    
Property, Plant and Equipment [Line Items]    
Property plant and equipment,gross $ 1,062 $ 445
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.22.1
Equipment and Leasehold Improvements (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Property, Plant and Equipment [Abstract]    
Depreciation expense $ 444 $ 348
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.22.1
Quantitative information regarding the Company’s leases is as follows: (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Finance lease cost components:    
Amortization of finance lease assets $ 52 $ 70
Interest on finance lease liabilities 18 36
Total finance lease costs 70 106
Operating lease cost components:    
Operating lease cost 554 565
Variable lease cost 134 146
Short-term lease cost 49 33
Total operating lease costs 737 744
Total lease cost: $ 807 $ 850
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.22.1
Supplemental cash flow information related to leases is as follows for the years ended December 31, 2021 and 2020: (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Leases [Abstract]    
Operating cash outflow from operating leases $ 741 $ 690
Lease liabilities arising from obtaining right-of-use assets $ 10,505  
Weighted-average remaining lease term-finance leases (in years) 8 months 12 days 1 year 4 months 24 days
Weighted-average remaining lease term-operating leases (in years) 9 years 6 months 3 years 2 months 12 days
Weighted-average discount rate-finance leases 9.30% 9.30%
Weighted-average discount rate-operating leases 7.50% 14.30%
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.22.1
The future maturities of the Company’s finance and operating leases as of December 31, 2021 are as follows: (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Leases [Abstract]    
Finance Leases, Year 1 $ 109 $ 196
Operating Leases, Year 1 1,456 701
Total, Year 1 1,565 897
Finance Leases, Year 2 6 109
Operating Leases, Year 2 2,099 720
Total, Year 2 2,105 829
Finance Leases, Year 3 0 5
Operating Leases, Year 3 2,025 705
Total, Year 3 2,025 710
Operating Leases, Year 4 1,470 595
Total, Year 4 1,470 595
Operating Leases, Year 5 1,468 1
Total, Year 5 1,468 1
Operating Leases, thereafter 8,668  
Total, thereafter 8,668  
Finance Lease, Liability, Payment, Due 115 310
Lessee, Operating Lease, Liability, to be Paid 17,186 2,722
Total payments 17,301 3,032
Finance Lease, Liability, Undiscounted Excess Amount (4) (23)
Lessee, Operating Lease, Liability, Undiscounted Excess Amount (4,897) (640)
Less amounts representing interest (4,901) (663)
Finance Leases, Total minimum payments required: 111 287
Operating Leases, Total minimum payments required: 12,289 2,082
Total, Total minimum payments required: $ 12,400 $ 2,369
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.22.1
Lease Commitments (Details Narrative) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Leases [Abstract]    
Operating leases, right of use $ 12,075 $ 1,827
Current portion of operating lease obligations 1,983 431
Long-term portion of operating lease obligations $ 10,306 $ 1,651
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.22.1
Accrued expenses consist of the following: (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Payables and Accruals [Abstract]    
Accrued payroll and related expenses $ 471 $ 315
Accrued accounts payable 320 122
Tenant Security Deposit / Advance Rent 122
Other 33 47
 Total $ 946 $ 484
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.22.1
A reconciliation of income tax expense to the amount computed by applying the Federal income tax rate to loss before provision for income taxes as of December 31, 2021 and 2020 is as follows: (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Income Tax Disclosure [Abstract]    
Income tax credit at statutory rates $ 495 $ 208
Nondeductible expenses 5
Tax Exempt Income - PPP Loan (271)
Permanent Tax Deduction Stock Options Exercised (63)
State income tax, net of federal benefits 177 74
Expiration of NOL & Credits 899 2,543
Tax basis in excess of book Convertible Debt
Expiration of Stock Options 92 122
Other 2 (7)
Change in valuation allowance (1,294) (2,945)
 TOTAL $ 37
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.22.1
Significant components of our deferred income taxes consist of the following: (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Deferred tax liabilities:    
  Excess tax basis convertible debt $ (257)
     Total deferred tax liabilities (257)
Deferred tax assets:    
  Net operating loss carryforwards 14,566 15,597
  Inventory and other allowances 148 23
  Charitable contribution & other carryforwards 9
  Excess (tax) book depreciation 31 375
  Excess (tax) book amortization 63 61
  Share-based compensation 308 624
  Other accrued costs 161 138
     Total deferred tax assets 15,277 16,827
  Less:  Valuation allowance (15,277) (16,570)
Deferred income taxes
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.22.1
Income Taxes (Details Narrative) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Operating Loss Carryforwards [Line Items]    
Increase (decrease) in valuation allowance $ 1,300 $ 6,400
Net operating loss carryforwards 1,000 $ 6,300
Net operating loss carryforwards 62,000  
Deferred Tax Assets, Tax Credit Carryforwards $ 57,000  
Capital loss carryforwards expiration period start 2029  
Capital loss carryforwards expiration period end 2039  
Tax Year 2012 [Member]    
Operating Loss Carryforwards [Line Items]    
Net operating loss carryforwards $ 21,000  
Expiring Operating Loss Carry forwards [Member]    
Operating Loss Carryforwards [Line Items]    
Net operating loss carryforwards $ 5,000  
Domestic Tax Authority [Member]    
Operating Loss Carryforwards [Line Items]    
Capital loss carryforwards expiration period start 2022  
Capital loss carryforwards expiration period end 2037  
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.22.1
Capital Stock (Details Narrative) - shares
Dec. 31, 2021
Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Preferred stock, shares authorized 24,088 24,088
Plan [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Authorized, unissued shares of common stock 10,000,000  
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.22.1
We follow ASC Topic 718, Share-Based Payments, in which compensation expense is recognized only for share-based payments expected to vest. (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Remaining weighted average-period, expense recognition (years) 2 years 10 months 25 days  
Share-based Payment Arrangement, Option [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Share-based compensation expense $ 160 $ 195
Remaining unrecognized compensation expense  $ 1,581  
XML 63 R52.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of assumptions used to calculate Black-Scholes option pricing model for options granted (Details) - $ / shares
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Share-based Payment Arrangement [Abstract]    
Weighted-average risk-free interest rates 1.40% 0.50%
Dividend yield 0.00% 0.00%
Weighted-average expected life (years) of the option 5 years 5 years
Weighted-average expected stock price volatility 115.00% 95.00%
Weighted-average fair value of the options granted $ 2.59 $ 0.28
XML 64 R53.htm IDEA: XBRL DOCUMENT v3.22.1
Additional disclosures for options granted for all years presented: (Details) - Share-based Payment Arrangement, Option [Member]
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Vesting period (years) of shares granted in period 3 years 3 years
Contractual life (years) of shares granted in period 7 years 7 years
Estimated forfeitures 4.00% 4.00%
XML 65 R54.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of option activity (Details)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2021
USD ($)
$ / shares
shares
Share-based Payment Arrangement [Abstract]  
Shares Outstanding, Beginning 3,412,686
Shares Outstanding Beginning, (per share) | $ / shares $ 0.57
Granted 567,500
Granted (per share) | $ / shares $ 4.14
Exercised (535,100)
Exercised (per share) | $ / shares $ 0.44
Forfeited or expired (251,870)
Forfeited or expired (per share) | $ / shares $ 1.09
Shares Outstanding, Beginning 3,193,216
Shares Outstanding Ending, (per share) | $ / shares $ 1.18
Shares Outstanding (years) 5 years 1 month 6 days
Shares Outstanding (Intrinsic value) | $ $ 10,267
Shares Exercisable 2,189,378
Shares Exercisable, (per share) | $ / shares $ 0.56
Shares Exercisable (years) 4 years 4 months 24 days
Shares Exercisable (Intrinsic value) | $ $ 8,405
Shares for grants 1,887,500
XML 66 R55.htm IDEA: XBRL DOCUMENT v3.22.1
The aggregate intrinsic value in the table above is based on our closing stock price of $4.40 on the last business day for the year ended December 31, 2021. (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Shares exercised 535,100  
Cash received $ 234 $ 37
Share-based Payment Arrangement, Option [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Shares exercised 535,100 84,500
Total intrinsic value $ 1,169 $ 10
Cash received $ 234 $ 37
XML 67 R56.htm IDEA: XBRL DOCUMENT v3.22.1
Stock Options and Stock Grants (Details Narrative)
 12 Months Ended
Dec. 31, 2021
:Equity Compensation Plan 2019 [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Shares based compensation payment award expiration period 7 years
Equity Compensation Plan 2010 [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Shares based compensation payment award expiration period 10 years
XML 68 R57.htm IDEA: XBRL DOCUMENT v3.22.1
401(k) Profit-Sharing Plan (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Retirement Benefits [Abstract]    
Employer's matching contribution percentage 10.00%  
Percentage of employee's matching contribution 8.00%  
Participant salary percentage matched 80.00%  
Defined Contribution Plan, Cost $ 107 $ 21
XML 69 R58.htm IDEA: XBRL DOCUMENT v3.22.1
We had five significant customers for the year ended December 31, 2021. (Details) - Customer Concentration Risk [Member] - Revenue Benchmark [Member]
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Customer One - Personal Care Ingredients [Member]    
Concentration Risk [Line Items]    
Revenue from customers 26.00% 30.00%
Customer Two - Solesence [Member]    
Concentration Risk [Line Items]    
Revenue from customers 19.00% 14.00%
Customer Three - Solesence [Member]    
Concentration Risk [Line Items]    
Revenue from customers 15.00% 11.00%
Customer Four - Solesence [Member]    
Concentration Risk [Line Items]    
Revenue from customers 10.00% 5.00%
Customer Five - Medical Diagnostics [Member]    
Concentration Risk [Line Items]    
Revenue from customers 8.00% 20.00%
Customers One through Five [Member]    
Concentration Risk [Line Items]    
Revenue from customers 78.00% 80.00%
XML 70 R59.htm IDEA: XBRL DOCUMENT v3.22.1
Accounts receivable balances for these five customers were approximately: (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Total $ 2,462 $ 2,437
Customer One - Personal Care Ingredients [Member]    
Total 641 381
Customer Two - Solesence [Member]    
Total 534 342
Customer Three - Solesence [Member]    
Total 1,048 116
Customer Four - Solesence [Member]    
Total $ 239 863
Customer Five - Medical Diagnostics [Member]    
Total   $ 735
XML 71 R60.htm IDEA: XBRL DOCUMENT v3.22.1
Significant Customers and Contingencies (Details Narrative)
Dec. 31, 2021
Supply Commitment [Line Items]  
Equipment sale - net book value 115.00%
Supply Commitment [Member]  
Supply Commitment [Line Items]  
Equipment sale - net book value 115.00%
Equipment sale- original book value 30.00%
XML 72 R61.htm IDEA: XBRL DOCUMENT v3.22.1
The revenues for 2021 and 2020 by category are as follows: (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Revenue from External Customer [Line Items]    
Total revenue $ 29,475 $ 17,123
Personal Care Ingredients [Member]    
Revenue from External Customer [Line Items]    
Total revenue 18,175 6,737
Advanced Materials [Member]    
Revenue from External Customer [Line Items]    
Total revenue 7,739 5,536
Solesence [Member]    
Revenue from External Customer [Line Items]    
Total revenue $ 3,561 $ 4,850
XML 73 R62.htm IDEA: XBRL DOCUMENT v3.22.1
Business Segmentation and Geographical Distribution (Details Narrative) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Product [Member]    
Revenues from External Customers and Long-Lived Assets [Line Items]    
Revenues $ 2,335 $ 3,450
Non-US [Member]    
Revenues from External Customers and Long-Lived Assets [Line Items]    
Revenues $ 3,236 $ 3,714
XML 74 nanx-10k_123121_htm.xml IDEA: XBRL DOCUMENT 0000883107 2021-01-01 2021-12-31 0000883107 2021-06-30 0000883107 2022-03-31 0000883107 2021-12-31 0000883107 2020-12-31 0000883107 2020-01-01 2020-12-31 0000883107 us-gaap:ProductMember 2021-01-01 2021-12-31 0000883107 us-gaap:ProductMember 2020-01-01 2020-12-31 0000883107 us-gaap:ProductAndServiceOtherMember 2021-01-01 2021-12-31 0000883107 us-gaap:ProductAndServiceOtherMember 2020-01-01 2020-12-31 0000883107 us-gaap:PreferredStockMember 2019-12-31 0000883107 us-gaap:CommonStockMember 2019-12-31 0000883107 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000883107 us-gaap:RetainedEarningsMember 2019-12-31 0000883107 2019-12-31 0000883107 us-gaap:PreferredStockMember 2020-12-31 0000883107 us-gaap:CommonStockMember 2020-12-31 0000883107 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000883107 us-gaap:RetainedEarningsMember 2020-12-31 0000883107 us-gaap:PreferredStockMember 2020-01-01 2020-12-31 0000883107 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0000883107 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0000883107 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0000883107 us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0000883107 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0000883107 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0000883107 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0000883107 us-gaap:PreferredStockMember 2021-12-31 0000883107 us-gaap:CommonStockMember 2021-12-31 0000883107 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000883107 us-gaap:RetainedEarningsMember 2021-12-31 0000883107 srt:MinimumMember us-gaap:EquipmentMember 2021-01-01 2021-12-31 0000883107 srt:MaximumMember us-gaap:EquipmentMember 2021-01-01 2021-12-31 0000883107 srt:MinimumMember us-gaap:LeaseholdImprovementsMember 2021-01-01 2021-12-31 0000883107 srt:MaximumMember us-gaap:LeaseholdImprovementsMember 2021-01-01 2021-12-31 0000883107 srt:MinimumMember us-gaap:OtherCapitalizedPropertyPlantAndEquipmentMember 2021-01-01 2021-12-31 0000883107 srt:MaximumMember us-gaap:OtherCapitalizedPropertyPlantAndEquipmentMember 2021-01-01 2021-12-31 0000883107 nanx:Year2021Member 2021-12-31 0000883107 nanx:Year2022Member 2021-12-31 0000883107 nanx:Year2023Member 2021-12-31 0000883107 nanx:LibertyvilleBankAndTrustMember 2021-01-01 2021-12-31 0000883107 nanx:LibertyvilleBankAndTrustMember 2021-12-31 0000883107 nanx:LibertyvilleBankAndTrustMember 2020-12-31 0000883107 nanx:LibertyvilleBankAndTrustOneMember 2021-01-01 2021-12-31 0000883107 nanx:LibertyvilleBankAndTrustOneMember 2020-12-31 0000883107 nanx:LibertyvilleBankAndTrustTwoMember 2021-01-01 2021-12-31 0000883107 nanx:LibertyvilleBankAndTrustTwoMember 2021-12-31 0000883107 nanx:BeachcorpLLCMember 2021-01-01 2021-12-31 0000883107 nanx:BeachcorpLLCMember 2021-12-31 0000883107 nanx:BeachcorpLLCMember 2020-12-31 0000883107 nanx:BeachcorpLLCOneMember 2021-01-01 2021-12-31 0000883107 nanx:BeachcorpLLCOneMember 2021-12-31 0000883107 nanx:BeachcorpLLCOneMember 2020-12-31 0000883107 nanx:SecuredConvertiblePromissoryNoteMember 2021-01-01 2021-12-31 0000883107 nanx:SecuredConvertiblePromissoryNoteMember 2020-12-31 0000883107 nanx:PPPLoanLibertyvillePromissoryNoteMember 2021-01-01 2021-12-31 0000883107 nanx:PPPLoanLibertyvillePromissoryNoteMember 2020-12-31 0000883107 nanx:BeachcorpLLCThreeMember 2021-01-01 2021-12-31 0000883107 nanx:BeachcorpLLCFourMember 2021-01-01 2021-12-31 0000883107 nanx:StrandlerLLCMember 2021-01-01 2021-12-31 0000883107 us-gaap:LetterOfCreditMember 2014-07-31 0000883107 us-gaap:LetterOfCreditMember 2014-07-01 2014-07-31 0000883107 nanx:CreditAgreementMember 2021-12-31 0000883107 us-gaap:LetterOfCreditMember nanx:NewBusinessLoanAgreementMember 2021-01-01 2021-12-31 0000883107 nanx:BeachcorpLLCMember nanx:TermLoanMember nanx:BusinessLoanAgreementMember 2018-11-16 0000883107 nanx:BeachcorpLLCMember nanx:TermLoanMember nanx:BusinessLoanAgreementMember 2018-11-15 2018-11-16 0000883107 nanx:BeachcorpLLCMember us-gaap:RevolvingCreditFacilityMember nanx:BusinessLoanAgreementMember 2018-11-16 0000883107 nanx:BeachcorpLLCMember us-gaap:RevolvingCreditFacilityMember nanx:BusinessLoanAgreementMember 2018-11-15 2018-11-16 0000883107 nanx:BeachcorpLLCMember srt:MinimumMember us-gaap:RevolvingCreditFacilityMember nanx:BusinessLoanAgreementMember 2018-11-16 0000883107 nanx:BeachcorpLLCMember nanx:TermLoanAndTheRevolverFacilityMember nanx:FirstAmendmentMember 2020-03-21 2020-03-23 0000883107 nanx:BeachcorpLLCMember us-gaap:RevolvingCreditFacilityMember nanx:SecondAmendmentMember 2020-09-08 0000883107 nanx:BeachcorpLLCMember us-gaap:RevolvingCreditFacilityMember nanx:ThirdAmendmentMember 2020-12-23 0000883107 nanx:BeachcorpLLCMember nanx:TermLoanAndTheRevolverFacilityMember nanx:FirstAmendmentMember 2020-12-22 2020-12-23 0000883107 nanx:BeachcorpLLCMember us-gaap:RevolvingCreditFacilityMember nanx:FourthAmendmentMember 2021-04-21 0000883107 nanx:BeachcorpLLCMember us-gaap:RevolvingCreditFacilityMember nanx:FourthAmendmentMember 2021-04-20 2021-04-21 0000883107 nanx:BeachcorpLLCMember nanx:TermLoanMember nanx:FourthAmendmentMember 2021-04-21 0000883107 nanx:BeachcorpLLCMember nanx:TermLoanMember nanx:FourthAmendmentMember 2021-04-20 2021-04-21 0000883107 nanx:SecuredConvertiblePromissoryNoteMember nanx:BradfordTWhitmoreMember 2019-11-20 0000883107 nanx:SecuredConvertiblePromissoryNoteMember nanx:BradfordTWhitmoreMember 2019-11-18 2019-11-20 0000883107 nanx:RelatedPartyCreditFacilitiesMember 2021-01-01 2021-12-31 0000883107 nanx:WhitmoreMember 2021-05-06 2021-05-07 0000883107 nanx:WhitmoreMember 2021-05-07 0000883107 nanx:PromissoryNoteMember nanx:LibertyvilleMember 2020-04-17 0000883107 nanx:PromissoryNoteMember 2021-12-31 0000883107 nanx:BeachcorpLLCMember nanx:BusinessLoanAgreementMember 2022-01-27 2022-01-28 0000883107 nanx:BeachcorpLLCMember us-gaap:RevolvingCreditFacilityMember nanx:AAndRLoanAgreementMember 2022-01-27 2022-01-28 0000883107 nanx:StrandlerLLCMember us-gaap:RevolvingCreditFacilityMember nanx:AAndRLoanAgreementMember 2022-01-27 2022-01-28 0000883107 nanx:RelatedPartyTransactionMember 2021-12-31 0000883107 nanx:RelatedPartyTransactionMember 2020-12-31 0000883107 nanx:SecuredConvertiblePromissoryNotesMember 2021-12-31 0000883107 nanx:SecuredConvertiblePromissoryNotesMember 2020-12-31 0000883107 us-gaap:MachineryAndEquipmentMember 2021-12-31 0000883107 us-gaap:MachineryAndEquipmentMember 2020-12-31 0000883107 us-gaap:OfficeEquipmentMember 2021-12-31 0000883107 us-gaap:OfficeEquipmentMember 2020-12-31 0000883107 us-gaap:FurnitureAndFixturesMember 2021-12-31 0000883107 us-gaap:FurnitureAndFixturesMember 2020-12-31 0000883107 us-gaap:LeaseholdImprovementsMember 2021-12-31 0000883107 us-gaap:LeaseholdImprovementsMember 2020-12-31 0000883107 us-gaap:ConstructionInProgressMember 2021-12-31 0000883107 us-gaap:ConstructionInProgressMember 2020-12-31 0000883107 us-gaap:DomesticCountryMember 2021-01-01 2021-12-31 0000883107 nanx:ExpiringOperatingLossCarryforwardsMember 2021-12-31 0000883107 us-gaap:TaxYear2012Member 2021-12-31 0000883107 nanx:PlanMember 2021-12-31 0000883107 nanx:EquityCompensationPlan2019Member 2021-01-01 2021-12-31 0000883107 nanx:EquityCompensationPlan2010Member 2021-01-01 2021-12-31 0000883107 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0000883107 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0000883107 nanx:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0000883107 nanx:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0000883107 nanx:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0000883107 nanx:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0000883107 nanx:CustomerThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0000883107 nanx:CustomerThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0000883107 nanx:CustomerFourMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0000883107 nanx:CustomerFourMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0000883107 nanx:CustomerFiveMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0000883107 nanx:CustomerFiveMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0000883107 nanx:CustomersOneThroughFiveMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0000883107 nanx:CustomersOneThroughFiveMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0000883107 nanx:CustomerOneMember 2021-12-31 0000883107 nanx:CustomerOneMember 2020-12-31 0000883107 nanx:CustomerTwoMember 2021-12-31 0000883107 nanx:CustomerTwoMember 2020-12-31 0000883107 nanx:CustomerThreeMember 2021-12-31 0000883107 nanx:CustomerThreeMember 2020-12-31 0000883107 nanx:CustomerFourMember 2021-12-31 0000883107 nanx:CustomerFourMember 2020-12-31 0000883107 nanx:CustomerFiveMember 2020-12-31 0000883107 us-gaap:SupplyCommitmentMember 2021-12-31 0000883107 us-gaap:NonUsMember 2021-01-01 2021-12-31 0000883107 us-gaap:NonUsMember 2020-01-01 2020-12-31 0000883107 nanx:PersonalCareIngredientsMember 2021-01-01 2021-12-31 0000883107 nanx:PersonalCareIngredientsMember 2020-01-01 2020-12-31 0000883107 nanx:AdvancedMaterialsMember 2021-01-01 2021-12-31 0000883107 nanx:AdvancedMaterialsMember 2020-01-01 2020-12-31 0000883107 nanx:SolesenceMember 2021-01-01 2021-12-31 0000883107 nanx:SolesenceMember 2020-01-01 2020-12-31 iso4217:USD shares iso4217:USD shares pure 0000883107 false FY --12-31 2021 P0Y8M12D P1Y4M24D P2Y10M25D P3Y P3Y P7Y P7Y P5Y1M6D P4Y4M24D 10-K true 2021-12-31 false 000-22333 NANOPHASE TECHNOLOGIES CORPORATION DE 36-3687863 1319 Marquette Drive Romeoville IL 60446 630 771-6708 Common Stock, par value $.01 per share No No Yes Yes Non-accelerated Filer true false false 27240325 48893573 RSM US LLP 49 Chicago, Illinois 657000 957000 60000 9000 3937000 2932000 6095000 4340000 910000 606000 11599000 8835000 4712000 2868000 12075000 1827000 8000 10000 28394000 13540000 500000 1351000 2155000 500000 105000 177000 1983000 431000 3566000 2126000 783000 411000 946000 484000 8734000 6784000 6000 110000 10306000 1651000 1000000 1097000 952000 661000 222000 214000 12195000 4024000 0.01 0.01 24088 24088 0 0 0 0 0.01 0.01 55000000 55000000 48893573 48893573 38221292 38221292 489000 382000 104423000 102117000 -97447000 -99767000 7465000 2732000 28394000 13540000 29325000 16422000 150000 701000 29475000 17123000 20785000 11133000 8690000 5990000 2235000 1571000 3896000 2934000 2559000 1485000 1154000 496000 952000 2357000 989000 37000 2320000 989000 0.05 0.03 45021173 38158586 0.05 0.03 47039173 38545586 38136792 381000 101886000 -100756000 1511000 84500 1000 36000 37000 195000 195000 989000 989000 38221292 382000 102117000 -99767000 2732000 2732000 576726 6000 228000 234000 10095555 101000 1918000 2019000 160000 160000 2320000 2320000 48893573 489000 104423000 -97447000 7465000 7465000 2320000 989000 454000 358000 952000 903000 267000 160000 195000 1005000 1962000 1755000 1786000 304000 339000 1026000 295000 1033000 -164000 481000 113000 40000 27000 2321000 -2061000 1874000 878000 -1874000 -878000 177000 218000 500000 2000000 1000000 2000000 952000 24750000 14515000 25554000 12584000 500000 234000 37000 -747000 2702000 -300000 -237000 957000 1194000 657000 957000 218000 178000 414000 83000 2000000 2000000 19000 10505000 <p id="xdx_804_eus-gaap--NatureOfOperations_zmeu5eqXtN87" style="margin-top: 0; margin-bottom: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(1)</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_820_zvRUX13JtMy6">Description of Business</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Nanophase Technologies Corporation (“Nanophase,” “Company,” “we,” “our,” or “us”) is a science-driven company which, along with its wholly owned subsidiary, Solésence, LLC (our “Solésence beauty science subsidiary”), is focused in various beauty- and life-science markets.  Using consumer health as our end-goal and science and innovation to guide the path, skin health and medical diagnostics combined currently make up the great majority of our business and drive our forward growth strategy.  We offer engineered materials, formulation development and commercial manufacturing through an integrated family of technologies. Our expertise in materials engineering allows us to effectively coat and disperse particles on a nano and “non-nano” scale for use in a variety of skin health markets, including for use in sunscreens as active ingredients and as fully developed prestige skin care and cosmetics products, marketed and sold through our Solésence beauty science subsidiary.  In terms of our life sciences focus, we have seen current conditions significantly increase demand for our medical diagnostics ingredients, as testing for various viruses, most notably COVID-19, has become a critical use of our technology.<span style="text-decoration: line-through"> </span> Additionally, we continue to sell products in legacy markets, including architectural coatings, industrial coating applications, abrasion-resistant additives, plastics additives, and surface finishing technologies (polishing) applications, all of which, along with medical diagnostics, fall into the advanced materials product category. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> We target markets<span style="text-decoration: line-through">,</span> primarily related to skin health products and ingredients<span style="text-decoration: line-through">,</span> as well as diagnostic life sciences ingredients where we believe our materials and products offer practical and competitive minerals-based solutions. We traditionally work closely with current customers in these target markets to identify their material and performance requirements. We market our materials to various end-use applications manufacturers, and our Solésence® products to cosmetics and skin care brands.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recently developed technologies have made certain new products possible and opened potential new markets. During 2015 we were granted a patent on a new type of particle surface treatment (coating) — now called Active Stress Defense ™ Technology — which became the cornerstone of our new product development in personal care, with first revenue recognized during 2016. Active Stress Defense™ now refers to a suite of three proprietary technologies — Original Active Stress Defense™, Kleair™, and Bloom™ — all three of which either utilize a unique and proprietary, mineral-based technology or work synergistically with one of our unique and proprietary, mineral-based technologies to improve performance and/or aesthetics. Our ongoing innovation efforts include new IP in areas that advance environmental protection, align with market needs, and complement our existing technologies Through the creation of our Solésence beauty science subsidiary, we utilize our technology suite to manufacture and sell fully developed solutions to targeted customers in the skin care industry, typically in prestige skin care and cosmetics markets, in addition to the ingredients we have traditionally sold in the personal care area. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although our primary strategic focus has been the North American market, we currently sell materials to customers overseas and have been working to expand our reach within foreign markets. Our common stock trades on the OTCQB marketplace under the symbol NANX. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While product sales comprise the majority of our revenue, we also recognize revenue from other sources from time to time. These activities are not expected to drive the long-term growth of the business. For this reason, we classify such revenue as “other revenue” in our Consolidated Statements of Operations, as it does not represent revenue directly from the sale of our products. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> The Company has recorded positive net income and positive cash flow from operations in 2021. We have also significantly improved our borrowing flexibility and capacity in early 2022, as discussed in Note 3. Based upon our financial performance, as well as our current liquidity and available borrowing capacity, there is not substantial doubt regarding the Company's ability to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p id="xdx_805_eus-gaap--SignificantAccountingPoliciesTextBlock_zm8x3iQG2xGj" style="margin-top: 0; margin-bottom: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(2)</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_827_zpCvylYhhOGi">Summary of Significant Accounting Policies</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_84E_eus-gaap--UseOfEstimates_ze9HXmWSqhXj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_86E_z8IgJhjHn9u8">Use of Estimates and Risks and Uncertainties</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. Certain assumptions are also necessary to assess the impact of risks and uncertainties on the financial statements, such as cash flow projections, availability of capital if needed to support the ongoing operations of the business, and our expected compliance with contractual commitments. These risks and uncertainties are further discussed in Note 12. Any changes in these assumptions or business plans could have a material impact on the financial statements.</span></p> <p id="xdx_85C_zwt5nQg12K93" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_848_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zhRhWXdCX71l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zH7AYYD53W0g">Cash</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Cash balance on December 31, 2021 consists of funds borrowed from our Revolving Line of Credit, which is facilitated by Beachcorp, LLC. Our ability to access cash from our credit facility solely depends on carrying an Accounts Receivable balance greater than the outstanding loan balance in the Revolving Line of Credit. As part of the agreement, we are required to have a bank account in place to act as a depository account for our customers. This account is referred to as the Control Account. Furthermore, there is an Account Control Agreement in place which provides Beachcorp, LLC the ability to exercise control over the account via approval of requested transfers. According to our agreements with Beachcorp, LLC, Nanophase is to be the party initiating any transfers, whether to Nanophase or to Beachcorp, LLC, and approval to access any monies within this account can only be withheld by Beachcorp, LLC if the borrowing base falls below the Company’s qualified receivables, or if we are in arrears with respect to interest payments due Beachcorp, LLC. The failure of Nanophase to remedy the previously mentioned conditions could lead to Beachcorp, LLC gaining the right, through a “springing” feature administered by Libertyville Bank and Trust, a Wintrust Community Bank (“Libertyville”), to transfer funds to itself without direct approval from Nanophase.  Cash is held at a federally insured institution, but our cash balances at times exceed insured limits. The Company has not experienced any losses related to these statutory limits.</span></p> <p id="xdx_853_zyceTLOX0JJc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zF4jANM5I8aa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <b><span id="xdx_861_zop3LnyPIqS9">Trade Accounts Receivable</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade accounts receivable are carried at original invoice amount less an estimate made for doubtful receivables based on a review of all outstanding amounts on a monthly basis. We determine the allowance for doubtful accounts by identifying troubled accounts and by using historical experience applied to an aging of accounts. Trade accounts receivable are written off when deemed uncollectible. Recoveries of trade accounts receivable previously written off are recorded when received. Our typical credit terms are between thirty and sixty days from shipment and invoicing.</span></p> <p id="xdx_855_zPiXH4Co5mPk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_eus-gaap--InventoryPolicyTextBlock_zRfq59eWsrKa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zaBtw16xyqA2">Inventories</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories are stated at the lower of cost, maintained on an average cost basis, or net realizable value. We have recorded allowances to reduce inventory relating to excess quantities of certain materials. Write-downs of inventories establish a new cost basis, which is not increased for future increases in market value of inventories or changes in estimated excess quantities.</span></p> <p id="xdx_85E_zDm8yT85IP87" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zgvtJa5FfQ75" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zdxbj3OtHXRc">Equipment and Leasehold Improvements</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equipment is stated at cost and is being depreciated over its estimated useful life (<span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MinimumMember_zwvz4acx4It8" title="Equipment leasehold improvements and leased assets useful life">3</span>-<span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MaximumMember_zsAVXuUPs2Zj" title="Equipment leasehold improvements and leased assets useful life">20</span> years) using the straight-line method. Leasehold improvements are stated at cost and are being amortized using the straight-line method over the shorter of the useful life of the asset or the term of the lease (<span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MinimumMember_zMDugXLDYXZ5" title="Equipment leasehold improvements and leased assets useful life">3</span>-<span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MaximumMember_zcqDvmsOzcee" title="Equipment leasehold improvements and leased assets useful life">7</span> years). Depreciation expense for leased assets is included with depreciation expense for owned assets. From time to time we have self-constructed assets. These assets are stated at cost plus the capitalization of labor and are depreciated over an estimated useful life (<span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OtherCapitalizedPropertyPlantAndEquipmentMember__srt--RangeAxis__srt--MinimumMember_zmg6cVQ1VH8c" title="Equipment leasehold improvements and leased assets useful life">7</span>-<span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OtherCapitalizedPropertyPlantAndEquipmentMember__srt--RangeAxis__srt--MaximumMember_zWqk5Mi38F4g" title="Equipment leasehold improvements and leased assets useful life">10</span> years) using the straight-line method.</span></p> <p id="xdx_85F_z91F1OUNfjt7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zXdy3HzsYiJc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zrcPqt0z7lI6">Long Lived Assets</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We review long-lived assets for impairment whenever events or changes in circumstances indicate that the asset’s carrying amount may not be recoverable. We conduct long-lived asset impairment analyses in accordance with ASC 360-10-15, <i>Impairment or Disposal of Long-Lived Assets</i>. ASC 360-10-15 requires us to group assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities and evaluate the asset group against the sum of the undiscounted future cash flows. If the undiscounted cash flows do not indicate the carrying amount of the asset is recoverable, an impairment charge is measured as the amount by which the carrying amount of the asset group exceeds its fair value based on discounted cash flow analysis or appraisals. Based upon our analysis, there were no impairment charges recognized in either period presented.</span></p> <p id="xdx_850_z1zFxNd41tah" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_z35fN8vy5jn9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_z5V2jotDWbxk">Deferred Revenue</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company records a contract liability for development projects due to the contractual billing of these projects not always aligning with revenue recognition. In addition, it is now the Company’s policy to frequently require deposits relating to the initial production of our Solésence products. Of the total $<span id="xdx_90A_eus-gaap--DeferredRevenue_iI_pn3n3_c20211231_z220MWNWenR4" title="Deferred revenue">1,444</span> in deferred revenue reported in 2021, approximately <span id="xdx_90A_eus-gaap--FinancingReceivablePercentPastDue1_iI_dp_c20211231__us-gaap--TaxPeriodAxis__custom--Year2021Member_zZqtWF6EM8I6" title="Percentage of prepayments">70</span>% is comprised of prepayment received from our medical diagnostics application customer for purchase orders to be filled in 2022 and 2023, <span id="xdx_90F_eus-gaap--FinancingReceivablePercentPastDue1_iI_dp_c20211231__us-gaap--TaxPeriodAxis__custom--Year2022Member_z9w0GgpqRCb">25</span>% related to prepayments received from new customers as per Company policy, and the remaining <span id="xdx_905_eus-gaap--FinancingReceivablePercentPastDue1_iI_dp_c20211231__us-gaap--TaxPeriodAxis__custom--Year2023Member_zKEeUoUnO2Y8">5</span>% related to prepayments from a product development agreement with a personal care ingredient customer.</span></p> <p id="xdx_85A_zCuIwbw01dVf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_eus-gaap--AssetRetirementObligationsPolicy_zxZsuAssaDK9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zL8wp68CCIJe">Asset Retirement Obligations</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with our leased facilities, we are required to remove certain leasehold improvements upon termination of our occupancy. We follow the provisions of the FASB issued ASC 410-20, <i>Asset Retirement Obligations</i>, under which we recognize a liability for the fair value of these asset retirement obligations. The fair value of that liability is measured based on an expected cash flow approach and accretion expense is recognized each period to recognize increases to the fair value of the liability due to the passage of time. Increases to the fair value of the liability, except for accretion, are added to the carrying value of the long-lived asset. Those increases are then reported in amortization expense over the estimated useful life of the long-lived asset.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_893_eus-gaap--ScheduleOfChangeInAssetRetirementObligationTableTextBlock_zeNLzYns2s9e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <span id="xdx_8B4_zw0i4wtOU0V5">Activity in the asset retirement obligation account for the years ended December 31, is as follows:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20210101__20211231_zwmM1Pi8PPxb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20200101__20201231_zvy3wfOGCyi9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_403_eus-gaap--AssetRetirementObligationsNoncurrent_iS_z17o9GLwbKf5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: left">Balance, beginning</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">214</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">206</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--AssetRetirementObligationAccretionExpense_zS4qqtHlIO4l" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0.125in">Accretion of liability due to passage of time</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AccretionExpenseIncludingAssetRetirementObligations_zYIXtLEHmXk1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Amortization of asset due to passage of time</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0495">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0496">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--AssetRetirementObligationsNoncurrent_iE_z37I18QFPmN" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance, ending</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">222</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">214</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A0_zfja9alZa6cb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_855_zO5hEM7uyAB2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p id="xdx_84B_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zNAZvANYf55l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_865_zYrg3C4vvRIk">Financial Instruments</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We follow ASC Topic 820, <i>Fair Value Measurements and Disclosures</i>, which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. The fair value framework requires the categorization of assets and liabilities into three levels based upon the assumptions (inputs) used to price the assets or liabilities. Level 1 provides the most reliable measure of fair value, whereas Level 3 generally requires significant management judgment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our financial instruments include cash, any cash equivalents, accounts receivable, accounts payable and accrued expenses, along with any short term and long-term borrowings as described in Note 3. There were no financial instruments adjusted to fair value on December 31, 2021 and 2020.</span></p> <p id="xdx_85E_zhYfxZ9nFVx1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--RevenueRecognitionPolicyTextBlock_zSy2OOJVGrok" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zUrFvZlIjEeg">Product Revenue</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues are recognized when control of the promised goods is transferred to customers, in an amount that reflects the consideration we expect to receive in exchange for those goods. When our ingredients and finished products are shipped, with control being transferred at the shipping point almost universally, is the point in time at which we recognize the related revenue.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We generally expense sales commissions when incurred because the amortization period would have been one year or less. These costs are recorded within selling, general and administrative expenses. Customers’ deposits, deferred revenue and other receipts are deferred and recognized when the revenue is realized and earned. Cash payments to customers are classified as reductions of revenue in our statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_zGaKTYofbRZ1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; visibility: hidden"><span id="xdx_8BA_zXwPxXnEBClc">Contract balances for the year 2021 and 2020</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract balances for the year ended December 31, 2021 is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts <br/> Receivable, <br/> net</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract <br/> Assets</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract <br/> Liabilities</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 61%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance, beginning</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--AccountsReceivableNetCurrent_iI_pn3n3_c20201231_zG5Ff51w2OCf" style="width: 10%; text-align: right" title="Accounts receivable net"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,932</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20201231_zWNhFlhnCv1k" style="width: 10%; text-align: right" title="Contract liability"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">411</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance, ending</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--AccountsReceivableNetCurrent_iI_pn3n3_c20211231_zBKfaGNgeW6b" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,937</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98F_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20211231_zxl1wQyqqxx1" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,444</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract balances for the year ended December 31, 2020 is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts <br/> Receivable, <br/> net</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract <br/> Assets</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract <br/> Liabilities</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 61%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance, beginning</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--AccountsReceivableNetCurrent_iI_pn3n3_c20191231_zMM38iijMSVf" style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">970</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20191231_zsUeBTuPPuH3" style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">575</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance, ending</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98F_eus-gaap--AccountsReceivableNetCurrent_iI_pn3n3_c20201231_zSnw5rMsWVYk" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,932</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_986_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20201231_zrHL8kLBHkRh" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">411</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8AC_z87ePJRI4Uzf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue recognized in the reporting period that was included in the contract liability balance at the beginning of the period was $<span id="xdx_90E_ecustom--RevenueFromContractWithCustomerExcludingAssessedTaxUnderContactLiability_pn3n3_c20210101__20211231_zcE9YNTJdAdd" title="Revenue from contract with customer excluding assessed tax">260</span> and $<span id="xdx_907_ecustom--RevenueFromContractWithCustomerExcludingAssessedTaxUnderContactLiability_pn3n3_c20200101__20201231_zR359zkgCNE4" title="Revenue from contract with customer excluding assessed tax">468</span> for the years ended December 31, 2021 and 2020, respectively.</span></p> <p id="xdx_856_zvKcJVOssGZ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_ecustom--OtherRevenuePolicyTextBlock_za8mLaKyng47" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_ziCZj9rgKi07">Other Revenue</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other revenue may include revenue from technology license fees and paid development projects. Technology license fees and paid development projects are recognized over time when the obligations under the agreed upon contractual arrangements are performed on our part.  Revenue recognized over time was $<span id="xdx_903_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20211231__srt--ProductOrServiceAxis__us-gaap--ProductAndServiceOtherMember_zEufKELZrCOe" title="Revenue">150</span> and $<span id="xdx_90E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20201231__srt--ProductOrServiceAxis__us-gaap--ProductAndServiceOtherMember_zQ8RXAyUg69h" title="Revenue">701</span> for the years ended December 31, 2021 and 2020, respectively.</span></p> <p id="xdx_851_zF1jQe3rPSw9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--ResearchAndDevelopmentExpensePolicy_z4kUV8uRpUuk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zmyQEJawr7ri">Research and Development Expenses</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development expenses are recognized as expense when incurred.</span></p> <p id="xdx_856_z2NAP6LXskH" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--IncomeTaxPolicyTextBlock_zfhJbQ6R0Jil" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zVe9uhvKlpY5">Income Taxes</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We account for income taxes using the liability method. As such, deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Deferred tax assets and liabilities are calculated using the enacted tax rates and laws that are expected to be in effect when the anticipated reversal of these differences is scheduled to occur. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some or all of the deferred tax assets will not be realized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than <span id="xdx_90C_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxSettlementsDomestic_dp_c20210101__20211231_zsn34P7RvWgh" title="Tax rate reconciliation and settlement">50</span> percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured, as described above, is reflected as a liability for uncertain tax benefits in the accompanying balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have not recorded a reserve for any tax positions for which the ultimate deductibility is highly certain but for which there is uncertainty about the timing of such deductibility. We file tax returns in all appropriate jurisdictions, which includes a federal tax return and Illinois state tax return. When and if applicable, potential interest and penalty costs are accrued as incurred, with expenses recognized in selling, general and administrative expenses in the statements of operations. As of December 31, 2021, and 2020, we had no liability for unrecognized tax benefits.</span></p> <p id="xdx_854_zpVHhQKhDwj1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--EarningsPerSharePolicyTextBlock_ztO0yxB6czr5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zgU05fFpopqb">Earnings Per Share</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options to purchase approximately<span id="xdx_909_eus-gaap--IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_pid_c20210101__20211231_zQwBkQfuSWld" title="Options included in computation of earnings per share"> 2,018,000</span> shares of common stock that were outstanding as of December 31, 2021 were included in the computation of earnings per share for the year ended December 31, 2021.  Options to purchase approximately <span id="xdx_902_eus-gaap--IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_pid_c20200101__20201231_zGF43T7wy72g" title="Options included in computation of earnings per share">387,000</span> shares of common stock that were outstanding as of December 31, 2020 were included in the computation of earnings per share for the year ended December 31, 2020.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_ze96VGo2pEHe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_zyk8lvzn3Bnf">Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_494_20210101__20211231_zx9T38H3Vhm5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_494_20200101__20201231_z3CGTz5nMOt9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Years Ended December 31,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasicAbstract_iB_zS8WIHRQTyp2" style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Numerator: (in Thousands)</span></span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_eus-gaap--NetIncomeLoss_i01_pn3n3_zi7vkZxCbJK3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net income</span></td><td style="width: 1%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,320</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">989</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_eus-gaap--WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_iB_zRegAPRvIBE4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Denominator:</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i01_pid_uShares_maEPS_zPma1NAu127b" style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted average number of basic common shares outstanding</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">45,021,173</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">38,158,586</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_402_eus-gaap--IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_i01_pid_uShares_maEPS_zgsu21ySjcxc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted average additional shares assuming conversion of in-the-money stock options to common shares</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,018,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">387,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_i01T_pid_uShares_mtEPS_zcjT1wRe6Vdg" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted average number of diluted common shares outstanding</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47,039,173</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">38,545,586</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40D_eus-gaap--EarningsPerShareBasicAbstract_iB_zCnJB29qjKh2" style="vertical-align: bottom; background-color: White"> <td style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 2.25in"/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Basic earnings per common share:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_eus-gaap--EarningsPerShareBasic_i01_pid_uUSDPShares_zEtArimUW4w2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net income per share – basic</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.05</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.03</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40D_eus-gaap--EarningsPerShareDilutedAbstract_iB_zmA3fATrhuS" style="vertical-align: bottom; background-color: White"> <td style="text-decoration: underline"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diluted earnings per common share:</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_404_eus-gaap--EarningsPerShareDiluted_i01_pid_uUSDPShares_zHyY6IB3Mofk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net income per share – diluted</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.05</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.03</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A9_zMcxFf10vrPk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_85D_zhBs3NwCPdvf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zNEHwI2VjiEb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zDisIGwjwq06">New Accounting Pronouncements</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span style="background-color: white">In June 2016, the FASB issued ASU 2016-13, “Measurement of Credit Losses on Financial Instruments,” which replaces existing incurred loss impairment guidance and establishes a single allowance framework for financial assets carried at amortized cost. The effective date for our adoption (as amended) of this updated Standard will be January 1, 2023. The Company is currently evaluating the impact of the adoption of this standard on the consolidated financial statements.</span></span></p> <p id="xdx_857_zyvMB80D6FDl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><span style="background-color: white"> </span></span></p> <p id="xdx_84E_eus-gaap--UseOfEstimates_ze9HXmWSqhXj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_86E_z8IgJhjHn9u8">Use of Estimates and Risks and Uncertainties</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. Certain assumptions are also necessary to assess the impact of risks and uncertainties on the financial statements, such as cash flow projections, availability of capital if needed to support the ongoing operations of the business, and our expected compliance with contractual commitments. These risks and uncertainties are further discussed in Note 12. Any changes in these assumptions or business plans could have a material impact on the financial statements.</span></p> <p id="xdx_848_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zhRhWXdCX71l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zH7AYYD53W0g">Cash</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Cash balance on December 31, 2021 consists of funds borrowed from our Revolving Line of Credit, which is facilitated by Beachcorp, LLC. Our ability to access cash from our credit facility solely depends on carrying an Accounts Receivable balance greater than the outstanding loan balance in the Revolving Line of Credit. As part of the agreement, we are required to have a bank account in place to act as a depository account for our customers. This account is referred to as the Control Account. Furthermore, there is an Account Control Agreement in place which provides Beachcorp, LLC the ability to exercise control over the account via approval of requested transfers. According to our agreements with Beachcorp, LLC, Nanophase is to be the party initiating any transfers, whether to Nanophase or to Beachcorp, LLC, and approval to access any monies within this account can only be withheld by Beachcorp, LLC if the borrowing base falls below the Company’s qualified receivables, or if we are in arrears with respect to interest payments due Beachcorp, LLC. The failure of Nanophase to remedy the previously mentioned conditions could lead to Beachcorp, LLC gaining the right, through a “springing” feature administered by Libertyville Bank and Trust, a Wintrust Community Bank (“Libertyville”), to transfer funds to itself without direct approval from Nanophase.  Cash is held at a federally insured institution, but our cash balances at times exceed insured limits. The Company has not experienced any losses related to these statutory limits.</span></p> <p id="xdx_84B_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zF4jANM5I8aa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <b><span id="xdx_861_zop3LnyPIqS9">Trade Accounts Receivable</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade accounts receivable are carried at original invoice amount less an estimate made for doubtful receivables based on a review of all outstanding amounts on a monthly basis. We determine the allowance for doubtful accounts by identifying troubled accounts and by using historical experience applied to an aging of accounts. Trade accounts receivable are written off when deemed uncollectible. Recoveries of trade accounts receivable previously written off are recorded when received. Our typical credit terms are between thirty and sixty days from shipment and invoicing.</span></p> <p id="xdx_84E_eus-gaap--InventoryPolicyTextBlock_zRfq59eWsrKa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zaBtw16xyqA2">Inventories</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories are stated at the lower of cost, maintained on an average cost basis, or net realizable value. We have recorded allowances to reduce inventory relating to excess quantities of certain materials. Write-downs of inventories establish a new cost basis, which is not increased for future increases in market value of inventories or changes in estimated excess quantities.</span></p> <p id="xdx_841_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zgvtJa5FfQ75" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zdxbj3OtHXRc">Equipment and Leasehold Improvements</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equipment is stated at cost and is being depreciated over its estimated useful life (<span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MinimumMember_zwvz4acx4It8" title="Equipment leasehold improvements and leased assets useful life">3</span>-<span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MaximumMember_zsAVXuUPs2Zj" title="Equipment leasehold improvements and leased assets useful life">20</span> years) using the straight-line method. Leasehold improvements are stated at cost and are being amortized using the straight-line method over the shorter of the useful life of the asset or the term of the lease (<span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MinimumMember_zMDugXLDYXZ5" title="Equipment leasehold improvements and leased assets useful life">3</span>-<span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MaximumMember_zcqDvmsOzcee" title="Equipment leasehold improvements and leased assets useful life">7</span> years). Depreciation expense for leased assets is included with depreciation expense for owned assets. From time to time we have self-constructed assets. These assets are stated at cost plus the capitalization of labor and are depreciated over an estimated useful life (<span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OtherCapitalizedPropertyPlantAndEquipmentMember__srt--RangeAxis__srt--MinimumMember_zmg6cVQ1VH8c" title="Equipment leasehold improvements and leased assets useful life">7</span>-<span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OtherCapitalizedPropertyPlantAndEquipmentMember__srt--RangeAxis__srt--MaximumMember_zWqk5Mi38F4g" title="Equipment leasehold improvements and leased assets useful life">10</span> years) using the straight-line method.</span></p> P3Y P20Y P3Y P7Y P7Y P10Y <p id="xdx_843_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zXdy3HzsYiJc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zrcPqt0z7lI6">Long Lived Assets</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We review long-lived assets for impairment whenever events or changes in circumstances indicate that the asset’s carrying amount may not be recoverable. We conduct long-lived asset impairment analyses in accordance with ASC 360-10-15, <i>Impairment or Disposal of Long-Lived Assets</i>. ASC 360-10-15 requires us to group assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities and evaluate the asset group against the sum of the undiscounted future cash flows. If the undiscounted cash flows do not indicate the carrying amount of the asset is recoverable, an impairment charge is measured as the amount by which the carrying amount of the asset group exceeds its fair value based on discounted cash flow analysis or appraisals. Based upon our analysis, there were no impairment charges recognized in either period presented.</span></p> <p id="xdx_84F_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_z35fN8vy5jn9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_z5V2jotDWbxk">Deferred Revenue</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company records a contract liability for development projects due to the contractual billing of these projects not always aligning with revenue recognition. In addition, it is now the Company’s policy to frequently require deposits relating to the initial production of our Solésence products. Of the total $<span id="xdx_90A_eus-gaap--DeferredRevenue_iI_pn3n3_c20211231_z220MWNWenR4" title="Deferred revenue">1,444</span> in deferred revenue reported in 2021, approximately <span id="xdx_90A_eus-gaap--FinancingReceivablePercentPastDue1_iI_dp_c20211231__us-gaap--TaxPeriodAxis__custom--Year2021Member_zZqtWF6EM8I6" title="Percentage of prepayments">70</span>% is comprised of prepayment received from our medical diagnostics application customer for purchase orders to be filled in 2022 and 2023, <span id="xdx_90F_eus-gaap--FinancingReceivablePercentPastDue1_iI_dp_c20211231__us-gaap--TaxPeriodAxis__custom--Year2022Member_z9w0GgpqRCb">25</span>% related to prepayments received from new customers as per Company policy, and the remaining <span id="xdx_905_eus-gaap--FinancingReceivablePercentPastDue1_iI_dp_c20211231__us-gaap--TaxPeriodAxis__custom--Year2023Member_zKEeUoUnO2Y8">5</span>% related to prepayments from a product development agreement with a personal care ingredient customer.</span></p> 1444000 0.70 0.25 0.05 <p id="xdx_84A_eus-gaap--AssetRetirementObligationsPolicy_zxZsuAssaDK9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zL8wp68CCIJe">Asset Retirement Obligations</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with our leased facilities, we are required to remove certain leasehold improvements upon termination of our occupancy. We follow the provisions of the FASB issued ASC 410-20, <i>Asset Retirement Obligations</i>, under which we recognize a liability for the fair value of these asset retirement obligations. The fair value of that liability is measured based on an expected cash flow approach and accretion expense is recognized each period to recognize increases to the fair value of the liability due to the passage of time. Increases to the fair value of the liability, except for accretion, are added to the carrying value of the long-lived asset. Those increases are then reported in amortization expense over the estimated useful life of the long-lived asset.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_893_eus-gaap--ScheduleOfChangeInAssetRetirementObligationTableTextBlock_zeNLzYns2s9e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <span id="xdx_8B4_zw0i4wtOU0V5">Activity in the asset retirement obligation account for the years ended December 31, is as follows:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20210101__20211231_zwmM1Pi8PPxb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20200101__20201231_zvy3wfOGCyi9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_403_eus-gaap--AssetRetirementObligationsNoncurrent_iS_z17o9GLwbKf5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: left">Balance, beginning</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">214</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">206</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--AssetRetirementObligationAccretionExpense_zS4qqtHlIO4l" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0.125in">Accretion of liability due to passage of time</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AccretionExpenseIncludingAssetRetirementObligations_zYIXtLEHmXk1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Amortization of asset due to passage of time</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0495">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0496">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--AssetRetirementObligationsNoncurrent_iE_z37I18QFPmN" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance, ending</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">222</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">214</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A0_zfja9alZa6cb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_893_eus-gaap--ScheduleOfChangeInAssetRetirementObligationTableTextBlock_zeNLzYns2s9e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">        <span id="xdx_8B4_zw0i4wtOU0V5">Activity in the asset retirement obligation account for the years ended December 31, is as follows:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20210101__20211231_zwmM1Pi8PPxb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20200101__20201231_zvy3wfOGCyi9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_403_eus-gaap--AssetRetirementObligationsNoncurrent_iS_z17o9GLwbKf5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: left">Balance, beginning</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">214</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">206</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--AssetRetirementObligationAccretionExpense_zS4qqtHlIO4l" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0.125in">Accretion of liability due to passage of time</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AccretionExpenseIncludingAssetRetirementObligations_zYIXtLEHmXk1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Amortization of asset due to passage of time</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0495">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0496">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--AssetRetirementObligationsNoncurrent_iE_z37I18QFPmN" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance, ending</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">222</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">214</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 214000 206000 8000 8000 222000 214000 <p id="xdx_84B_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zNAZvANYf55l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_865_zYrg3C4vvRIk">Financial Instruments</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We follow ASC Topic 820, <i>Fair Value Measurements and Disclosures</i>, which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. The fair value framework requires the categorization of assets and liabilities into three levels based upon the assumptions (inputs) used to price the assets or liabilities. Level 1 provides the most reliable measure of fair value, whereas Level 3 generally requires significant management judgment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our financial instruments include cash, any cash equivalents, accounts receivable, accounts payable and accrued expenses, along with any short term and long-term borrowings as described in Note 3. There were no financial instruments adjusted to fair value on December 31, 2021 and 2020.</span></p> <p id="xdx_843_eus-gaap--RevenueRecognitionPolicyTextBlock_zSy2OOJVGrok" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zUrFvZlIjEeg">Product Revenue</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues are recognized when control of the promised goods is transferred to customers, in an amount that reflects the consideration we expect to receive in exchange for those goods. When our ingredients and finished products are shipped, with control being transferred at the shipping point almost universally, is the point in time at which we recognize the related revenue.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We generally expense sales commissions when incurred because the amortization period would have been one year or less. These costs are recorded within selling, general and administrative expenses. Customers’ deposits, deferred revenue and other receipts are deferred and recognized when the revenue is realized and earned. Cash payments to customers are classified as reductions of revenue in our statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_zGaKTYofbRZ1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; visibility: hidden"><span id="xdx_8BA_zXwPxXnEBClc">Contract balances for the year 2021 and 2020</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract balances for the year ended December 31, 2021 is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts <br/> Receivable, <br/> net</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract <br/> Assets</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract <br/> Liabilities</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 61%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance, beginning</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--AccountsReceivableNetCurrent_iI_pn3n3_c20201231_zG5Ff51w2OCf" style="width: 10%; text-align: right" title="Accounts receivable net"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,932</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20201231_zWNhFlhnCv1k" style="width: 10%; text-align: right" title="Contract liability"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">411</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance, ending</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--AccountsReceivableNetCurrent_iI_pn3n3_c20211231_zBKfaGNgeW6b" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,937</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98F_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20211231_zxl1wQyqqxx1" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,444</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract balances for the year ended December 31, 2020 is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts <br/> Receivable, <br/> net</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract <br/> Assets</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract <br/> Liabilities</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 61%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance, beginning</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--AccountsReceivableNetCurrent_iI_pn3n3_c20191231_zMM38iijMSVf" style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">970</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20191231_zsUeBTuPPuH3" style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">575</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance, ending</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98F_eus-gaap--AccountsReceivableNetCurrent_iI_pn3n3_c20201231_zSnw5rMsWVYk" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,932</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_986_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20201231_zrHL8kLBHkRh" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">411</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8AC_z87ePJRI4Uzf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue recognized in the reporting period that was included in the contract liability balance at the beginning of the period was $<span id="xdx_90E_ecustom--RevenueFromContractWithCustomerExcludingAssessedTaxUnderContactLiability_pn3n3_c20210101__20211231_zcE9YNTJdAdd" title="Revenue from contract with customer excluding assessed tax">260</span> and $<span id="xdx_907_ecustom--RevenueFromContractWithCustomerExcludingAssessedTaxUnderContactLiability_pn3n3_c20200101__20201231_zR359zkgCNE4" title="Revenue from contract with customer excluding assessed tax">468</span> for the years ended December 31, 2021 and 2020, respectively.</span></p> <p id="xdx_89E_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_zGaKTYofbRZ1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; visibility: hidden"><span id="xdx_8BA_zXwPxXnEBClc">Contract balances for the year 2021 and 2020</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract balances for the year ended December 31, 2021 is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts <br/> Receivable, <br/> net</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract <br/> Assets</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract <br/> Liabilities</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 61%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance, beginning</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--AccountsReceivableNetCurrent_iI_pn3n3_c20201231_zG5Ff51w2OCf" style="width: 10%; text-align: right" title="Accounts receivable net"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,932</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20201231_zWNhFlhnCv1k" style="width: 10%; text-align: right" title="Contract liability"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">411</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance, ending</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--AccountsReceivableNetCurrent_iI_pn3n3_c20211231_zBKfaGNgeW6b" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,937</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98F_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20211231_zxl1wQyqqxx1" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,444</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract balances for the year ended December 31, 2020 is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts <br/> Receivable, <br/> net</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract <br/> Assets</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract <br/> Liabilities</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 61%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance, beginning</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--AccountsReceivableNetCurrent_iI_pn3n3_c20191231_zMM38iijMSVf" style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">970</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20191231_zsUeBTuPPuH3" style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">575</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance, ending</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98F_eus-gaap--AccountsReceivableNetCurrent_iI_pn3n3_c20201231_zSnw5rMsWVYk" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,932</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_986_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20201231_zrHL8kLBHkRh" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">411</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 2932000 411000 3937000 1444000 970000 575000 2932000 411000 260000 468000 <p id="xdx_84A_ecustom--OtherRevenuePolicyTextBlock_za8mLaKyng47" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_ziCZj9rgKi07">Other Revenue</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other revenue may include revenue from technology license fees and paid development projects. Technology license fees and paid development projects are recognized over time when the obligations under the agreed upon contractual arrangements are performed on our part.  Revenue recognized over time was $<span id="xdx_903_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20211231__srt--ProductOrServiceAxis__us-gaap--ProductAndServiceOtherMember_zEufKELZrCOe" title="Revenue">150</span> and $<span id="xdx_90E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20201231__srt--ProductOrServiceAxis__us-gaap--ProductAndServiceOtherMember_zQ8RXAyUg69h" title="Revenue">701</span> for the years ended December 31, 2021 and 2020, respectively.</span></p> 150000 701000 <p id="xdx_840_eus-gaap--ResearchAndDevelopmentExpensePolicy_z4kUV8uRpUuk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zmyQEJawr7ri">Research and Development Expenses</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development expenses are recognized as expense when incurred.</span></p> <p id="xdx_84F_eus-gaap--IncomeTaxPolicyTextBlock_zfhJbQ6R0Jil" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zVe9uhvKlpY5">Income Taxes</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We account for income taxes using the liability method. As such, deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Deferred tax assets and liabilities are calculated using the enacted tax rates and laws that are expected to be in effect when the anticipated reversal of these differences is scheduled to occur. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some or all of the deferred tax assets will not be realized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than <span id="xdx_90C_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxSettlementsDomestic_dp_c20210101__20211231_zsn34P7RvWgh" title="Tax rate reconciliation and settlement">50</span> percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured, as described above, is reflected as a liability for uncertain tax benefits in the accompanying balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have not recorded a reserve for any tax positions for which the ultimate deductibility is highly certain but for which there is uncertainty about the timing of such deductibility. We file tax returns in all appropriate jurisdictions, which includes a federal tax return and Illinois state tax return. When and if applicable, potential interest and penalty costs are accrued as incurred, with expenses recognized in selling, general and administrative expenses in the statements of operations. As of December 31, 2021, and 2020, we had no liability for unrecognized tax benefits.</span></p> 0.50 <p id="xdx_842_eus-gaap--EarningsPerSharePolicyTextBlock_ztO0yxB6czr5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zgU05fFpopqb">Earnings Per Share</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options to purchase approximately<span id="xdx_909_eus-gaap--IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_pid_c20210101__20211231_zQwBkQfuSWld" title="Options included in computation of earnings per share"> 2,018,000</span> shares of common stock that were outstanding as of December 31, 2021 were included in the computation of earnings per share for the year ended December 31, 2021.  Options to purchase approximately <span id="xdx_902_eus-gaap--IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_pid_c20200101__20201231_zGF43T7wy72g" title="Options included in computation of earnings per share">387,000</span> shares of common stock that were outstanding as of December 31, 2020 were included in the computation of earnings per share for the year ended December 31, 2020.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_ze96VGo2pEHe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_zyk8lvzn3Bnf">Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_494_20210101__20211231_zx9T38H3Vhm5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_494_20200101__20201231_z3CGTz5nMOt9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Years Ended December 31,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasicAbstract_iB_zS8WIHRQTyp2" style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Numerator: (in Thousands)</span></span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_eus-gaap--NetIncomeLoss_i01_pn3n3_zi7vkZxCbJK3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net income</span></td><td style="width: 1%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,320</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">989</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_eus-gaap--WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_iB_zRegAPRvIBE4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Denominator:</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i01_pid_uShares_maEPS_zPma1NAu127b" style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted average number of basic common shares outstanding</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">45,021,173</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">38,158,586</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_402_eus-gaap--IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_i01_pid_uShares_maEPS_zgsu21ySjcxc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted average additional shares assuming conversion of in-the-money stock options to common shares</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,018,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">387,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_i01T_pid_uShares_mtEPS_zcjT1wRe6Vdg" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted average number of diluted common shares outstanding</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47,039,173</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">38,545,586</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40D_eus-gaap--EarningsPerShareBasicAbstract_iB_zCnJB29qjKh2" style="vertical-align: bottom; background-color: White"> <td style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 2.25in"/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Basic earnings per common share:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_eus-gaap--EarningsPerShareBasic_i01_pid_uUSDPShares_zEtArimUW4w2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net income per share – basic</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.05</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.03</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40D_eus-gaap--EarningsPerShareDilutedAbstract_iB_zmA3fATrhuS" style="vertical-align: bottom; background-color: White"> <td style="text-decoration: underline"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diluted earnings per common share:</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_404_eus-gaap--EarningsPerShareDiluted_i01_pid_uUSDPShares_zHyY6IB3Mofk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net income per share – diluted</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.05</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.03</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A9_zMcxFf10vrPk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 2018000 387000 <p id="xdx_896_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_ze96VGo2pEHe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_zyk8lvzn3Bnf">Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_494_20210101__20211231_zx9T38H3Vhm5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_494_20200101__20201231_z3CGTz5nMOt9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Years Ended December 31,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasicAbstract_iB_zS8WIHRQTyp2" style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Numerator: (in Thousands)</span></span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_eus-gaap--NetIncomeLoss_i01_pn3n3_zi7vkZxCbJK3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net income</span></td><td style="width: 1%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,320</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">989</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_eus-gaap--WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_iB_zRegAPRvIBE4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Denominator:</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i01_pid_uShares_maEPS_zPma1NAu127b" style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted average number of basic common shares outstanding</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">45,021,173</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">38,158,586</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_402_eus-gaap--IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_i01_pid_uShares_maEPS_zgsu21ySjcxc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted average additional shares assuming conversion of in-the-money stock options to common shares</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,018,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">387,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_i01T_pid_uShares_mtEPS_zcjT1wRe6Vdg" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted average number of diluted common shares outstanding</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47,039,173</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">38,545,586</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40D_eus-gaap--EarningsPerShareBasicAbstract_iB_zCnJB29qjKh2" style="vertical-align: bottom; background-color: White"> <td style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 2.25in"/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Basic earnings per common share:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_eus-gaap--EarningsPerShareBasic_i01_pid_uUSDPShares_zEtArimUW4w2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net income per share – basic</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.05</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.03</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40D_eus-gaap--EarningsPerShareDilutedAbstract_iB_zmA3fATrhuS" style="vertical-align: bottom; background-color: White"> <td style="text-decoration: underline"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diluted earnings per common share:</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_404_eus-gaap--EarningsPerShareDiluted_i01_pid_uUSDPShares_zHyY6IB3Mofk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net income per share – diluted</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.05</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.03</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 2320000 989000 45021173 38158586 2018000 387000 47039173 38545586 0.05 0.03 0.05 0.03 <p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zNEHwI2VjiEb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zDisIGwjwq06">New Accounting Pronouncements</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span style="background-color: white">In June 2016, the FASB issued ASU 2016-13, “Measurement of Credit Losses on Financial Instruments,” which replaces existing incurred loss impairment guidance and establishes a single allowance framework for financial assets carried at amortized cost. The effective date for our adoption (as amended) of this updated Standard will be January 1, 2023. The Company is currently evaluating the impact of the adoption of this standard on the consolidated financial statements.</span></span></p> <p id="xdx_80E_eus-gaap--DebtDisclosureTextBlock_z8Sprs88sfN9" style="margin-top: 0; margin-bottom: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(3)</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_822_zoethq0PAmo1">Notes and Lines of Credit</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_eus-gaap--ScheduleOfLineOfCreditFacilitiesTextBlock_zokfT8AbpBoa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zXyGeujPJCu6">Notes and lines of credit consist of the following:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-left: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31,</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font-weight: bold"/><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2020</b></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="3" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rate</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Available</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding<br/> Balance</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Available</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding<br/> Balance</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%; text-align: left; padding-left: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--LineOfCreditFacilityDescription_c20210101__20211231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustMember_z9qAgR9kys4b" title="Line of credit facility, description">Libertyville Bank &amp; Trust</span> <sup>(1)</sup></span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_906_eus-gaap--LineOfCreditFacilityCommitmentFeePercentage_pid_dp_uPure_c20210101__20211231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustMember_zny5P4aU1tTa">4.25</span></span></td><td style="width: 5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_pn3n3_c20211231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustMember_zIoZ1RKJJE27" style="width: 10%; text-align: right" title="Available"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20211231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustMember_zyOJoex2ABza" style="width: 10%; text-align: right" title="Outsanding balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0582">—</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_pn3n3_c20201231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustMember_zhD2oV9bn2s7" style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20201231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustMember_zvbz2rvy2PW1" style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0584">—</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--LineOfCreditFacilityDescription_c20210101__20211231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustOneMember_zvVIUOka5st3">Libertyville Bank &amp; Trust</span> <sup>(2)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--LineOfCreditFacilityCommitmentFeePercentage_pid_dp_uPure_c20210101__20211231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustOneMember_zLNeYZ6ufDyf">4.25</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_pn3n3_c20201231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustOneMember_zhvu90FPbES5" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20201231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustOneMember_zaWtokiaIz6i" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--LineOfCreditFacilityDescription_c20210101__20211231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustTwoMember_zMMW4dzZSYv1">Libertyville Bank &amp; Trust </span><sup>(2)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--LineOfCreditFacilityCommitmentFeePercentage_pid_dp_uPure_c20210101__20211231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustTwoMember_zsma3koneqf8">4.25</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_pn3n3_c20211231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustTwoMember_ztpAAMRKE8Xf" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20211231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustTwoMember_zpsV7zdnI1t6" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0592">—</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--LineOfCreditFacilityDescription_c20210101__20211231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCMember_zzubhvWWuGfl">Beachcorp, LLC</span> <sup>(3)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--LineOfCreditFacilityCommitmentFeePercentage_pid_dp_uPure_c20210101__20211231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCMember_zzDzIi28O3z3">5.25</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_985_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_pn3n3_c20211231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCMember_zuyzq4Y647P5" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,467</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_982_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20211231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCMember_z1Bk0dGdRzOi" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,351</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_pn3n3_c20201231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCMember_zZVyhcHovuK" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,776</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98D_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20201231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCMember_zZ3fQBWWJAA5" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,155</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--LineOfCreditFacilityDescription_c20210101__20211231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCOneMember_zvSwVDbiL43c">Beachcorp</span>, LLC <sup>(3)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--LineOfCreditFacilityCommitmentFeePercentage_pid_dp_uPure_c20210101__20211231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCOneMember_zXiSkcXtW5wl">5.25</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_pn3n3_c20211231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCOneMember_z9i0gsjpmztg" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20211231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCOneMember_zzyMcQwofgv5" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_pn3n3_c20201231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCOneMember_zqmwzeETvmE7" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20201231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCOneMember_zJxm8uU1SEkf" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--LineOfCreditFacilityDescription_c20210101__20211231__us-gaap--CreditFacilityAxis__custom--SecuredConvertiblePromissoryNoteMember_znzgcOOxzUNe">Secured convertible promissory note</span> <sup>(4)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--LineOfCreditFacilityCommitmentFeePercentage_pid_dp_uPure_c20210101__20211231__us-gaap--CreditFacilityAxis__custom--SecuredConvertiblePromissoryNoteMember_znFaShGxQtK3">2.00</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_pn3n3_c20201231__us-gaap--CreditFacilityAxis__custom--SecuredConvertiblePromissoryNoteMember_zDgpbPzcHSYb" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98F_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20201231__us-gaap--CreditFacilityAxis__custom--SecuredConvertiblePromissoryNoteMember_z3divrQ9EZLi" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,097</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--LineOfCreditFacilityDescription_c20210101__20211231__us-gaap--CreditFacilityAxis__custom--PPPLoanLibertyvillePromissoryNoteMember_zPcVU4NqwyCa">PPP Loan / Libertyville promissory note</span> <sup>(5)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--LineOfCreditFacilityCommitmentFeePercentage_pid_dp_uPure_c20210101__20211231__us-gaap--CreditFacilityAxis__custom--PPPLoanLibertyvillePromissoryNoteMember_zFNFe8Zw2AGc">1.00</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98D_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_pn3n3_c20201231__us-gaap--CreditFacilityAxis__custom--PPPLoanLibertyvillePromissoryNoteMember_zCFonXeGtE2g" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">952</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98B_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20201231__us-gaap--CreditFacilityAxis__custom--PPPLoanLibertyvillePromissoryNoteMember_zXsow3uLoR8l" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">952</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--LineOfCreditFacilityDescription_c20210101__20211231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCThreeMember_zOAgkKL6itue">Beachcorp</span>, LLC <sup>(6)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--LineOfCreditFacilityCommitmentFeePercentage_pid_dp_uPure_c20210101__20211231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCThreeMember_zrmvoSoq9Qkl">4.00</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--LineOfCreditFacilityDescription_c20210101__20211231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCFourMember_z1ItgYE9FS5i">Beachcorp</span>, LLC <sup>(7)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--LineOfCreditFacilityCommitmentFeePercentage_pid_dp_uPure_c20210101__20211231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCFourMember_zh0K8idt0vvh">4.00</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--LineOfCreditFacilityDescription_c20210101__20211231__us-gaap--CreditFacilityAxis__custom--StrandlerLLCMember_zwxGLNUEaL3g">Strandler</span>, LLC <sup>(8)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--LineOfCreditFacilityCommitmentFeePercentage_pid_dp_uPure_c20210101__20211231__us-gaap--CreditFacilityAxis__custom--StrandlerLLCMember_z0reDkDQUyhe">4.00</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1)</span></td><td style="width: 5pt"/><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since July 2014, we have maintained a bank-issued letter of credit for up to $</span><span id="xdx_907_eus-gaap--ShortTermBorrowings_iI_c20140731__us-gaap--ShortTermDebtTypeAxis__us-gaap--LetterOfCreditMember_z3niEhORxYli" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30 </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in borrowings, with interest at the <span id="xdx_90C_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20140701__20140731__us-gaap--ShortTermDebtTypeAxis__us-gaap--LetterOfCreditMember_zFDt57Mlnoj9">prime rate</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">plus <span id="xdx_900_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20140701__20140731__us-gaap--ShortTermDebtTypeAxis__us-gaap--LetterOfCreditMember_zHQqTgKKnkDg">1</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%, to support our obligations under our Romeoville, Illinois facility lease agreement. No borrowings have been incurred under this promissory note. It is our intention to renew this note annually. Because there were no amounts outstanding on the note at any time during 2021 or 2020, we have recorded no related liability on our balance sheet.</span></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2)</span></td><td style="width: 5pt"/><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company maintains a credit agreement with Libertyville which most recently served the primary purpose of insuring that it met its cash balance requirements at quarter end relating to a contract with the Company’s largest customer. Outstanding borrowings were $</span><span id="xdx_90C_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20211231__us-gaap--TypeOfArrangementAxis__custom--CreditAgreementMember_zoOKcjwwKVo9">500 </span>on this line of credit as of December 31, 2020. Interest on drawn balances was at the <span id="xdx_90C_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20210101__20211231__us-gaap--ShortTermDebtTypeAxis__us-gaap--LetterOfCreditMember__us-gaap--TypeOfArrangementAxis__custom--NewBusinessLoanAgreementMember_z3QuDWBQaGV2">prime rate</span> plus <span id="xdx_902_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20210101__20211231__us-gaap--ShortTermDebtTypeAxis__us-gaap--LetterOfCreditMember__us-gaap--TypeOfArrangementAxis__custom--NewBusinessLoanAgreementMember_zlQhpHMLbvW4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span>%. On December 21, 2021, the existing credit agreement with Libertyville was converted for use to support our obligations under our newly leased manufacturing and warehouse space in Bolingbrook, Illinois. Interest on drawn balances will be at the prime rate plus 1%. This credit agreement has a maturity of December 22, 2022. We expect to renew this agreement annually, as the lease requires. This credit agreement is secured by all the unencumbered assets of the Company, and has superior collateral rights to those credit facilities with Beachcorp, LLC and Strandler, LLC.</td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3)</span></td><td style="width: 5pt"/><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 16, 2018, we entered into a Business Loan Agreement (the “Master Agreement”) with Beachcorp, LLC. The Master Agreement relates to two loan facilities, each evidenced by a separate promissory note dated as of November 16, 2018: a term loan to the Company of up to $</span><span id="xdx_906_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20181116__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--TermLoanMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zxqRxefCDY2f" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">500 </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to be disbursed in a single advance (the “Term Loan”) with a fixed annual interest rate of <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20181116__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--TermLoanMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_znm4tkvUOxl">8.25</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%, payable quarterly, and with principal due on <span id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_dd_c20181115__20181116__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--TermLoanMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zVcuxx95wdy7">December 31, 2020</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">; and an asset-based revolving loan facility for the Company of up to $<span id="xdx_90A_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20181116__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_z1NGASZrOW12">2,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(the “A/R Revolver Facility”), with floating interest accruing at the <span id="xdx_907_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20181115__20181116__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zQbiYOtaXXWj">prime rate</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">plus <span id="xdx_90D_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20181115__20181116__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zb1mRWQLOlF4">3</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% (<span id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20181116__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember__srt--RangeAxis__srt--MinimumMember_zcwBwiKQZGB5">8.25</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% minimum) per year, with a borrowing base consisting of qualified accounts receivable of the Company, and a maturity of <span id="xdx_909_eus-gaap--LineOfCreditFacilityExpirationDate1_dd_c20181115__20181116__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_z95yFQRMr1sl">March 31, 2020</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, as amended. On March 23, 2020, the Company and Beachcorp, LLC executed the First Amendment to our Master Agreement that extended the maturities of both the Term Loan and the A/R Revolver Facility to <span id="xdx_901_eus-gaap--DebtInstrumentMaturityDate_dd_c20200321__20200323__us-gaap--TypeOfArrangementAxis__custom--FirstAmendmentMember__us-gaap--CreditFacilityAxis__custom--TermLoanAndTheRevolverFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zmVnYgRKKqw3">March 31, 2021</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. Effective September 8, 2020, the Company and Beachcorp, LLC executed the Second Amendment to our Master Agreement that expanded the limit on the A/R Revolver Facility from $<span id="xdx_908_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20181116__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zWM72SMBz6Al">2,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to $<span id="xdx_904_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20200908__us-gaap--TypeOfArrangementAxis__custom--SecondAmendmentMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zo6ck3jjGV8d">2,750</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.  On December 23, 2020, the Company and Beachcorp, LLC executed the Third Amendment to our Master Agreement that expanded the limit on the A/R Revolver Facility from $<span id="xdx_901_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20200908__us-gaap--TypeOfArrangementAxis__custom--SecondAmendmentMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_ziWvVpK5yI7k">2,750 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to $<span id="xdx_904_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20201223__us-gaap--TypeOfArrangementAxis__custom--ThirdAmendmentMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zXNYNI2RQJS9">4,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and extended the maturities of both the Term Loan and the A/R Revolver Facility to <span id="xdx_90C_eus-gaap--DebtInstrumentMaturityDate_dd_c20201222__20201223__us-gaap--TypeOfArrangementAxis__custom--FirstAmendmentMember__us-gaap--CreditFacilityAxis__custom--TermLoanAndTheRevolverFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zL9I4TBfGbh9">March 31, 2022</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. Effective April 21, 2021 the Company and Beachcorp, LLC executed the Fourth Amendment to our Master Agreement that expanded the limit on the A/R Revolver Facility from $<span id="xdx_900_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20201223__us-gaap--TypeOfArrangementAxis__custom--ThirdAmendmentMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zSUJiBwTd86f">4,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to $<span id="xdx_90F_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20210421__us-gaap--TypeOfArrangementAxis__custom--FourthAmendmentMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zkpdhMmzYZv2">6,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, changed the interest rate to fully floating and reduced the rate to the prime rate plus 2%, also extending the maturity of the A/R Revolver Facility to <span id="xdx_900_eus-gaap--LineOfCreditFacilityExpirationDate1_dd_c20210420__20210421__us-gaap--TypeOfArrangementAxis__custom--FourthAmendmentMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zeTVSFpO86mj">March 31, 2023</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. This amendment also increased the amount of the Term Loan from $<span id="xdx_90E_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20181116__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--TermLoanMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zdy3ZhQ5DmN9">500 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to $<span id="xdx_907_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20210421__us-gaap--TypeOfArrangementAxis__custom--FourthAmendmentMember__us-gaap--CreditFacilityAxis__custom--TermLoanMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zySbd8wH9tq">1,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, changed the interest rate to fully floating and reduced the rate to the <span id="xdx_902_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20210420__20210421__us-gaap--TypeOfArrangementAxis__custom--FourthAmendmentMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zPODSzc7qrK9">prime rate</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">plus <span id="xdx_905_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20210420__20210421__us-gaap--TypeOfArrangementAxis__custom--FourthAmendmentMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zC8F8dizzsoe">2</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%. The maturity of the Term Loan remained <span id="xdx_90A_eus-gaap--DebtInstrumentMaturityDate_dd_c20210420__20210421__us-gaap--TypeOfArrangementAxis__custom--FourthAmendmentMember__us-gaap--CreditFacilityAxis__custom--TermLoanMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zhnEhJUl7gkf">March 31, 2022</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The Term Loan and A/R Revolver Facility are secured by all the unencumbered assets of the Company and subordinated to Libertyville’s secured interest under the New Business Loan Credit Agreement. The Master Agreement substantially restricts the Company’s ability to incur additional indebtedness during the terms of both the Term Loan and the A/R Revolver Facility.</span></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4)</span></td><td style="width: 5pt"/><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 20, 2019, we entered into a </span><span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20191120__us-gaap--LongtermDebtTypeAxis__custom--SecuredConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BradfordTWhitmoreMember_zKEEAx9H6iO7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% Secured Convertible Promissory Note with Bradford T. Whitmore in the principal amount of $<span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20191120__us-gaap--LongtermDebtTypeAxis__custom--SecuredConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BradfordTWhitmoreMember_zemRysSRWBk4">2,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(the “Convertible Note”). The principal amount was payable in a single payment on May 15, 2024 (the “Maturity Date”). The principal amount of the Convertible Note accrued interest at the rate of 2.0% per year, which <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateTerms_c20191118__20191120__us-gaap--LongtermDebtTypeAxis__custom--SecuredConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BradfordTWhitmoreMember_zB2Ykb09hQa3">interest was payable semi-annually</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">on the 15th day of May and November, commencing on <span id="xdx_907_eus-gaap--DebtInstrumentDateOfFirstRequiredPayment1_dd_c20191118__20191120__us-gaap--LongtermDebtTypeAxis__custom--SecuredConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BradfordTWhitmoreMember_zJMQ6IhXDWge">May 15, 2020</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The principal amount and, at the holder’s option, accrued interest under the Convertible Note was convertible at the holder’s option into additional shares of the Company’s common stock in whole or in part and from time to time up to the Maturity Date at a conversion price of $<span id="xdx_90B_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_uUSDPShares_c20191120__us-gaap--LongtermDebtTypeAxis__custom--SecuredConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BradfordTWhitmoreMember_zqKMjb31TTH5">0.20 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share. The convertible note contained a beneficial conversion feature since the Company’s stock was trading at $<span id="xdx_908_eus-gaap--SharePrice_iI_pid_uUSDPShares_c20191120__us-gaap--LongtermDebtTypeAxis__custom--SecuredConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BradfordTWhitmoreMember_zuNxxT5UyvIf">0.32 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share on the date the Company entered into the agreement. The intrinsic value of the beneficial conversion feature was $<span id="xdx_90C_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_dm_c20191120__us-gaap--LongtermDebtTypeAxis__custom--SecuredConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BradfordTWhitmoreMember_z9XsoMz1Iopj">1.2 million</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">on November 20, 2019 and was recorded as a discount on the convertible note. The discount was to be accreted to the convertible note over the life of the note using the straight-line method. The offset to these discounts was interest expense. The Company recognized amortized interest expense relating to this discount of $267 in 2020. Upon exercise of the conversion right in 2021, the acceleration of the remaining discount, in addition to the amortization of interest in 2021 prior to the conversion, amounted to $<span id="xdx_902_eus-gaap--InterestExpense_pn3n3_c20210101__20211231__us-gaap--CreditFacilityAxis__custom--RelatedPartyCreditFacilitiesMember_zXfa9PACBBLf">903</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, all of which was recognized as interest expense. Mr. Whitmore chose to exercise his conversion rights effective May 7, 2021, with any interest to be paid in the form of shares, as allowed in the Convertible Note. In addition to the <span id="xdx_905_eus-gaap--ConversionOfStockSharesIssued1_c20210506__20210507__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WhitmoreMember_z4bK79U879T4">10,000,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares issued upon conversion, the Company issued <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210506__20210507__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WhitmoreMember_zSwUWMNxXF4">95,555 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of additional stock to Mr. Whitmore in lieu of cash for the $<span id="xdx_909_eus-gaap--Cash_iI_pn3n3_c20210507__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WhitmoreMember_zUf3wtzrGhD2">19 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in accrued interest owed at May 7, 2021. The note and related interest obligations were paid in full and cancelled in May, 2021 via conversion.</span></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5)</span></td><td style="width: 5pt"/><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 17, 2020, we entered into a Promissory Note (the “PPP Note”), dated as of April 16, 2020, in favor of Libertyville in the principal amount of $</span><span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20200417__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LibertyvilleMember_zVgN8TN74Dhj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">952 </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for our loan under the Paycheck Protection Program (“PPP”). The Company was allowed to apply for forgiveness of the amount due on the PPP Note in an amount equal to the sum of the following costs incurred during the 24-week period beginning on the date of the first disbursement of the loan: (a) payroll costs, (b) any payment of interest on a covered obligation (which shall not include any prepayment of or payment of principal on a covered mortgage obligation), (c) any payment on a covered rent obligation, and (d) any covered utility payment, calculated in accordance with the terms of the CARES Act. The principal amount of the PPP Note would have accrued interest at the rate of <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20200417__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LibertyvilleMember_zcAI81xXh4k8">1.00</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% per year. The Company applied for, and received, PPP forgiveness during the first quarter of 2021. Under the terms of the PPP loan, it is subject to audit for six years from the date of forgiveness. If any portion of the PPP loan were to be deemed ineligible, the Company could be required to repay the funds. On December 31, 2021, the balance under the PPP note was $<span id="xdx_908_eus-gaap--LongTermDebt_iI_c20211231__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_z0sEatS03irk">0</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6)</span></td><td style="width: 5pt"/><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 28, 2022 </span><span id="xdx_90D_eus-gaap--LineOfCreditFacilityBorrowingCapacityDescription_c20220127__20220128__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zBefUIjUEkpl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Company entered into an Amended and Restated Business Loan Agreement (the “A&amp;R Loan Agreement”), which amends and restates the Master Agreement between the Company and Beachcorp, LLC, and a new promissory note in order to evidence the A/R Revolver facility, including an amendment to expand the limit on the A/R Revolver Facility from $6,000 to $8,000, reduce the interest rate to the prime rate plus 0.75%, and extend the maturity of the A/R Revolver Facility to March 31, 2024.</span></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7)</span></td><td style="width: 5pt"/><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 28, 2022 </span><span id="xdx_90A_eus-gaap--LineOfCreditFacilityBorrowingCapacityDescription_c20220127__20220128__us-gaap--TypeOfArrangementAxis__custom--AAndRLoanAgreementMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zutC6bKeP6ek" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Company entered into the A&amp;R Loan Agreement and a new revolving loan agreement (“Inventory Facility”) with Beachcorp, LLC, and a new promissory note in order to evidence the Inventory Facility. The maximum borrowing amount under the Inventory Facility is $4,000, with a borrowing base consisting of up to 50% of the value of qualified inventory of the Company. The interest rate for the Inventory Revolver is at the prime rate plus 0.75%, and it matures on March 31, 2024.</span></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8)</span></td><td style="width: 5pt"/><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 28, 2022 </span><span id="xdx_904_eus-gaap--LineOfCreditFacilityBorrowingCapacityDescription_c20220127__20220128__us-gaap--TypeOfArrangementAxis__custom--AAndRLoanAgreementMember__srt--CounterpartyNameAxis__custom--StrandlerLLCMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zvWsvJ8GGfz7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Company entered into an additional Business Loan Agreement (the “New Term Loan Agreement”) with Strandler, LLC, which effectively transferred or assigned the Term Loan to Strandler, LLC from Beachcorp, LLC. Interest on the New Term Loan is at the prime rate plus 0.75%, and it matures on March 31, 2024. Strandler, LLC is also an affiliate of Bradford T. Whitmore.</span></td> </tr></table> <p id="xdx_8A6_zRc2IxBRBzS1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89B_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_ztQPle9UgFmi" style="font: 10pt Times New Roman, Times, Serif; visibility: hidden; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_8B4_z5ABkYmmivw5">Schedule of Related Parties</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>Related party interest expense consists of the following:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_497_20210101__20211231_zNsbCXbVk0v" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_490_20200101__20201231_zwn3E1hCJVi3" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Twelve Months Ended December 31,</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40D_eus-gaap--InterestExpenseRelatedParty_pn3n3_zezxkvL1dqvl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left; padding-left: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest expense, related parties</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 12%; text-align: right" title="Interest expense related party"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,129</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">452</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>Accrued interest consists of the following:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_498_20211231__us-gaap--RelatedPartyTransactionAxis__custom--RelatedPartyTransactionMember_z334DPZ0wuP" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49E_20201231__us-gaap--RelatedPartyTransactionAxis__custom--RelatedPartyTransactionMember_zqBJyIz0hmuj" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31,</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40D_eus-gaap--InterestPayableCurrent_iI_zdrr5IZEEfB8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left; padding-left: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued interest expense, related parties</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 12%; text-align: right" title="Accrued interest expense, related parties"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>Outstanding balances associated with related parties are as follows:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; padding-left: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31,</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; padding-left: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left; padding-left: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beachcorp, LLC</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_pn3n3_c20211231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCMember_zR0uy27ahzdj" style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,351</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_pn3n3_c20201231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCMember_zkSCWn9zw6C5" style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,655</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Secured convertible promissory note</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_982_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_pn3n3_d0_c20211231__us-gaap--LongtermDebtTypeAxis__custom--SecuredConvertiblePromissoryNotesMember_zLrfFbRAcU9a" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98E_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_pn3n3_d0_c20201231__us-gaap--LongtermDebtTypeAxis__custom--SecuredConvertiblePromissoryNotesMember_zbjTyhcfPIyk" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,097</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Strandler, LLC</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8AB_zWiDBA4vvQ26" style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beachcorp, LLC and Strandler, LLC are affiliates of Mr. Bradford T. Whitmore, who beneficially owns a majority of the Company’s common stock and is the brother of Ms. R. Janet Whitmore, a director of the Company and the chair of the Company’s board of directors. The A/R Revolver Facility, the Inventory Facility and the New Term Loan are all secured by all the unencumbered assets of the Company and subordinated to the Company’s credit facility with Libertyville Bank &amp; Trust. </span></p> <p id="xdx_896_eus-gaap--ScheduleOfLineOfCreditFacilitiesTextBlock_zokfT8AbpBoa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zXyGeujPJCu6">Notes and lines of credit consist of the following:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-left: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31,</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font-weight: bold"/><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2020</b></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="3" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rate</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Available</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding<br/> Balance</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Available</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding<br/> Balance</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%; text-align: left; padding-left: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--LineOfCreditFacilityDescription_c20210101__20211231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustMember_z9qAgR9kys4b" title="Line of credit facility, description">Libertyville Bank &amp; Trust</span> <sup>(1)</sup></span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_906_eus-gaap--LineOfCreditFacilityCommitmentFeePercentage_pid_dp_uPure_c20210101__20211231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustMember_zny5P4aU1tTa">4.25</span></span></td><td style="width: 5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_pn3n3_c20211231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustMember_zIoZ1RKJJE27" style="width: 10%; text-align: right" title="Available"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20211231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustMember_zyOJoex2ABza" style="width: 10%; text-align: right" title="Outsanding balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0582">—</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_pn3n3_c20201231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustMember_zhD2oV9bn2s7" style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20201231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustMember_zvbz2rvy2PW1" style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0584">—</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--LineOfCreditFacilityDescription_c20210101__20211231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustOneMember_zvVIUOka5st3">Libertyville Bank &amp; Trust</span> <sup>(2)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--LineOfCreditFacilityCommitmentFeePercentage_pid_dp_uPure_c20210101__20211231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustOneMember_zLNeYZ6ufDyf">4.25</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_pn3n3_c20201231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustOneMember_zhvu90FPbES5" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20201231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustOneMember_zaWtokiaIz6i" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--LineOfCreditFacilityDescription_c20210101__20211231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustTwoMember_zMMW4dzZSYv1">Libertyville Bank &amp; Trust </span><sup>(2)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--LineOfCreditFacilityCommitmentFeePercentage_pid_dp_uPure_c20210101__20211231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustTwoMember_zsma3koneqf8">4.25</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_pn3n3_c20211231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustTwoMember_ztpAAMRKE8Xf" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20211231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustTwoMember_zpsV7zdnI1t6" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0592">—</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--LineOfCreditFacilityDescription_c20210101__20211231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCMember_zzubhvWWuGfl">Beachcorp, LLC</span> <sup>(3)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--LineOfCreditFacilityCommitmentFeePercentage_pid_dp_uPure_c20210101__20211231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCMember_zzDzIi28O3z3">5.25</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_985_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_pn3n3_c20211231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCMember_zuyzq4Y647P5" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,467</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_982_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20211231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCMember_z1Bk0dGdRzOi" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,351</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_pn3n3_c20201231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCMember_zZVyhcHovuK" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,776</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98D_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20201231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCMember_zZ3fQBWWJAA5" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,155</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--LineOfCreditFacilityDescription_c20210101__20211231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCOneMember_zvSwVDbiL43c">Beachcorp</span>, LLC <sup>(3)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--LineOfCreditFacilityCommitmentFeePercentage_pid_dp_uPure_c20210101__20211231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCOneMember_zXiSkcXtW5wl">5.25</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_pn3n3_c20211231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCOneMember_z9i0gsjpmztg" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20211231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCOneMember_zzyMcQwofgv5" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_pn3n3_c20201231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCOneMember_zqmwzeETvmE7" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20201231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCOneMember_zJxm8uU1SEkf" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--LineOfCreditFacilityDescription_c20210101__20211231__us-gaap--CreditFacilityAxis__custom--SecuredConvertiblePromissoryNoteMember_znzgcOOxzUNe">Secured convertible promissory note</span> <sup>(4)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--LineOfCreditFacilityCommitmentFeePercentage_pid_dp_uPure_c20210101__20211231__us-gaap--CreditFacilityAxis__custom--SecuredConvertiblePromissoryNoteMember_znFaShGxQtK3">2.00</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_pn3n3_c20201231__us-gaap--CreditFacilityAxis__custom--SecuredConvertiblePromissoryNoteMember_zDgpbPzcHSYb" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98F_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20201231__us-gaap--CreditFacilityAxis__custom--SecuredConvertiblePromissoryNoteMember_z3divrQ9EZLi" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,097</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--LineOfCreditFacilityDescription_c20210101__20211231__us-gaap--CreditFacilityAxis__custom--PPPLoanLibertyvillePromissoryNoteMember_zPcVU4NqwyCa">PPP Loan / Libertyville promissory note</span> <sup>(5)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--LineOfCreditFacilityCommitmentFeePercentage_pid_dp_uPure_c20210101__20211231__us-gaap--CreditFacilityAxis__custom--PPPLoanLibertyvillePromissoryNoteMember_zFNFe8Zw2AGc">1.00</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98D_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_pn3n3_c20201231__us-gaap--CreditFacilityAxis__custom--PPPLoanLibertyvillePromissoryNoteMember_zCFonXeGtE2g" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">952</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98B_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20201231__us-gaap--CreditFacilityAxis__custom--PPPLoanLibertyvillePromissoryNoteMember_zXsow3uLoR8l" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">952</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--LineOfCreditFacilityDescription_c20210101__20211231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCThreeMember_zOAgkKL6itue">Beachcorp</span>, LLC <sup>(6)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--LineOfCreditFacilityCommitmentFeePercentage_pid_dp_uPure_c20210101__20211231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCThreeMember_zrmvoSoq9Qkl">4.00</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--LineOfCreditFacilityDescription_c20210101__20211231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCFourMember_z1ItgYE9FS5i">Beachcorp</span>, LLC <sup>(7)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--LineOfCreditFacilityCommitmentFeePercentage_pid_dp_uPure_c20210101__20211231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCFourMember_zh0K8idt0vvh">4.00</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--LineOfCreditFacilityDescription_c20210101__20211231__us-gaap--CreditFacilityAxis__custom--StrandlerLLCMember_zwxGLNUEaL3g">Strandler</span>, LLC <sup>(8)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--LineOfCreditFacilityCommitmentFeePercentage_pid_dp_uPure_c20210101__20211231__us-gaap--CreditFacilityAxis__custom--StrandlerLLCMember_z0reDkDQUyhe">4.00</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1)</span></td><td style="width: 5pt"/><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since July 2014, we have maintained a bank-issued letter of credit for up to $</span><span id="xdx_907_eus-gaap--ShortTermBorrowings_iI_c20140731__us-gaap--ShortTermDebtTypeAxis__us-gaap--LetterOfCreditMember_z3niEhORxYli" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30 </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in borrowings, with interest at the <span id="xdx_90C_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20140701__20140731__us-gaap--ShortTermDebtTypeAxis__us-gaap--LetterOfCreditMember_zFDt57Mlnoj9">prime rate</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">plus <span id="xdx_900_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20140701__20140731__us-gaap--ShortTermDebtTypeAxis__us-gaap--LetterOfCreditMember_zHQqTgKKnkDg">1</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%, to support our obligations under our Romeoville, Illinois facility lease agreement. No borrowings have been incurred under this promissory note. It is our intention to renew this note annually. Because there were no amounts outstanding on the note at any time during 2021 or 2020, we have recorded no related liability on our balance sheet.</span></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2)</span></td><td style="width: 5pt"/><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company maintains a credit agreement with Libertyville which most recently served the primary purpose of insuring that it met its cash balance requirements at quarter end relating to a contract with the Company’s largest customer. Outstanding borrowings were $</span><span id="xdx_90C_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20211231__us-gaap--TypeOfArrangementAxis__custom--CreditAgreementMember_zoOKcjwwKVo9">500 </span>on this line of credit as of December 31, 2020. Interest on drawn balances was at the <span id="xdx_90C_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20210101__20211231__us-gaap--ShortTermDebtTypeAxis__us-gaap--LetterOfCreditMember__us-gaap--TypeOfArrangementAxis__custom--NewBusinessLoanAgreementMember_z3QuDWBQaGV2">prime rate</span> plus <span id="xdx_902_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20210101__20211231__us-gaap--ShortTermDebtTypeAxis__us-gaap--LetterOfCreditMember__us-gaap--TypeOfArrangementAxis__custom--NewBusinessLoanAgreementMember_zlQhpHMLbvW4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span>%. On December 21, 2021, the existing credit agreement with Libertyville was converted for use to support our obligations under our newly leased manufacturing and warehouse space in Bolingbrook, Illinois. Interest on drawn balances will be at the prime rate plus 1%. This credit agreement has a maturity of December 22, 2022. We expect to renew this agreement annually, as the lease requires. This credit agreement is secured by all the unencumbered assets of the Company, and has superior collateral rights to those credit facilities with Beachcorp, LLC and Strandler, LLC.</td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3)</span></td><td style="width: 5pt"/><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 16, 2018, we entered into a Business Loan Agreement (the “Master Agreement”) with Beachcorp, LLC. The Master Agreement relates to two loan facilities, each evidenced by a separate promissory note dated as of November 16, 2018: a term loan to the Company of up to $</span><span id="xdx_906_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20181116__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--TermLoanMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zxqRxefCDY2f" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">500 </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to be disbursed in a single advance (the “Term Loan”) with a fixed annual interest rate of <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20181116__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--TermLoanMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_znm4tkvUOxl">8.25</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%, payable quarterly, and with principal due on <span id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_dd_c20181115__20181116__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--TermLoanMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zVcuxx95wdy7">December 31, 2020</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">; and an asset-based revolving loan facility for the Company of up to $<span id="xdx_90A_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20181116__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_z1NGASZrOW12">2,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(the “A/R Revolver Facility”), with floating interest accruing at the <span id="xdx_907_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20181115__20181116__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zQbiYOtaXXWj">prime rate</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">plus <span id="xdx_90D_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20181115__20181116__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zb1mRWQLOlF4">3</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% (<span id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20181116__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember__srt--RangeAxis__srt--MinimumMember_zcwBwiKQZGB5">8.25</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% minimum) per year, with a borrowing base consisting of qualified accounts receivable of the Company, and a maturity of <span id="xdx_909_eus-gaap--LineOfCreditFacilityExpirationDate1_dd_c20181115__20181116__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_z95yFQRMr1sl">March 31, 2020</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, as amended. On March 23, 2020, the Company and Beachcorp, LLC executed the First Amendment to our Master Agreement that extended the maturities of both the Term Loan and the A/R Revolver Facility to <span id="xdx_901_eus-gaap--DebtInstrumentMaturityDate_dd_c20200321__20200323__us-gaap--TypeOfArrangementAxis__custom--FirstAmendmentMember__us-gaap--CreditFacilityAxis__custom--TermLoanAndTheRevolverFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zmVnYgRKKqw3">March 31, 2021</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. Effective September 8, 2020, the Company and Beachcorp, LLC executed the Second Amendment to our Master Agreement that expanded the limit on the A/R Revolver Facility from $<span id="xdx_908_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20181116__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zWM72SMBz6Al">2,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to $<span id="xdx_904_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20200908__us-gaap--TypeOfArrangementAxis__custom--SecondAmendmentMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zo6ck3jjGV8d">2,750</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.  On December 23, 2020, the Company and Beachcorp, LLC executed the Third Amendment to our Master Agreement that expanded the limit on the A/R Revolver Facility from $<span id="xdx_901_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20200908__us-gaap--TypeOfArrangementAxis__custom--SecondAmendmentMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_ziWvVpK5yI7k">2,750 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to $<span id="xdx_904_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20201223__us-gaap--TypeOfArrangementAxis__custom--ThirdAmendmentMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zXNYNI2RQJS9">4,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and extended the maturities of both the Term Loan and the A/R Revolver Facility to <span id="xdx_90C_eus-gaap--DebtInstrumentMaturityDate_dd_c20201222__20201223__us-gaap--TypeOfArrangementAxis__custom--FirstAmendmentMember__us-gaap--CreditFacilityAxis__custom--TermLoanAndTheRevolverFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zL9I4TBfGbh9">March 31, 2022</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. Effective April 21, 2021 the Company and Beachcorp, LLC executed the Fourth Amendment to our Master Agreement that expanded the limit on the A/R Revolver Facility from $<span id="xdx_900_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20201223__us-gaap--TypeOfArrangementAxis__custom--ThirdAmendmentMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zSUJiBwTd86f">4,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to $<span id="xdx_90F_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20210421__us-gaap--TypeOfArrangementAxis__custom--FourthAmendmentMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zkpdhMmzYZv2">6,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, changed the interest rate to fully floating and reduced the rate to the prime rate plus 2%, also extending the maturity of the A/R Revolver Facility to <span id="xdx_900_eus-gaap--LineOfCreditFacilityExpirationDate1_dd_c20210420__20210421__us-gaap--TypeOfArrangementAxis__custom--FourthAmendmentMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zeTVSFpO86mj">March 31, 2023</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. This amendment also increased the amount of the Term Loan from $<span id="xdx_90E_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20181116__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--TermLoanMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zdy3ZhQ5DmN9">500 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to $<span id="xdx_907_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20210421__us-gaap--TypeOfArrangementAxis__custom--FourthAmendmentMember__us-gaap--CreditFacilityAxis__custom--TermLoanMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zySbd8wH9tq">1,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, changed the interest rate to fully floating and reduced the rate to the <span id="xdx_902_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20210420__20210421__us-gaap--TypeOfArrangementAxis__custom--FourthAmendmentMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zPODSzc7qrK9">prime rate</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">plus <span id="xdx_905_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20210420__20210421__us-gaap--TypeOfArrangementAxis__custom--FourthAmendmentMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zC8F8dizzsoe">2</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%. The maturity of the Term Loan remained <span id="xdx_90A_eus-gaap--DebtInstrumentMaturityDate_dd_c20210420__20210421__us-gaap--TypeOfArrangementAxis__custom--FourthAmendmentMember__us-gaap--CreditFacilityAxis__custom--TermLoanMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zhnEhJUl7gkf">March 31, 2022</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The Term Loan and A/R Revolver Facility are secured by all the unencumbered assets of the Company and subordinated to Libertyville’s secured interest under the New Business Loan Credit Agreement. The Master Agreement substantially restricts the Company’s ability to incur additional indebtedness during the terms of both the Term Loan and the A/R Revolver Facility.</span></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4)</span></td><td style="width: 5pt"/><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 20, 2019, we entered into a </span><span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20191120__us-gaap--LongtermDebtTypeAxis__custom--SecuredConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BradfordTWhitmoreMember_zKEEAx9H6iO7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% Secured Convertible Promissory Note with Bradford T. Whitmore in the principal amount of $<span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20191120__us-gaap--LongtermDebtTypeAxis__custom--SecuredConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BradfordTWhitmoreMember_zemRysSRWBk4">2,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(the “Convertible Note”). The principal amount was payable in a single payment on May 15, 2024 (the “Maturity Date”). The principal amount of the Convertible Note accrued interest at the rate of 2.0% per year, which <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateTerms_c20191118__20191120__us-gaap--LongtermDebtTypeAxis__custom--SecuredConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BradfordTWhitmoreMember_zB2Ykb09hQa3">interest was payable semi-annually</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">on the 15th day of May and November, commencing on <span id="xdx_907_eus-gaap--DebtInstrumentDateOfFirstRequiredPayment1_dd_c20191118__20191120__us-gaap--LongtermDebtTypeAxis__custom--SecuredConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BradfordTWhitmoreMember_zJMQ6IhXDWge">May 15, 2020</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The principal amount and, at the holder’s option, accrued interest under the Convertible Note was convertible at the holder’s option into additional shares of the Company’s common stock in whole or in part and from time to time up to the Maturity Date at a conversion price of $<span id="xdx_90B_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_uUSDPShares_c20191120__us-gaap--LongtermDebtTypeAxis__custom--SecuredConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BradfordTWhitmoreMember_zqKMjb31TTH5">0.20 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share. The convertible note contained a beneficial conversion feature since the Company’s stock was trading at $<span id="xdx_908_eus-gaap--SharePrice_iI_pid_uUSDPShares_c20191120__us-gaap--LongtermDebtTypeAxis__custom--SecuredConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BradfordTWhitmoreMember_zuNxxT5UyvIf">0.32 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share on the date the Company entered into the agreement. The intrinsic value of the beneficial conversion feature was $<span id="xdx_90C_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_dm_c20191120__us-gaap--LongtermDebtTypeAxis__custom--SecuredConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BradfordTWhitmoreMember_z9XsoMz1Iopj">1.2 million</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">on November 20, 2019 and was recorded as a discount on the convertible note. The discount was to be accreted to the convertible note over the life of the note using the straight-line method. The offset to these discounts was interest expense. The Company recognized amortized interest expense relating to this discount of $267 in 2020. Upon exercise of the conversion right in 2021, the acceleration of the remaining discount, in addition to the amortization of interest in 2021 prior to the conversion, amounted to $<span id="xdx_902_eus-gaap--InterestExpense_pn3n3_c20210101__20211231__us-gaap--CreditFacilityAxis__custom--RelatedPartyCreditFacilitiesMember_zXfa9PACBBLf">903</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, all of which was recognized as interest expense. Mr. Whitmore chose to exercise his conversion rights effective May 7, 2021, with any interest to be paid in the form of shares, as allowed in the Convertible Note. In addition to the <span id="xdx_905_eus-gaap--ConversionOfStockSharesIssued1_c20210506__20210507__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WhitmoreMember_z4bK79U879T4">10,000,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares issued upon conversion, the Company issued <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210506__20210507__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WhitmoreMember_zSwUWMNxXF4">95,555 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of additional stock to Mr. Whitmore in lieu of cash for the $<span id="xdx_909_eus-gaap--Cash_iI_pn3n3_c20210507__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WhitmoreMember_zUf3wtzrGhD2">19 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in accrued interest owed at May 7, 2021. The note and related interest obligations were paid in full and cancelled in May, 2021 via conversion.</span></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5)</span></td><td style="width: 5pt"/><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 17, 2020, we entered into a Promissory Note (the “PPP Note”), dated as of April 16, 2020, in favor of Libertyville in the principal amount of $</span><span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20200417__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LibertyvilleMember_zVgN8TN74Dhj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">952 </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for our loan under the Paycheck Protection Program (“PPP”). The Company was allowed to apply for forgiveness of the amount due on the PPP Note in an amount equal to the sum of the following costs incurred during the 24-week period beginning on the date of the first disbursement of the loan: (a) payroll costs, (b) any payment of interest on a covered obligation (which shall not include any prepayment of or payment of principal on a covered mortgage obligation), (c) any payment on a covered rent obligation, and (d) any covered utility payment, calculated in accordance with the terms of the CARES Act. The principal amount of the PPP Note would have accrued interest at the rate of <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20200417__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LibertyvilleMember_zcAI81xXh4k8">1.00</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% per year. The Company applied for, and received, PPP forgiveness during the first quarter of 2021. Under the terms of the PPP loan, it is subject to audit for six years from the date of forgiveness. If any portion of the PPP loan were to be deemed ineligible, the Company could be required to repay the funds. On December 31, 2021, the balance under the PPP note was $<span id="xdx_908_eus-gaap--LongTermDebt_iI_c20211231__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_z0sEatS03irk">0</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6)</span></td><td style="width: 5pt"/><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 28, 2022 </span><span id="xdx_90D_eus-gaap--LineOfCreditFacilityBorrowingCapacityDescription_c20220127__20220128__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zBefUIjUEkpl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Company entered into an Amended and Restated Business Loan Agreement (the “A&amp;R Loan Agreement”), which amends and restates the Master Agreement between the Company and Beachcorp, LLC, and a new promissory note in order to evidence the A/R Revolver facility, including an amendment to expand the limit on the A/R Revolver Facility from $6,000 to $8,000, reduce the interest rate to the prime rate plus 0.75%, and extend the maturity of the A/R Revolver Facility to March 31, 2024.</span></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7)</span></td><td style="width: 5pt"/><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 28, 2022 </span><span id="xdx_90A_eus-gaap--LineOfCreditFacilityBorrowingCapacityDescription_c20220127__20220128__us-gaap--TypeOfArrangementAxis__custom--AAndRLoanAgreementMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zutC6bKeP6ek" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Company entered into the A&amp;R Loan Agreement and a new revolving loan agreement (“Inventory Facility”) with Beachcorp, LLC, and a new promissory note in order to evidence the Inventory Facility. The maximum borrowing amount under the Inventory Facility is $4,000, with a borrowing base consisting of up to 50% of the value of qualified inventory of the Company. The interest rate for the Inventory Revolver is at the prime rate plus 0.75%, and it matures on March 31, 2024.</span></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8)</span></td><td style="width: 5pt"/><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 28, 2022 </span><span id="xdx_904_eus-gaap--LineOfCreditFacilityBorrowingCapacityDescription_c20220127__20220128__us-gaap--TypeOfArrangementAxis__custom--AAndRLoanAgreementMember__srt--CounterpartyNameAxis__custom--StrandlerLLCMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zvWsvJ8GGfz7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Company entered into an additional Business Loan Agreement (the “New Term Loan Agreement”) with Strandler, LLC, which effectively transferred or assigned the Term Loan to Strandler, LLC from Beachcorp, LLC. Interest on the New Term Loan is at the prime rate plus 0.75%, and it matures on March 31, 2024. Strandler, LLC is also an affiliate of Bradford T. Whitmore.</span></td> </tr></table> Libertyville Bank & Trust 0.0425 30000 30000 Libertyville Bank & Trust 0.0425 500000 500000 Libertyville Bank & Trust 0.0425 500000 Beachcorp, LLC 0.0525 3467000 1351000 2776000 2155000 Beachcorp 0.0525 1000000 1000000 500000 500000 Secured convertible promissory note 0.0200 2000000 1097000 PPP Loan / Libertyville promissory note 0.0100 952000 952000 Beachcorp 0.0400 Beachcorp 0.0400 Strandler 0.0400 30000 prime rate 0.01 500000 prime rate 0.01 500000 0.0825 2020-12-31 2000000 prime rate 0.03 0.0825 2020-03-31 2021-03-31 2000000 2750000 2750000 4000000 2022-03-31 4000000 6000000 2023-03-31 500000 1000000 prime rate 0.02 2022-03-31 0.02 2000000 interest was payable semi-annually 2020-05-15 0.20 0.32 1200000000 903000 10000000000 95555000 19000 952000 0.0100 0 the Company entered into an Amended and Restated Business Loan Agreement (the “A&R Loan Agreement”), which amends and restates the Master Agreement between the Company and Beachcorp, LLC, and a new promissory note in order to evidence the A/R Revolver facility, including an amendment to expand the limit on the A/R Revolver Facility from $6,000 to $8,000, reduce the interest rate to the prime rate plus 0.75%, and extend the maturity of the A/R Revolver Facility to March 31, 2024. the Company entered into the A&R Loan Agreement and a new revolving loan agreement (“Inventory Facility”) with Beachcorp, LLC, and a new promissory note in order to evidence the Inventory Facility. The maximum borrowing amount under the Inventory Facility is $4,000, with a borrowing base consisting of up to 50% of the value of qualified inventory of the Company. The interest rate for the Inventory Revolver is at the prime rate plus 0.75%, and it matures on March 31, 2024. the Company entered into an additional Business Loan Agreement (the “New Term Loan Agreement”) with Strandler, LLC, which effectively transferred or assigned the Term Loan to Strandler, LLC from Beachcorp, LLC. Interest on the New Term Loan is at the prime rate plus 0.75%, and it matures on March 31, 2024. Strandler, LLC is also an affiliate of Bradford T. Whitmore. <p id="xdx_89B_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_ztQPle9UgFmi" style="font: 10pt Times New Roman, Times, Serif; visibility: hidden; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_8B4_z5ABkYmmivw5">Schedule of Related Parties</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>Related party interest expense consists of the following:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_497_20210101__20211231_zNsbCXbVk0v" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_490_20200101__20201231_zwn3E1hCJVi3" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Twelve Months Ended December 31,</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40D_eus-gaap--InterestExpenseRelatedParty_pn3n3_zezxkvL1dqvl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left; padding-left: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest expense, related parties</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 12%; text-align: right" title="Interest expense related party"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,129</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">452</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>Accrued interest consists of the following:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_498_20211231__us-gaap--RelatedPartyTransactionAxis__custom--RelatedPartyTransactionMember_z334DPZ0wuP" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49E_20201231__us-gaap--RelatedPartyTransactionAxis__custom--RelatedPartyTransactionMember_zqBJyIz0hmuj" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31,</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40D_eus-gaap--InterestPayableCurrent_iI_zdrr5IZEEfB8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left; padding-left: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued interest expense, related parties</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 12%; text-align: right" title="Accrued interest expense, related parties"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>Outstanding balances associated with related parties are as follows:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; padding-left: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31,</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; padding-left: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left; padding-left: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beachcorp, LLC</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_pn3n3_c20211231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCMember_zR0uy27ahzdj" style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,351</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_pn3n3_c20201231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCMember_zkSCWn9zw6C5" style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,655</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Secured convertible promissory note</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_982_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_pn3n3_d0_c20211231__us-gaap--LongtermDebtTypeAxis__custom--SecuredConvertiblePromissoryNotesMember_zLrfFbRAcU9a" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98E_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_pn3n3_d0_c20201231__us-gaap--LongtermDebtTypeAxis__custom--SecuredConvertiblePromissoryNotesMember_zbjTyhcfPIyk" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,097</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Strandler, LLC</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 1129000 452000 13000 20000 2351000 2655000 0 1097000 <p id="xdx_805_eus-gaap--InventoryDisclosureTextBlock_zT5pJJbP0QB4" style="margin-top: 0; margin-bottom: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(4)</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_828_z2JOSxyaDWl3">Inventories</span>  </b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89B_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zMrdmW9a7MS3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zORrU4TaX6wf">Inventories consist of the following:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="font-weight: bold; text-align: center"> </td> <td id="xdx_491_20211231_zzZ5PvyD8sub" style="font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; text-align: center"> </td> <td id="xdx_491_20201231_zjw6wiuS88Q8" style="font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_eus-gaap--InventoryRawMaterials_iI_pn3n3_maIGzvZ1_maIGzRb9_maINz43N_zKJ989KeccQc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Raw materials</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,819</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,825</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40B_eus-gaap--InventoryFinishedGoods_iI_pn3n3_maIGzvZ1_maIGzRb9_maINz43N_zNIzuY5V15Rj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finished goods</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,682</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,545</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_402_eus-gaap--InventoryGross_iTI_pn3n3_maIGzvZ1_mtIGzRb9_maINz8YJ_maINz43N_zbpaLJlKtlO8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font: 10pt Times New Roman, Times, Serif; display: none; visibility: hidden"> Inventories, gross</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,501</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,370</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_402_eus-gaap--InventoryValuationReserves_iNI_pn3n3_di_msINzpr1_msINz8YJ_msINz43N_zMkUTvEoMbjc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allowance for excess quantities</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(406</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(30</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_404_eus-gaap--InventoryNet_iTI_pn3n3_msINzpr1_mtINz8YJ_mtINz43N_zsXIQ5EoS9ra" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif; display: none; visibility: hidden"> Inventories, net</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,095</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,340</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p style="margin-top: 0; margin-bottom: 0"> </p> <p id="xdx_8A9_z7GIQ1P6gZI6" style="margin-top: 0; margin-bottom: 0"> </p> <p id="xdx_89B_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zMrdmW9a7MS3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zORrU4TaX6wf">Inventories consist of the following:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="font-weight: bold; text-align: center"> </td> <td id="xdx_491_20211231_zzZ5PvyD8sub" style="font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; text-align: center"> </td> <td id="xdx_491_20201231_zjw6wiuS88Q8" style="font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_eus-gaap--InventoryRawMaterials_iI_pn3n3_maIGzvZ1_maIGzRb9_maINz43N_zKJ989KeccQc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Raw materials</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,819</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,825</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40B_eus-gaap--InventoryFinishedGoods_iI_pn3n3_maIGzvZ1_maIGzRb9_maINz43N_zNIzuY5V15Rj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finished goods</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,682</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,545</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_402_eus-gaap--InventoryGross_iTI_pn3n3_maIGzvZ1_mtIGzRb9_maINz8YJ_maINz43N_zbpaLJlKtlO8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font: 10pt Times New Roman, Times, Serif; display: none; visibility: hidden"> Inventories, gross</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,501</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,370</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_402_eus-gaap--InventoryValuationReserves_iNI_pn3n3_di_msINzpr1_msINz8YJ_msINz43N_zMkUTvEoMbjc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allowance for excess quantities</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(406</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(30</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_404_eus-gaap--InventoryNet_iTI_pn3n3_msINzpr1_mtINz8YJ_mtINz43N_zsXIQ5EoS9ra" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif; display: none; visibility: hidden"> Inventories, net</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,095</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,340</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p style="margin-top: 0; margin-bottom: 0"> </p> 4819000 2825000 1682000 1545000 6501000 4370000 406000 30000 6095000 4340000 <p id="xdx_80E_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zoewPUwRKTsa" style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(5)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5pt"/></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span><span id="xdx_826_zWpYbf0BzxCd">Equipment and Leasehold Improvements</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/></td></tr> </table> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_890_eus-gaap--PropertyPlantAndEquipmentTextBlock_zhVU6zZy1T0a" style="margin-top: 0; margin-bottom: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_z2ncbzRH0MB3">Equipment and leasehold improvements consist of the following:</span> </span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Machinery and equipment</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zaxvMJ8yxhFe" style="width: 10%; text-align: right" title="Machinery and equipment"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18,289</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zPHyXNLm9Xu" style="width: 10%; text-align: right" title="Machinery and equipment"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16,758</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office equipment</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zvs2c6obs2Yl" style="text-align: right" title="Office equipment"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">961</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_ziGk9RqU2cO5" style="text-align: right" title="Office equipment"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">870</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office furniture</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zs4eHOdW7G8g" style="text-align: right" title="Office furniture"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">110</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zLmUTSqppRs6" style="text-align: right" title="Office furniture"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">110</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold improvements</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zS3iaQcKbeS7" style="text-align: right" title="Leasehold improvements"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,900</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zGPmnO6zaw87" style="text-align: right" title="Leasehold improvements"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,850</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Construction in progress</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_zmcyUDC7fKm9" style="border-bottom: Black 1pt solid; text-align: right" title="Construction in progress"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,062</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_zOog8JDKF20j" style="border-bottom: Black 1pt solid; text-align: right" title="Construction in progress"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">445</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20211231_zEErcOoXUdK9" style="text-align: right" title="Property plant and equipment,gross"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,322</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231_zKO0YwThYUna" style="text-align: right" title="Property plant and equipment,gross"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23,033</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less: Accumulated depreciation and amortization</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_983_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20211231_zzfv4Y8l1sWf" style="border-bottom: Black 1pt solid; text-align: right" title="Less: Accumulated depreciation and amortization"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(20,610</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_986_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20201231_zm1o2DeSSsjh" style="border-bottom: Black 1pt solid; text-align: right" title="Less: Accumulated depreciation and amortization"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(20,165</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20211231_zKpLdRlJMgAi" style="border-bottom: Black 2.5pt double; text-align: right" title="Property, Plant and Equipment, Net, Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,712</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20201231_z7b2Ytwumwjj" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,868</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A5_zc1A1o2YuQva" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation expense was $<span id="xdx_901_eus-gaap--Depreciation_c20210101__20211231_zFk7SFwhVl48" title="Depreciation expense">444</span> and $<span id="xdx_90A_eus-gaap--Depreciation_c20200101__20201231_zMnSeAItofdc">348</span>, for the years ended December 31, 2021 and 2020, respectively.</span></p> <p id="xdx_890_eus-gaap--PropertyPlantAndEquipmentTextBlock_zhVU6zZy1T0a" style="margin-top: 0; margin-bottom: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_z2ncbzRH0MB3">Equipment and leasehold improvements consist of the following:</span> </span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Machinery and equipment</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zaxvMJ8yxhFe" style="width: 10%; text-align: right" title="Machinery and equipment"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18,289</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zPHyXNLm9Xu" style="width: 10%; text-align: right" title="Machinery and equipment"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16,758</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office equipment</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zvs2c6obs2Yl" style="text-align: right" title="Office equipment"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">961</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_ziGk9RqU2cO5" style="text-align: right" title="Office equipment"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">870</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office furniture</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zs4eHOdW7G8g" style="text-align: right" title="Office furniture"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">110</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zLmUTSqppRs6" style="text-align: right" title="Office furniture"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">110</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold improvements</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zS3iaQcKbeS7" style="text-align: right" title="Leasehold improvements"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,900</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zGPmnO6zaw87" style="text-align: right" title="Leasehold improvements"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,850</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Construction in progress</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_zmcyUDC7fKm9" style="border-bottom: Black 1pt solid; text-align: right" title="Construction in progress"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,062</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_zOog8JDKF20j" style="border-bottom: Black 1pt solid; text-align: right" title="Construction in progress"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">445</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20211231_zEErcOoXUdK9" style="text-align: right" title="Property plant and equipment,gross"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,322</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231_zKO0YwThYUna" style="text-align: right" title="Property plant and equipment,gross"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23,033</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less: Accumulated depreciation and amortization</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_983_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20211231_zzfv4Y8l1sWf" style="border-bottom: Black 1pt solid; text-align: right" title="Less: Accumulated depreciation and amortization"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(20,610</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_986_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20201231_zm1o2DeSSsjh" style="border-bottom: Black 1pt solid; text-align: right" title="Less: Accumulated depreciation and amortization"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(20,165</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20211231_zKpLdRlJMgAi" style="border-bottom: Black 2.5pt double; text-align: right" title="Property, Plant and Equipment, Net, Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,712</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20201231_z7b2Ytwumwjj" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,868</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 18289000 16758000 961000 870000 110000 110000 4900000 4850000 1062000 445000 25322000 23033000 20610000 20165000 4712000 2868000 444 348 <p id="xdx_80D_eus-gaap--LeasesOfLesseeDisclosureTextBlock_zh6IQSV9ss1e" style="margin-top: 0; margin-bottom: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(6)</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_821_zQesxhBUwfIe">Lease Commitments</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s operating lease portfolio is comprised of operating leases for office, warehouse space and equipment. Certain of the Company’s leases include one or more options to renew or terminate the lease at the Company’s discretion. The Company regularly evaluates the renewal and termination options and when they are reasonably certain of exercise, includes the renewal or termination option in our lease term. During the first seven months of the term of our newly leased building, we have subleased a portion of the unused floorspace on a temporary basis. This sublease may convert to a month-to-month lease upon expiration.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2021, the ROU asset had a balance of $<span id="xdx_908_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20211231_zSf4Zcm8eVp2" title="Operating leases, right of use">12,075</span> which is included in the “Operating lease right-of-use assets” line item of these consolidated financial statements and current and non-current lease liabilities related to the ROU asset of $<span id="xdx_908_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pn3n3_c20211231_zmzu543BsNE9" title="Current portion of operating lease obligations">1,983</span> and $<span id="xdx_90F_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_c20211231_zlbiMTE2FvXh" title="Long-term portion of operating lease obligations">10,306</span>, respectively.  As of December 31, 2020, the ROU asset had a balance of $<span id="xdx_90C_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20201231_zDFyF6H68r67" title="Operating leases, right of use">1,827</span> which is included in the “Operating lease right-of-use assets” line item of these consolidated financial statements and current and non-current lease liabilities related to the ROU asset of $<span id="xdx_900_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pn3n3_c20201231_zgYV9FMyl6Nh" title="Current portion of operating lease obligations">431</span> and $<span id="xdx_904_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_c20201231_zYEodDCDbE3i" title="Long-term portion of operating lease obligations">1,651</span>, respectively.  These amounts are included in the “Current portion of operating lease obligations” and “Long-term portion of operating lease obligations” line items of these consolidated financial statements. The discount rates used for leases accounted for under ASC 842 are based on an interest rate yield curve developed for the leases in the Company’s portfolio.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The office leases contain variable lease payments which consist primarily of rent escalations based on an established index or rate and taxes, insurance, and common area or other maintenance costs, which are paid based on actual costs incurred by the lessor. The Company has elected to utilize the available practical expedient to not separate lease and non-lease components.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_897_eus-gaap--LeaseCostTableTextBlock_z7EWeEWrpld2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_zOqgXwjcVcQ4">Quantitative information regarding the Company’s leases is as follows:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20210101__20211231_zhtYfzv7uEQ7" style="font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20200101__20201231_zEIBK6zv2lY1" style="font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Twelve Months Ended December 31, 2021</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Twelve Months Ended December 31, 2020</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_eus-gaap--LeaseCostAbstract_iB_zHFEJqMgKGM3" style="vertical-align: bottom"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Components of lease cost</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_402_ecustom--FinanceLeaseCostComponentsAbstract_i01B_zhAVrV6CyUG9" style="vertical-align: bottom"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finance lease cost components:</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_404_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_i02_pn3n3_maLCFzzmZ_zcLWwblDThp2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: left; padding-left: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization of finance lease assets</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_eus-gaap--FinanceLeaseInterestExpense_i02_pn3n3_maLCFzzmZ_zIFR0g9B58cg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest on finance lease liabilities</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40B_ecustom--LeaseCostsFinance_i02T_pn3n3_mtLCFzzmZ_maLCzWd6_zKRJZN5Mz0df" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total finance lease costs</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">106</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_407_ecustom--OperatingLeaseCostComponentsAbstract_i01B_zGY0NMUYG6N2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating lease cost components:</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_403_eus-gaap--OperatingLeaseCost_i02_pn3n3_maOLEzncp_zhkSuAunFn7i" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating lease cost</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">554</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">565</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_401_eus-gaap--VariableLeaseCost_i02_pn3n3_maOLEzncp_zkBeDvC8tAFi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Variable lease cost</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">134</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">146</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_eus-gaap--ShortTermLeaseCost_i02_pn3n3_maOLEzncp_zRQinR5GthU6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Short-term lease cost</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--OperatingLeaseExpense_i02T_pn3n3_mtOLEzncp_maLCzWd6_zl7xqdwSLQ95" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total operating lease costs</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">737</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">744</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--LeaseCost_i01T_pn3n3_mtLCzWd6_ztfClTFezrOa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total lease cost:</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">807</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">850</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A0_zoLsYbmnZ8b5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89D_ecustom--SummaryOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_zLcRcrY88hqd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zLiLKajdMdK">Supplemental cash flow information related to leases is as follows for the years ended December 31, 2021 and 2020:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: left; padding-left: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating cash outflow from operating leases</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--OperatingLeasePayments_pn3n3_c20210101__20211231_zppOWcRSDx1j" style="width: 14%; text-align: right" title="Operating cash outflow from operating leases"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">741</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--OperatingLeasePayments_pn3n3_c20200101__20201231_zSk6r1PZ4WK9" style="width: 14%; text-align: right" title="Operating cash outflow from operating leases"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">690</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease liabilities arising from obtaining right-of-use assets</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98F_eus-gaap--PaymentForContingentConsiderationLiabilityOperatingActivities_pn3n3_c20210101__20211231_zSJPHZAXpI73" style="text-align: right" title="Lease liabilities arising from obtaining right-of-use assets"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,505</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted-average remaining lease term-finance leases (in years)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--LesseeFinanceLeaseRemainingLeaseTerm_iI_dtYxL_c20211231_ztiUEhQgoXsj" title="Weighted-average remaining lease term-finance leases (in years)::XDX::P0Y8M12D"><span style="-sec-ix-hidden: xdx2ixbrl0792">0.7</span></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--LesseeFinanceLeaseRemainingLeaseTerm_iI_dtYxL_c20201231_znsTaESWetF" title="Weighted-average remaining lease term-finance leases (in years)::XDX::P1Y4M24D"><span style="-sec-ix-hidden: xdx2ixbrl0794">1.4</span></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted-average remaining lease term-operating leases (in years)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtY_c20211231_zRX1JWqXK3d3" title="Weighted-average remaining lease term-operating leases (in years)">9.5</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtY_c20201231_zGF1AYi5oqQ8" title="Weighted-average remaining lease term-operating leases (in years)">3.2</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted-average discount rate-finance leases</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_pip0_dp_c20211231_zgQ90I4EFInd" title="Weighted-average discount rate-finance leases">9.3</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_pip0_dp_c20201231_zYpA7cNAAkbk" title="Weighted-average discount rate-finance leases">9.3</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted-average discount rate-operating leases</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pip0_dp_c20211231_zM27dJHLppOi" title="Weighted-average discount rate-operating leases">7.5</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pip0_dp_c20201231_zzNHAYUnnIvg" title="Weighted-average discount rate-operating leases">14.3</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/> <p id="xdx_8A3_zrDHfKPQYuHh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_ecustom--ScheduleOfFutureMaturitiesOfFinanceAndOperatingLeasesTableTextBlock_zK9b3EATrbT4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zf4CrBbMQfTe">The future maturities of the Company’s finance and operating leases as of December 31, 2021 are as follows:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finance <br/> Leases</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating <br/> Leases</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 30%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maFLO_c20211231_zRXtE3y5nYXk" style="width: 10%; text-align: right" title="Finance Leases, Year 1"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">109</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maOLO_c20211231_zLB9OcdDtq91" style="width: 10%; text-align: right" title="Operating Leases, Year 1"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,456</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_ecustom--LeaseLiabilityPaymentsDueYearOne_iI_pn3n3_maTLO_c20211231_zgl3ECPBxqxd" style="width: 10%; text-align: right" title="Total, Year 1"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,565</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maFLO_c20211231_zRF01atqpWbb" style="text-align: right" title="Finance Leases, Year 2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_989_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maOLO_c20211231_zNm1SwpLuWv3" style="text-align: right" title="Operating Leases, Year 2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,099</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_ecustom--LeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maTLO_c20211231_zAf5k6lM5Zoi" style="text-align: right" title="Total, Year 2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,105</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_d0_maFLO_c20211231_zGChPrROGB4h" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_980_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maOLO_c20211231_zWEEYRwqKYy8" style="text-align: right" title="Operating Leases, Year 3"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,025</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_985_ecustom--LeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maTLO_c20211231_z3gBnGxg5o68" style="text-align: right" title="Total, Year 3"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,025</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_985_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maOLO_c20211231_znF96nXkknm3" style="text-align: right" title="Operating Leases, Year 4"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,470</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_ecustom--LeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maTLO_c20211231_zWfFJA35jK2k" style="text-align: right" title="Total, Year 4"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,470</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2026</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_pn3n3_maOLO_c20211231_zhNkf05DMTB7" style="text-align: right" title="Operating Leases, Year 5"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,468</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_987_ecustom--LeaseLiabilityPaymentsDueYearFive_iI_pn3n3_maTLO_c20211231_zPtF105Bk4g8" style="text-align: right" title="Total, Year 5"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,468</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thereafter</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_pn3n3_maOLO_c20211231_zVcSnnWQuati" style="border-bottom: Black 1pt solid; text-align: right" title="Operating Leases, thereafter"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,668</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_983_ecustom--LeaseLiabilityPaymentsDueYearThereafter_iI_pn3n3_maTLO_c20211231_z0pHsaF78Mec" style="border-bottom: Black 1pt solid; text-align: right" title="Total, thereafter"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,668</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total payments</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_982_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iTI_pn3n3_mtFLO_c20211231_zsK2scRE5Qkk" style="text-align: right" title="Finance Lease, Liability, Payment, Due"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">115</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_980_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtOLO_c20211231_ztCxT7gvl7Ie" style="text-align: right" title="Lessee, Operating Lease, Liability, to be Paid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17,186</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_985_ecustom--LeaseLiabilityPaymentDue_iTI_pn3n3_mtTLO_c20211231_zUStH74joPk9" style="text-align: right" title="Total payments"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17,301</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less amounts representing interest</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98B_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_c20211231_zjPChCzaplbd" style="text-align: right" title="Finance Lease, Liability, Undiscounted Excess Amount"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_c20211231_z0WUP6zGkt4j" style="text-align: right" title="Lessee, Operating Lease, Liability, Undiscounted Excess Amount"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,897</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_986_ecustom--LeaseImputedInterest_iNI_pn3n3_di_c20211231_zpaUzj4yJAma" style="text-align: right" title="Less amounts representing interest"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,901</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total minimum payments required</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--FinanceLeaseLiability_iI_pn3n3_c20211231_zCWjl9Qp6Iu7" style="border-bottom: Black 2.5pt double; text-align: right" title="Finance Leases, Total minimum payments required:"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">111</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--OperatingLeaseLiability_iI_pn3n3_c20211231_z64X15pLHjK6" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating Leases, Total minimum payments required:"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,289</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_986_ecustom--LeaseLiability_iI_pn3n3_c20211231_zdLni16vCfY7" style="border-bottom: Black 2.5pt double; text-align: right" title="Total, Total minimum payments required:"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,400</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The future maturities of the Company’s finance and operating leases as of December 31, 2020 were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finance <br/> Leases</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating <br/> Leases</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 30%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_983_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maFL_c20201231_zyeNWF9d9Dja" style="width: 10%; text-align: right" title="Finance Leases, Year 1"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">196</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maOL_c20201231_zk6t0OVK3Yeh" style="width: 10%; text-align: right" title="Operating Leases, Year 1"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">701</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98A_ecustom--LeaseLiabilityPaymentsDueYearOne_iI_pn3n3_maTL_c20201231_zC51crPw8JL1" style="width: 10%; text-align: right" title="Total, Year 1"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">897</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_981_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maFL_c20201231_zAoWyLQx9Qs7" style="text-align: right" title="Finance Leases, Year 2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">109</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maOL_c20201231_zXW7EoKaTJV7" style="text-align: right" title="Operating Leases, Year 2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">720</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_ecustom--LeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maTL_c20201231_zrIaOnvERe0a" style="text-align: right" title="Total, Year 2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">829</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maFL_c20201231_z7jb9C3KSZ94" style="text-align: right" title="Finance Leases, Year 3"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_985_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maOL_c20201231_zspss3dgfTUb" style="text-align: right" title="Operating Leases, Year 3"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">705</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_983_ecustom--LeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maTL_c20201231_zyMO0LyUpkN9" style="text-align: right" title="Total, Year 3"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">710</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_980_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maOL_c20201231_zt7PLJ7O1WO" style="text-align: right" title="Operating Leases, Year 4"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">595</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_981_ecustom--LeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maTL_c20201231_zAIl6V4FUolh" style="text-align: right" title="Total, Year 4"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">595</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_980_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_pn3n3_maOL_c20201231_zJ8dtHssPSC6" style="text-align: right" title="Operating Leases, Year 5"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98D_ecustom--LeaseLiabilityPaymentsDueYearFive_iI_pn3n3_maTL_c20201231_z0xu3tEZHsLe" style="text-align: right" title="Total, Year 5"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thereafter</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total payments</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iTI_pn3n3_mtFL_c20201231_zffSk4MSv3md" style="text-align: right" title="Finance Lease, Liability, Payment, Due"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">310</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtOL_c20201231_znqcnF8saFk6" style="text-align: right" title="Lessee, Operating Lease, Liability, to be Paid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,722</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_ecustom--LeaseLiabilityPaymentDue_iTI_pn3n3_mtTL_c20201231_zjitKHuy2Szc" style="text-align: right" title="Total payments"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,032</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less amounts representing interest</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_981_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_c20201231_zbKfOYGGvcl4" style="text-align: right" title="Finance Lease, Liability, Undiscounted Excess Amount"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(23</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_989_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_c20201231_zZUO9NG00kP4" style="text-align: right" title="Lessee, Operating Lease, Liability, Undiscounted Excess Amount"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(640</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_982_ecustom--LeaseImputedInterest_iNI_pn3n3_di_c20201231_zPO46JYhyFL1" style="text-align: right" title="Less amounts representing interest"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(663</span></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total minimum payments required</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--FinanceLeaseLiability_iI_pn3n3_c20201231_zArSgooIDpM5" style="border-bottom: Black 2.5pt double; text-align: right" title="Finance Leases, Total minimum payments required:"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">287</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_982_eus-gaap--OperatingLeaseLiability_iI_pn3n3_c20201231_zHl7QC17IQj3" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating Leases, Total minimum payments required:"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,082</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_ecustom--LeaseLiability_iI_pn3n3_c20201231_zQLfCxzko4y9" style="border-bottom: Black 2.5pt double; text-align: right" title="Total, Total minimum payments required:"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,369</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A6_zPjQ9FHfMzIg" style="margin-top: 0; margin-bottom: 0"> </p> 12075000 1983000 10306000 1827000 431000 1651000 <p id="xdx_897_eus-gaap--LeaseCostTableTextBlock_z7EWeEWrpld2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_zOqgXwjcVcQ4">Quantitative information regarding the Company’s leases is as follows:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20210101__20211231_zhtYfzv7uEQ7" style="font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20200101__20201231_zEIBK6zv2lY1" style="font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Twelve Months Ended December 31, 2021</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Twelve Months Ended December 31, 2020</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_eus-gaap--LeaseCostAbstract_iB_zHFEJqMgKGM3" style="vertical-align: bottom"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Components of lease cost</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_402_ecustom--FinanceLeaseCostComponentsAbstract_i01B_zhAVrV6CyUG9" style="vertical-align: bottom"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finance lease cost components:</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_404_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_i02_pn3n3_maLCFzzmZ_zcLWwblDThp2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: left; padding-left: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization of finance lease assets</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_eus-gaap--FinanceLeaseInterestExpense_i02_pn3n3_maLCFzzmZ_zIFR0g9B58cg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest on finance lease liabilities</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40B_ecustom--LeaseCostsFinance_i02T_pn3n3_mtLCFzzmZ_maLCzWd6_zKRJZN5Mz0df" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total finance lease costs</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">106</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_407_ecustom--OperatingLeaseCostComponentsAbstract_i01B_zGY0NMUYG6N2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating lease cost components:</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_403_eus-gaap--OperatingLeaseCost_i02_pn3n3_maOLEzncp_zhkSuAunFn7i" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating lease cost</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">554</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">565</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_401_eus-gaap--VariableLeaseCost_i02_pn3n3_maOLEzncp_zkBeDvC8tAFi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Variable lease cost</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">134</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">146</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_eus-gaap--ShortTermLeaseCost_i02_pn3n3_maOLEzncp_zRQinR5GthU6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Short-term lease cost</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--OperatingLeaseExpense_i02T_pn3n3_mtOLEzncp_maLCzWd6_zl7xqdwSLQ95" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total operating lease costs</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">737</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">744</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--LeaseCost_i01T_pn3n3_mtLCzWd6_ztfClTFezrOa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total lease cost:</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">807</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">850</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 52000 70000 18000 36000 70000 106000 554000 565000 134000 146000 49000 33000 737000 744000 807000 850000 <p id="xdx_89D_ecustom--SummaryOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_zLcRcrY88hqd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zLiLKajdMdK">Supplemental cash flow information related to leases is as follows for the years ended December 31, 2021 and 2020:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: left; padding-left: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating cash outflow from operating leases</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--OperatingLeasePayments_pn3n3_c20210101__20211231_zppOWcRSDx1j" style="width: 14%; text-align: right" title="Operating cash outflow from operating leases"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">741</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--OperatingLeasePayments_pn3n3_c20200101__20201231_zSk6r1PZ4WK9" style="width: 14%; text-align: right" title="Operating cash outflow from operating leases"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">690</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease liabilities arising from obtaining right-of-use assets</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98F_eus-gaap--PaymentForContingentConsiderationLiabilityOperatingActivities_pn3n3_c20210101__20211231_zSJPHZAXpI73" style="text-align: right" title="Lease liabilities arising from obtaining right-of-use assets"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,505</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted-average remaining lease term-finance leases (in years)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--LesseeFinanceLeaseRemainingLeaseTerm_iI_dtYxL_c20211231_ztiUEhQgoXsj" title="Weighted-average remaining lease term-finance leases (in years)::XDX::P0Y8M12D"><span style="-sec-ix-hidden: xdx2ixbrl0792">0.7</span></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--LesseeFinanceLeaseRemainingLeaseTerm_iI_dtYxL_c20201231_znsTaESWetF" title="Weighted-average remaining lease term-finance leases (in years)::XDX::P1Y4M24D"><span style="-sec-ix-hidden: xdx2ixbrl0794">1.4</span></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted-average remaining lease term-operating leases (in years)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtY_c20211231_zRX1JWqXK3d3" title="Weighted-average remaining lease term-operating leases (in years)">9.5</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtY_c20201231_zGF1AYi5oqQ8" title="Weighted-average remaining lease term-operating leases (in years)">3.2</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted-average discount rate-finance leases</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_pip0_dp_c20211231_zgQ90I4EFInd" title="Weighted-average discount rate-finance leases">9.3</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_pip0_dp_c20201231_zYpA7cNAAkbk" title="Weighted-average discount rate-finance leases">9.3</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted-average discount rate-operating leases</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pip0_dp_c20211231_zM27dJHLppOi" title="Weighted-average discount rate-operating leases">7.5</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pip0_dp_c20201231_zzNHAYUnnIvg" title="Weighted-average discount rate-operating leases">14.3</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/> 741000 690000 10505000 P9Y6M P3Y2M12D 0.093 0.093 0.075 0.143 <p id="xdx_896_ecustom--ScheduleOfFutureMaturitiesOfFinanceAndOperatingLeasesTableTextBlock_zK9b3EATrbT4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zf4CrBbMQfTe">The future maturities of the Company’s finance and operating leases as of December 31, 2021 are as follows:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finance <br/> Leases</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating <br/> Leases</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 30%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maFLO_c20211231_zRXtE3y5nYXk" style="width: 10%; text-align: right" title="Finance Leases, Year 1"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">109</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maOLO_c20211231_zLB9OcdDtq91" style="width: 10%; text-align: right" title="Operating Leases, Year 1"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,456</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_ecustom--LeaseLiabilityPaymentsDueYearOne_iI_pn3n3_maTLO_c20211231_zgl3ECPBxqxd" style="width: 10%; text-align: right" title="Total, Year 1"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,565</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maFLO_c20211231_zRF01atqpWbb" style="text-align: right" title="Finance Leases, Year 2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_989_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maOLO_c20211231_zNm1SwpLuWv3" style="text-align: right" title="Operating Leases, Year 2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,099</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_ecustom--LeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maTLO_c20211231_zAf5k6lM5Zoi" style="text-align: right" title="Total, Year 2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,105</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_d0_maFLO_c20211231_zGChPrROGB4h" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_980_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maOLO_c20211231_zWEEYRwqKYy8" style="text-align: right" title="Operating Leases, Year 3"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,025</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_985_ecustom--LeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maTLO_c20211231_z3gBnGxg5o68" style="text-align: right" title="Total, Year 3"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,025</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_985_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maOLO_c20211231_znF96nXkknm3" style="text-align: right" title="Operating Leases, Year 4"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,470</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_ecustom--LeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maTLO_c20211231_zWfFJA35jK2k" style="text-align: right" title="Total, Year 4"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,470</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2026</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_pn3n3_maOLO_c20211231_zhNkf05DMTB7" style="text-align: right" title="Operating Leases, Year 5"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,468</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_987_ecustom--LeaseLiabilityPaymentsDueYearFive_iI_pn3n3_maTLO_c20211231_zPtF105Bk4g8" style="text-align: right" title="Total, Year 5"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,468</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thereafter</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_pn3n3_maOLO_c20211231_zVcSnnWQuati" style="border-bottom: Black 1pt solid; text-align: right" title="Operating Leases, thereafter"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,668</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_983_ecustom--LeaseLiabilityPaymentsDueYearThereafter_iI_pn3n3_maTLO_c20211231_z0pHsaF78Mec" style="border-bottom: Black 1pt solid; text-align: right" title="Total, thereafter"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,668</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total payments</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_982_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iTI_pn3n3_mtFLO_c20211231_zsK2scRE5Qkk" style="text-align: right" title="Finance Lease, Liability, Payment, Due"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">115</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_980_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtOLO_c20211231_ztCxT7gvl7Ie" style="text-align: right" title="Lessee, Operating Lease, Liability, to be Paid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17,186</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_985_ecustom--LeaseLiabilityPaymentDue_iTI_pn3n3_mtTLO_c20211231_zUStH74joPk9" style="text-align: right" title="Total payments"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17,301</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less amounts representing interest</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98B_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_c20211231_zjPChCzaplbd" style="text-align: right" title="Finance Lease, Liability, Undiscounted Excess Amount"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_c20211231_z0WUP6zGkt4j" style="text-align: right" title="Lessee, Operating Lease, Liability, Undiscounted Excess Amount"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,897</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_986_ecustom--LeaseImputedInterest_iNI_pn3n3_di_c20211231_zpaUzj4yJAma" style="text-align: right" title="Less amounts representing interest"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,901</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total minimum payments required</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--FinanceLeaseLiability_iI_pn3n3_c20211231_zCWjl9Qp6Iu7" style="border-bottom: Black 2.5pt double; text-align: right" title="Finance Leases, Total minimum payments required:"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">111</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--OperatingLeaseLiability_iI_pn3n3_c20211231_z64X15pLHjK6" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating Leases, Total minimum payments required:"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,289</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_986_ecustom--LeaseLiability_iI_pn3n3_c20211231_zdLni16vCfY7" style="border-bottom: Black 2.5pt double; text-align: right" title="Total, Total minimum payments required:"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,400</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The future maturities of the Company’s finance and operating leases as of December 31, 2020 were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finance <br/> Leases</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating <br/> Leases</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 30%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_983_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maFL_c20201231_zyeNWF9d9Dja" style="width: 10%; text-align: right" title="Finance Leases, Year 1"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">196</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maOL_c20201231_zk6t0OVK3Yeh" style="width: 10%; text-align: right" title="Operating Leases, Year 1"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">701</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98A_ecustom--LeaseLiabilityPaymentsDueYearOne_iI_pn3n3_maTL_c20201231_zC51crPw8JL1" style="width: 10%; text-align: right" title="Total, Year 1"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">897</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_981_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maFL_c20201231_zAoWyLQx9Qs7" style="text-align: right" title="Finance Leases, Year 2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">109</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maOL_c20201231_zXW7EoKaTJV7" style="text-align: right" title="Operating Leases, Year 2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">720</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_ecustom--LeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maTL_c20201231_zrIaOnvERe0a" style="text-align: right" title="Total, Year 2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">829</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maFL_c20201231_z7jb9C3KSZ94" style="text-align: right" title="Finance Leases, Year 3"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_985_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maOL_c20201231_zspss3dgfTUb" style="text-align: right" title="Operating Leases, Year 3"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">705</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_983_ecustom--LeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maTL_c20201231_zyMO0LyUpkN9" style="text-align: right" title="Total, Year 3"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">710</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_980_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maOL_c20201231_zt7PLJ7O1WO" style="text-align: right" title="Operating Leases, Year 4"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">595</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_981_ecustom--LeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maTL_c20201231_zAIl6V4FUolh" style="text-align: right" title="Total, Year 4"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">595</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_980_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_pn3n3_maOL_c20201231_zJ8dtHssPSC6" style="text-align: right" title="Operating Leases, Year 5"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98D_ecustom--LeaseLiabilityPaymentsDueYearFive_iI_pn3n3_maTL_c20201231_z0xu3tEZHsLe" style="text-align: right" title="Total, Year 5"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thereafter</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total payments</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iTI_pn3n3_mtFL_c20201231_zffSk4MSv3md" style="text-align: right" title="Finance Lease, Liability, Payment, Due"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">310</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtOL_c20201231_znqcnF8saFk6" style="text-align: right" title="Lessee, Operating Lease, Liability, to be Paid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,722</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_ecustom--LeaseLiabilityPaymentDue_iTI_pn3n3_mtTL_c20201231_zjitKHuy2Szc" style="text-align: right" title="Total payments"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,032</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less amounts representing interest</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_981_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_c20201231_zbKfOYGGvcl4" style="text-align: right" title="Finance Lease, Liability, Undiscounted Excess Amount"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(23</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_989_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_c20201231_zZUO9NG00kP4" style="text-align: right" title="Lessee, Operating Lease, Liability, Undiscounted Excess Amount"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(640</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_982_ecustom--LeaseImputedInterest_iNI_pn3n3_di_c20201231_zPO46JYhyFL1" style="text-align: right" title="Less amounts representing interest"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(663</span></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total minimum payments required</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--FinanceLeaseLiability_iI_pn3n3_c20201231_zArSgooIDpM5" style="border-bottom: Black 2.5pt double; text-align: right" title="Finance Leases, Total minimum payments required:"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">287</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_982_eus-gaap--OperatingLeaseLiability_iI_pn3n3_c20201231_zHl7QC17IQj3" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating Leases, Total minimum payments required:"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,082</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_ecustom--LeaseLiability_iI_pn3n3_c20201231_zQLfCxzko4y9" style="border-bottom: Black 2.5pt double; text-align: right" title="Total, Total minimum payments required:"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,369</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 109000 1456000 1565000 6000 2099000 2105000 0 2025000 2025000 1470000 1470000 1468000 1468000 8668000 8668000 115000 17186000 17301000 4000 4897000 4901000 111000 12289000 12400000 196000 701000 897000 109000 720000 829000 5000 705000 710000 595000 595000 1000 1000 310000 2722000 3032000 23000 640000 663000 287000 2082000 2369000 <p id="xdx_80F_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zIilI8WitCy6" style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin-top: 0; margin-bottom: 0"/> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(7)</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span><span id="xdx_826_za6ATS8oaFw6">Accrued Expenses</span></span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_890_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zXReocb1FLc3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_zTML7TCrIjOf">Accrued expenses consist of the following:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="font-weight: bold; text-align: center"> </td> <td id="xdx_497_20211231_zJtEuPOp9Lj6" style="font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; text-align: center"> </td> <td id="xdx_49E_20201231_zkijfWMRfHr7" style="font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_maALCzPuI_zR496xXU9YF6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued payroll and related expenses</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">471</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">315</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_408_ecustom--CustomerNetVolumeRebatePayable_iI_maALCzPuI_zxE7Ay3UeCs6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued accounts payable</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">320</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">122</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_404_ecustom--TenantSecurityDeposit_iI_maALCzPuI_zbwSV3gcBSOb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tenant Security Deposit / Advance Rent</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">122</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0912">—</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_403_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maALCzPuI_zttacQNy18jf" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_402_eus-gaap--AccruedLiabilitiesCurrent_iI_mtALCzPuI_zolghAoT4i2a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt; padding-left: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">946</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">484</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8AF_zLyFxpHhZCuj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_890_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zXReocb1FLc3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_zTML7TCrIjOf">Accrued expenses consist of the following:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="font-weight: bold; text-align: center"> </td> <td id="xdx_497_20211231_zJtEuPOp9Lj6" style="font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; text-align: center"> </td> <td id="xdx_49E_20201231_zkijfWMRfHr7" style="font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_maALCzPuI_zR496xXU9YF6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued payroll and related expenses</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">471</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">315</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_408_ecustom--CustomerNetVolumeRebatePayable_iI_maALCzPuI_zxE7Ay3UeCs6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued accounts payable</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">320</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">122</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_404_ecustom--TenantSecurityDeposit_iI_maALCzPuI_zbwSV3gcBSOb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tenant Security Deposit / Advance Rent</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">122</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0912">—</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_403_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maALCzPuI_zttacQNy18jf" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_402_eus-gaap--AccruedLiabilitiesCurrent_iI_mtALCzPuI_zolghAoT4i2a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt; padding-left: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">946</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">484</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 471000 315000 320000 122000 122000 33000 47000 946000 484000 <p id="xdx_80F_eus-gaap--IncomeTaxDisclosureTextBlock_zxPNOdfDUma2" style="margin-top: 0; margin-bottom: 0"/> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 48px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(8)</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82F_zfNesQMtNPc9">Income Taxes</span></b></span></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our net income tax provision, including both current and deferred, related to U.S. federal and state income taxes, is $37. This is due to a change in law for the state of Illinois limiting the use of net loss deductions to $100 each year for tax years ending on or after December 31, 2021, and before December 31, 2024. Our current federal and deferred tax expenses are zero.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_898_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zFxKRLrSee2c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_zXpWWiYcYN36">A reconciliation of income tax expense to the amount computed by applying the Federal income tax rate to loss before provision for income taxes as of December 31, 2021 and 2020 is as follows:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="padding-left: 4pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49B_20210101__20211231_z0XwTAnFaTlg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49B_20200101__20201231_zX6W0quJQND3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_404_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzicN_zJMEcDG8pUmg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left; padding-left: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income tax credit at statutory rates</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">495</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">208</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_405_eus-gaap--IncomeTaxReconciliationNondeductibleExpense_maITEBzicN_zpX1QXegZoZ1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nondeductible expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0927">—</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationTaxExemptIncome_iN_di_msITEBzicN_zrgCW5YSuOE4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax Exempt Income - PPP Loan</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(271</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0931">—</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationMinorityInterestIncomeExpense_iN_di_msITEBzicN_zMt95BRG3K54" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Permanent Tax Deduction Stock Options Exercised</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(63</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0934">—</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzicN_zTOeMnEmPCK5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State income tax, net of federal benefits</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">177</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">74</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--InformationTechnologyAndDataProcessing_maITEBzicN_zWhpAr4AiKq1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expiration of NOL &amp; Credits</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">899</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,543</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationChangeInEnactedTaxRate_maITEBzicN_zygdL1SvvHqf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax basis in excess of book Convertible Debt</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0942">—</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0943">—</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_maITEBzicN_zKKf1tVArSF4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expiration of Stock Options</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">92</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">122</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--IncomeTaxReconciliationOtherAdjustments_maITEBzicN_zhCqR8PsxDlj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_405_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzicN_zqcQCuAlUQee" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 4pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change in valuation allowance</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,294</span></td><td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,945</span></td><td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_403_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzicN_zcsYavriSp8i" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 4pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif; display: none; visibility: hidden"> TOTAL</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">37</span></td><td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0955">—</span></span></td><td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A5_zwR7ezqmmMYf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p id="xdx_89A_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zEaBYNg8CjMf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. <span id="xdx_8BF_zuDFBfkELoqg">Significant components of our deferred income taxes consist of the following:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="font-weight: bold; text-align: center"> </td> <td id="xdx_499_20211231_za6cHyTxJvB7" style="font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; text-align: center"> </td> <td id="xdx_496_20201231_zSzkIU92y7Xe" style="font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40D_eus-gaap--DeferredTaxLiabilitiesAbstract_iB_zskF6M5aYO15" style="vertical-align: bottom"> <td style="text-align: left; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred tax liabilities:</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_409_eus-gaap--DeferredTaxLiabilitiesFinancingArrangements_iNI_pn3n3_di_maDTLzzT5_zwzLxlrWHu94" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">  Excess tax basis convertible debt</span></td><td style="width: 1%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0962">—</span></span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(257</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxLiabilities_iNI_pn3n3_di_mtDTLzzT5_msDTANzkIN_zbAOPA6YO4W5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">     Total deferred tax liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0965">—</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(257</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40C_eus-gaap--ComponentsOfDeferredTaxAssetsAbstract_iB_z6gsYDtHZkT5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred tax assets:</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGzqfm_z5495mCO5mic" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">  Net operating loss carryforwards</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14,566</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,597</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsInventory_iI_pn3n3_maDTAGzqfm_zKXNQ8ljWow3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">  Inventory and other allowances</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">148</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_409_eus-gaap--DeferredTaxAssetsCharitableContributionCarryforwards_iI_pn3n3_maDTAGzqfm_z9Cc9cGEiQD1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">  Charitable contribution &amp; other carryforwards</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0977">—</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_pn3n3_maDTAGzqfm_zXCA2zaYxbvj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">  Excess (tax) book depreciation</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">375</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_pn3n3_maDTAGzqfm_zMvVPLYYny0c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">  Excess (tax) book amortization</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_maDTAGzqfm_zzhLxCWHC5ki" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">  Share-based compensation</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">308</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">624</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_iI_pn3n3_maDTAGzqfm_zWhwFmg0wSm9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">  Other accrued costs</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">161</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">138</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsGross_iI_pn3n3_mtDTAGzqfm_maDTANzkIN_znF6bOndMGOi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">     Total deferred tax assets</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,277</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16,827</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTANzkIN_zUuXzkE9aye8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">  Less:  Valuation allowance</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(15,277</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(16,570</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_406_eus-gaap--DeferredTaxAssetsNet_iI_pn3n3_mtDTANzkIN_z8WGv2fL2YCa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred income taxes</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0998">—</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0999">—</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8AD_zVR8uAwdGpU9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The valuation allowance decreased approximately $<span id="xdx_90D_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn3n6_dc_c20210101__20211231_zyacJrGt4eN5" title="Increase (decrease) in valuation allowance">1.3</span> million and $<span id="xdx_900_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn3n6_dc_c20200101__20201231_z2UxX96teGJk">6.4</span> million for the years ended December 31, 2021 and 2020, respectively (net of approximately $<span id="xdx_90A_eus-gaap--TaxCreditCarryforwardValuationAllowance_iI_pn3n6_dc_c20211231_zoSEbaeWJhq9" title="Net operating loss carryforwards">1</span> million and $<span id="xdx_90C_eus-gaap--TaxCreditCarryforwardValuationAllowance_iI_pn3n6_dc_c20201231_zkSWb9H0rloe">6.3</span> million for the years ended December 31, 2021 and 2020, respectively, for expiring net operating loss carryforwards and credits) due principally to the change in the net operating loss carryforward and uncertainty as to whether future taxable income will be generated prior to the expiration of the carryforward period. Under the Internal Revenue Code, certain ownership changes, including the prior issuance of preferred stock and our public offering of common stock, may subject us to annual limitations on the utilization of our net operating loss carryforward. As of December 31, 2021, it has been determined that we are not subject to annual limitations on the utilization of our net operating loss carryforward.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have federal net operating loss carryforwards for tax purposes of approximately $<span id="xdx_906_eus-gaap--OperatingLossCarryforwards_iI_pn6n6_dc_c20211231_ze5xLJ68wqM2" title="Net operating loss carryforwards">62</span> million on December 31, 2021. $<span id="xdx_908_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwards_iI_pn6n6_dc_c20211231_zIWx24fCODj">57</span> million expire between <span id="xdx_900_ecustom--OperatingLossCarryforwardsExpirationYearStart_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zLzToDj8d1u" title="Capital loss carryforwards expiration period start">2022</span> and <span id="xdx_90E_ecustom--OperatingLossCarryforwardsExpirationYearEnd_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zZ40apZAT9z9" title="Capital loss carryforwards expiration period end">2037</span>. All net operating loss carryforwards generated after January 1, 2018 do not expire. Therefore, $<span id="xdx_90B_eus-gaap--OperatingLossCarryforwards_iI_pn3n6_dc_c20211231__us-gaap--ValuationAllowanceByDeferredTaxAssetAxis__custom--ExpiringOperatingLossCarryforwardsMember_zB3JSHnvr9i2">5</span> million in net operating losses generated since January 1, 2018 do not expire. We have Illinois net loss deduction carryforwards for tax purposes of approximately $<span id="xdx_903_eus-gaap--OperatingLossCarryforwards_iI_pn3n6_dc_c20211231__us-gaap--TaxPeriodAxis__us-gaap--TaxYear2012Member_zkYa0R6cJnd2">21</span> million on December 31, 2021. Due to the provisions of Illinois Public Act 102-0669 signed November 16, 2021, Illinois net loss deductions expire between <span id="xdx_901_ecustom--OperatingLossCarryforwardsExpirationYearStart_c20210101__20211231_zdq9m15RSRpb">2029</span> and <span id="xdx_90A_ecustom--OperatingLossCarryforwardsExpirationYearEnd_c20210101__20211231_z6pEQxfhl7zh">2039</span>.</span></p> <p id="xdx_898_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zFxKRLrSee2c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_zXpWWiYcYN36">A reconciliation of income tax expense to the amount computed by applying the Federal income tax rate to loss before provision for income taxes as of December 31, 2021 and 2020 is as follows:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="padding-left: 4pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49B_20210101__20211231_z0XwTAnFaTlg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49B_20200101__20201231_zX6W0quJQND3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_404_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzicN_zJMEcDG8pUmg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left; padding-left: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income tax credit at statutory rates</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">495</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">208</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_405_eus-gaap--IncomeTaxReconciliationNondeductibleExpense_maITEBzicN_zpX1QXegZoZ1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nondeductible expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0927">—</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationTaxExemptIncome_iN_di_msITEBzicN_zrgCW5YSuOE4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax Exempt Income - PPP Loan</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(271</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0931">—</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationMinorityInterestIncomeExpense_iN_di_msITEBzicN_zMt95BRG3K54" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Permanent Tax Deduction Stock Options Exercised</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(63</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0934">—</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzicN_zTOeMnEmPCK5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State income tax, net of federal benefits</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">177</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">74</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--InformationTechnologyAndDataProcessing_maITEBzicN_zWhpAr4AiKq1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expiration of NOL &amp; Credits</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">899</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,543</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationChangeInEnactedTaxRate_maITEBzicN_zygdL1SvvHqf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax basis in excess of book Convertible Debt</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0942">—</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0943">—</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_maITEBzicN_zKKf1tVArSF4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expiration of Stock Options</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">92</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">122</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--IncomeTaxReconciliationOtherAdjustments_maITEBzicN_zhCqR8PsxDlj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_405_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzicN_zqcQCuAlUQee" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 4pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change in valuation allowance</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,294</span></td><td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,945</span></td><td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_403_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzicN_zcsYavriSp8i" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 4pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif; display: none; visibility: hidden"> TOTAL</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">37</span></td><td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0955">—</span></span></td><td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 495000 208000 5000 271000 63000 177000 74000 899000 2543000 92000 122000 2000 -7000 -1294000 -2945000 37000 <p id="xdx_89A_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zEaBYNg8CjMf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. <span id="xdx_8BF_zuDFBfkELoqg">Significant components of our deferred income taxes consist of the following:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="font-weight: bold; text-align: center"> </td> <td id="xdx_499_20211231_za6cHyTxJvB7" style="font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; text-align: center"> </td> <td id="xdx_496_20201231_zSzkIU92y7Xe" style="font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40D_eus-gaap--DeferredTaxLiabilitiesAbstract_iB_zskF6M5aYO15" style="vertical-align: bottom"> <td style="text-align: left; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred tax liabilities:</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_409_eus-gaap--DeferredTaxLiabilitiesFinancingArrangements_iNI_pn3n3_di_maDTLzzT5_zwzLxlrWHu94" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">  Excess tax basis convertible debt</span></td><td style="width: 1%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0962">—</span></span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(257</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxLiabilities_iNI_pn3n3_di_mtDTLzzT5_msDTANzkIN_zbAOPA6YO4W5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">     Total deferred tax liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0965">—</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(257</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40C_eus-gaap--ComponentsOfDeferredTaxAssetsAbstract_iB_z6gsYDtHZkT5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred tax assets:</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGzqfm_z5495mCO5mic" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">  Net operating loss carryforwards</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14,566</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,597</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsInventory_iI_pn3n3_maDTAGzqfm_zKXNQ8ljWow3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">  Inventory and other allowances</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">148</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_409_eus-gaap--DeferredTaxAssetsCharitableContributionCarryforwards_iI_pn3n3_maDTAGzqfm_z9Cc9cGEiQD1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">  Charitable contribution &amp; other carryforwards</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0977">—</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_pn3n3_maDTAGzqfm_zXCA2zaYxbvj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">  Excess (tax) book depreciation</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">375</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_pn3n3_maDTAGzqfm_zMvVPLYYny0c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">  Excess (tax) book amortization</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_maDTAGzqfm_zzhLxCWHC5ki" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">  Share-based compensation</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">308</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">624</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_iI_pn3n3_maDTAGzqfm_zWhwFmg0wSm9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">  Other accrued costs</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">161</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">138</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsGross_iI_pn3n3_mtDTAGzqfm_maDTANzkIN_znF6bOndMGOi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">     Total deferred tax assets</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,277</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16,827</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTANzkIN_zUuXzkE9aye8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">  Less:  Valuation allowance</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(15,277</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(16,570</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_406_eus-gaap--DeferredTaxAssetsNet_iI_pn3n3_mtDTANzkIN_z8WGv2fL2YCa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred income taxes</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0998">—</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0999">—</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 257000 257000 14566000 15597000 148000 23000 9000 31000 375000 63000 61000 308000 624000 161000 138000 15277000 16827000 15277000 16570000 1300000 6400000 1000000 6300000 62000000 57000000 2022 2037 5000000 21000000 2029 2039 <p id="xdx_801_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_ztqI4bfD3Hig" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(9)</b></span></p></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span><span id="xdx_82F_zLDZhfbRjKO5">Capital Stock</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2021, and 2020, we had <span id="xdx_90B_eus-gaap--PreferredStockSharesAuthorized_iI_pii_uShares_c20211231_zFx1hEpc06Y6" title="Preferred stock, shares authorized"><span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_iI_pii_uShares_c20201231_zN9kz3DGKGf5" title="Preferred stock, shares authorized">24,088</span></span> authorized but unissued shares of preferred stock. In addition, as of December 31, 2020, we had <span id="xdx_90C_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pii_uShares_c20211231__us-gaap--PlanNameAxis__custom--PlanMember_zsTkKwKz2HJ3" title="Authorized, unissued shares of common stock">10,000,000</span> authorized but unissued shares of common stock reserved to meet the conversion requirement of the Convertible Note discussed in Note 3. These shares were issued at the conversion of this note in May of 2021.</span></p> 24088 24088 10000000 <p id="xdx_80B_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zgNzm2c94U8b" style="margin-top: 0; margin-bottom: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(10)</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82F_z9XfhXqfyNQe">Stock Options and Stock Grants</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have entered into stock option agreements with certain officers, employees and directors. The stock options granted prior to the adoption of the 2019 Equity Compensation Plan (the “2019 Plan”) on November 19, 2019 generally expire ten years from the date of grant. Future options to be granted under the 2019 Plan will expire <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20210101__20211231__us-gaap--PlanNameAxis__custom--EquityCompensationPlan2019Member_zEogC4cMhYm5" title="Shares based compensation payment award expiration period">seven years</span> from the date of grant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Employee Stock Options</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_894_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock_zt3qID1YaQZc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zx8qzKYR26Bf">We follow ASC Topic 718, Share-Based Payments, in which compensation expense is recognized only for share-based payments expected to vest.</span> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="font-weight: bold; text-align: center"> </td> <td id="xdx_49E_20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zLPw68xKfcif" style="font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; text-align: center"> </td> <td id="xdx_495_20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNCjqJhF16lb" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Years ended <br/> December 31,</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_405_eus-gaap--StockOptionPlanExpense_zcVIrXftH1Ld" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 34%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based compensation expense</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">160</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">195</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_402_eus-gaap--EmployeeStockOwnershipPlanESOPCompensationExpense_zkfNaYjb9trg" style="vertical-align: bottom; background-color: White"> <td><span style="font: 10pt Times New Roman, Times, Serif">Remaining unrecognized compensation expense</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,581</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Remaining weighted average-period, expense recognition (years)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dxL_c20210101__20211231_zQRwPPfl1z0k" title="Remaining weighted average-period, expense recognition (years)::XDX::P2Y10M25D"><span style="-sec-ix-hidden: xdx2ixbrl1038">2.9</span></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p style="margin-top: 0; margin-bottom: 0"> </p> <p id="xdx_8AF_zKfMDnyDdZfl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We use the Black-Scholes option pricing model to determine the fair value of stock-based compensation. The Black-Scholes model requires us to make several assumptions, including the estimated length of time employees will retain their vested stock options before exercising them (“expected term”), the estimated volatility of our common stock price over the expected term, and estimated forfeitures. Expected price volatility is based on the daily market rate changes of our stock. The active shares granted prior to fiscal 2020 had a contractual life of <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dt_c20210101__20211231__us-gaap--PlanNameAxis__custom--EquityCompensationPlan2010Member_zbtvoWPvWqoi" title="Shares based compensation payment award expiration period">10 years</span> as dictated by the 2010 Plan. The Black-Scholes model also requires a risk-free interest rate, which is based on the U.S. Treasury yield curve in effect at the time of the grant, and the dividend yield on our common stock, which is assumed to be zero since we do not pay dividends and have no current plans to do so in the future. Changes in these assumptions can materially affect the estimate of fair value of stock-based compensation and consequently, the related expense recognized on the statement of operations. We recognize stock-based compensation expense on a straight-line basis over the requisite service period. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_890_eus-gaap--ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_zV6hh8xSKMb3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table illustrates the various assumptions used to calculate the Black-Scholes option pricing model for options granted for all years presented:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B8_zjhTv0Rpqh1k" style="display: none; visibility: hidden">Schedule of assumptions used to calculate Black-Scholes option pricing model for options granted</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"><b> </b></td><td style="padding-bottom: 1pt"><b> </b></td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><b>Years Ended <br/> December 31,</b></td><td style="font-weight: bold; padding-bottom: 1pt"><b> </b></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> 2021</b></span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted-average risk-free interest rates:</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20210101__20211231_zkqm23QC30Ej" title="Weighted-average risk-free interest rates">1.4</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20200101__20201231_z7ngDvsuA16g" title="Weighted-average risk-free interest rates">0.5</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend yield:</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20210101__20211231_zOmZBsRq1qE1" title="Dividend yield">0</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20200101__20201231_zfnYKRkUbcc6" title="Dividend yield">0</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted-average expected life (years) of the option:</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231_znB6TULyCpmb" title="Weighted-average expected life (years) of the option">5</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231_ziTbTtaFK311" title="Weighted-average expected life (years) of the option">5</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted-average expected stock price volatility:</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pip0_dp_uPure_c20210101__20211231_z5M0W6epk5Id" title="Weighted-average expected stock price volatility">115</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pip0_dp_uPure_c20200101__20201231_zDhDFPbFiQnh" title="Weighted-average expected stock price volatility">95</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted-average fair value of the options granted:</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20210101__20211231_zRxi47tPn942" style="text-align: right" title="Weighted-average fair value of the options granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.59</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20200101__20201231_zNEk0cqOasJj" style="text-align: right" title="Weighted-average fair value of the options granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.28</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A2_zYO6OXjn6yv1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">  </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_893_ecustom--AdditionalDisclosuresForOptionsGrantedTableTextBlock_zjcybq8DSOT8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zL2QwXOEdns9">Additional disclosures for options granted for all years presented:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"><b> </b></td><td style="padding-bottom: 1pt"><b> </b></td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; padding-bottom: 1pt"><b>Years Ended <br/> December 31,</b></td><td style="font-weight: bold; padding-bottom: 1pt"><b> </b></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> 2021</b></span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2020</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vesting period (years) of shares granted in period</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dxL_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zFnliBRy81rl" style="width: 12%; text-align: right" title="Vesting period (years) of shares granted in period::XDX::P3Y"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1066">3</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dxL_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z7wGbXqnK4O9" style="width: 12%; text-align: right" title="Vesting period (years) of shares granted in period::XDX::P3Y"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1068">3</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contractual life (years) of shares granted in period</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardContractualLife_dxL_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zwEHM7j3Vjz1" style="text-align: right" title="Contractual life (years) of shares granted in period::XDX::P7Y"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1070">7</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardContractualLife_dtYxL_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zR2X4gnICgT2" style="text-align: right" title="Contractual life (years) of shares granted in period::XDX::P7Y"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1072">7</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimated forfeitures</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFortfeitureRate_pid_dp_uPure_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z3FUsDjF6bf3" style="text-align: right" title="Estimated forfeitures"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFortfeitureRate_pid_dp_uPure_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zinWvggg54m6" style="text-align: right" title="Estimated forfeitures"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> </table> <p id="xdx_8A2_zcZVbbG2ZHKg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zCiiAvbfkki7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the option activity for our employees and directors during the year ended December 31, 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span id="xdx_8B5_zvJKmWLt00Tj" style="display: none; visibility: hidden">Schedule of option activity</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options</span></td><td style="font-weight: bold; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares <br/> (Rounded)</span></td><td style="font-weight: bold; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted <br/> Average <br/> Exercise <br/> Price <br/> per Share</span></td><td style="font-weight: bold; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted <br/> Average <br/> Remaining<br/> Contractual <br/> Term (Years)</span></td><td style="font-weight: bold; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aggregate <br/> Intrinsic <br/> Value <br/> (000s)</span></td><td style="font-weight: bold; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding on January 1, 2021</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20210101__20211231_zVSVJYgQh2yg" style="width: 10%; text-align: right" title="Shares Outstanding, Beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,412,686</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20210101__20211231_zK8NY8T0wgw5" style="width: 10%; text-align: right" title="Shares Outstanding Beginning, (per share)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.57</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210101__20211231_zhNFmUCE0dm2" style="text-align: right" title="Granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">567,500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20210101__20211231_z5Bl0XR06EN6" style="text-align: right" title="Granted (per share)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.14</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20210101__20211231_zJKwktyYyeT4" style="text-align: right" title="Exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(535,100</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20210101__20211231_zFkAsbN8WDLl" style="text-align: right" title="Exercised (per share)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.44</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited or expired</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20210101__20211231_z3ILrBqbCl6c" style="border-bottom: Black 1pt solid; text-align: right" title="Forfeited or expired"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(251,870</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20210101__20211231_zhb3lLrnc7n4" style="text-align: right" title="Forfeited or expired (per share)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.09</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding on December 31, 2021</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20210101__20211231_zIksghtsyld1" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares Outstanding, Beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,193,216</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20210101__20211231_zK6KRGtCCfw9" style="text-align: right" title="Shares Outstanding Ending, (per share)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.18</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dxL_c20210101__20211231_zCDs2Wwclhn5" style="text-align: right" title="Shares Outstanding (years)::XDX::P5Y1M6D"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1100">5.1</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20211231_zaRDoyy7FDJ3" style="text-align: right" title="Shares Outstanding (Intrinsic value)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,267</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable on December 31, 2021</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20210101__20211231_zE3FUOsoysYf" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,189,378</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20210101__20211231_znGrsZZh5iQ1" style="text-align: right" title="Shares Exercisable, (per share)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.56</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dxL_c20210101__20211231_zdGlYNX5WFMe" style="text-align: right" title="Shares Exercisable (years)::XDX::P4Y4M24D"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1108">4.4</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20211231_zlutfritDjP8" style="text-align: right" title="Shares Exercisable (Intrinsic value)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,405</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares available for grant</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20211231_zxYrhuv6X3L6" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares for grants"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,887,500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A7_zj6wb2aNvMq3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_ecustom--StockOptionsRecognizedTableTextBlock_z3o80CF08mt9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The aggregate intrinsic value in the table above is based on our closing stock price of $<span id="xdx_90C_eus-gaap--SharePrice_iI_pid_uUSDPShares_c20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zF7jfWXiCvt4">4.40</span> on the last business day for the year ended December 31, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; visibility: visible; text-align: justify; text-indent: 0.5in"><span style="visibility: visible; font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; visibility: visible; border-collapse: collapse; width: 60%" summary="xdx: Disclosure - Stock Options Recognized"> <tr style="visibility: visible; vertical-align: bottom"> <td style="visibility: visible; padding-bottom: 1pt"> </td><td style="visibility: visible; font-weight: bold; padding-bottom: 1pt"> </td> <td style="visibility: visible; font-weight: bold; text-align: center"> </td> <td id="xdx_491_20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zpjWjo3wC7A3" style="visibility: visible; font-weight: bold; text-align: center"> </td> <td style="visibility: visible; font-weight: bold; text-align: center"> </td> <td style="visibility: visible; font-weight: bold; text-align: center"> </td> <td colspan="2" id="xdx_492_20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_ztpqox9wayA5" style="visibility: visible; font-weight: bold; text-align: center"> </td><td style="visibility: visible; padding-bottom: 1pt"> </td></tr> <tr style="visibility: visible; vertical-align: bottom"> <td style="visibility: visible; padding-bottom: 1pt"><span style="visibility: visible; font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="visibility: visible; font-weight: bold; padding-bottom: 1pt"><span style="visibility: visible; font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; visibility: visible; font-weight: bold; text-align: center"><span style="visibility: visible; font-family: Times New Roman, Times, Serif; font-size: 10pt">Years ended <br/> December 31,</span></td><td style="visibility: visible; padding-bottom: 1pt"><span style="visibility: visible; font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="visibility: visible; vertical-align: bottom"> <td style="visibility: visible; padding-bottom: 1pt"><span style="visibility: visible; font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="visibility: visible; font-weight: bold; padding-bottom: 1pt"><span style="visibility: visible; font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; visibility: visible; font-weight: bold; text-align: center"><span style="visibility: visible; font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="visibility: visible; font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="visibility: visible; font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="visibility: visible; font-weight: bold; padding-bottom: 1pt"><span style="visibility: visible; font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; visibility: visible; font-weight: bold; text-align: center"><span style="visibility: visible; font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="visibility: visible; font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="visibility: visible; font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_zu91UOE0LG5e" style="visibility: visible; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="visibility: visible; width: 30%"><span style="visibility: visible; font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares exercised</span></td><td style="visibility: visible; width: 1%"><span style="visibility: visible; font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="visibility: visible; width: 1%; text-align: left"><span style="visibility: visible; font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="visibility: visible; width: 12%; text-align: right"><span style="visibility: visible; font-family: Times New Roman, Times, Serif; font-size: 10pt">535,100</span></td><td style="visibility: visible; width: 1%; text-align: left"><span style="visibility: visible; font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="visibility: visible; width: 1%"><span style="visibility: visible; font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="visibility: visible; width: 1%; text-align: left"><span style="visibility: visible; font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="visibility: visible; width: 12%; text-align: right"><span style="visibility: visible; font-family: Times New Roman, Times, Serif; font-size: 10pt">84,500</span></td><td style="visibility: visible; width: 1%; text-align: left"><span style="visibility: visible; font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_zmeGNYtsgnsg" style="visibility: visible; vertical-align: bottom; background-color: White"> <td style="visibility: visible"><span style="visibility: visible; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total intrinsic value</span></td><td style="visibility: visible"><span style="visibility: visible; font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="visibility: visible; text-align: left"><span style="visibility: visible; font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="visibility: visible; text-align: right"><span style="visibility: visible; font-family: Times New Roman, Times, Serif; font-size: 10pt">1,169</span></td><td style="visibility: visible; text-align: left"><span style="visibility: visible; font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="visibility: visible"><span style="visibility: visible; font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="visibility: visible; text-align: left"><span style="visibility: visible; font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="visibility: visible; text-align: right"><span style="visibility: visible; font-family: Times New Roman, Times, Serif; font-size: 10pt">10</span></td><td style="visibility: visible; text-align: left"><span style="visibility: visible; font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40C_eus-gaap--ProceedsFromStockOptionsExercised_ziE40tfIfbDf" style="visibility: visible; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="visibility: visible; text-align: left"><span style="visibility: visible; font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash received</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">234</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">37</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A3_zw1aREnzUzQ7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on our election of the “with and without” approach, no realized tax benefits from stock options were recognized for the years ended December 31, 2021 and 2020.</span></p> P7Y <p id="xdx_894_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock_zt3qID1YaQZc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zx8qzKYR26Bf">We follow ASC Topic 718, Share-Based Payments, in which compensation expense is recognized only for share-based payments expected to vest.</span> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="font-weight: bold; text-align: center"> </td> <td id="xdx_49E_20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zLPw68xKfcif" style="font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; text-align: center"> </td> <td id="xdx_495_20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNCjqJhF16lb" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Years ended <br/> December 31,</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_405_eus-gaap--StockOptionPlanExpense_zcVIrXftH1Ld" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 34%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based compensation expense</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">160</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">195</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_402_eus-gaap--EmployeeStockOwnershipPlanESOPCompensationExpense_zkfNaYjb9trg" style="vertical-align: bottom; background-color: White"> <td><span style="font: 10pt Times New Roman, Times, Serif">Remaining unrecognized compensation expense</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,581</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Remaining weighted average-period, expense recognition (years)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dxL_c20210101__20211231_zQRwPPfl1z0k" title="Remaining weighted average-period, expense recognition (years)::XDX::P2Y10M25D"><span style="-sec-ix-hidden: xdx2ixbrl1038">2.9</span></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p style="margin-top: 0; margin-bottom: 0"> </p> 160000 195000 1581000 P10Y <p id="xdx_890_eus-gaap--ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_zV6hh8xSKMb3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table illustrates the various assumptions used to calculate the Black-Scholes option pricing model for options granted for all years presented:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B8_zjhTv0Rpqh1k" style="display: none; visibility: hidden">Schedule of assumptions used to calculate Black-Scholes option pricing model for options granted</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"><b> </b></td><td style="padding-bottom: 1pt"><b> </b></td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><b>Years Ended <br/> December 31,</b></td><td style="font-weight: bold; padding-bottom: 1pt"><b> </b></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> 2021</b></span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted-average risk-free interest rates:</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20210101__20211231_zkqm23QC30Ej" title="Weighted-average risk-free interest rates">1.4</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20200101__20201231_z7ngDvsuA16g" title="Weighted-average risk-free interest rates">0.5</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend yield:</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20210101__20211231_zOmZBsRq1qE1" title="Dividend yield">0</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20200101__20201231_zfnYKRkUbcc6" title="Dividend yield">0</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted-average expected life (years) of the option:</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231_znB6TULyCpmb" title="Weighted-average expected life (years) of the option">5</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231_ziTbTtaFK311" title="Weighted-average expected life (years) of the option">5</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted-average expected stock price volatility:</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pip0_dp_uPure_c20210101__20211231_z5M0W6epk5Id" title="Weighted-average expected stock price volatility">115</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pip0_dp_uPure_c20200101__20201231_zDhDFPbFiQnh" title="Weighted-average expected stock price volatility">95</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted-average fair value of the options granted:</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20210101__20211231_zRxi47tPn942" style="text-align: right" title="Weighted-average fair value of the options granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.59</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20200101__20201231_zNEk0cqOasJj" style="text-align: right" title="Weighted-average fair value of the options granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.28</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 0.014 0.005 0 0 P5Y P5Y 1.15 0.95 2.59 0.28 <p id="xdx_893_ecustom--AdditionalDisclosuresForOptionsGrantedTableTextBlock_zjcybq8DSOT8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zL2QwXOEdns9">Additional disclosures for options granted for all years presented:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"><b> </b></td><td style="padding-bottom: 1pt"><b> </b></td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; padding-bottom: 1pt"><b>Years Ended <br/> December 31,</b></td><td style="font-weight: bold; padding-bottom: 1pt"><b> </b></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> 2021</b></span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2020</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vesting period (years) of shares granted in period</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dxL_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zFnliBRy81rl" style="width: 12%; text-align: right" title="Vesting period (years) of shares granted in period::XDX::P3Y"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1066">3</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dxL_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z7wGbXqnK4O9" style="width: 12%; text-align: right" title="Vesting period (years) of shares granted in period::XDX::P3Y"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1068">3</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contractual life (years) of shares granted in period</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardContractualLife_dxL_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zwEHM7j3Vjz1" style="text-align: right" title="Contractual life (years) of shares granted in period::XDX::P7Y"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1070">7</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardContractualLife_dtYxL_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zR2X4gnICgT2" style="text-align: right" title="Contractual life (years) of shares granted in period::XDX::P7Y"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1072">7</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimated forfeitures</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFortfeitureRate_pid_dp_uPure_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z3FUsDjF6bf3" style="text-align: right" title="Estimated forfeitures"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFortfeitureRate_pid_dp_uPure_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zinWvggg54m6" style="text-align: right" title="Estimated forfeitures"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> </table> 0.04 0.04 <p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zCiiAvbfkki7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the option activity for our employees and directors during the year ended December 31, 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span id="xdx_8B5_zvJKmWLt00Tj" style="display: none; visibility: hidden">Schedule of option activity</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options</span></td><td style="font-weight: bold; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares <br/> (Rounded)</span></td><td style="font-weight: bold; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted <br/> Average <br/> Exercise <br/> Price <br/> per Share</span></td><td style="font-weight: bold; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted <br/> Average <br/> Remaining<br/> Contractual <br/> Term (Years)</span></td><td style="font-weight: bold; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aggregate <br/> Intrinsic <br/> Value <br/> (000s)</span></td><td style="font-weight: bold; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding on January 1, 2021</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20210101__20211231_zVSVJYgQh2yg" style="width: 10%; text-align: right" title="Shares Outstanding, Beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,412,686</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20210101__20211231_zK8NY8T0wgw5" style="width: 10%; text-align: right" title="Shares Outstanding Beginning, (per share)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.57</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210101__20211231_zhNFmUCE0dm2" style="text-align: right" title="Granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">567,500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20210101__20211231_z5Bl0XR06EN6" style="text-align: right" title="Granted (per share)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.14</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20210101__20211231_zJKwktyYyeT4" style="text-align: right" title="Exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(535,100</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20210101__20211231_zFkAsbN8WDLl" style="text-align: right" title="Exercised (per share)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.44</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited or expired</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20210101__20211231_z3ILrBqbCl6c" style="border-bottom: Black 1pt solid; text-align: right" title="Forfeited or expired"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(251,870</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20210101__20211231_zhb3lLrnc7n4" style="text-align: right" title="Forfeited or expired (per share)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.09</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding on December 31, 2021</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20210101__20211231_zIksghtsyld1" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares Outstanding, Beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,193,216</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20210101__20211231_zK6KRGtCCfw9" style="text-align: right" title="Shares Outstanding Ending, (per share)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.18</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dxL_c20210101__20211231_zCDs2Wwclhn5" style="text-align: right" title="Shares Outstanding (years)::XDX::P5Y1M6D"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1100">5.1</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20211231_zaRDoyy7FDJ3" style="text-align: right" title="Shares Outstanding (Intrinsic value)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,267</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable on December 31, 2021</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20210101__20211231_zE3FUOsoysYf" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,189,378</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20210101__20211231_znGrsZZh5iQ1" style="text-align: right" title="Shares Exercisable, (per share)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.56</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dxL_c20210101__20211231_zdGlYNX5WFMe" style="text-align: right" title="Shares Exercisable (years)::XDX::P4Y4M24D"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1108">4.4</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20211231_zlutfritDjP8" style="text-align: right" title="Shares Exercisable (Intrinsic value)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,405</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares available for grant</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20211231_zxYrhuv6X3L6" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares for grants"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,887,500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 3412686 0.57 567500 4.14 535100 0.44 251870 1.09 3193216 1.18 10267000 2189378 0.56 8405000 1887500 <p id="xdx_899_ecustom--StockOptionsRecognizedTableTextBlock_z3o80CF08mt9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The aggregate intrinsic value in the table above is based on our closing stock price of $<span id="xdx_90C_eus-gaap--SharePrice_iI_pid_uUSDPShares_c20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zF7jfWXiCvt4">4.40</span> on the last business day for the year ended December 31, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; visibility: visible; text-align: justify; text-indent: 0.5in"><span style="visibility: visible; font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; visibility: visible; border-collapse: collapse; width: 60%" summary="xdx: Disclosure - Stock Options Recognized"> <tr style="visibility: visible; vertical-align: bottom"> <td style="visibility: visible; padding-bottom: 1pt"> </td><td style="visibility: visible; font-weight: bold; padding-bottom: 1pt"> </td> <td style="visibility: visible; font-weight: bold; text-align: center"> </td> <td id="xdx_491_20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zpjWjo3wC7A3" style="visibility: visible; font-weight: bold; text-align: center"> </td> <td style="visibility: visible; font-weight: bold; text-align: center"> </td> <td style="visibility: visible; font-weight: bold; text-align: center"> </td> <td colspan="2" id="xdx_492_20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_ztpqox9wayA5" style="visibility: visible; font-weight: bold; text-align: center"> </td><td style="visibility: visible; padding-bottom: 1pt"> </td></tr> <tr style="visibility: visible; vertical-align: bottom"> <td style="visibility: visible; padding-bottom: 1pt"><span style="visibility: visible; font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="visibility: visible; font-weight: bold; padding-bottom: 1pt"><span style="visibility: visible; font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; visibility: visible; font-weight: bold; text-align: center"><span style="visibility: visible; font-family: Times New Roman, Times, Serif; font-size: 10pt">Years ended <br/> December 31,</span></td><td style="visibility: visible; padding-bottom: 1pt"><span style="visibility: visible; font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="visibility: visible; vertical-align: bottom"> <td style="visibility: visible; padding-bottom: 1pt"><span style="visibility: visible; font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="visibility: visible; font-weight: bold; padding-bottom: 1pt"><span style="visibility: visible; font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; visibility: visible; font-weight: bold; text-align: center"><span style="visibility: visible; font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="visibility: visible; font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="visibility: visible; font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="visibility: visible; font-weight: bold; padding-bottom: 1pt"><span style="visibility: visible; font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; visibility: visible; font-weight: bold; text-align: center"><span style="visibility: visible; font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="visibility: visible; font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="visibility: visible; font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_zu91UOE0LG5e" style="visibility: visible; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="visibility: visible; width: 30%"><span style="visibility: visible; font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares exercised</span></td><td style="visibility: visible; width: 1%"><span style="visibility: visible; font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="visibility: visible; width: 1%; text-align: left"><span style="visibility: visible; font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="visibility: visible; width: 12%; text-align: right"><span style="visibility: visible; font-family: Times New Roman, Times, Serif; font-size: 10pt">535,100</span></td><td style="visibility: visible; width: 1%; text-align: left"><span style="visibility: visible; font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="visibility: visible; width: 1%"><span style="visibility: visible; font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="visibility: visible; width: 1%; text-align: left"><span style="visibility: visible; font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="visibility: visible; width: 12%; text-align: right"><span style="visibility: visible; font-family: Times New Roman, Times, Serif; font-size: 10pt">84,500</span></td><td style="visibility: visible; width: 1%; text-align: left"><span style="visibility: visible; font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_zmeGNYtsgnsg" style="visibility: visible; vertical-align: bottom; background-color: White"> <td style="visibility: visible"><span style="visibility: visible; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total intrinsic value</span></td><td style="visibility: visible"><span style="visibility: visible; font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="visibility: visible; text-align: left"><span style="visibility: visible; font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="visibility: visible; text-align: right"><span style="visibility: visible; font-family: Times New Roman, Times, Serif; font-size: 10pt">1,169</span></td><td style="visibility: visible; text-align: left"><span style="visibility: visible; font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="visibility: visible"><span style="visibility: visible; font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="visibility: visible; text-align: left"><span style="visibility: visible; font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="visibility: visible; text-align: right"><span style="visibility: visible; font-family: Times New Roman, Times, Serif; font-size: 10pt">10</span></td><td style="visibility: visible; text-align: left"><span style="visibility: visible; font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40C_eus-gaap--ProceedsFromStockOptionsExercised_ziE40tfIfbDf" style="visibility: visible; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="visibility: visible; text-align: left"><span style="visibility: visible; font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash received</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">234</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">37</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 535100 84500 1169000 10000 234000 37000 <p id="xdx_80D_eus-gaap--PensionAndOtherPostretirementBenefitsDisclosureTextBlock_zjfzgYH79rZ6" style="margin-top: 0; margin-bottom: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(11)</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_829_z3cSSYs53M41">401(k) Profit-Sharing Plan</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have a 401(k) profit-sharing plan covering substantially all employees who meet defined service requirements. During 2020, we maintained a Company contribution program, in which <span id="xdx_903_eus-gaap--DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_dp_c20210101__20211231_zoN4WM7H0d7d" title="Employer's matching contribution percentage">10</span>% of the first <span id="xdx_902_eus-gaap--DefinedContributionPlanEmployerMatchingContributionPercent_dp_c20210101__20211231_zcPLpifZFEGk" title="Percentage of employee's matching contribution">8</span>% of any employee’s was matched (for a match of up to <span id="xdx_90C_ecustom--DefinedContributionPlanEmployerMatchingContributionPercentOfSalary_c20210101__20211231_zrqLB6yZUaEh" title="Participant salary percentage matched">0.8</span>% of a participant’s salary). In 2021, we implemented a new Company match program, in which the Company matches the first 3% of eligible pay that any employee contributes on a dollar-for-dollar basis. Contributions made in 2021 and 2020 aggregated to $<span id="xdx_90E_eus-gaap--DefinedContributionPlanCostRecognized_c20210101__20211231_zzOluRoFDlci">107</span> and $<span id="xdx_90D_eus-gaap--DefinedContributionPlanCostRecognized_c20200101__20201231_z5I9R0Y9xza7">21</span>, respectively.</span></p> 0.10 0.08 0.8 107 21 <p id="xdx_801_eus-gaap--ConcentrationRiskDisclosureTextBlock_zFoiFh7oOqe1" style="margin-top: 0; margin-bottom: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(12)</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_828_zbJtA5BrZWTj">Significant Customers and Contingencies</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.3pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_892_eus-gaap--SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_zuK2bMSYhM1f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.3pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zrpgkzHobzu6">We had five significant customers for the year ended December 31, 2021.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.3pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td style="text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the years ended <br/> December 31,</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer #</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Product Category</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 33%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Personal Care Ingredients</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zVvV9IWxkJzh" title="Revenue from customers">26</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20200101__20201231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerOneMember_ztDQIlE4tbL" title="Revenue from customers">30</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Solésence®</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zBTZlP4N69W7" title="Revenue from customers">19</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20200101__20201231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zC5rTwHU0zyj" title="Revenue from customers">14</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Solésence®</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerThreeMember_zRuPK2quBNSh" title="Revenue from customers">15</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20200101__20201231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerThreeMember_zJVRUcrzJ11f" title="Revenue from customers">11</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Solésence®</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerFourMember_zC5gAACPzi43" title="Revenue from customers">10</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20200101__20201231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerFourMember_zWTqzQoiUbkh" title="Revenue from customers">5</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advanced Materials (Medical Diagnostics customer)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerFiveMember_z4LiwLp2LJUh" title="Revenue from customers">8</span></span></td><td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20200101__20201231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerFiveMember_zRHZhIA8fFnk" title="Revenue from customers">20</span></span></td><td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="padding-bottom: 2.5pt; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomersOneThroughFiveMember_zvlX6U4gZZ93" title="Revenue from customers">78</span></span></td><td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20200101__20201231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomersOneThroughFiveMember_zfgwsdAUCBy" title="Revenue from customers">80</span></span></td><td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> </table> <p id="xdx_8A1_ziYz4iDK0Ac9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.3pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><br/></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.3pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89D_ecustom--ContractWithCustomerAccountReceivablesTableTextBlock_zZOPY25Fpr65" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BB_zu4Xk45UTcNj">Accounts receivable balances for these five customers were approximately:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td style="text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the years ended</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31,</span></p></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer #</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Product Category</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 33%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Personal Care Ingredients</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_c20211231__srt--MajorCustomersAxis__custom--CustomerOneMember_z6foYLRN2IAb" style="width: 10%; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">641</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_c20201231__srt--MajorCustomersAxis__custom--CustomerOneMember_zIe4NCbbMXw9" style="width: 10%; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">381</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Solésence®</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98F_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_c20211231__srt--MajorCustomersAxis__custom--CustomerTwoMember_zkyMAMx8sBLk" style="text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">534</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98E_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_c20201231__srt--MajorCustomersAxis__custom--CustomerTwoMember_z6IN9fuitond" style="text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">342</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Solésence®</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_987_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_c20211231__srt--MajorCustomersAxis__custom--CustomerThreeMember_zYD76qgPDLS" style="text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,048</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_981_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_c20201231__srt--MajorCustomersAxis__custom--CustomerThreeMember_zQAT3rtus9yf" style="text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">116</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Solésence®</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_c20211231__srt--MajorCustomersAxis__custom--CustomerFourMember_znM5wY7ZXYZ1" style="text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">239</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_987_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_c20201231__srt--MajorCustomersAxis__custom--CustomerFourMember_zDTy6JSm8Yzk" style="text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">863</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advanced Materials (Medical Diagnostics customer)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_986_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_c20211231__srt--MajorCustomersAxis__custom--CustomerFiveMember_zTFDIvhOv0Eg" style="border-bottom: Black 1pt solid; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-0-</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_c20201231__srt--MajorCustomersAxis__custom--CustomerFiveMember_zICmHGjYAFVi" style="border-bottom: Black 1pt solid; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">735</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="padding-bottom: 2.5pt; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_c20211231_z6J13VuZlZpj" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,462</span></td><td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_982_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_c20201231_zByuqzql0ZU5" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,437</span></td><td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8AD_z3hZBpFPSj44" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3pt; text-align: justify; text-indent: 35.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3pt; text-align: justify; text-indent: 35.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We currently have exclusive supply agreements with BASF Corporation (“BASF”), our largest customer, that have contingencies outlined which could potentially result in the license of technology and/or the sale of production equipment from the Company to the customer intended to provide capacity sufficient to meet the customer’s production needs. This outcome may occur if we fail to meet certain performance requirements. Our supply agreements with BASF also “trigger” a technology transfer right in the event of our insolvency, as further defined within the agreements. In the event of an equipment sale, upon incurring a triggering event, the equipment would be sold to the customer at either <span id="xdx_901_ecustom--EquipmentSaleNetBookValueEquipment_iI_dp_c20211231__us-gaap--SupplyCommitmentAxis__us-gaap--SupplyCommitmentMember_zdfZZucyGe92" title="Equipment sale - net book value">115</span>% of the equipment’s net book value or the greater of <span id="xdx_90F_ecustom--EquipmentSaleOriginalBookValueOfEquipmentAndUpgrades_iI_dp_c20211231__us-gaap--SupplyCommitmentAxis__us-gaap--SupplyCommitmentMember_z5VbFOnqqS52" title="Equipment sale- original book value">30</span>% of the original book value of such equipment, and any associated upgrades to it, or <span id="xdx_901_ecustom--EquipmentSaleNetBookValueEquipment_iI_dp_c20211231_zVKnkiFcxfxc" title="Equipment sale - net book value">115</span>% of the equipment’s net book value, depending on the equipment and related products.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3pt; text-align: justify; text-indent: 35.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If a triggering event were to occur and BASF elected to proceed with the license and related equipment sale mentioned above, we would receive royalty payments from this customer for products sold using our technology; however, we would lose both significant revenue and the ability to generate significant revenue to replace that which was lost in the near term. Replacement of necessary equipment that could be purchased and removed by the customer pursuant to this triggering event could take in excess of twelve months. Any additional capital outlays required to rebuild capacity would probably be greater than the proceeds from the purchase of the assets as dictated by our agreement with the customer. Similar consequences would occur if we were determined to have materially breached certain other provisions of the supply agreement with BASF. Any such event would also likely result in the loss of many of our key staff and line employees due to economic realities. We believe that our employees are a critical component of our success, and it could be difficult to replace them quickly. Given the occurrence of any such event, we might not be able to hire and retain skilled employees given the stigma relating to such an event and its impact on us.</span></p> <p id="xdx_892_eus-gaap--SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_zuK2bMSYhM1f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.3pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zrpgkzHobzu6">We had five significant customers for the year ended December 31, 2021.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.3pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td style="text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the years ended <br/> December 31,</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer #</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Product Category</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 33%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Personal Care Ingredients</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zVvV9IWxkJzh" title="Revenue from customers">26</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20200101__20201231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerOneMember_ztDQIlE4tbL" title="Revenue from customers">30</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Solésence®</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zBTZlP4N69W7" title="Revenue from customers">19</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20200101__20201231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zC5rTwHU0zyj" title="Revenue from customers">14</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Solésence®</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerThreeMember_zRuPK2quBNSh" title="Revenue from customers">15</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20200101__20201231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerThreeMember_zJVRUcrzJ11f" title="Revenue from customers">11</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Solésence®</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerFourMember_zC5gAACPzi43" title="Revenue from customers">10</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20200101__20201231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerFourMember_zWTqzQoiUbkh" title="Revenue from customers">5</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advanced Materials (Medical Diagnostics customer)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerFiveMember_z4LiwLp2LJUh" title="Revenue from customers">8</span></span></td><td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20200101__20201231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerFiveMember_zRHZhIA8fFnk" title="Revenue from customers">20</span></span></td><td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="padding-bottom: 2.5pt; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomersOneThroughFiveMember_zvlX6U4gZZ93" title="Revenue from customers">78</span></span></td><td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20200101__20201231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomersOneThroughFiveMember_zfgwsdAUCBy" title="Revenue from customers">80</span></span></td><td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> </table> 0.26 0.30 0.19 0.14 0.15 0.11 0.10 0.05 0.08 0.20 0.78 0.80 <p id="xdx_89D_ecustom--ContractWithCustomerAccountReceivablesTableTextBlock_zZOPY25Fpr65" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BB_zu4Xk45UTcNj">Accounts receivable balances for these five customers were approximately:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td style="text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the years ended</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31,</span></p></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer #</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Product Category</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 33%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Personal Care Ingredients</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_c20211231__srt--MajorCustomersAxis__custom--CustomerOneMember_z6foYLRN2IAb" style="width: 10%; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">641</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_c20201231__srt--MajorCustomersAxis__custom--CustomerOneMember_zIe4NCbbMXw9" style="width: 10%; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">381</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Solésence®</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98F_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_c20211231__srt--MajorCustomersAxis__custom--CustomerTwoMember_zkyMAMx8sBLk" style="text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">534</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98E_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_c20201231__srt--MajorCustomersAxis__custom--CustomerTwoMember_z6IN9fuitond" style="text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">342</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Solésence®</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_987_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_c20211231__srt--MajorCustomersAxis__custom--CustomerThreeMember_zYD76qgPDLS" style="text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,048</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_981_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_c20201231__srt--MajorCustomersAxis__custom--CustomerThreeMember_zQAT3rtus9yf" style="text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">116</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Solésence®</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_c20211231__srt--MajorCustomersAxis__custom--CustomerFourMember_znM5wY7ZXYZ1" style="text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">239</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_987_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_c20201231__srt--MajorCustomersAxis__custom--CustomerFourMember_zDTy6JSm8Yzk" style="text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">863</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advanced Materials (Medical Diagnostics customer)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_986_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_c20211231__srt--MajorCustomersAxis__custom--CustomerFiveMember_zTFDIvhOv0Eg" style="border-bottom: Black 1pt solid; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-0-</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_c20201231__srt--MajorCustomersAxis__custom--CustomerFiveMember_zICmHGjYAFVi" style="border-bottom: Black 1pt solid; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">735</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="padding-bottom: 2.5pt; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_c20211231_z6J13VuZlZpj" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,462</span></td><td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_982_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_c20201231_zByuqzql0ZU5" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,437</span></td><td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 641000 381000 534000 342000 1048000 116000 239000 863000 735000 2462000 2437000 1.15 0.30 1.15 <p id="xdx_800_eus-gaap--SegmentReportingDisclosureTextBlock_zrOpcuQG11md" style="margin-top: 0; margin-bottom: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(13)</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_829_zjiRvpTHoJK">Business Segmentation and Geographical Distribution</span> </b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue from international sources approximated $<span id="xdx_90E_eus-gaap--Revenues_pn3n3_c20210101__20211231__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zVFbWyHa9E97">3,236</span> and $<span id="xdx_904_eus-gaap--Revenues_pn3n3_c20200101__20201231__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zL2rjd8iqZ8e">3,714</span> for the years ended December 31, 2021 and 2020, respectively. As part of our revenue from international sources, we recognized approximately $<span id="xdx_90C_eus-gaap--Revenues_pn3n3_c20210101__20211231__srt--ProductOrServiceAxis__us-gaap--ProductMember_zqIWqfrZvPqf">2,335</span> and $<span id="xdx_908_eus-gaap--Revenues_pn3n3_c20200101__20201231__srt--ProductOrServiceAxis__us-gaap--ProductMember_zytUugZa29je">3,450</span> in product revenue from German companies, in the aggregate, for the years ended December 31, 2021 and 2020, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_892_eus-gaap--DisaggregationOfRevenueTableTextBlock_zvaLCDbH53Nl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Operations comprise a single business segment and all of our long-lived assets are located within the United States. We categorize our revenue stream into three main product categories, Personal Care Ingredients, Advanced Materials and Solésence. <span id="xdx_8BF_zRdZcSdAPs7c">The revenues for 2021 and 2020 by category are as follows:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the years ended </b> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31</b> </span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Product Category</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Solésence</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20211231__srt--ProductOrServiceAxis__custom--PersonalCareIngredientsMember_zOAf5M19cewg" style="width: 10%; text-align: right" title="Total revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18,175</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20201231__srt--ProductOrServiceAxis__custom--PersonalCareIngredientsMember_zuuYNsYnlpR" style="width: 10%; text-align: right" title="Total revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,737</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Personal Care Ingredients</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20211231__srt--ProductOrServiceAxis__custom--AdvancedMaterialsMember_zWKX3RuDs5jc" style="text-align: right" title="Total revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,739</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--ProductOrServiceAxis__custom--AdvancedMaterialsMember_zpB61E2Tpmnd" style="text-align: right" title="Total revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,536</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advanced Materials</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20211231__srt--ProductOrServiceAxis__custom--SolesenceMember_zqrkE4Dr4n36" style="border-bottom: Black 1pt solid; text-align: right" title="Total revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,561</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20201231__srt--ProductOrServiceAxis__custom--SolesenceMember_z4j9sUNgXys5" style="border-bottom: Black 1pt solid; text-align: right" title="Total revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,850</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total Sales</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20211231_zE6FJbMivBoj" style="border-bottom: Black 2.5pt double; text-align: right" title="Total revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29,475</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20201231_zQXxYY5Gxs35" style="border-bottom: Black 2.5pt double; text-align: right" title="Total revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17,123</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A1_zdkadeOBZHZh" style="margin-top: 0; margin-bottom: 0"> </p> 3236000 3714000 2335000 3450000 <p id="xdx_892_eus-gaap--DisaggregationOfRevenueTableTextBlock_zvaLCDbH53Nl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Operations comprise a single business segment and all of our long-lived assets are located within the United States. We categorize our revenue stream into three main product categories, Personal Care Ingredients, Advanced Materials and Solésence. <span id="xdx_8BF_zRdZcSdAPs7c">The revenues for 2021 and 2020 by category are as follows:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the years ended </b> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31</b> </span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Product Category</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Solésence</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20211231__srt--ProductOrServiceAxis__custom--PersonalCareIngredientsMember_zOAf5M19cewg" style="width: 10%; text-align: right" title="Total revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18,175</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20201231__srt--ProductOrServiceAxis__custom--PersonalCareIngredientsMember_zuuYNsYnlpR" style="width: 10%; text-align: right" title="Total revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,737</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Personal Care Ingredients</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20211231__srt--ProductOrServiceAxis__custom--AdvancedMaterialsMember_zWKX3RuDs5jc" style="text-align: right" title="Total revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,739</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--ProductOrServiceAxis__custom--AdvancedMaterialsMember_zpB61E2Tpmnd" style="text-align: right" title="Total revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,536</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advanced Materials</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20211231__srt--ProductOrServiceAxis__custom--SolesenceMember_zqrkE4Dr4n36" style="border-bottom: Black 1pt solid; text-align: right" title="Total revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,561</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20201231__srt--ProductOrServiceAxis__custom--SolesenceMember_z4j9sUNgXys5" style="border-bottom: Black 1pt solid; text-align: right" title="Total revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,850</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total Sales</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20211231_zE6FJbMivBoj" style="border-bottom: Black 2.5pt double; text-align: right" title="Total revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29,475</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20201231_zQXxYY5Gxs35" style="border-bottom: Black 2.5pt double; text-align: right" title="Total revenue"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17,123</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 18175000 6737000 7739000 5536000 3561000 4850000 29475000 17123000 <p id="xdx_80B_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_znapyiRNRihk" style="margin-top: 0; margin-bottom: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(14)</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_827_znkSDh6DL3Df">Contingencies</span></b> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2019, a novel strain of coronavirus (SARS-CoV-2) emerged in Wuhan, Hubei Province, China, <span style="background-color: white">which was proclaimed by the World Health Organization to have been the cause of a global pandemic (COVID-19).   </span>COVID-19 has been followed by a series of variants that have also impacted our operations, but to a lesser extent than the initial strain.. <span style="background-color: white">Some of the raw materials that are critical to the production of our products and parts that are critical to the operation of our equipment are sourced from single suppliers, suppliers from China and Korea, and in some cases, a single supplier from China. </span>Although <span style="background-color: white">operations of our third-party suppliers were disrupted to a certain extent in 2020 from the pandemic, particularly related to receiving packaging for our Solésence products on a timely basis, we are currently seeing a more limited impact relating to COVID-19 on our suppliers. The biggest challenge in 2021 and during the beginning of 2022 related to the pandemic is now slowdowns in production and shipping due to capacity limitations which seems to be a function of company’s inability to keep up with renewed market demand. We typically maintain no less than one month’s supply of raw materials and parts that are sourced from sole suppliers and make efforts to identify additional suppliers who may be able to provide such raw materials or parts. During 2021, shortages of labor, which may have been related to COVID-19, created challenges to the Company as we navigated a rapidly growing business under these conditions.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is aware that such changes in its business as a result of COVID-19-related changes to our economy could occur, but is uncertain of the impacts of those changes on its consolidated statements of position, operations, or cash flows. The Company’s management believes any resulting cessations, reductions, and disruptions in its customers’ and suppliers’ operations would probably be temporary; however, the Company’s management also believes the duration and, hence, the potential impact of such cessations, reductions, and disruptions is currently unknowable. As a result, we are unable to estimate the potential impact on our business as of the date of this filing.</span></p> EXCEL 75 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

4+CF'X\VX4N;:5VI!"B#N$XV^3XWFS$Z<4$Q) .-,#)RA672V\'NK^+(',X M8FB=!$-WU=0AX^D!>A)E!K2:XJN^-4PTAFS+\C/5\3-I07"UG'UD;9" *FY6 MTZ7* .$.IL8LQY.I9L:ORO#5D[!(LX:?TC6/7!41@0Y%+/S%/0_KI9 YEYQV M$LC&.-US@T$$]!XP'-UC>.'5IPIX+W(>/"[>YM8W?GY@2VE&-67?Q HT&!LA M51:U_6&3[W1O0IQCH%L"NMR&TV0HSHBSQ85X+X$EI0FC*9@ZYFN]_%J ML+8-L1;9>&67U']+9R=G^1@Z&7%"?%IG6=KE"2J)$26(BB33PWAB& MZ"1LWTA?H]D566[IOR[ 16K+\[7X;%J!2<'=5'#TQC@^BTA>]=3^%K(V&O1" M<3#Q2K0!):4K&LY'>R>@^P,+QPS_UAD.-.4C_^&!C&*^R(U[$US#G6MJ6&BP M5]UP(X8",5:+ 'IJ0%'M86LJ:&"N@762.VBN(LA\-95NY*!+(/R2HTQ*;>9E M>=Z=90K69TWO[Y!DI/*IJ'Q**I_2VH/6!%TVF,#U-^V\EF*M2K=IC?9+0XVN MO4]@LW3$O%6R*QL4B0)0S9PV;22=1A7?2&! XYNH ]WI5R'CM&MR+@0D,\ ( MZO>CBFX)#J92HS 4]_V>H\>N(TO@>_:#M;FC1?&KAD%MHY/1K<;&4V=/_0Y? M#)5-5_+QME?( _6I@3C8)!9'W$BLI6->2AV[0779=E)' MRF65$ A@=P.]N"J0-Q)B;2OLB;/G2%I1.>D>AMV?*1M2*#Y,MZ_XEWL4>50D MCLU=H)6NJ#@^[,3U[4"P@6-1:Q8% Q7=Q1>L>;TB/3]OHH,[2H,E7\3QT=Q& M) (%G4PO1Y/)1,TOG_#?O,S>LEQUH&B#[Z/T*.6*[."'0-O%_)MH:,RB,<]0 MU[KDB95%W!LI<+A) ,O( G(V ]+]/]0>*M[=8^B#?M"G?DV&=?Z9>H2=OZY< M'[!+^+GX9.CBG'D E0_S&1'RIY=/P0-:Q["$2<4W?NF,?"'>"[0][Y)%3GJR MAL7P]NC\8D2G-GTRA_%&TXO+T<7EX[Q@D19,74S":S$3O[%!*X!\$@>()K(M M\,:<8C>SBW9UZ0T?=RC'_7.[ITBQ5R19_'") U6PQOQI4N4"FI$JK\D Q<$Y M#9=X1B9.5 L/"SE$KF>FSZ/Y?E*3\>1"_LR+MW?.OOB3:R9-#E95G\SVX-4L M[UI'@";!]Z$M_MZW!NXR?3PZTN;\C9^<3N>C='D\Z+_M7^-0'_D6E-)H[NRI M06=OE&Z:!># 5NE]".+J@ AJ=>FWH+),>DW.HGV5D_W?==L3TQ?XFA_>)6,BJ\N]>!,9*:QP^,X7DZ>T>]HP MI(U<+FC!%:Q(&PO=V]R:W-H M965TT:1)5FRG=<9.VGGTDE: MC^->/]S_[[)*O-V7UQ2RT MMO+K,B_,FZ.%M:N79VBE,OURI0OON9KM]7;UV5M\ZS0MY4T]7*IJNV-SLO-FZ/A4;APE\T7EBZ,+&?R7:73S+X^LR!/B\X23^K&D1H]0&HXDI_*PBZ, M_+%(=;I+X Q\-W(T& T?H7?>"'O.],X?I#>U\GUF MDKPT=:7E/Z^GQE9PC'\]0GS<$!\S\?'_0Y./DJ) ?&E6*M%OCA!I1E=K??3V MY/Q4=LX0S1GNCJ [>3@]<7>2$A%D+%VQ"RUG98Y S(KY2W'-!*!DO9SJBA0M M2-&D[8&X4U;+Z[7*OBH^9B!BM^LLS[6X4<47^8-:KE[) M^PI>+$^&IW+<'TWDL7PFSP?X]\/?KD;#T:O.SV^1&35DBC/%?Y/!@/Z>OI$V MA,,]$7&C5;)(RFK5$Q\_OI.DZXE;?=X;7US*8>]\ L7T+B\O\'\XF;0[XL7/ ML' P&$2?D_!??-8)?"X5L,<:C&:DOU55+C-CRFHK"QA0GHQ/Y:B/+<<-A^%S MQ 1!]L6EN+V]%1]+5<@S&4N]3VYR*H>'R;V8C.@O%N."-,2+@VKWM"-/+A]< M! >&)^1PI).K!Q?!"SYG1:+%SW6^A:,-QSVYT7*AUEI2";'XTZE4R+3%E^>0 MI<:O7%L+LJU+HQ;)>B5MR&SF4QST! J9>KS145"R-KI+"*K]Z52UVR?GOR0X[H*C,C M9RK)\LQNP1M*@E3S2FN4*MM'($;,.,&F6A=@".8'^YZR78!*:R]!]NK+#U;B M,IU*_!=P@2:Q. M5:Y@4LE%J"\0:/<++=Z5RQ4=$JR*M!7,UVC+F6K'A3>++%G(90G+X7"L@9MP M DP;,P([R%5=K4K(#9\ :2>"74 ND%]J^C R468A G.5_K/.*C[5D/Q_UJHB MI]+(F"P94RB)2=0PJ@F..3K4B\*A<_G*R%Q5$$5;GC%>M?LN"DY '%S4QO*YT9RO%\WFCLAQHBCT>#5 M)V5(E.8F7QZ^.G42M*E-(K7UR3BRNT,XXQK2@-V4,J?#O(]G&C%%-*1>9ZF& M,E,YW8(UHU?*!50G[:3L)XJ+T)Z0+[$39R_=&71>JV$J1R&N26GX,@6YS$SK MRK!.Z%BH%HZBTC4;-E;$/>AR8MS5@)*S["MQQ&'3I@9F'D=>UQJF0;L5R39"MO36I/GA[(I/#X9R%>\&D(I8[1]3EB1?&M=YFORBUBG M6T$I+))<1I)SIA>Q7-=G=_*."4&1/WD204:7\,0,]-F)V\R7)%5-5QY(@>?R M6)QXX06@9;:LEZ=RA2.V6E6]H+O&GQG]!CC!*65&JLJS64;*31*7="ALLS4K MTD,.+Z/3ID)&L A8RS)_4E6R:%78(Z]1\$CD'$15X>[+T;F[CXP=J8RH[3JW MU%]19*W/%3]E%;1P3=0X9*!<2E==WW=Y0W^U?"KO]!QF#D=-2Y\'R+TX#AEG MT96#AJ&#=N0:RK[\<3;3W(#(SWIE74A<>:F(E'BJ5( 1)98\62P0#6+EV1+I MT1>"@ZR+&4*Y<4'OC9>3@>R+7UN7;^TAO\<>]XNL^M\8%P_KO&$W8]AHQELM1,'N/EK[!K4,V[M>L%XLB>2A2KF MGM!N9L2R60V4(9O4HKA8IG7BUX=E37:1;789'2.8"O\NN>%#+ MYY+J5N9S ZN!:2,G5YKS+-%RL$=XRDVT!N$G0?3A7R%ZE%A'\K@O[@\(V[($ M).*0[IXSW>^LHV,/1ZH"M#"NI>!RG.=\1%V@0M<4I5R"48A,)PTS35,CK<,H M7*DA1HS!&IP3R#>Z"=!5RU^ 1P,T<6'C^]#K%@D? AIT,"$EFQ%^E42URA+P M> AG!9QI2X>>4?-Q!# Q%_$4S;Q.&1LY#,O9@:#% UG[\NVW[NMD5"U)![ %:I%.4^E?=]^?LBL\NR(G\+KN-AA7->XOP0 M H@/(AWPDY;CB!6E/E$83+K<%N M/2"4)81,?--#][V< _F &-C?"RPNRAQ.'GQ0E"MRN)["@/T+7 A&9(:>X6"A&^M0K-1T[FM19EB"P141Q MINE 30Z8Z(-1[F0AG:'M2CU>I?//1^WYP?(II]THF<6!R0E [28@7(>U39;( MM1BVN?C0QMEN?8>!\C=2,)W*!.[^DKS3!I$/Z.*FY< P"XU? UGHPG@N@Y9)PGF1_9L,C?1E^5MWRTX?S<.*< 25Y&>C MBTOR4HK#OOQM!>T _U1)9AI1(DM4)(-?/G0P$^K1N:YX/A-VN#)*1X:C>ISO M?#@%37J>>:O@D8'GW!] ?D_]6-EAH^<3A+/),_EB< [80*461%S2"O8/VCFD MR4]5E/B3!K+GM>$:\J )YMCG/.L5):&HD*/:HA# METI<3T5#7]VLZ*:LOORPK[7A@,H0ER*?E/P\KB;CQ5J* ]*M$2\FO-5.111YIFL>\RFSD*%#1B"^H!'?7@9F@9 K(OVPUPH_(TN;D56[ M)9KP\7 FJ(W0'F]):*@ $,170=DC^746Y\F^F#!6<'!_>-EKQV8=H- %!'&A MO;V]W:GEO9W!B:=]$6@3DVI=\AAT9]3]*)*@$2\IDCH)'D"T9>M6;9.%AB' MH_7/R/!U7JFE/&E9;!" B!/")O(I$G2U(K",@_ WA],R+/-!ZOGQV(!"QAK1#-)3Z$WOR9'K*$],&/\W:^*-'BUBW9K.W M#B9/7() !( .7)(P;%ZGVA&J=$N+ZG?TJ[7D#FG*87,UU]$9ISUQDG0XB[=4 M?*59[@8P)ZG;$1;5UJ%L3P'X2>5)'0*'YSI5RJ.V9B#:@&P._.N['S^+Z\0^ MCA$;FV_*.D_=>/E;,-$]NQ !*.[6)/(Y&CS!XWH^VFGPI 'EZ*S8$2-'<<8/ MTU^"HIPV?FO"8D. 5N5O$!%+L MS%F*:E%;PL(1+A_YB2^D6, KTN"T&6JG[AD!#.A$1(P;GI[% MC_:B2AIFXE$N !-%@*[ 7K(O+CC#_:R O)&\1E>^08U'5;NYKG"S"YZSINBO MT.:1"SUE@'W-3^KN.DNB 2='$O?^QIN:J1MA#_684VTW],CE\>%4&$?2HY7N M!!M^3XB.(4&8>N^WCF&8VQ,NM-V<()I1<)5?A;;SR6,:-YHAQ''%%=@/'@[/ M*0X-( ;]R\FQD\]-7[XY>MD?< 6?&??%Y7>Z A,_:-)(Y9W!>/M,*-2>#ZBV MH(83NQ/O[G,-\=]:<_\(EV*6ZBL-PZ/1M\]E;<3L;Z7\\&SL#/:4T;GKR29H MA+T]F@:E':IGS2F[_6#3VT2^X/&2:#EKC)N9G6< \J"GT),S;G^,:YMW?>#J M^]-!A/B>D@1HI-3.:AYXF-4\9/8A[#)#@Y7SK: %9J89($ CRIAL7H0)=$,> M'.Z2S5$GE0K>*I:NTR011IKDG:F\W@5KZ.'!HA83/P6UKS MU^J^9=T>QAK)?B?J/A-")^E>>A=T2">H0GVVL0 M]\JS0@%C9XG(WGMZGV+G1YAX]&74_8(/<; .4W4!COOJO@*:,@]RB3C M'>Q?W>TT>D!)='R9;W#5>8F$YGCTU@A]7J 7>LH+(.'U#/>>1^L=3#"\2-$Y MA[RLXT?,=G @UBZU6H>\B$*HC,8A-&3;\,/ZI?JCC,M%=V[C1E'"-7/LZ6Z* M.T4[L7#8ZA-@R%U?(FMH&YU(,Q* ->N:F6Z5YA9\H;+NS>;@::D@ VX&*L;U M)@?K6>^!;-T^:K(O')NL'5>=?8PF\[+\&T7U_J2\/O:%V%KWW MM]35G-]N),N@5KE7 )NKS0N4U^Z]P7:Y>_L2B6E.+VGD>H:ME+^.W"0B_+#E MBM\BG);6EDO^NM *Y9 6X/ZLA/_Z'W1 \UKIV_\ 4$L#!!0 ( +:!?U0< M5#=\@@( $4% 9 >&PO=V]R:W-H965T)[?*1%+G92/>L:TI]C8W<+?W(/Q@>>54; M:PBRQ995^(3FV_9!T2D86 K>HM!<"E!8+OU5-%^GUM\Y?.>XTT=[L)ELI'RV MA[MBZ8=6$#:8&\O :'G%:VP:2T0R7O:<_A#2 H_W!_9;ESOELF$:KV7S@Q>F M7OHS'PHL6=>81[G[BOM\)I8OEXUV7]CUODGL0]YI(]L]F!2T7/0K>]O7X0@P M"S\!Q'M ['3W@9S*&V98ME!R!\IZ$YO=N%0=FL1Q87_*DU%TRPEGLCOQBL)( MQ5$O D.$UASD>_"Z!\>?@*,8[J4PM88OHL#B(T% 2@8Y\4'..C[)>(/Y&))H M!'$81R?XDB&]Q/$E_TCO'6ZXSANI.X7P<[711M%[^'4B0CI$2%V$]/\*>!)L M.VZNMRS'I4\MI5&]HI^=IQ=PQ'J\]W))[: -R!),C5#*AKJ*BVKNK;1'1JH? MMAM4MH:>K:$M9.@]LAT]&H.*LT;#&:2C671%:SR:Q1/OE@M.+ZCP*BD+#=%H M.HOI.TDGWE'L$51*:@W3T22,B"&Y#+V5#<]$CAZ-!\"W',GAI6/"<&.EGZ?A M%"[@/ GAXB.7H'ES1ESAU<3I2=(0_O8W@J.GW:*J7 -KR&4G3/_*!^LP(U9] M:_QQ[P?,/5,5%QH:+ D:CB\G/JB^:?N#D5O7*!MIJ.W\?^R>:.N:R8@AM1_>"Y+J=NZI(<"M95^E%L/L,VG\3P9:)2 M]DTV/3;&B%FGM*BWSCBN>=-_V=MV'PX,M;K(FK,G)/6""I:AR\J5NI7@%LZ(F MOL9(!N]G6]9%STJ/L(:4/(A&EXK<-3GD?Q/X*''027%;2KS74K][9%FQ;?;[O?@Y7RDM\<;\.A$J'D+%-E3\G[?X M-.MY6E:A+OEMN&!(](V'JT?3*&"-OG*3.UZ+@&1Q KD8A2Y_YCI;%W%03X3I/ N4'56G:VOAW>$(2M)2A%0B\841+'B4,3 M+Z*4T,@+H@@YE<*4LJRKNXIIR+& L9=EG/4M I-@M9":_^XGSFG@C5#/A;7" M44(NG#,,/L8+?D:HEXY2W)H]@P-OV"T5D U3"(CCF$1Q^M$=\@]*M@:YMHW) MG$/7Z+YZA]FA]\W[DM_#^\;YP.2:-PJ/MD#7X'*O('QO+W8! MQ]:W[30)D-UMT0(MNMW=M@\7]X&6J(BH)*HD%2?]]?<,*=E.G*0!BCZ8^N#, MXOB\O9R$9)!I16$+@N-R*]Z)I" AF_#%BSO9+DN+Q_83^K?,=OFRY M$>]5\YLL;7TY6\]8*2H^-/:3VGTG1G\RPBM48]S(=EXV@G Q&*O:41D6M++S M5WXWQN%(81T^HQ"/"K&SVR_DK/S +;^ZT&K'-$D#C6ZJ;:5%K*VY6%K TN2R&"'>>8CX&8@H9C^JSM:&?=.5HGP(L(0] M>Z/BR:AW\8N('T2Q8$DT9W$81R_@)7LG$X>7O.2D8?^]WAJKD0?_>P$SW6.F M#C/].X%[$8+J[=STO!"7,Q24$?I6S*[>Y&_9"3;[4HL SSWO[O_SKW4JQI&$H9KRO9"'F;,>UJ-4 &<+ MXUW)Q!^#[&GE!7LOM$5M!X"QM3/J@1$CH.R*9B@%4QU^FK5*X]I3W1EF%:JW M0WUBP@J-).96.#!O-[=/(I?2%%H0Q.+8?6#=# W7S3T3M[P9@&6K^K14?"]PQ.0X,;U?$MH KO)05+W E=('+SR2D''TSP1TX)D6B6UL^E(9PTFBCB$H Q^6.(B2;0?9E- '/X+5 M_%8$9MB.<]Q1[5;W*$,WT/NJ44I[$JG? ;R%(%HM]2UI*(S(C D'701^J^X6 MKA-'W)MV9M69NQF=&7I@B;M>:NZYN#:4"RA1T6Z%WI?IW%GRZ:=?&#<&FTG- MR= M;WA']E3LWRR*Y^$J8]%\LTY8%,Z3,,?#.EZQ-(EPEV>18]IGYI1:,-%1 M<\NU!%=3UO3\WI?&KI9%35)PT3(D/387B4!B27!FF3 %C/ YL'7QH^# )V,! M)]$Z2]!7BCNB%DZ*P&40OQ.&4L ,FCR8N_Q!5;6DCRPSHK.^5DH M8Z'F;:( M%*('VP N/Q1MD'6(NI7P,UJS) ^^*,N;H#I9WP (>9T'/SWJS"?&[06"@P#+ MLI1E>1;\.B;Z\5R4I"Q*\^!S#:_.J&LSST/>-H+*"4,%-32UEQQZF VK))^-3W+N=A1+E7G"-U'V&>LI# M8O<\<(^>:%K/E0MA\%8-"%4P]F J48?;8M%!.QOW^7!,T7%LG0I)!A;^"CB]M;%BY6+%JDK\0Y<>L(:;/(6+*( M3Y%H?Z48!]0?'INR623L*S_^E>;)XBNL^!6RU4%0/Z\&"\K0)W'Q@7WF,#$9 M0>EQ LN=VA.YI,6#YC/VA:,\\$D/8:KU*-S0.$^SW%VIXC"5L)QA>]IL,$:A M>Y5.;-)$G/F1)O8T$PR5/(TTD1]/Y&L_4C_'?E&!J?WT>IYCVHW>NL-V!INB MC,;5/%KG_B8)(V2G,5-5( O<@;%S[LFQ=;$W*7N+8;[>K/S-)HS8V]%]G%AD M.[2'A30=\FC[H14COSW'ZXV_2YZ]9T#R<]I43H"F#K M>..)S""!7Q0^)#';9/1[1""+GN+GT?64HR0*,<;SEUX*70)(#Y2BD[/= " M^W\9KOX/4$L#!!0 ( +:!?U0Z&04(A0( %<% 9 >&PO=V]R:W-H M965T&U MP)4"W34-4_LEZ>R*F\9H9E,R5WH&PTH=F% M*]5ED[A:V$.Y-XIV:\HSV2+/58<%W#S1,6O4L\ 0JMT+\@/"LD>(GT&(8KB5 MPE0:;D2!Q9\ 1+##-]4MRW'NTW1I5%OTL]>7 M;^!OZ,'AX>#()\P[ M59L]$;=2U\8+8%%LF<@1[I#V*11>O9C$4?S>^TR*25A"--Z#-(P3U[OTPO). M4OC7R01'E[U!M7$C;9M DOI[/WK'5V/1#\OO\/[)N65J4PL-'$M*#<\NSWU0 M_1CWAI&M&YVU-#2(;EG1RX?*!M!^*:49#$LPOJ79+U!+ P04 " "V@7]4 MV@ "4:X% !P# &0 'AL+W=O=7#+Q%X0"N;R5TF00#H?302I5UCD_]7LKH#%<&;)&FTCQ>8J(/9YV@ M4V]\5KN]XXW!^6DN=[A&]R5?&7H;-%9BE6)FE<[ X/:LQHU(&HL$ZGE3)% MD*JL_)4/51U:"O/A;Q3"2B'T<9>.?)37TLGS4Z,/8%B:K/'"I^JU*3B5<5/6 MSM"I(CUW_B&+=(IP)Q_0G@X<6>3]051I7Y;:X6^T@Q ^ZLSM+;S+8HR/#0PH ME":>L([G,GS1XC5&?1@%/0B'8?""O5&3W\C;&_UG?G"M;)1H6QB$ORXVUAE" MQ-\ON!@W+L;>Q?A_EO!E[>[\!$H+PEN V\*(C-BH2K..(L^-OE=,@Q[O)D6L MLAULM-L30HS!S(',8L8BTEO<([(DTF$,3L.7_KH/6XS1R,1+64='+>-HR:B% M5Z-9'^[VM%)6Q 6RKH1H+[,=2T,B#T C -P>*Q-Z"Q\2RD:33J)2Y3@H/BZL M/^0/(/,\>:R+\+[RW+)@N&JD[HM2Q=]TE@LA MVET!:3F"7]+WN=!BR%TCF:U.:+#:I?"'?" J.+'/B!)6! _GFU8X;1Y]'-1P M&"\F] R'<_%)9U63-@F*IC:O_YB'0?@6)HQ,\>X!T]Q56(4WL%JMX$;+#+KA M+("36EJLD(9E1M47GG1U\V'M=/0=;O,2"63-1,I2Y;K344M[S=AJ%:+G<42% MJ%NYP0RWRED(9C.8C2FL7!G?,$%2GVYOX+5,\[=PY3.W,%\L(.Q-QB.?! UP MAGA&[8S0^@KS%P.N=':/QN=/(6]TX@E9* M2VHD-][OEV"(6JV/N?6OF@YTPPGW\DX[2O]H?K2K])/TD>NRL$OQ"9V@BQ0C MB.KG)X#O ]7J($W,= S&OOTHI8B]TT"L*0Q\P]>C6'!K:8!41H9SF(;CDAQ"1I$IJ(21MLS@:0#!:/Y< M?2M 4BE"HGDP[:3:/.I%"1"D>QD-FSWX0A/3\U]6MWM43S' MTAAI?')*/-J-?E!T"<3DD5O4IZS[8PCH.8)O*/;R'IL1Y2?62\VN/WH-CYB" M/[F8AD!P(C"']*"I,($2VPM^73QW;1FT;H$IFIV_ZS*^B9KEA;#9;:[3%^4M M\DF\O(M_E&:G:+(EN"7587\VZ8 I[[?EB].YOU/2)81NJ'ZYI[\$:%B SK=: MN_J%'31_,L[_!5!+ P04 " "V@7]4'J4!.P<" !Z! &0 'AL+W=O M1^_0P:R3INCK0&0O$JA M[#*J$9M[2FU1@V1VJAM0;J?21C)TJ3E0VQA@91!)0=,X_D EXRK*L["V-7FF M6Q1 ;A\Z>Q<1WLM?ZZ),OY3**O2$04* G,'?[!1L0PH.! M&8U'>N%Y?*)_"KV[7O;,PD:+[[S$>ADM(E)"Q5J!S[K[#$,_MYY7:&'#E71] M;>**B]:BEH/8.9!<]7?V.CR',\'=)4$Z"-+@NS\HN'Q@R/+,Z(X87^UH/@BM M!K4SQY7_4W9HW"YW.LPWK.'(!-FA+HX918?T&[08Y.M>GEZ0)REYT@IK2QY5 M">7? .J\C(;2DZ%U>I7X ,64S)()2>,TN<*;C0W. F]V@??XTG)\(S]6>XO& MS<#/*\SYR)P'YOQ_']IU^;N/[\F N D(LK(WNB*N=9![,&/[$\)4Z:-X0CH@ M-7/)?!(O%B2))W$?]6/C%S MX,H2 963QM.[VXB8?M+[!'43IFNOT$G_ ^+G)?P-0 M2P,$% @ MH%_5/?OHDW(!@ /Q !D !X;"]W;W)K&ULK5A=;]M&%GWGK[A0-PL'H"62^G9L [;C=+= 6R/.)BB*?1B1 M(Y$PR5%GAI+=7]]S9TA94FRC6.Q#K"$Y]]QSOV=ROE7ZP>126GJLRMI<]')K MUV>#@4ES60G35VM9X\M2Z4I8/.K5P*RU%)D3JLI!$D63026*NG=Y[M[=ZW.M>?"Y6N>47@\OSM5C)>VG_L[[3>!KL4+*B MDK4I5$U:+B]Z5_'9]8CWNPU?"[DU>VMB2Q9*/?##O[.+7L2$9"E3RP@"/QMY M(\N2@4#CCQ:SMU/)@OOK#OV3LQVV+(21-ZK\5F0VO^C->I3)I6A*^UEM_R5; M>\:,EZK2N+^T]7M'PQZEC;&J:H7!H"IJ_RL>6S_L":GPM(&)V\B?I1IGX9Q M2$F4Q&_@#7<6#QW>\#6+]7"V,ULN6_;R@; M[92-G++1_\V];^.=Q-%[.@ -CD'IFPQRL9$$8Z2&D45M%1FW0ZU]*:RT=,8: M9)O-*97:HGY)+9<%UB8D6:U+]22EYYP5&D6DM.G3EUP>8!E:L5:H6>M":8(J MF\M 9*TJM>1GQ"Z>T^T?36&?Z$95:"E&N.]WI:CIA+?\\X=9DD0?W$Y^ZY[C M#^\)NWY1&UDMI*9X'GJLE:RE%F7Y1/)Q#7ID94U/4FA#2ZVJ@!$S8243< S[ M]*FQ#39VO,%T(7?L&V2K?J;J:&V+LNS@C=SL%-RVS@D.HPN_+U6)+D=7]S?T M1:V+E*;Q+"2?<=?[&0<7P]_;O$CA_7U_0!W6D@J#EI>J55W\"2E5PU!T8#)[ MR;MNH9Q,"B,"F+21QO:#WYAG(+D" RX;KITHV,O\X$6E_Z!X$O'?^3CX++FE M%_4*KGEF\JI<.)[%>S);UPVQ'XFHT=Q/UQ+ID84[D1;2P9PXM[ZGI#]G)S;X MS(&X+D7Z<'J?YJI$'K;YA"Q+64&E,EER##.)+$=C]#)+46C:B+)Q@7>)VGIK MG[A/XT-\#Z@E5CS=%+RR9C)JP63B\P(:"FE/4* M%<5IC]FU5T*A&L_$5G.=5L0OAGDV;[P>0(==[\ P%,DM9<-V@]F^[G1YA M3PVRU7M9.>-0>042%E/^ <<*S668YMQ@34?(,?%A\'/99_:NFP2[;K(L3 KG MD=1?TSO@H_%ILC01.BI MD"781_P%[X_AGAN0"T=7SFWK]Q3/:$SC-R3W4_,YL< G!A.:CU]2R\4>[(K] M6=?.'6?H3$E_/,=/U$]F=)5EKN.(,LB05J4RG-@O.9)>"Z'W,!U[^"N7#"+C MV]R>"X+#O.:NW^X9TC"X.4[E5C#@YO6:X)2FP>U+%4H<.O[W4A'X4S=ZN-GS ME"\^KF#G Q3F*X.?LD9WS8XIDILMA+.9G\O=^>P@Q8^5!-VD=(/([ +ZO+A: MX62R@EW!KXTU%A18*2!^$G6#.P/FC'?Z,!S%23B935QHQU-W>HB3#]UO\&/K MMO%D&HXC'FJC?CSZ;MNM[[/8>#(>CL,8.]\[R-'W>S]Y3W.7T^VQ &+). YG M4R\6]Z/Y=V)'EGSG,M@2SX=A$D\<0CRC<3_F910FDVG'T,7P1?$DC&?S<#B= M>5=,8.@(RUDXBL9^Y".6&S1D!X$X!RZEX,K9S/N&TT5TGN>.@% ;'%Y\:?EY MU6:16&!N'+1[-UY026S>P7Q9.I^/HK<.(WQVZ0+0^7\V8E+!%V51%,=D^*01 M3^;./<&-,#D?)"3F1\:E/F3#AU-R1ZV@);>[ +8]HIVD[N#+.[W=O=[?C*7PJ?M_NK]<]"K^!%'$Z6$(WZTW&/ MM+^N^@>KUNZ*N% 6%TZWS''#EYHWX/M2*=L]L(+=_QE<_@502P,$% @ MMH%_5*LC>+)F @ . 4 !D !X;"]W;W)K&UL MK91+;]LP#(#O_16$3RW0Q8^D:U D 9)VPW8H$+38>AAV4&S&%JJ'*\EQ\^]' MR8Z7 4U.N]BB1'XD)9*S5IM76R$Z>)="V7E4.5??Q;'-*Y3,CG2-BDZVVDCF M2#1E;&N#K A&4L19DGR.)>,J6LS"WMHL9KIQ@BM<&["-E,SL5RAT.X_2Z+#Q MQ,O*^8UX,:M9B<_H?M1K0U(\4 HN45FN%1CK>:>/V@\)-C:X_6X#/9 M:/WJA>_%/$I\0"@P=Y[ Z+?#>Q3"@RB,MYX9#2Z]X?'Z0/\:%ZNA0U?:#O=,7G,&^NT[(U)EEQU?_;>W\.1 MP30Y89#U!EF(NW,4HGQ@CBUF1K=@O#;1_"*D&JPI.*[\HSP[0Z><[-QBDJ27 MKU>P-GK+W:?GBAFN2E@+IF:Q([[7BO.>M>I8V0E6FL&C5JZR\$456/P+B"FP M(;KL$-TJ.TM\P'P$X_0:LB1+S_#&0[;CP!N?X#VAXP:IIARL4"&E;.'7KX?<;!9' P"0XF_^4ZS[,NT_0*/@1>>""\X$7%=@CLH%1W2K;W6GNE7.\P M2+:A-)ERG FQ!_H REKH/:*%MM(@_02@&ULK5=+D]LV M$K[S5W3)B9+-86L/$-F24 ,2# ".S'^_7P,4 MI8D]LY=<)))H]./K[J^!RYUUCW[+'.AK96I_-=J&T'R83GVQY4KYB6VXQLK: MNDH%O+K-U#>.51DW56::SV:GTTKI>G1]&;_=N^M+VP:C:[YWY-NJ4JZ[96-W M5Z/Y:/_AB]YL@WR87E\V:L,/''YO[AW>IH.64E=<>VUK^(Z-$45PX\]>YV@P*1N/G_?: M?XVQ(Y:5\GQGS1^Z#-NKT?F(2EZKUH0O=O=/[N,Y$7V%-3[^TB[)+F5KM._^MKC<+3A_*4->;\ACWXG0]'+CRJHZTMG=^1$&MKD(88:=\,Y M74M2'H+#JL:^ZT+5@>ZB.7:>5%W2G:V#KC=<%YK]Y33 F&R9%KWB MVZ0X?T'Q/*?/T+#U]$M=#J[F>U=O\UV?+M@C9G0J\L:Z+N^1GELWI'F9LK0Q6'=.G>N.XU%P'3_DI M_4B+&?V8Y?1@S=LW^6)QX>$ZOWTS/UM>T/QG",R7$%B\(' B G,(+%\0@':" M4'9"-^63PD*9?8:73BOCZ=UGN%(H0Q^UVM36!UWX 9OW=(Z]N;CWFPT0.I/W M3L M_X#\T^PG.EN<]!C_0/EX>9JG_\69%'#1.H= 3$=;!3SY:V%:'PNZ;1I\50B5 MJQCJ3H\X!T'=-I=('YQ637%+C8UM;8 M32?=/^WS[96)JTW*J;C)?[:ZD3AH[6P5I>YLU:BZRX*-KWLW826D4L$"-#SI M$HNJ484.'6!9H\LE][),!/LJAK;PT^%-V8%/JO=1!Q,J)3QF"SWW;P9((6 M>:Y)'6= TC.FM@$VNI8"1"5D\"LYBI>T;YQ4#-MVL2Q62*\U,3G/LH;*8AU= MFX.WP'OR]VG]';V)*K _)B!.C0A:/-,,:2^XC^Y9R8FP8Z-$[GE )$](-Q;4 MRCXA0*0UNMSS&')H.V500XWJ4L+Z4M2'CHW\UM>.3X&B'>&YI.*0N O:VAV" M<0,4DK;:2.$22ZC]'$_#UY67?<&(72BUV;.G.' M"H"=H5)JF6N@HFI"7Y)TU2>\1LS>XT!Z@"F+BHI]%IO6%5N<_,H>U J@8:%[ MGE9(^5:E;HM(?9/-I#"H1Q:O0&"P&ZEAQZA;JN)Q:4(WZ'15EEIR!"I$0VNA M1*$>U?E]?Y4I\%6KH7-H^@0PTK+",.K$>92Z4+!@DY#H*\8?Z&4?7_1%D/>> M,=2 ( @[Q I"L)+7H7$.];:/?X+#2*7!I,*8'CYRG(+)H52_B4!B39Q\0+\1-7C;$=([(RU1XC7%MI'-E8H5XQ)":8 M5D#>:!A.)2G0'3;*8%94. C+. 3+@E^.> Q.2V6,8R?HHSHLM3"Z^/RLYKDB M5$3Q:+H)_0/=F^*)D#M)0F*U8S!B+U:12&L;1'4\ND@FM-M3AP"?^4=MC##( MX/UFL( )OJE4(ADI#488O*],_7TZ/Z"4MK$6YJG M>+A*5YGAZW 1O$GWGX-XND5^QBC'("##:VR=3XS+(3 :RO+:9Y_R(&ANOQ]?\ 4$L#!!0 ( +:!?U1 "KAY40, !4' M 9 >&PO=V]R:W-H965T[W M09&GU4GI+Z9!M/#4"FG686-M=QW'IFRP96:F.I2TBNXQ)T&T[CMW^3[A3XXG\V(,SLE!J2]N\KY:AXD3 MA )+ZQ 8O1[Q%H5P0"3CGQ$SG"A=X*N^FL1QZ3[*WFI:Y51G-]O>4,08V&-->VW9 ML%>R@M]1U9IU#2^9@#MNK.:'WJVN8DO$KCPN1Y+M0)*]0I)F<*^D;0R\DQ56 MWP+$I'B2G9UE;[.+B'=8SB!/(\B2++V ET_;D'N\_!6\T3T\8*>TY;*&OVX. M9)D.S=\7X.<3_-S#S__?7;Y(XJ[OM>E8B>N0[J=!_8CAYJ= M>$398W#4J@4N+6KIRRC/J%Z7:(!UG59/G*X&5O &\BC+%_1M?!%U>BAJ# MEI@U4K3TQ"=N&R[!-@B?)'>1/1E$,X//""ZE5IK_BX%#TH,I()_(O"U%A1H1 M7/\"LE/UI9VJT$2P0VV\ZUM'^E[6&BM.(FGIIGIDLB3">\K7G GCE>^5^/&' M+,]_-4BK,_C88# 2&Z VZL^LSZ1! H?G,]^S]\5P;PT XV^%8%?9[T*DJ7!0T6T3)?!J_Z@B6MOX4B M*O)%<+88?+681\4BA7ET523!1V69"/9,D+,WD+V-YIXA749IEL/W+D[\HE6U MJ&O?D-VAZ*4=NM84G7K^S=#JOJ8//XQ[IFM.!TK@D4J3V;((00]->)A8U?G& M=U"6VJ@?-O3?0NT2:/VHE#U/','T)]S\!U!+ P04 " "V@7]4U*A%U\0% M "B# &0 'AL+W=O[S.[2C/KU/;.D*#JMC:(O M-B]S.3-SYG!UTCI_%TKF2-\K8\/IM(RQ?K=8A+SD2H6YJ]GBS=KY2D7<^LTB MU)Y5D9PJLU@='OZTJ)2VT[.3].S:GYVX)AIM^=I3:*I*^>T%&]>>3I?3W8,O M>E-&>; X.ZG5AF\X_EY?>]PMABB%KM@&[2QY7I].SY?O+H[%/AE\U=R&T35) M)9ES=W+SL3B='@H@-IQ'B:#P[YXOV1@)!!C?^IC3(:4XCJ]WT7])M:.63 6^ M=.96%[$\G;Z94L%KU9CXQ;4?N*_GE<3+G0GI+[6=[:O5E/(F1%?USD!0:=O] M5]_[/HP->2%VM$DXM4:O(&.&UE*#?1XZV& M7SR[=#9JNV&;:PXGBXB0\F*1]^X7G?OJ$??EBCXA0AGH9UMP\3# E@&0*L= MH(O5DQ&O.)_3T7)&J\/5\HEX1T.!1RG>T:,%5I6.H%$,I&Q!#PJF*QURXT+C MF?XXST+T8,F?3V0]'K(>IZS'_[>M3[N_6!Z__ 'I1SM!:[C*V*,UR[RV*96=T8/5P?+MR_G=..J9"4N M7K7@=62OE0EXHB(I3"7W.NH< 9!#S "K:+J%AJ-K_.Y)-]U:^1@FCWI#R[P: M._.W1M="CF0>\"A'P6OO*@KHO<&SIJZ-9A]F^\O.(+4L9?W500]GZ5+;29"J MS\/0I\ M7&%A#KOPJ5%]PV>I)SIOC/)F"QTUJH_A02>-\6]@D=^IC5Q!Y1..&V>>/UL= M';T/H!]/AAZ+CE($*Q *8JA18LM=JQOO 03/ [.$4E2A+60TUD^H5R%+[/++ M:P#8,4&B2M*AX#G]A@HRO=EPB)27RAC&(DRZ(I>IT47C4Q@Q9&"WH<"W:CH@C1DG<4.JZEEA%P^*?*^#6<=L5TDUKDM9$"JV" MV&1H :T;._ R=ZC6;I\_>[-:OGXO:52FC42!]1US34T-H<<>H6?< BF^B'?X M! ,F0,SI%KFWM5 7#95O:YJU=60X)'XCC65T&-H[9$G]VTK^A\LT+,9^K1XR MW8UYGLPK=CE+HO;[TLYV,"#3#HG,:^,"5L)O] M93<*4K)&).JX298*J&I=H%\;:+O R!KL*MI+#=@BJ\C0L-S9KN".E)-=.#!) MM=+)U-)4)7*GQ!B41M>&<,B,9!QP3I#2=J /=B3=^0%PDB2D=-46F1O(K[6"=X^F.M (!:FJXN4*("^W'T)85^[D J;C61H M)L.!=)6TQHKT>WCYD,P3,!1C2J*9,0APS\*9;5^B=#)'V;N GOOM"IU ]C*6 M1*_O5'?, 9'Z%-T>[MBU>[A'.6E3:T"Q#'1+M$-=M?,X5;ZGTK6 A)[%?V*G M$790T>T+$&-(BMKIP(Q*3A_&I!].-!;D[?L]0?NZD?_70L-('QM[!Q&219G3 M^9X;@Y(V=K=$4#\M>_,0Q*27TEXUQSSK62'C[JZ1> WAL9OYOQUJ%J-S8SHA MR.E82-/8V!TAAZ?# ?R\.W?NS;O3^R?E(<(!^K2&Z^'\]:LI^>Y$W-U$5Z=3 M:.8BAITN2_R(8"\&>+]VJ*^_D03#SY*SOP%02P,$% @ MH%_5)(H&ULI5MK;QLYLOW> MOX+P#A890)$EV8Z=)Y G-HM,$B29#2XN[@>JFY(X:34U9+=M[:_?4U4DNV7+ MBFIXJ4L^NG/\15L:TZGI=-^'YT:IM-T^.CT.Y,FL=QFYC&CQ9 M.+_6+3[ZY7'8>*,KGK2NCV>3R:/CM;;-T8MG_-UG_^*9Z]K:-N:S5Z%;K[7? MOC*UNWI^-#U*7WRQRU5+7QR_>+;12_/5M+]O/GM\.LY4*KLV3;"N4=XLGA^] MG#YY-;V@"3SB7]9#/KROGA]-B"-3F[(E$AHOE^:UJ6NB!#[^ MC$2/\IHT.D\'!VC;RJJ^C( 83+B9W3)C%"3/F6Q9B+M_H5K]X MYMV5\C0:U.@-;Y5G@SG;D%:^MAY/+>:U+[Z*-I1;J*]VV=B%+773JI=EZ;JF MM,Z,SQ+CKV8'*;XQY5B=3$=J-IE-#] [R8(X87HG=]#;M^/_?3D/K8?A_-^! M!4[S J>\P.D="_P>#$GY;6@MC G4=5.I+S;\D'>_-Z7Q+=RHQEU;4*+>;#[]H K_NSLQX3NJ!:![/[893964$' MN/.&B&#$2K=*+Q;P-[PW2J])H$1EXWQK*F4;_CXO50R68F)0P7JCFRTIH7%8 M8PQ#;#LP!2;@9D%!1W6E*HM5O%IXMP9%%P9@.:]J#G3HXU9C2A$ & MW[H"(_"!>;)8%VQ#$#[+K-N1F;O!_$!.(\2T'!#M^(#CG67'.SOH&J^AE'T.]?-9["C\9JYK%BQ81> QZSF$DX(/ M"3K8T+*.%EU3!35W'DQ";&RBI*4OYM+5EZ33#UB(1K[VIK+M2%VM+(S'!K70 M)5F()EW.M^J5T>6J='XS*CY\>#U6GT EV1#,!?=<&82XP NW;9,$:I%FYV+IA:XMAAKT@FLA<-S\X'H"_ BO BK 4;[LE M1].T)Q=LZ^#*<9P"1A$I<-HTGDT=@DW/+<4B!(ZXE!;7?TUN@KP;I3%6[\3X MU\Z;$8WPIB B65[]C+03E3D49<+Y+VT%[^AUJ*!#V7ZO0G-M?&GA.V4DZ"Y9 MXB9S?&FUTALBAVA!P0F20J@C_CW<:L%[)+8\ZP4T:?]9PD$"P2X7(_51-VZS M I0AB6#.W/"BI*0MMF);JULQD6V_SJBX6AD."IC14W#\^>8*',TCWP-C)8)K MUU"4(<;8<@;Z ?* B<)>YQ+!5J;>XPG*QDC(/D9\$BJ#S=<2^*G1,L: M(/NV<(LE C4K>T4Q')B3C-2[;HD,I&B[L\E3('0,P7_^/'VJ%O!F8DI7P)"( M5<9+D/E@$'@0MJN_8-KTG::X[6,:VX$$/XCK#Z7&I M7T?$2&+4UR#;; -$*XH%DB4'DHF M$PV=YYR$K-]V)+,1$DXKSC\(UX%F AC@C;DNC4SAJ;5%.I14F"P%H2<0ZN"$ MZJW!_(HMMG:$$PIO:@[-M#O.>)2E.@Y D=J!7/4HYZI'![/.-Z\KLR\P[TM@ M!TE1.?PMV#\I3EZH7B!8E_DERF]A%V#\@8Y#P3J8'5(U4C? MS:6S90)ZL%=V\8S%D.>Q%PK*E>OF[:*KAZ['7EM12M**W 'UFUL4T.].IDD8 MDH>MJ8*@\*"1;L?JNT$2@"6O*=]PU*SA_)R3=A;-6X*](RK#WQ:< 1%R.W!2 MY0$,AC"(H,M2(3)!N2B'ZH%%D,'6-N8/\+1DE+;(),8B1G67&*^\;5M#B!NN ML,*;BB(U0S!7,":J%1F98RJ!$>UV MP_N*<(%D*+AO;MHK8RCA6\H%)(]@K_&NTML@/AI6=L,YCQZ*!4 &AVS_/-O^ M^4';?]]<@J[S=]0_]YZL!N\+VE403*4%6\-&$)<(A3L*<2LSK -,F+)TLXV2$$/,:/J&"()0UO%022F:@I) M@1,33+*-NHY(/&-DLG-HUCRLW)54 7:P4[@:N+&!0G\##QKRS%"$D O%--M MU^QPY!J+CI-!^I)1_%K[']@B[^OF,I@RP/O)OZO;.SAD!A?9#"X.:O(MP&!O M81^(P95#$GB_IE0AN&:??=R3:G$W5=4/@MAZJV&ILKD3P"#M 7Q"XY8',&A# M^!_(I0N& @_PAE$/U FJ!/PYQ[_IY(" 'F=%2G!]7$1@,UM]9+=?@) M(7HI;9R]6C](;C^.XS6*_6M Z@64V<2^-VN')%+'!"#- 4O5SYX"'/3@=CD/ MU3E2VF&D[#;4M&'LI8=2=V790:WE=EQ\)QA6IW*,2^(P[&2]>_GU%0PB=.1G M\,U3..9L,E*'Q$?M0'M)94CL.D@$\/U@EP?OM 5H[)8+.T/]Y]TF#I6@(3(; MGA3P:LZ?IM>?&"#8&$[-99.B0XE4PSH4(:)]D#:_N8 0=4%*?P=XK#Z%^..WV!MG1^TA!&72]1? M'36A@5R+OD=H!Z0!9.JN,ES[C;AFXRJ0K!IX1EJT>^#SX$M4]8+1I0WM.T8W M&],$$Q)]R2X(-JC*A]"B0^^;I"1><5 ;0G\:I M_=O1U1]=B*7F@H0305E3W.X]$@-DJX>0U[0_ YF>'-3<9XF2!W/4O2CD%!5? M!8C'W/#O5)7DOMI\F1PX0]R%=,DEP'$IQ$CV6H!+#!%TD,!+ V\0>Q30H$PJDK)!+JA]L@([ M*:%P *6B:&.JT:#QCFT)5ASLH8@8B(?3LXVSA%KJ-2',K@%;/E"+@V,2BX0' M4+"CB*#;V&"\&LA2&D&Q.1&S, &F8@F8)@V3:,D*M$V0LX @L9C5 /?I6,1S M4^HNF'1ZTX>&!-1(5"4$1=5_.EH@P-QK7*I0Z?<%P\!BI")S MXG"Q*47: NGD=V/U.ND[HH2, T9T\"IFD7 ''X=P?Y(5O(D,Y''T_*;]B>1D M/C>'J;R+8[&MANIE;D3EIM_0"*4O4B-J2U]1$X6(0BC+%9FTF-+@M(NR93[: M&4M#F1!;[EL-<]:NH^?!Q?[!>_(;S[^1Y%('J,CD\IN49XJ=K#=Z?$+))B6E M7Y"OI[=2T@E&G><*YV33QZY!WZGHY+H_CV?*?!%]P(U2/K11)T^NC@4S_LCY^GA M4^%/[!"'HOD]YN=8+I^255.IEA)O^DY.9$VY:ESMEM08+3GP+$P\+T;-5>VM M1! Z_L*T(MF89)QELG]M5N3T;(*ZXM#=A&E_A#D]?!KY!6%5>SID)E TD-_;&"SW M*O=^-(N[:*J=$4.MI1!]4_PZY%RSDUD.HI.^-SX]W!Q_WR!UH>K5UW?L]S[3 M"YY.^7%8'U@AW?(SZ?]RKS"[\-H 'U1\F$F'_8,$M#,U@A">3!U#?*L,7XF0 MNL>L$4;H^H%<8:#2-!2QZRK18[!&C M2_V_GN4\>%SD!@5]?<>2!YOI\.Z365^E:B#?]104Y M_BYLGB>>UR". 1P%BP]TW8^7EE9V)I I2R\LDLZ_$B%>;\D M0R*Y@:-_P(P$I8%Z %*1SC:'.7.M<[D^EX-(+,BVUL&XO?0$( JL*E J@MMN M_D?$SOU-$0AR3N=X $*VS35]8B5R$O-\1.FWQG &39(K/8J*M.CH>%2P]&AQ$03'QJDZ-BH&.\!DN]$9 MY\L6AAE^:@P[.V65'U3(**;2?+!K@JOY9),ZDAK%A:ZYTTJ.&/L;R('4?J<" MU2ZHZAU3:+QE#II+31+?@IH-9*!+)+\E>YDTAQ@EY'DWR!2\GS7=$"7.:,L/ M9'T29PQXA67DM%7Z7;%K7V2T/M]-XFL%A2,2^5Y,H"10Y% MJ.:2(RTDYRPJ]L(XH/%-A9V]T[=2*]&JR;C@D S08U"_[55TBKPSE8Y)0G'; M[ME[[#J".+[_M4.;6];DOVKHU#8:&9UZ;SR='Z@_8(NALNFJ6+P-)+B*NKGQ MV'L0&SBTOJ6TNS8N)8./[G9()<9!%LA=M?8%Q=M MN61%Q0_/1-U:R@6/G2\" M+1?10:IA8HZ/69!.%$N>6%E$)2/5,4L">A,"8CF#BNU_J-U:O+U5W@WZJQ^[ M-:G=^2?J 5;^MG)=P"KAU^*CH6M?C%*H]CR9437W^.(Q4$KC.&AB4O&=[UR3 MI<8SVZ;C53++:9^\PV)XL>#T;$0V-3T_@?!&T[.+T=G%HTRP2 33Z05E$Q$3 MWW,D"J@:"*%$$=D&T= \Q&IF&^7JTKU8M\O';;W=VDC1;R1)?)?$SE9 X^1Q MVLH9=D9;>44"*';T-"3QA$2<@" >%J)$+H:G3Z/X?E&3\>1,7DZ*-S=T7_Q% MFFDG.U0/=J[[(^/IX=/=C^9JY\JZ=XVCF'UW!_NG](H[Z='YRC^[QL"&IX]& M>\XR?NC&TK#8]!E9^7@DQM9Z8X IQ-"[/7.51FOUX9^.7&CGHAH=7#O)W8$V19# MR]BL$ 1/\;VB-)1N8.I*C%\]H+N::^[Q_"H T-+A4<7@XRM9L/95QD?_U$U' MQ9%$_)/=ZUF8R-OE@T$303RDL'M]F_%F6CTM&-)"+K=H *^L<''O:\?'@U]9 M(&XM^;4'%_G;_'N5E_(KC7ZX_-CE-Z @B]!0FP6F3L;GJ-2]_'Y$ M/K1NP[_9F+NV=6M^NS(:2( &X/G"(9G'#[1 _A7/B_\ 4$L#!!0 ( +:! M?U2-U!Y$. 0 .L+ 9 >&PO=V]R:W-H965TZ^1;7-A G&;:'%D'3K1B&/=#2L4V$(C62BIO]^AY2 ME]B-(ZP;ACW8HJ1SOO.=J\Y\K_2]V0%8^J40TBR"G;7E+ Q-MH."F7-5@L0W M&Z4+9O%6;T-3:F"Y5RI$F$31."P8E\%R[I_=ZN5<559P";>:FJHHF'Y<@5#[ M11 '[8./?+NS[D&XG)=L"W=@?REO-=Z%'4K."Y"&*TDU;!;!93Q;C9V\%_B5 MP]X'N *A'! 2.//!C/H3#K%PW.+_J/W M'7U9,P-72GSFN=TM@FE <]BP2MB/:O\3-/Z,'%ZFA/'_=-_(1@'-*F-5T2@C M@X++^LJ^-''X.PI)HY!XWK4AS_*:6;:<:[6GVDDCFCMX5[TVDN/2)>7.:GS+ M4<\N[^ID4+6A=WPK^89G3%IZF66JDI;++;U5@F<<#'W]B:T%F#?ST*)AIQYF MC9%5;21YP4B&D7 MAM3CI2_@G?+W]\NUL1K+YH\> \/.P- ;&+YH *N/VT?*);4[H,P8[#@-EFO M&K=4K07?LJ92/1F*+>=E'X%I0\&%CJ+C4*Q!>^>Y01P4$]A:9G8J+[VD7,// M3,DR6 38T0;T P1+VE(E_QU5XM+F1%1-,9C"@:]AR*5T&SF@2#]U_-":8 M&&<936&%"L[67+@HYA50JVB)W'!TN'<61P6=TBFY+)2V_"_6*M7T7U#XX=4T MB9-W[?6)#;K04$F2AE!/%8RZ*ACU5L$5=H&K*!PDWHXY"IPO9LID[B-S*IV] MZ*?3^3TF:2M,3@N?R*O7_R:Y33,9TL%UAS:^Y"C;@XO4!;E-QAD=QO&S5*0H M->EDXL%P./QG?*-_R_=B$AVQ'4U&S]C6/K4RZ$]?^8R[\AGWEL\-TXX"LB]+ M'%)N'+NBSE118*WCMR*[][D\>F!V#(N!5@9#T71TQD16B:Y#\*O&,Z^8D3^?X_(;VYVD9MG-7,PK#Y4!6AFE9[1UVCY MTTY5!JV8-^0#6)R72!-\0:>)*Y&+Z06Y!JGPN^V5R&>_)" ^>T +&!8(5N_9AKJQTJ]BW5/NTWVLE[@GL3K-?@]TSAI M#!6P0=7H?((S7]>K97UC5>G7N;6RN!SZXPZW<=!. -]OE++MC3/0[??+KU!+ M P04 " "V@7]4DJ/O=SH. !*0 &0 'AL+W=OO0'GC*;M*D27:\I6CRDYF:C.59%R.9^=A:Q\@ M$I*P(0D. $K1_OKM;@ D=-AQ=FL>;$DDT.B[OV[R]4J;KW8AI>/?JK*V;PX6 MSC77)R9*-1NJ6MX9;MNJ$F9]*TN]>G,P/H@7[M5\X?#"R=O7C9C++]+]WMP9^'72 M42E4)6NK=,V-G+TYN!E?WTYP/2WXAY(KFWSG*,E4ZZ_XXT/QYF"$#,E2Y@XI M"/A8RG>R+)$0L/%GH'G0'8D;T^^1^B\D.\@R%5:^T^4?JG"+-P>7![R0,]&6 M[EZO_BZ#/,1@KDM+__G*KYUD!SQOK=-5V P<5*KVG^);T$.RX7+TR(8L;,B( M;W\0./'VM=$K;G U4,,O)"KM!N94C4;YX@S<5;#/O?VLG;1O3QR<@ZM/\D#SUM/,'J$YSO@G7;N%Y3_7A2PV"9P M@QV76>3R-GN2XGN9#_GI>,"S439^@MYI)_4IT3M]E-[4\??*YJ6VK9'\GS=3 MZPQXR+^>('[6$3\CXF??56D959I[E>8:G-DZO.(6DL]T"3&AZOGU/AT_XQ#V M0X>P&\O@(NA25E-I4)\,]8E*';%[X22_60I5HMGY;ZVS#LC#QOU7V4<%1-QZ MJ"T_&A_SLV$VX8?\!3\=P;^?_G:9C;-76S^_1R;K MR-0G@OXFHQ'^/7\C;HB'!R+L5HI\D6O3#-C'C^_XT>DQG_C5IX.S\PL^'IQ. M0#&#BXMS^#^>3/H=Z>(7L' T&B6?D_B??9$YN%;!P!Y+8%2A_AJC*V6M-FM> M@P'YT=DQSX:PY;#C,'YF1!#(7EVPN[L[]E&+FI_P5.I=YHAQ]=/+H(O!$\H01'.KI\=!%XP1=5YY+]VI9K<+3QV8"O)%^( MI>18,AS\R8(+R*SUUY<@2PN_2NDJ\KJ4F_ _ZAA.C2RO*9R%6IW!IX@Q+ Q=Q(":7)#?EGG3#C!9M*60-#8'Y@ M/U!V"Z#2VXNAO8;\@^-P&4]%_FNJ4\"DD364,]I"=A5UW8JR7 _YK-$:O(V!ST"M&/N]28P$JT/* M1J)&EJ ]S"]BZF4'DLCJ5)0"3,JIZ P9!-K#0K)WNFKPD&A5R(#1?)VVO*DV M7'BU4/F"5QHL!X?#&G 3*\T2#HYF!*S F]8T&N0&GP#27@2W +F ?"7QP_)< MV 6+S!GY9ZL,G6I1_C];8="I)&1,DHPH:&022A6F?L\<'AI$H="Y>&5Y*,?G6,C&EZ1W28Y;H ,@-[>M MQ7QN.<7[3:>Y(V0,."ZH%1Q'%D@R;*N(!Z%)BW-2 X#/U#3FB ML.E3 S$/1UY2\AZP1JRIJ@7?*-<#JMI$ ^Q7YZJ![44KT?-CV60!AHSX*UH- M0@EKI7N)V!!]:ZG+)?I%JM,UPQ262,X3R2G3LU2NFY-[?D^$0)&_!!)11I_P MV SHDQ/WF2_/38M7'DF!I_R0'07A&4!)5;75,6_@B+449A!UU_DSH=T()RBE MS%!5I9HI5&Z>^Z2#8:N6I,@ .8*,7IL",H*#@'4D\R=A\D6OP@%ZC0"/A)P# M457[^SP[]?S20U'/R+;)P/BJYM/:;Z,=MF&[:]@1@K>1;-GJ:V[WHKZ )X M^6OL&M5SUMOUG/#D@.4+4<\#HA)8LWXX9 ][!&V9PF0B$>Z.\[TL+$.C]T?J0*@A?4M!97CLJ0CVAHJ M=(M12B48"I'=2L-$T[:0UL$H5*E!C!2#=3@GDN]T$Z&KY)\!CT9HXL,F3 EN M>B2\#VC@P8B4G$+\RI&J43GPN ]G19SIM$?/4//A",#$5,0+Z-EE0=C(8UC* M#@@M'LG:3T?VD)UMHC),;P!8KO:A,K!P[.> Z[Z?N^N1$#;D 8 944"Y+_C# MD/^Q4*[2!OTMNDZ %=YYD?-]"" ]!"G'XN^UW%%A@*!$!\SEWBCWLJ#.H.TJ E[%\T^S_OQH M^8+2;I+,TL"D!" V$Q!3(1_OV\CU,G@<0.Y.$KJ# MF=C75QQ;XN#Y)8X!&;3""UWX$_5L!M4@$+<]!Y98Z/P:D(6L;> R:ADEG-?J M/VAH2%^.OFUOV>BC:5@1C\"2_"([OT OQ3@<\M\;T [@'Y,KVXF26,*@#&'Y MV,-,4(\LI:'Y3-SARR@>&8\:4+X+X10U&7BFK8Q&!H'S< #Z/?9C>HN-04@0 MWB8O^-7H%& #EEH@XI-6M'_4SCY-?C))XL\7.+=PNI<>-;4MNN6R Y68J2\& M01.^*0,\V1WCG:<1JHA%!1_-((<^E?B>"H>^LENQG;*&_,.NUL8C+$-4BD)2 M"O.X%HV7:BD-2+^&74T&D\F$]=DL37$4\8CQS$9%9*62+8WYA%WPV"%#(%[A MB&\G Y- D"L2_9#7LC C*[J15;\EF?#1<":J#=$>;3 M2 )'O*A(["1H -&7K3NQSA<2# $\NO!,#+[.C:CX4<]BAP!8FA!6B4^AH$V# M8!D.@K\Y."W!LA"D@9\P-Z&C@^04JW5<('&8$)W/MM7.$PNP@'66=9/4(L[] M),_.7JZD_(J80FD Q'*NZCH9>Q8!>! ]F@O$J9+'0_X.:NB:'XECA!\&CO4G M#OC1])@FIAU^FO7QAX\28=V2S-X[&#_R"0(B .B 2R*&+=M">D)&]K2P?B>_ M>DMND,8<-A=SF9QQ/&!'^19GZ19#5[KE?@!S5/@=<5'K/,H.% _B3)O8^#0 M7,<4-&KK!J(=R*; O[G_^0N[R=W3&+&S^4JW9>''R]^#B?[9!8M <;,FH<_A MX D\;A"B'0=/$J #< K<;>$"4BQ,V\IK$5]"8M'^'P4)IZ(8% M$DR'27HC MQ0*\0@U.NZ%VX9\1@ &]B!#CEJ9GZ:.]I)+&F7B2"X").D)7P%Y\R,XIP_TJ M 'E#\LHN0X.:CJHV3L5Q)#Y:V9Y@@]\CHB-($*?>NZUC'.8.F ]M/R=( M9A14Y9O8=CY[3.-',X@X+JD"A\'#_CG%O@'$:'@Q.?3R^>G+=T:-%'YUF"\?R84:\\'J+9 #4[8,\9G?N>; *-<+!'UZ#T0W75G;+9#W:]3>(+ 2^Q MGK/.N,IN/ /@>ST%GYQ1^V-]V[SI Y<_G@X2Q/><)( CI7Y6\\C#K.XA'K8M>V$;E\$S2X[LGV'CR!9H=0D\Q M<(I3O]'&^S2A2EMT89TKVD$QL+T=QR-0MCU?]CM<;;WH@K-&?+,%/\^A7WO. M2RKQ%1+_+DKOP40PONRQSSE/DM?2*FGF]/(=]KZ06OT;:MW5[OV^&_]:6[_< MOQP(<33'=PI*.8.M&&X'OG&./YQNZ"6WJ79.5_1U(05D;UP ]V<:1 D_\(#N MK<>W_P502P,$% @ MH%_5$M"6R^% @ 6 4 !D !X;"]W;W)K&ULC53=3^,P#'_O7V%5/( TT<^-,6V3-CAT/" AN(^' MTSUDK==&I,E(,@K__3GIUAL2[.ZEB1W[][-=V]-6Z2=3(UIX;80TL["V=C.) M(E/4V#!SKC8HZ66M=,,LB;J*S$8C*[U3(Z(TCD=1P[@,YU.ON]?SJ=I:P27> M:S#;IF'Z;8E"M;,P"?>*!U[5UBFB^73#*GQ$^WUSKTF*>I22-R@-5Q(TKF?A M(IDLG'!;SL+8!80""^L0&!TO>(5"." *XWF'&?:4 MSO'POD>_\;E3+BMF\$J)G[RT]2P]W5XU-P7+J?\F@UO7+RL_-;^8+2*LW1P.DWMA)HSJ:1)63W'A4[E&6'DGZ"DJ1P MIZ2M#7R1)9;O 2(*J8\KW<>U3(\B7F-Q#EDR@#1.DR-X69]GYO&R?^3Y!M?< M%$*9K4;XM5@9JZDQ?A]AR'N&W#/D_U')0E'7&@MJ#;9&6"M!S<]E-?FHM$=A MW5!.S(85. MIZ@SJ%PP/N8)/N8*%"4A)E<1FA=I5,W#5="6-@P?64A]9U)P) M R>0#\;))9WI8)P.@QLN.355&51*E0:2P6B8#X,#[@%46AD#H\$P3@@A MNXB#A:-GLL" -@;@:X%D\+QETG+KFRR/1W &IUD,9^^Q)*V@$\**+X<^GBR/ MX:/_$AUT>X.Z\C/M:KZ5MFO\7MNOC44W+7_-NYUSQW3%I0&!:W*-SR^&(>AN MCCO!JHV?G96R-(G^6M/J0^T,Z'VME-T+CJ!?IO,_4$L#!!0 ( +:!?U1> M;+R'U0( H& 9 >&PO=V]R:W-H965TI1EP"&O%2BUC._-*:9A*'.2JB8/I<-U'A32%4Q@T>U M"76C@.7.J1(AC:)16#%>^_.ITZW4?"I;(W@-*T5T6U5,O2Y!R.W,C_V]XIYO M2F,5X7S:L T\@/G6K!2>PAXEYQ74FLN:*"AF_B*>+ ?6WAE\Y[#5!S*QF:RE M?+2'FWSF1Y80",B,16#X]PR7((0%0AI/.TR_#VD=#^4]^B>7.^:R9AHNI?C! M9>;C_#+I^AQ:'+ZE:T%Z+-I:#"D=0RS'?RR@Z4 MW,G:E)I$E_0HXA5DYR2) T(C&A_!2_H") XO^0!OI?"! M*_,:D)5@NS*\%>7G8JV-PJ?SZTBH01]JX$(-_JG6HJ\U/ZQU)O'!:T-D04P) MI) "YX;7F\E[Q3\:S\[S1#0GNHQ"9 M09E&^'9 M1MAN1-X=RTKDH%X=-O3IGI X#6AZ8851,!ZFWI>BX!D/(_KS;]YD.@HLHPF\ZC+Q+9&U4Z\;=XS5!LPWFK4D<1"-*!H.A1X=! M0BFA21 E"6)JC2EE65NU@AG(<9ZQ4AEGW<; )%@EE>&_.\4IC8(1\CES4CP: MDC/O!(./\9F?$!JDHY2\]T["@_FL0&W<%K)5;FO3C6JO[1?=HIOO-_-N2]XQ MM>&UQL85Z!J=CX<^4=WFZ0Y&-F[:U]+@[G!BB&PO=V]R:W-H965TLQL)JJTJ*A^N62G6TY[?VW[XR)L M5ES4(%DQ[5WYX^O$R%N!3YRMU+:8\8AUC)OIM\TZG*,0;!0"Z[J7@UWK!%OL 0W2L\R[8>G<=G$1\P_(!A'X? A+X M)_#"+MK0XH6GHE7PU]5<:8F$^/L$9M1A1A8S>@;SCY;6FFMJV 6\=G7B*+ND MB57>*&U@^__#0*_/25@M*YPA50!84HL3K4^-B:G[1N:G:L&IJS:0^+ M4C%YSWI[+GG_T27O;LU*A-G-+&!>6#5GLLL-G"-%/&-1U)9FHG#VO%PH[;WE M-:USYCZ!_91WLF/OJA)2\W]L$!YJ%GOB5"F&B#]#'&"3$N]=K1DNAO8PY'W1 MDM,Y+[GF&*<_@C#Q[H2FI5<4HVYUN(H?;"7EFL/C$H% M[!GVT'IA"7*T ,[WT?LA/GKVU?'9V&LH7U@,6HD6&8$5EY>M >&UQ:W0:"NM MCQWM=YFX2R$; 1Z>-HA"B@J><,#P/(U\;).,>.\/6(U\4P;(ZMNI(-0GCAVN]I'AA/T>(+ M+$JC?*)PDJYPDI.DO,.L%ZW&I.-9C9U+#>;^V+:[#<,0[, Q:M6.L%&R[QT< M)UT\?G"@W]X/]7N[\>]4@-O54-ALYC[)3-N/XL3V9DO%J1 2"/HDR[#UB?T4 M;7EL)H+8M6:B([B!,7NZ:XJQ:*K?#_K!*'.#B!#XOU-'8,W.SYWU,$OL<6S&&*1+ MJ4EHBF"C('.)C%$"'Y_L)S'.8O,\22#XQ_+SI#_,4>@3;(-^:CD5]DD8G)4A M= \SDT3$=DEX5GJ"46J-D5%@^S#)CI[%PYV?]HK)I;V:*+"[E/M_[[YVMY\K M]]/_*.ZN3A^H7/+:_, 5J(K[,!Z9TEU'W(L6C;T"S(7&"X4=KO &QZ01P/E" M"+U],0:Z.^'L7U!+ P04 " "V@7]4++ZU@H<" !E!0 &0 'AL+W=O M(?V>[/4-(L&E)+7* U7 M$C2NI^$\&2]R%^\#?G#U].$@8Q2\DI/N$U.ONB+S*2V;9;*+5%K2+ M)C0W\*7Z;!+'I3N4.ZMIEU.>G!*EEC^#Q"1KD%OIV$[32G>(HV"V<-BWD)^GM W2T[[!.JK0K72&F@Z=R%+8TC2-+A' MR:2%.RQ:S>V.B!MEN TBF)>/3!8(MTC[% KOWHS2)/T62:( MZU-^YGA'.3QW/-'!U:]1;WR#.Q-(4M<%P^KPALR[UOD7WCU -TQON#0@<$VI M\O./"*P@':.G()BJ1&DG% MR7[]#BE9M8O4&]"'O=B\G/OYOB->[+3Y:K>(#IZ*7-G+SM:Y9\/!N-^(:3J+"["VG?9B3K[@\]RLW7^H+^X*,4&[]']5JX,[?JME506J*S4"@QFEYUE-+^* MO7P0^")Q9P_6X#-9:_W5;SZDEYV!#PAS3)RW(.CO$:\QS[TA"N.OQF:G=>D5 M#]=[Z^]#[I3+6EB\UOGO,G7;R\ZT REFHLK=9[W[%9M\0H")SFWXA5TC.^A M4EFGBT:9(BBDJO_%4U.'_Z+ &P4>XJX=A2AOA!.+"Z-W8+PT6?.+D&K0IN"D M\DVY=X9N)>FYQ0>5Z +A03RAA>Z#6.=HSR[ZCDQ[@7[2F+FJS? ?F(DX?-3* M;2V\4RFFQP;Z%%,;&-\'=L5/6KS!Y!R&40_X@$<#%J78R"B]$/7"P)I8E6B4PA?4SB++,GZ7:A/OWF*(1^:$%(UQ0I^ MK)$HB5 :_2@# M16A[($SM%-9'0(7$8HVF+28(E?K% &20R71.U+3SE[I^,F$_,.:V% E>=F@B M6#2/V%DLV?]=!?8S56#ATE^P&C+,^TP,IM*!<&"=<)73YCG$8>$5C&8Q_?+! ME'W2'OP5#1JB$6LRM?#ZERF/^%N(&:&/O7O"HG30X/$-K%8KN-5"09=/(CC; M2[,5TM!1J!P+F*WM4H+W3B=?X:[T&Z+;$YI$6JI<=SP\T+ZG,/&@$#U0-.&I M$%E3T#4JS*2S$$TF,!E16*4TH6&,I#[=W<)K491OX3ID;F$ZFP'OQ:-A2((& M(95-*FIG@C94V$]>N-;J$4W(GT)>NS;W?5S';HYSF7&(.&=WU'<#'+H3.&/7 M6Z$V/A%X%'E5 TKX3@F5('2C'I^-*.TN[\U&,8>R#6^"-8O\NRD^Y=Y M=M-X/48[?=/\!R^X]!T/E,LR.@KA.L*>-O3UA532J4&JHB>1VR&JH)0(8P+[ M:F8&+6$MTLHSADB])F8[B38,G$PJZH04.;&>+#NO65:FU![X7N$;R2U4'J?' M8ZH5/H>?*S([+C);6O8=[0^8W=;.1W"0TISPZ?$(3CVB7[7 ZO+8 M0_1!.TJ_C>\[D]]+'[FN"SMGG] Q>F=Y8E#]PF +?:!:[81)_92)1KUX//:+ MN!?/)C2<'JD\-(>8K[(.G&F)0:P>38$//7V,=/ZKSB@19^2Z"A2JN5UK'7O: MASO;EZ)+@9[5[$Z1X)U,^8;<4QQR^ M[,<$.QP3M2#-"9*-)X/#/ASAZ5MS7YV<'_V#%U>!9A/>E1XLA//Z\=6>MD_7 M9?UB^R9>OWL_"K.1-/URS$AU<#ZA66#JMV2]<;H,[[>U=O0:#,LM/;_1> &Z MS[1V^XUWT#[H%_\ 4$L#!!0 ( +:!?U1IUBM\C@4 *@/ 9 >&PO M=V]R:W-H965T6NW 46#)FLQ#/M 2[1-A!(]DK*3_?K=D;+B)HX:%"CVP19%W?L]=SP>;92^ M-4O.+=R5LC+'O:6UJ\/!P.1+7C+35RM>X9>YTB6S^*H7 [/2G!6.J92#)(K& M@Y*)JG=RY/:N],F1JJT4%;_28.JR9/K^C$NU.>[%O>W&)[%86MH8G!RMV()? M<_O'ZDKCVZ"54HB25T:H"C2?'_=.X\.SC.@=P6?!-V9G#>3)3*E;>OFM..Y% M9!"7/+%CS<^YE"0(S?BGD=EK51+C[GHK_9WS'7V9,>-/2O)R)8W[ATU#&_4@KXU59<.,%I2B\D]VU\3A)0Q)PY X MN[TB9^4%L^SD2*L-:*)&:;1PKCIN-$Y4E)1KJ_&K0#Y[ S+SAY1G"

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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 77 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 78 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 139 325 1 false 70 0 false 4 false false R1.htm 00000001 - Document - Cover Sheet http://nanophase.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://nanophase.com/role/ConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://nanophase.com/role/ConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://nanophase.com/role/ConsolidatedStatementsOfOperations CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Sheet http://nanophase.com/role/ConsolidatedStatementsOfStockholdersEquity CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statements 5 false false R6.htm 00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://nanophase.com/role/ConsolidatedStatementsOfCashFlows CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 00000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) Sheet http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsParenthetical CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) Statements 7 false false R8.htm 00000008 - Disclosure - Description of Business Sheet http://nanophase.com/role/DescriptionOfBusiness Description of Business Notes 8 false false R9.htm 00000009 - Disclosure - Summary of Significant Accounting Policies Sheet http://nanophase.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 00000010 - Disclosure - Notes and Lines of Credit Notes http://nanophase.com/role/NotesAndLinesOfCredit Notes and Lines of Credit Notes 10 false false R11.htm 00000011 - Disclosure - Inventories Sheet http://nanophase.com/role/Inventories Inventories Notes 11 false false R12.htm 00000012 - Disclosure - Equipment and Leasehold Improvements Sheet http://nanophase.com/role/EquipmentAndLeaseholdImprovements Equipment and Leasehold Improvements Notes 12 false false R13.htm 00000013 - Disclosure - Lease Commitments Sheet http://nanophase.com/role/LeaseCommitments Lease Commitments Notes 13 false false R14.htm 00000014 - Disclosure - Accrued Expenses Sheet http://nanophase.com/role/AccruedExpenses Accrued Expenses Notes 14 false false R15.htm 00000015 - Disclosure - Income Taxes Sheet http://nanophase.com/role/IncomeTaxes Income Taxes Notes 15 false false R16.htm 00000016 - Disclosure - Capital Stock Sheet http://nanophase.com/role/CapitalStock Capital Stock Notes 16 false false R17.htm 00000017 - Disclosure - Stock Options and Stock Grants Sheet http://nanophase.com/role/StockOptionsAndStockGrants Stock Options and Stock Grants Notes 17 false false R18.htm 00000018 - Disclosure - 401(k) Profit-Sharing Plan Sheet http://nanophase.com/role/KProfit-sharingPlan 401(k) Profit-Sharing Plan Notes 18 false false R19.htm 00000019 - Disclosure - Significant Customers and Contingencies Sheet http://nanophase.com/role/SignificantCustomersAndContingencies Significant Customers and Contingencies Notes 19 false false R20.htm 00000020 - Disclosure - Business Segmentation and Geographical Distribution Sheet http://nanophase.com/role/BusinessSegmentationAndGeographicalDistribution Business Segmentation and Geographical Distribution Notes 20 false false R21.htm 00000021 - Disclosure - Contingencies Sheet http://nanophase.com/role/Contingencies Contingencies Notes 21 false false R22.htm 00000022 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://nanophase.com/role/SummaryOfSignificantAccountingPolicies 22 false false R23.htm 00000023 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://nanophase.com/role/SummaryOfSignificantAccountingPolicies 23 false false R24.htm 00000024 - Disclosure - Notes and Lines of Credit (Tables) Notes http://nanophase.com/role/NotesAndLinesOfCreditTables Notes and Lines of Credit (Tables) Tables http://nanophase.com/role/NotesAndLinesOfCredit 24 false false R25.htm 00000025 - Disclosure - Inventories (Tables) Sheet http://nanophase.com/role/InventoriesTables Inventories (Tables) Tables http://nanophase.com/role/Inventories 25 false false R26.htm 00000026 - Disclosure - Equipment and Leasehold Improvements (Tables) Sheet http://nanophase.com/role/EquipmentAndLeaseholdImprovementsTables Equipment and Leasehold Improvements (Tables) Tables http://nanophase.com/role/EquipmentAndLeaseholdImprovements 26 false false R27.htm 00000027 - Disclosure - Lease Commitments (Tables) Sheet http://nanophase.com/role/LeaseCommitmentsTables Lease Commitments (Tables) Tables http://nanophase.com/role/LeaseCommitments 27 false false R28.htm 00000028 - Disclosure - Accrued Expenses (Tables) Sheet http://nanophase.com/role/AccruedExpensesTables Accrued Expenses (Tables) Tables http://nanophase.com/role/AccruedExpenses 28 false false R29.htm 00000029 - Disclosure - Income Taxes (Tables) Sheet http://nanophase.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://nanophase.com/role/IncomeTaxes 29 false false R30.htm 00000030 - Disclosure - Stock Options and Stock Grants (Tables) Sheet http://nanophase.com/role/StockOptionsAndStockGrantsTables Stock Options and Stock Grants (Tables) Tables http://nanophase.com/role/StockOptionsAndStockGrants 30 false false R31.htm 00000031 - Disclosure - Significant Customers and Contingencies (Tables) Sheet http://nanophase.com/role/SignificantCustomersAndContingenciesTables Significant Customers and Contingencies (Tables) Tables http://nanophase.com/role/SignificantCustomersAndContingencies 31 false false R32.htm 00000032 - Disclosure - Business Segmentation and Geographical Distribution (Tables) Sheet http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionTables Business Segmentation and Geographical Distribution (Tables) Tables http://nanophase.com/role/BusinessSegmentationAndGeographicalDistribution 32 false false R33.htm 00000033 - Disclosure - Activity in the asset retirement obligation account for the years ended December 31, is as follows: (Details) Sheet http://nanophase.com/role/ActivityInAssetRetirementObligationAccountForYearsEndedDecember31IsAsFollowsDetails Activity in the asset retirement obligation account for the years ended December 31, is as follows: (Details) Details 33 false false R34.htm 00000034 - Disclosure - Contract balances for the year 2021 and 2020 (Details) Sheet http://nanophase.com/role/ContractBalancesForYear2021And2020Details Contract balances for the year 2021 and 2020 (Details) Details 34 false false R35.htm 00000035 - Disclosure - Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows: (Details) Sheet http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows: (Details) Details 35 false false R36.htm 00000036 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) Sheet http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative Summary of Significant Accounting Policies (Details Narrative) Details http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesTables 36 false false R37.htm 00000037 - Disclosure - Notes and lines of credit consist of the following: (Details) Notes http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails Notes and lines of credit consist of the following: (Details) Details 37 false false R38.htm 00000038 - Disclosure - Schedule of Related Parties (Details) Sheet http://nanophase.com/role/ScheduleOfRelatedPartiesDetails Schedule of Related Parties (Details) Details 38 false false R39.htm 00000039 - Disclosure - Inventories consist of the following: (Details) Sheet http://nanophase.com/role/InventoriesConsistOfFollowingDetails Inventories consist of the following: (Details) Details 39 false false R40.htm 00000040 - Disclosure - Equipment and leasehold improvements consist of the following: (Details) Sheet http://nanophase.com/role/EquipmentAndLeaseholdImprovementsConsistOfFollowingDetails Equipment and leasehold improvements consist of the following: (Details) Details 40 false false R41.htm 00000041 - Disclosure - Equipment and Leasehold Improvements (Details Narrative) Sheet http://nanophase.com/role/EquipmentAndLeaseholdImprovementsDetailsNarrative Equipment and Leasehold Improvements (Details Narrative) Details http://nanophase.com/role/EquipmentAndLeaseholdImprovementsTables 41 false false R42.htm 00000042 - Disclosure - Quantitative information regarding the Company???s leases is as follows: (Details) Sheet http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails Quantitative information regarding the Company???s leases is as follows: (Details) Details 42 false false R43.htm 00000043 - Disclosure - Supplemental cash flow information related to leases is as follows for the years ended December 31, 2021 and 2020: (Details) Sheet http://nanophase.com/role/SupplementalCashFlowInformationRelatedToLeasesIsAsFollowsForYearsEndedDecember312021And2020Details Supplemental cash flow information related to leases is as follows for the years ended December 31, 2021 and 2020: (Details) Details 43 false false R44.htm 00000044 - Disclosure - The future maturities of the Company???s finance and operating leases as of December 31, 2021 are as follows: (Details) Sheet http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfDecember312021AreAsFollowsDetails The future maturities of the Company???s finance and operating leases as of December 31, 2021 are as follows: (Details) Details 44 false false R45.htm 00000045 - Disclosure - Lease Commitments (Details Narrative) Sheet http://nanophase.com/role/LeaseCommitmentsDetailsNarrative Lease Commitments (Details Narrative) Details http://nanophase.com/role/LeaseCommitmentsTables 45 false false R46.htm 00000046 - Disclosure - Accrued expenses consist of the following: (Details) Sheet http://nanophase.com/role/AccruedExpensesConsistOfFollowingDetails Accrued expenses consist of the following: (Details) Details 46 false false R47.htm 00000047 - Disclosure - A reconciliation of income tax expense to the amount computed by applying the Federal income tax rate to loss before provision for income taxes as of December 31, 2021 and 2020 is as follows: (Details) Sheet http://nanophase.com/role/ReconciliationOfIncomeTaxExpenseToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312021And2020IsAsFollowsDetails A reconciliation of income tax expense to the amount computed by applying the Federal income tax rate to loss before provision for income taxes as of December 31, 2021 and 2020 is as follows: (Details) Details 47 false false R48.htm 00000048 - Disclosure - Significant components of our deferred income taxes consist of the following: (Details) Sheet http://nanophase.com/role/SignificantComponentsOfOurDeferredIncomeTaxesConsistOfFollowingDetails Significant components of our deferred income taxes consist of the following: (Details) Details 48 false false R49.htm 00000049 - Disclosure - Income Taxes (Details Narrative) Sheet http://nanophase.com/role/IncomeTaxesDetailsNarrative Income Taxes (Details Narrative) Details http://nanophase.com/role/IncomeTaxesTables 49 false false R50.htm 00000050 - Disclosure - Capital Stock (Details Narrative) Sheet http://nanophase.com/role/CapitalStockDetailsNarrative Capital Stock (Details Narrative) Details http://nanophase.com/role/CapitalStock 50 false false R51.htm 00000051 - Disclosure - We follow ASC Topic 718, Share-Based Payments, in which compensation expense is recognized only for share-based payments expected to vest. (Details) Sheet http://nanophase.com/role/WeFollowAscTopic718Share-basedPaymentsInWhichCompensationExpenseIsRecognizedOnlyForShare-basedPaymentsExpectedToVest.Details We follow ASC Topic 718, Share-Based Payments, in which compensation expense is recognized only for share-based payments expected to vest. (Details) Details 51 false false R52.htm 00000052 - Disclosure - Schedule of assumptions used to calculate Black-Scholes option pricing model for options granted (Details) Sheet http://nanophase.com/role/ScheduleOfAssumptionsUsedToCalculateBlack-scholesOptionPricingModelForOptionsGrantedDetails Schedule of assumptions used to calculate Black-Scholes option pricing model for options granted (Details) Details 52 false false R53.htm 00000053 - Disclosure - Additional disclosures for options granted for all years presented: (Details) Sheet http://nanophase.com/role/AdditionalDisclosuresForOptionsGrantedForAllYearsPresentedDetails Additional disclosures for options granted for all years presented: (Details) Details 53 false false R54.htm 00000054 - Disclosure - Schedule of option activity (Details) Sheet http://nanophase.com/role/ScheduleOfOptionActivityDetails Schedule of option activity (Details) Details 54 false false R55.htm 00000055 - Disclosure - The aggregate intrinsic value in the table above is based on our closing stock price of $4.40 on the last business day for the year ended December 31, 2021. (Details) Sheet http://nanophase.com/role/AggregateIntrinsicValueInTableAboveIsBasedOnOurClosingStockPriceOf4.40OnLastBusinessDayForYearEndedDecember312021.Details The aggregate intrinsic value in the table above is based on our closing stock price of $4.40 on the last business day for the year ended December 31, 2021. (Details) Details 55 false false R56.htm 00000056 - Disclosure - Stock Options and Stock Grants (Details Narrative) Sheet http://nanophase.com/role/StockOptionsAndStockGrantsDetailsNarrative Stock Options and Stock Grants (Details Narrative) Details http://nanophase.com/role/StockOptionsAndStockGrantsTables 56 false false R57.htm 00000057 - Disclosure - 401(k) Profit-Sharing Plan (Details Narrative) Sheet http://nanophase.com/role/KProfit-sharingPlanDetailsNarrative 401(k) Profit-Sharing Plan (Details Narrative) Details http://nanophase.com/role/KProfit-sharingPlan 57 false false R58.htm 00000058 - Disclosure - We had five significant customers for the year ended December 31, 2021. (Details) Sheet http://nanophase.com/role/WeHadFiveSignificantCustomersForYearEndedDecember312021.Details We had five significant customers for the year ended December 31, 2021. (Details) Details 58 false false R59.htm 00000059 - Disclosure - Accounts receivable balances for these five customers were approximately: (Details) Sheet http://nanophase.com/role/AccountsReceivableBalancesForTheseFiveCustomersWereApproximatelyDetails Accounts receivable balances for these five customers were approximately: (Details) Details 59 false false R60.htm 00000060 - Disclosure - Significant Customers and Contingencies (Details Narrative) Sheet http://nanophase.com/role/SignificantCustomersAndContingenciesDetailsNarrative Significant Customers and Contingencies (Details Narrative) Details http://nanophase.com/role/SignificantCustomersAndContingenciesTables 60 false false R61.htm 00000061 - Disclosure - The revenues for 2021 and 2020 by category are as follows: (Details) Sheet http://nanophase.com/role/RevenuesFor2021And2020ByCategoryAreAsFollowsDetails The revenues for 2021 and 2020 by category are as follows: (Details) Details 61 false false R62.htm 00000062 - Disclosure - Business Segmentation and Geographical Distribution (Details Narrative) Sheet http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionDetailsNarrative Business Segmentation and Geographical Distribution (Details Narrative) Details http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionTables 62 false false All Reports Book All Reports nanx-10k_123121.htm ex21-1.htm ex23-1.htm ex31-1.htm ex31-2.htm ex32.htm nanx-20211231.xsd nanx-20211231_cal.xml nanx-20211231_def.xml nanx-20211231_lab.xml nanx-20211231_pre.xml http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021q4 true true JSON 81 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "nanx-10k_123121.htm": { "axisCustom": 0, "axisStandard": 21, "contextCount": 139, "dts": { "calculationLink": { "local": [ "nanx-20211231_cal.xml" ] }, "definitionLink": { "local": [ "nanx-20211231_def.xml" ] }, "inline": { "local": [ "nanx-10k_123121.htm" ] }, "labelLink": { "local": [ "nanx-20211231_lab.xml" ] }, "presentationLink": { "local": [ "nanx-20211231_pre.xml" ] }, "schema": { "local": [ "nanx-20211231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 524, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 59, "http://nanophase.com/20211231": 9, "http://xbrl.sec.gov/dei/2021q4": 5, "total": 73 }, "keyCustom": 32, "keyStandard": 293, "memberCustom": 43, "memberStandard": 24, "nsprefix": "nanx", "nsuri": "http://nanophase.com/20211231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://nanophase.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - Notes and Lines of Credit", "role": "http://nanophase.com/role/NotesAndLinesOfCredit", "shortName": "Notes and Lines of Credit", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - Inventories", "role": "http://nanophase.com/role/Inventories", "shortName": "Inventories", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - Equipment and Leasehold Improvements", "role": "http://nanophase.com/role/EquipmentAndLeaseholdImprovements", "shortName": "Equipment and Leasehold Improvements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - Lease Commitments", "role": "http://nanophase.com/role/LeaseCommitments", "shortName": "Lease Commitments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - Accrued Expenses", "role": "http://nanophase.com/role/AccruedExpenses", "shortName": "Accrued Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - Income Taxes", "role": "http://nanophase.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - Capital Stock", "role": "http://nanophase.com/role/CapitalStock", "shortName": "Capital Stock", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - Stock Options and Stock Grants", "role": "http://nanophase.com/role/StockOptionsAndStockGrants", "shortName": "Stock Options and Stock Grants", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - 401(k) Profit-Sharing Plan", "role": "http://nanophase.com/role/KProfit-sharingPlan", "shortName": "401(k) Profit-Sharing Plan", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - Significant Customers and Contingencies", "role": "http://nanophase.com/role/SignificantCustomersAndContingencies", "shortName": "Significant Customers and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - CONSOLIDATED BALANCE SHEETS", "role": "http://nanophase.com/role/ConsolidatedBalanceSheets", "shortName": "CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - Business Segmentation and Geographical Distribution", "role": "http://nanophase.com/role/BusinessSegmentationAndGeographicalDistribution", "shortName": "Business Segmentation and Geographical Distribution", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - Contingencies", "role": "http://nanophase.com/role/Contingencies", "shortName": "Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:AssetRetirementObligationsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfChangeInAssetRetirementObligationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - Summary of Significant Accounting Policies (Tables)", "role": "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AssetRetirementObligationsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfChangeInAssetRetirementObligationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - Notes and Lines of Credit (Tables)", "role": "http://nanophase.com/role/NotesAndLinesOfCreditTables", "shortName": "Notes and Lines of Credit (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - Inventories (Tables)", "role": "http://nanophase.com/role/InventoriesTables", "shortName": "Inventories (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - Equipment and Leasehold Improvements (Tables)", "role": "http://nanophase.com/role/EquipmentAndLeaseholdImprovementsTables", "shortName": "Equipment and Leasehold Improvements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:LeasesOfLesseeDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - Lease Commitments (Tables)", "role": "http://nanophase.com/role/LeaseCommitmentsTables", "shortName": "Lease Commitments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LeasesOfLesseeDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - Accrued Expenses (Tables)", "role": "http://nanophase.com/role/AccruedExpensesTables", "shortName": "Accrued Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - Income Taxes (Tables)", "role": "http://nanophase.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "role": "http://nanophase.com/role/ConsolidatedBalanceSheetsParenthetical", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - Stock Options and Stock Grants (Tables)", "role": "http://nanophase.com/role/StockOptionsAndStockGrantsTables", "shortName": "Stock Options and Stock Grants (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "us-gaap:ConcentrationRiskDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - Significant Customers and Contingencies (Tables)", "role": "http://nanophase.com/role/SignificantCustomersAndContingenciesTables", "shortName": "Significant Customers and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:ConcentrationRiskDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - Business Segmentation and Geographical Distribution (Tables)", "role": "http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionTables", "shortName": "Business Segmentation and Geographical Distribution (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "AsOf2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetRetirementObligationsNoncurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000033 - Disclosure - Activity in the asset retirement obligation account for the years ended December 31, is as follows: (Details)", "role": "http://nanophase.com/role/ActivityInAssetRetirementObligationAccountForYearsEndedDecember31IsAsFollowsDetails", "shortName": "Activity in the asset retirement obligation account for the years ended December 31, is as follows: (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfChangeInAssetRetirementObligationTableTextBlock", "us-gaap:AssetRetirementObligationsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "AsOf2019-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:AssetRetirementObligationsNoncurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000034 - Disclosure - Contract balances for the year 2021 and 2020 (Details)", "role": "http://nanophase.com/role/ContractBalancesForYear2021And2020Details", "shortName": "Contract balances for the year 2021 and 2020 (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "us-gaap:RevenueRecognitionPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "AsOf2019-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000035 - Disclosure - Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows: (Details)", "role": "http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails", "shortName": "Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows: (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R36": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredRevenue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000036 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)", "role": "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "shortName": "Summary of Significant Accounting Policies (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredRevenue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InterestExpense", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000037 - Disclosure - Notes and lines of credit consist of the following: (Details)", "role": "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails", "shortName": "Notes and lines of credit consist of the following: (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-05-062021-05-07_custom_WhitmoreMember", "decimals": "-3", "lang": null, "name": "us-gaap:ConversionOfStockSharesIssued1", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InterestExpenseRelatedParty", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000038 - Disclosure - Schedule of Related Parties (Details)", "role": "http://nanophase.com/role/ScheduleOfRelatedPartiesDetails", "shortName": "Schedule of Related Parties (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InterestExpenseRelatedParty", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000039 - Disclosure - Inventories consist of the following: (Details)", "role": "http://nanophase.com/role/InventoriesConsistOfFollowingDetails", "shortName": "Inventories consist of the following: (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS", "role": "http://nanophase.com/role/ConsolidatedStatementsOfOperations", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000040 - Disclosure - Equipment and leasehold improvements consist of the following: (Details)", "role": "http://nanophase.com/role/EquipmentAndLeaseholdImprovementsConsistOfFollowingDetails", "shortName": "Equipment and leasehold improvements consist of the following: (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000041 - Disclosure - Equipment and Leasehold Improvements (Details Narrative)", "role": "http://nanophase.com/role/EquipmentAndLeaseholdImprovementsDetailsNarrative", "shortName": "Equipment and Leasehold Improvements (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000042 - Disclosure - Quantitative information regarding the Company\u2019s leases is as follows: (Details)", "role": "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails", "shortName": "Quantitative information regarding the Company\u2019s leases is as follows: (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "nanx:SummaryOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000043 - Disclosure - Supplemental cash flow information related to leases is as follows for the years ended December 31, 2021 and 2020: (Details)", "role": "http://nanophase.com/role/SupplementalCashFlowInformationRelatedToLeasesIsAsFollowsForYearsEndedDecember312021And2020Details", "shortName": "Supplemental cash flow information related to leases is as follows for the years ended December 31, 2021 and 2020: (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "nanx:SummaryOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "nanx:ScheduleOfFutureMaturitiesOfFinanceAndOperatingLeasesTableTextBlock", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000044 - Disclosure - The future maturities of the Company\u2019s finance and operating leases as of December 31, 2021 are as follows: (Details)", "role": "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfDecember312021AreAsFollowsDetails", "shortName": "The future maturities of the Company\u2019s finance and operating leases as of December 31, 2021 are as follows: (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "nanx:ScheduleOfFutureMaturitiesOfFinanceAndOperatingLeasesTableTextBlock", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000045 - Disclosure - Lease Commitments (Details Narrative)", "role": "http://nanophase.com/role/LeaseCommitmentsDetailsNarrative", "shortName": "Lease Commitments (Details Narrative)", "subGroupType": "details", "uniqueAnchor": null }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000046 - Disclosure - Accrued expenses consist of the following: (Details)", "role": "http://nanophase.com/role/AccruedExpensesConsistOfFollowingDetails", "shortName": "Accrued expenses consist of the following: (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000047 - Disclosure - A reconciliation of income tax expense to the amount computed by applying the Federal income tax rate to loss before provision for income taxes as of December 31, 2021 and 2020 is as follows: (Details)", "role": "http://nanophase.com/role/ReconciliationOfIncomeTaxExpenseToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312021And2020IsAsFollowsDetails", "shortName": "A reconciliation of income tax expense to the amount computed by applying the Federal income tax rate to loss before provision for income taxes as of December 31, 2021 and 2020 is as follows: (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "AsOf2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxLiabilitiesFinancingArrangements", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000048 - Disclosure - Significant components of our deferred income taxes consist of the following: (Details)", "role": "http://nanophase.com/role/SignificantComponentsOfOurDeferredIncomeTaxesConsistOfFollowingDetails", "shortName": "Significant components of our deferred income taxes consist of the following: (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "AsOf2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxLiabilitiesFinancingArrangements", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000049 - Disclosure - Income Taxes (Details Narrative)", "role": "http://nanophase.com/role/IncomeTaxesDetailsNarrative", "shortName": "Income Taxes (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "AsOf2019-12-31_us-gaap_CommonStockMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "role": "http://nanophase.com/role/ConsolidatedStatementsOfStockholdersEquity", "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "AsOf2019-12-31_us-gaap_CommonStockMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "AsOf2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000050 - Disclosure - Capital Stock (Details Narrative)", "role": "http://nanophase.com/role/CapitalStockDetailsNarrative", "shortName": "Capital Stock (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "AsOf2021-12-31_custom_PlanMember", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockOptionPlanExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000051 - Disclosure - We follow ASC Topic 718, Share-Based Payments, in which compensation expense is recognized only for share-based payments expected to vest. (Details)", "role": "http://nanophase.com/role/WeFollowAscTopic718Share-basedPaymentsInWhichCompensationExpenseIsRecognizedOnlyForShare-basedPaymentsExpectedToVest.Details", "shortName": "We follow ASC Topic 718, Share-Based Payments, in which compensation expense is recognized only for share-based payments expected to vest. (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockOptionPlanExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000052 - Disclosure - Schedule of assumptions used to calculate Black-Scholes option pricing model for options granted (Details)", "role": "http://nanophase.com/role/ScheduleOfAssumptionsUsedToCalculateBlack-scholesOptionPricingModelForOptionsGrantedDetails", "shortName": "Schedule of assumptions used to calculate Black-Scholes option pricing model for options granted (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "nanx:AdditionalDisclosuresForOptionsGrantedTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember", "decimals": "INF", "first": true, "lang": null, "name": "nanx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFortfeitureRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000053 - Disclosure - Additional disclosures for options granted for all years presented: (Details)", "role": "http://nanophase.com/role/AdditionalDisclosuresForOptionsGrantedForAllYearsPresentedDetails", "shortName": "Additional disclosures for options granted for all years presented: (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "nanx:AdditionalDisclosuresForOptionsGrantedTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember", "decimals": "INF", "first": true, "lang": null, "name": "nanx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFortfeitureRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "AsOf2020-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000054 - Disclosure - Schedule of option activity (Details)", "role": "http://nanophase.com/role/ScheduleOfOptionActivityDetails", "shortName": "Schedule of option activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "AsOf2020-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000055 - Disclosure - The aggregate intrinsic value in the table above is based on our closing stock price of $4.40 on the last business day for the year ended December 31, 2021. (Details)", "role": "http://nanophase.com/role/AggregateIntrinsicValueInTableAboveIsBasedOnOurClosingStockPriceOf4.40OnLastBusinessDayForYearEndedDecember312021.Details", "shortName": "The aggregate intrinsic value in the table above is based on our closing stock price of $4.40 on the last business day for the year ended December 31, 2021. (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "nanx:StockOptionsRecognizedTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember", "decimals": "INF", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-012021-12-31_custom_EquityCompensationPlan2019Member", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000056 - Disclosure - Stock Options and Stock Grants (Details Narrative)", "role": "http://nanophase.com/role/StockOptionsAndStockGrantsDetailsNarrative", "shortName": "Stock Options and Stock Grants (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-012021-12-31_custom_EquityCompensationPlan2019Member", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000057 - Disclosure - 401(k) Profit-Sharing Plan (Details Narrative)", "role": "http://nanophase.com/role/KProfit-sharingPlanDetailsNarrative", "shortName": "401(k) Profit-Sharing Plan (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "us-gaap:ConcentrationRiskDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-012021-12-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember_custom_CustomerOneMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000058 - Disclosure - We had five significant customers for the year ended December 31, 2021. (Details)", "role": "http://nanophase.com/role/WeHadFiveSignificantCustomersForYearEndedDecember312021.Details", "shortName": "We had five significant customers for the year ended December 31, 2021. (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "us-gaap:ConcentrationRiskDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-012021-12-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember_custom_CustomerOneMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "nanx:ContractWithCustomerAccountReceivablesTableTextBlock", "us-gaap:ConcentrationRiskDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000059 - Disclosure - Accounts receivable balances for these five customers were approximately: (Details)", "role": "http://nanophase.com/role/AccountsReceivableBalancesForTheseFiveCustomersWereApproximatelyDetails", "shortName": "Accounts receivable balances for these five customers were approximately: (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "nanx:ContractWithCustomerAccountReceivablesTableTextBlock", "us-gaap:ConcentrationRiskDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "role": "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:ConcentrationRiskDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "AsOf2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "nanx:EquipmentSaleNetBookValueEquipment", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000060 - Disclosure - Significant Customers and Contingencies (Details Narrative)", "role": "http://nanophase.com/role/SignificantCustomersAndContingenciesDetailsNarrative", "shortName": "Significant Customers and Contingencies (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:ConcentrationRiskDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "AsOf2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "nanx:EquipmentSaleNetBookValueEquipment", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000061 - Disclosure - The revenues for 2021 and 2020 by category are as follows: (Details)", "role": "http://nanophase.com/role/RevenuesFor2021And2020ByCategoryAreAsFollowsDetails", "shortName": "The revenues for 2021 and 2020 by category are as follows: (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-012021-12-31_custom_PersonalCareIngredientsMember", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-012021-12-31_us-gaap_ProductMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000062 - Disclosure - Business Segmentation and Geographical Distribution (Details Narrative)", "role": "http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionDetailsNarrative", "shortName": "Business Segmentation and Geographical Distribution (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-012021-12-31_us-gaap_ProductMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtConversionOriginalDebtAmount1", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)", "role": "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsParenthetical", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtConversionOriginalDebtAmount1", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - Description of Business", "role": "http://nanophase.com/role/DescriptionOfBusiness", "shortName": "Description of Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - Summary of Significant Accounting Policies", "role": "http://nanophase.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "nanx-10k_123121.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 70, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r544" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r544" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r541", "r543", "r544" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r541", "r543", "r544" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r541", "r543", "r544" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r543" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r541", "r543", "r544" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r542" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r530" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r543" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r543" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r545" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r533" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r536" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r532" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r532" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r549" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r532" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r546" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r544" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r532" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r532" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r532" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r532" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r547" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r543" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r537" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r538" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r531" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r535" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r534" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r539" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r540" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r548" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "booleanItemType" }, "nanx_AAndRLoanAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This element represents member fact value.", "label": "A And R Loan Agreement [Member]" } } }, "localname": "AAndRLoanAgreementMember", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "xbrltype": "domainItemType" }, "nanx_AdditionalDisclosuresForOptionsGrantedTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This element represents a table text block fact value.", "label": "Additional disclosures for options granted for all years presented:" } } }, "localname": "AdditionalDisclosuresForOptionsGrantedTableTextBlock", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/StockOptionsAndStockGrantsTables" ], "xbrltype": "textBlockItemType" }, "nanx_AdvancedMaterialsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Advanced Materials.", "label": "Advanced Materials [Member]" } } }, "localname": "AdvancedMaterialsMember", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/RevenuesFor2021And2020ByCategoryAreAsFollowsDetails" ], "xbrltype": "domainItemType" }, "nanx_BeachcorpLLCFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This element represents member fact value.", "label": "Beachcorp LLC Four [Member]" } } }, "localname": "BeachcorpLLCFourMember", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "xbrltype": "domainItemType" }, "nanx_BeachcorpLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Beachcorp LLC.", "label": "Beachcorp, LLC [Member]" } } }, "localname": "BeachcorpLLCMember", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails", "http://nanophase.com/role/ScheduleOfRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "nanx_BeachcorpLLCOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This element represents member fact value.", "label": "Beachcorp LLC One [Member]" } } }, "localname": "BeachcorpLLCOneMember", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "xbrltype": "domainItemType" }, "nanx_BeachcorpLLCThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This element represents member fact value.", "label": "Beachcorp LLC Three [Member]" } } }, "localname": "BeachcorpLLCThreeMember", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "xbrltype": "domainItemType" }, "nanx_BradfordTWhitmoreMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bradford T Whitmore.", "label": "Bradford T. Whitmore [Member]" } } }, "localname": "BradfordTWhitmoreMember", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "xbrltype": "domainItemType" }, "nanx_BusinessLoanAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business loan agreement.", "label": "Business Loan Agreement [Member]" } } }, "localname": "BusinessLoanAgreementMember", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "xbrltype": "domainItemType" }, "nanx_ContractWithCustomerAccountReceivablesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This element represents a table text block fact value.", "label": "Accounts receivable balances for these five customers were approximately:" } } }, "localname": "ContractWithCustomerAccountReceivablesTableTextBlock", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/SignificantCustomersAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "nanx_ConversionOfConvertibleLoanRelatedParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents a monetary fact value.", "label": "Conversion of $2M convertible loan, related party" } } }, "localname": "ConversionOfConvertibleLoanRelatedParty", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "nanx_CreditAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This element represents member fact value.", "label": "Credit Agreement [Member]" } } }, "localname": "CreditAgreementMember", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "xbrltype": "domainItemType" }, "nanx_CustomerFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer five.", "label": "Customer Five - Medical Diagnostics [Member]" } } }, "localname": "CustomerFiveMember", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/AccountsReceivableBalancesForTheseFiveCustomersWereApproximatelyDetails", "http://nanophase.com/role/WeHadFiveSignificantCustomersForYearEndedDecember312021.Details" ], "xbrltype": "domainItemType" }, "nanx_CustomerFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer four.", "label": "Customer Four - Solesence [Member]" } } }, "localname": "CustomerFourMember", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/AccountsReceivableBalancesForTheseFiveCustomersWereApproximatelyDetails", "http://nanophase.com/role/WeHadFiveSignificantCustomersForYearEndedDecember312021.Details" ], "xbrltype": "domainItemType" }, "nanx_CustomerNetVolumeRebatePayable": { "auth_ref": [], "calculation": { "http://nanophase.com/role/AccruedExpensesConsistOfFollowingDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This element represents a monetary value.", "label": "Accrued accounts payable" } } }, "localname": "CustomerNetVolumeRebatePayable", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/AccruedExpensesConsistOfFollowingDetails" ], "xbrltype": "monetaryItemType" }, "nanx_CustomerOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer one.", "label": "Customer One - Personal Care Ingredients [Member]" } } }, "localname": "CustomerOneMember", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/AccountsReceivableBalancesForTheseFiveCustomersWereApproximatelyDetails", "http://nanophase.com/role/WeHadFiveSignificantCustomersForYearEndedDecember312021.Details" ], "xbrltype": "domainItemType" }, "nanx_CustomerThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer three.", "label": "Customer Three - Solesence [Member]" } } }, "localname": "CustomerThreeMember", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/AccountsReceivableBalancesForTheseFiveCustomersWereApproximatelyDetails", "http://nanophase.com/role/WeHadFiveSignificantCustomersForYearEndedDecember312021.Details" ], "xbrltype": "domainItemType" }, "nanx_CustomerTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer two.", "label": "Customer Two - Solesence [Member]" } } }, "localname": "CustomerTwoMember", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/AccountsReceivableBalancesForTheseFiveCustomersWereApproximatelyDetails", "http://nanophase.com/role/WeHadFiveSignificantCustomersForYearEndedDecember312021.Details" ], "xbrltype": "domainItemType" }, "nanx_CustomersOneThroughFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customers One through Five.", "label": "Customers One through Five [Member]" } } }, "localname": "CustomersOneThroughFiveMember", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/WeHadFiveSignificantCustomersForYearEndedDecember312021.Details" ], "xbrltype": "domainItemType" }, "nanx_DefinedContributionPlanEmployerMatchingContributionPercentOfSalary": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This element represents a monetary value.", "label": "Participant salary percentage matched" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfSalary", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/KProfit-sharingPlanDetailsNarrative" ], "xbrltype": "percentItemType" }, "nanx_EquipmentSaleNetBookValueEquipment": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of equipment's net book value to be sold to customer after a triggering event as stated in the supply agreement.", "label": "Equipment sale - net book value" } } }, "localname": "EquipmentSaleNetBookValueEquipment", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/SignificantCustomersAndContingenciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "nanx_EquipmentSaleOriginalBookValueOfEquipmentAndUpgrades": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of equipment's original value, including upgrades; to be sold to customer after a triggering event as stated in the supply agreement.", "label": "Equipment sale- original book value" } } }, "localname": "EquipmentSaleOriginalBookValueOfEquipmentAndUpgrades", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/SignificantCustomersAndContingenciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "nanx_EquityCompensationPlan2010Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This element represents a member fact value.", "label": "Equity Compensation Plan 2010 [Member]" } } }, "localname": "EquityCompensationPlan2010Member", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/StockOptionsAndStockGrantsDetailsNarrative" ], "xbrltype": "domainItemType" }, "nanx_EquityCompensationPlan2019Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This element represents a member fact value.", "label": ":Equity Compensation Plan 2019 [Member]" } } }, "localname": "EquityCompensationPlan2019Member", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/StockOptionsAndStockGrantsDetailsNarrative" ], "xbrltype": "domainItemType" }, "nanx_ExpiringOperatingLossCarryforwardsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This element represents a member fact value.", "label": "Expiring Operating Loss Carry forwards [Member]" } } }, "localname": "ExpiringOperatingLossCarryforwardsMember", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "domainItemType" }, "nanx_FinanceLeaseCostComponentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This element represents a abstract fact value.", "label": "Finance lease cost components:" } } }, "localname": "FinanceLeaseCostComponentsAbstract", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails" ], "xbrltype": "stringItemType" }, "nanx_FirstAmendmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First amendment.", "label": "First Amendment [Member]" } } }, "localname": "FirstAmendmentMember", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "xbrltype": "domainItemType" }, "nanx_FourthAmendmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fourth amendment.", "label": "Fourth Amendment [Member]" } } }, "localname": "FourthAmendmentMember", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "xbrltype": "domainItemType" }, "nanx_GainOnForgivenessOfPppLoan": { "auth_ref": [], "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This element reprsents a monetary fact value.", "label": "Gain On Forgiveness Of Ppp Loan", "negatedLabel": "Gain on forgiveness of PPP loan" } } }, "localname": "GainOnForgivenessOfPppLoan", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "nanx_LeaseCostsFinance": { "auth_ref": [], "calculation": { "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of finance lease costs recognized by lessee for lease contract.", "label": "Total finance lease costs", "totalLabel": "Total finance lease costs" } } }, "localname": "LeaseCostsFinance", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "nanx_LeaseImputedInterest": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for leases.", "label": "Less amounts representing interest", "negatedLabel": "Less amounts representing interest" } } }, "localname": "LeaseImputedInterest", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfDecember312021AreAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "nanx_LeaseLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments.", "label": "Total, Total minimum payments required:" } } }, "localname": "LeaseLiability", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfDecember312021AreAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "nanx_LeaseLiabilityPaymentDue": { "auth_ref": [], "calculation": { "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfDecember312021AreAsFollowsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments.", "label": "Total payments", "totalLabel": "Total payments" } } }, "localname": "LeaseLiabilityPaymentDue", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfDecember312021AreAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "nanx_LeaseLiabilityPaymentsDueYearFive": { "auth_ref": [], "calculation": { "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfDecember312021AreAsFollowsDetails": { "order": 5.0, "parentTag": "nanx_LeaseLiabilityPaymentDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments due in fifth fiscal year following latest fiscal year.", "label": "Total, Year 5" } } }, "localname": "LeaseLiabilityPaymentsDueYearFive", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfDecember312021AreAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "nanx_LeaseLiabilityPaymentsDueYearFour": { "auth_ref": [], "calculation": { "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfDecember312021AreAsFollowsDetails": { "order": 4.0, "parentTag": "nanx_LeaseLiabilityPaymentDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments due in fourth fiscal year following latest fiscal year.", "label": "Total, Year 4" } } }, "localname": "LeaseLiabilityPaymentsDueYearFour", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfDecember312021AreAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "nanx_LeaseLiabilityPaymentsDueYearOne": { "auth_ref": [], "calculation": { "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfDecember312021AreAsFollowsDetails": { "order": 1.0, "parentTag": "nanx_LeaseLiabilityPaymentDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments due in remainder of fiscal year following latest fiscal year ended.", "label": "Total, Year 1" } } }, "localname": "LeaseLiabilityPaymentsDueYearOne", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfDecember312021AreAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "nanx_LeaseLiabilityPaymentsDueYearThereafter": { "auth_ref": [], "calculation": { "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfDecember312021AreAsFollowsDetails": { "order": 6.0, "parentTag": "nanx_LeaseLiabilityPaymentDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments due after fifth fiscal year following latest fiscal year.", "label": "Total, thereafter" } } }, "localname": "LeaseLiabilityPaymentsDueYearThereafter", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfDecember312021AreAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "nanx_LeaseLiabilityPaymentsDueYearThree": { "auth_ref": [], "calculation": { "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfDecember312021AreAsFollowsDetails": { "order": 3.0, "parentTag": "nanx_LeaseLiabilityPaymentDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments due in third fiscal year following latest fiscal year.", "label": "Total, Year 3" } } }, "localname": "LeaseLiabilityPaymentsDueYearThree", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfDecember312021AreAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "nanx_LeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [], "calculation": { "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfDecember312021AreAsFollowsDetails": { "order": 2.0, "parentTag": "nanx_LeaseLiabilityPaymentDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments due in second fiscal year following latest fiscal year.", "label": "Total, Year 2" } } }, "localname": "LeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfDecember312021AreAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "nanx_LibertyvilleBankAndTrustMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This element represents member fact value.", "label": "Libertyville Bank And Trust [Member]" } } }, "localname": "LibertyvilleBankAndTrustMember", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "xbrltype": "domainItemType" }, "nanx_LibertyvilleBankAndTrustOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This element represents member fact value.", "label": "Libertyville Bank And Trust One [Member]" } } }, "localname": "LibertyvilleBankAndTrustOneMember", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "xbrltype": "domainItemType" }, "nanx_LibertyvilleBankAndTrustTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This element represents member fact value.", "label": "Libertyville Bank And Trust Two [Member]" } } }, "localname": "LibertyvilleBankAndTrustTwoMember", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "xbrltype": "domainItemType" }, "nanx_LibertyvilleMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Libertyville.", "label": "Libertyville [Member]" } } }, "localname": "LibertyvilleMember", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "xbrltype": "domainItemType" }, "nanx_LongtermDebtRelatedParty": { "auth_ref": [], "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This element represents a monetary fact value.", "label": "Long-term debt, related party" } } }, "localname": "LongtermDebtRelatedParty", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "nanx_NewBusinessLoanAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This element represents a member fact value.", "label": "New Business Loan Agreement [Member]" } } }, "localname": "NewBusinessLoanAgreementMember", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "xbrltype": "domainItemType" }, "nanx_OperatingLeaseCostComponentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This element represents a abstract fact value.", "label": "Operating lease cost components:" } } }, "localname": "OperatingLeaseCostComponentsAbstract", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails" ], "xbrltype": "stringItemType" }, "nanx_OperatingLossCarryforwardsExpirationYearEnd": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This element represents a time fact value.", "label": "Capital loss carryforwards expiration period end" } } }, "localname": "OperatingLossCarryforwardsExpirationYearEnd", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "gYearItemType" }, "nanx_OperatingLossCarryforwardsExpirationYearStart": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This element represents a time fact value.", "label": "Capital loss carryforwards expiration period start" } } }, "localname": "OperatingLossCarryforwardsExpirationYearStart", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "gYearItemType" }, "nanx_OtherRevenuePolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This element represents text block fact value", "label": "Other Revenue" } } }, "localname": "OtherRevenuePolicyTextBlock", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "nanx_PPPLoanLibertyvillePromissoryNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This element represents member fact value.", "label": "PPP Loan Libertyville Promissory Note [Member]" } } }, "localname": "PPPLoanLibertyvillePromissoryNoteMember", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "xbrltype": "domainItemType" }, "nanx_PersonalCareIngredientsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Personal Care Ingredients.", "label": "Personal Care Ingredients [Member]" } } }, "localname": "PersonalCareIngredientsMember", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/RevenuesFor2021And2020ByCategoryAreAsFollowsDetails" ], "xbrltype": "domainItemType" }, "nanx_PlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This element is a member fact value.", "label": "Plan [Member]" } } }, "localname": "PlanMember", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/CapitalStockDetailsNarrative" ], "xbrltype": "domainItemType" }, "nanx_ProceedsFromPppSbaLoan": { "auth_ref": [], "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a Paycheck Protection Program Loan by the SBA.", "label": "Proceeds from PPP / SBA loan" } } }, "localname": "ProceedsFromPppSbaLoan", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "nanx_ProceedsFromRelatedPartyTermLoan": { "auth_ref": [], "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents a monetary fact value.", "label": "Proceeds from related party term loan" } } }, "localname": "ProceedsFromRelatedPartyTermLoan", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "nanx_PromissoryNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Promissory note.", "label": "Promissory Note (PPP) [Member]" } } }, "localname": "PromissoryNoteMember", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "xbrltype": "domainItemType" }, "nanx_RelatedPartyCreditFacilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party Credit Facilities.", "label": "Related Party Credit Facilities [Member]" } } }, "localname": "RelatedPartyCreditFacilitiesMember", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "xbrltype": "domainItemType" }, "nanx_RelatedPartyTransactionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of related party transaction.", "label": "Related Party Transaction [Member]" } } }, "localname": "RelatedPartyTransactionMember", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/ScheduleOfRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "nanx_RevenueFromContractWithCustomerExcludingAssessedTaxUnderContactLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This element represents a monetary fact value.", "label": "Revenue from contract with customer excluding assessed tax" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTaxUnderContactLiability", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "nanx_RightOfUseAssetAcquiredThroughOperatingLease": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents a monetary fact value.", "label": "Right of use asset acquired through operating lease" } } }, "localname": "RightOfUseAssetAcquiredThroughOperatingLease", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "nanx_ScheduleOfFutureMaturitiesOfFinanceAndOperatingLeasesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of future maturities of finance and opertaing lease.", "label": "The future maturities of the Company\u2019s finance and operating leases as of December 31, 2021 are as follows:" } } }, "localname": "ScheduleOfFutureMaturitiesOfFinanceAndOperatingLeasesTableTextBlock", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/LeaseCommitmentsTables" ], "xbrltype": "textBlockItemType" }, "nanx_SecondAmendmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Second amendment.", "label": "Second Amendment [Member]" } } }, "localname": "SecondAmendmentMember", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "xbrltype": "domainItemType" }, "nanx_SecuredConvertiblePromissoryNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Secured Convertible Promissory Note.", "label": "2% Secured Convertible Promissory Note Due on May 15, 2024 [Member]" } } }, "localname": "SecuredConvertiblePromissoryNoteMember", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "xbrltype": "domainItemType" }, "nanx_SecuredConvertiblePromissoryNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Secured Convertible Promissory Note", "label": "Secured Convertible Promissory Note [Member]" } } }, "localname": "SecuredConvertiblePromissoryNotesMember", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/ScheduleOfRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "nanx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardContractualLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This element represents a duration fact value.", "label": "Contractual life (years) of shares granted in period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardContractualLife", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/AdditionalDisclosuresForOptionsGrantedForAllYearsPresentedDetails" ], "xbrltype": "durationItemType" }, "nanx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFortfeitureRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This element represents a percentage fact value.", "label": "Estimated forfeitures" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFortfeitureRate", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/AdditionalDisclosuresForOptionsGrantedForAllYearsPresentedDetails" ], "xbrltype": "percentItemType" }, "nanx_SolesenceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Solesence.", "label": "Solesence [Member]" } } }, "localname": "SolesenceMember", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/RevenuesFor2021And2020ByCategoryAreAsFollowsDetails" ], "xbrltype": "domainItemType" }, "nanx_StockOptionsRecognizedTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This element represents a table text block fact value.", "label": "The aggregate intrinsic value in the table above is based on our closing stock price of $4.40 on the last business day for the year ended December 31, 2021." } } }, "localname": "StockOptionsRecognizedTableTextBlock", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/StockOptionsAndStockGrantsTables" ], "xbrltype": "textBlockItemType" }, "nanx_StrandlerLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This element represents member fact value.", "label": "Strandler LLC [Member]" } } }, "localname": "StrandlerLLCMember", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "xbrltype": "domainItemType" }, "nanx_SummaryOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This element represents a table text block fact value.", "label": "Supplemental cash flow information related to leases is as follows for the years ended December 31, 2021 and 2020:" } } }, "localname": "SummaryOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/LeaseCommitmentsTables" ], "xbrltype": "textBlockItemType" }, "nanx_TenantSecurityDeposit": { "auth_ref": [], "calculation": { "http://nanophase.com/role/AccruedExpensesConsistOfFollowingDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This element represents a monetary value.", "label": "Tenant Security Deposit / Advance Rent" } } }, "localname": "TenantSecurityDeposit", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/AccruedExpensesConsistOfFollowingDetails" ], "xbrltype": "monetaryItemType" }, "nanx_TermLoanAndTheRevolverFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term Loan and The Revolver Facility.", "label": "Term Loan and The Revolver Facility [Member]" } } }, "localname": "TermLoanAndTheRevolverFacilityMember", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "xbrltype": "domainItemType" }, "nanx_TermLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term loan.", "label": "Term Loan [Member]" } } }, "localname": "TermLoanMember", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "xbrltype": "domainItemType" }, "nanx_ThirdAmendmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Third amendment.", "label": "Third Amendment [Member]" } } }, "localname": "ThirdAmendmentMember", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "xbrltype": "domainItemType" }, "nanx_WhitmoreMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Whit more member.", "label": "Whitmore [Member]" } } }, "localname": "WhitmoreMember", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "xbrltype": "domainItemType" }, "nanx_Year2021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This element represents member fact value.", "label": "Year 2021 [Member]" } } }, "localname": "Year2021Member", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "nanx_Year2022Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This element represents member fact value.", "label": "Year 2022 [Member]" } } }, "localname": "Year2022Member", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "nanx_Year2023Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This element represents member fact value.", "label": "Year 2023 [Member]" } } }, "localname": "Year2023Member", "nsuri": "http://nanophase.com/20211231", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r64", "r66", "r112", "r113", "r238", "r272" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "xbrltype": "stringItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r184", "r304", "r308", "r502" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://nanophase.com/role/AccountsReceivableBalancesForTheseFiveCustomersWereApproximatelyDetails", "http://nanophase.com/role/WeHadFiveSignificantCustomersForYearEndedDecember312021.Details" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r237", "r271", "r324", "r325", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r499", "r503", "r527", "r528" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r237", "r271", "r324", "r325", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r499", "r503", "r527", "r528" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails", "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r184", "r304", "r308", "r502" ], "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://nanophase.com/role/AccountsReceivableBalancesForTheseFiveCustomersWereApproximatelyDetails", "http://nanophase.com/role/WeHadFiveSignificantCustomersForYearEndedDecember312021.Details" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r180", "r304", "r306", "r455", "r498", "r500" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionDetailsNarrative", "http://nanophase.com/role/ConsolidatedStatementsOfOperations", "http://nanophase.com/role/RevenuesFor2021And2020ByCategoryAreAsFollowsDetails", "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r180", "r304", "r306", "r455", "r498", "r500" ], "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionDetailsNarrative", "http://nanophase.com/role/ConsolidatedStatementsOfOperations", "http://nanophase.com/role/RevenuesFor2021And2020ByCategoryAreAsFollowsDetails", "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r237", "r271", "r310", "r324", "r325", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r499", "r503", "r527", "r528" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails", "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r237", "r271", "r310", "r324", "r325", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r499", "r503", "r527", "r528" ], "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails", "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r65", "r66", "r112", "r113", "r238", "r272" ], "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r181", "r182", "r304", "r307", "r501", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526" ], "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r181", "r182", "r304", "r307", "r501", "r512", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r45" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accrued Expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/AccruedExpenses" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r44", "r445" ], "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r4", "r26", "r186", "r187" ], "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Trade accounts receivable, less allowance for doubtful accounts of $60 for December 31, 2021, and $9 for 2020", "verboseLabel": "Accounts receivable net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets", "http://nanophase.com/role/ContractBalancesForYear2021And2020Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionExpenseIncludingAssetRetirementObligations": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accretion expense, which includes, but is not limited to, accretion expense from asset retirement obligations, environmental remediation obligations, and other contingencies.", "label": "Amortization of asset due to passage of time" } } }, "localname": "AccretionExpenseIncludingAssetRetirementObligations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ActivityInAssetRetirementObligationAccountForYearsEndedDecember31IsAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r49" ], "calculation": { "http://nanophase.com/role/AccruedExpensesConsistOfFollowingDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://nanophase.com/role/ConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued expenses", "verboseLabel": "Total" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/AccruedExpensesConsistOfFollowingDetails", "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r42", "r206" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less: Accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/EquipmentAndLeaseholdImprovementsConsistOfFollowingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r27", "r358", "r445" ], "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r116", "r117", "r118", "r355", "r356", "r357", "r400" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r327", "r329", "r360", "r361" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net income to cash provided by (used in) operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r32", "r192", "r198" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r92", "r257", "r266", "r267", "r420" ], "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization of debt discount" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetRetirementObligationAccretionExpense": { "auth_ref": [ "r210", "r212" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accretion expense recognized during the period that is associated with an asset retirement obligation. Accretion expense measures and incorporates changes due to the passage of time into the carrying amount of the liability.", "label": "Accretion of liability due to passage of time" } } }, "localname": "AssetRetirementObligationAccretionExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ActivityInAssetRetirementObligationAccountForYearsEndedDecember31IsAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetRetirementObligationsNoncurrent": { "auth_ref": [ "r211" ], "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Noncurrent portion of the carrying amount of a liability for an asset retirement obligation. An asset retirement obligation is a legal obligation associated with the disposal or retirement of a tangible long-lived asset that results from the acquisition, construction or development, or the normal operations of a long-lived asset, except for certain obligations of lessees.", "label": "Asset retirement obligations", "periodEndLabel": "Balance, ending", "periodStartLabel": "Balance, beginning" } } }, "localname": "AssetRetirementObligationsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ActivityInAssetRetirementObligationAccountForYearsEndedDecember31IsAsFollowsDetails", "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetRetirementObligationsPolicy": { "auth_ref": [ "r213" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for legal obligation associated with retirement of long-lived asset that results from acquisition, construction, or development or from normal operation of long-lived asset. Excludes environmental remediation liability from improper or other-than-normal operation of long-lived asset, obligation arising in connection with leased property that meets definition of lease payments or variable lease payments and from plan to sell or otherwise dispose of a long-lived asset.", "label": "Asset Retirement Obligations" } } }, "localname": "AssetRetirementObligationsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Assets": { "auth_ref": [ "r108", "r167", "r171", "r176", "r196", "r221", "r222", "r223", "r225", "r226", "r227", "r228", "r229", "r230", "r232", "r233", "r396", "r398", "r409", "r443", "r445", "r469", "r484" ], "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Total Current Assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r5", "r6", "r63", "r108", "r196", "r221", "r222", "r223", "r225", "r226", "r227", "r228", "r229", "r230", "r232", "r233", "r396", "r398", "r409", "r443", "r445" ], "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r330", "r353" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/AdditionalDisclosuresForOptionsGrantedForAllYearsPresentedDetails", "http://nanophase.com/role/AggregateIntrinsicValueInTableAboveIsBasedOnOurClosingStockPriceOf4.40OnLastBusinessDayForYearEndedDecember312021.Details", "http://nanophase.com/role/WeFollowAscTopic718Share-basedPaymentsInWhichCompensationExpenseIsRecognizedOnlyForShare-basedPaymentsExpectedToVest.Details" ], "xbrltype": "stringItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r97", "r98", "r99" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Accounts payable incurred for the purchase of equipment and leasehold improvements" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_Cash": { "auth_ref": [ "r39", "r445", "r510", "r511" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash [Default Label]", "verboseLabel": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r39", "r94" ], "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r14", "r95" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "verboseLabel": "Cash" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r88", "r94", "r100" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash at end of period", "periodStartLabel": "Cash at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r88", "r410" ], "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Decrease in cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental non-cash investing and financing activities:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r55", "r218", "r475", "r491" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Contingent liabilities" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r215", "r216", "r217", "r219", "r514" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/Contingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r56" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Authorized, unissued shares of common stock" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/CapitalStockDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r116", "r117", "r400" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r25", "r284" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r25", "r445" ], "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, $.01 par value, 55,000,000 shares authorized; 48,893,573 and 38,221,292 shares issued and outstanding on December 31, 2021 and December 31, 2020, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Retirement Benefits [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred tax assets:" } } }, "localname": "ComponentsOfDeferredTaxAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/SignificantComponentsOfOurDeferredIncomeTaxesConsistOfFollowingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r152", "r153", "r184", "r406", "r407", "r513" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/WeHadFiveSignificantCustomersForYearEndedDecember312021.Details" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r152", "r153", "r184", "r406", "r407", "r509", "r513" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/WeHadFiveSignificantCustomersForYearEndedDecember312021.Details" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r152", "r153", "r184", "r406", "r407", "r509", "r513" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/WeHadFiveSignificantCustomersForYearEndedDecember312021.Details" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskDisclosureTextBlock": { "auth_ref": [ "r158" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.", "label": "Significant Customers and Contingencies" } } }, "localname": "ConcentrationRiskDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/SignificantCustomersAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/WeHadFiveSignificantCustomersForYearEndedDecember312021.Details" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r152", "r153", "r184", "r406", "r407" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Revenue from customers" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/WeHadFiveSignificantCustomersForYearEndedDecember312021.Details" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r150", "r152", "r153", "r154", "r406", "r408", "r513" ], "lang": { "en-us": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/WeHadFiveSignificantCustomersForYearEndedDecember312021.Details" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r152", "r153", "r184", "r406", "r407", "r513" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/WeHadFiveSignificantCustomersForYearEndedDecember312021.Details" ], "xbrltype": "domainItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress [Member]" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/EquipmentAndLeaseholdImprovementsConsistOfFollowingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r294" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.", "label": "Contract balances for the year 2021 and 2020" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r291", "r292", "r305" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract liability" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ContractBalancesForYear2021And2020Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent": { "auth_ref": [ "r291", "r293", "r305" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right to consideration is unconditional, classified as current.", "label": "Total" } } }, "localname": "ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/AccountsReceivableBalancesForTheseFiveCustomersWereApproximatelyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockSharesIssued1": { "auth_ref": [ "r97", "r98", "r99" ], "lang": { "en-us": { "role": { "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock, Shares Issued" } } }, "localname": "ConversionOfStockSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r79", "r455" ], "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of revenue" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails", "http://nanophase.com/role/ScheduleOfRelatedPartiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails", "http://nanophase.com/role/ScheduleOfRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r151", "r184" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/WeHadFiveSignificantCustomersForYearEndedDecember312021.Details" ], "xbrltype": "domainItemType" }, "us-gaap_DebtConversionOriginalDebtAmount1": { "auth_ref": [ "r97", "r99" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of convertible loan, related party" } } }, "localname": "DebtConversionOriginalDebtAmount1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r105", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r251", "r258", "r259", "r261", "r268" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Notes and Lines of Credit" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCredit" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r236", "r263" ], "lang": { "en-us": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Debt Instrument, Convertible, Conversion Price" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentDateOfFirstRequiredPayment1": { "auth_ref": [ "r53", "r482" ], "lang": { "en-us": { "role": { "documentation": "Date the debt agreement requires the first payment to be made, in YYYY-MM-DD format.", "label": "Debt Instrument, Date of First Required Payment" } } }, "localname": "DebtInstrumentDateOfFirstRequiredPayment1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentDescriptionOfVariableRateBasis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of reference rate used for variable rate of debt instrument.", "label": "Debt Instrument, Description of Variable Rate Basis" } } }, "localname": "DebtInstrumentDescriptionOfVariableRateBasis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r234", "r264", "r265", "r419", "r421", "r422" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r51", "r235" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateTerms": { "auth_ref": [ "r51" ], "lang": { "en-us": { "role": { "documentation": "Description of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets.", "label": "Debt Instrument, Interest Rate Terms" } } }, "localname": "DebtInstrumentInterestRateTerms", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r52", "r237", "r403" ], "lang": { "en-us": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.", "label": "Debt Instrument, Maturity Date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r53", "r107", "r114", "r234", "r235", "r236", "r237", "r238", "r239", "r241", "r247", "r248", "r249", "r250", "r252", "r253", "r254", "r255", "r256", "r257", "r260", "r264", "r265", "r266", "r267", "r285", "r286", "r287", "r288", "r418", "r419", "r421", "r422", "r483" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r247", "r418", "r422" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument, Unamortized Discount" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenue": { "auth_ref": [ "r33" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Deferred revenue" } } }, "localname": "DeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueCurrent": { "auth_ref": [ "r33" ], "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.", "label": "Current portion of deferred revenue" } } }, "localname": "DeferredRevenueCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueNoncurrent": { "auth_ref": [ "r33" ], "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Long-term portion of deferred revenue" } } }, "localname": "DeferredRevenueNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetDomain": { "auth_ref": [ "r376" ], "lang": { "en-us": { "role": { "documentation": "Identification of the deferred tax asset for which a valuation reserve exists." } } }, "localname": "DeferredTaxAssetDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards": { "auth_ref": [ "r382", "r383" ], "calculation": { "http://nanophase.com/role/SignificantComponentsOfOurDeferredIncomeTaxesConsistOfFollowingDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible charitable contribution carryforwards.", "label": "Charitable contribution & other carryforwards" } } }, "localname": "DeferredTaxAssetsCharitableContributionCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/SignificantComponentsOfOurDeferredIncomeTaxesConsistOfFollowingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": { "auth_ref": [], "calculation": { "http://nanophase.com/role/SignificantComponentsOfOurDeferredIncomeTaxesConsistOfFollowingDetails": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.", "label": "Excess (tax) book amortization" } } }, "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/SignificantComponentsOfOurDeferredIncomeTaxesConsistOfFollowingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r375" ], "calculation": { "http://nanophase.com/role/SignificantComponentsOfOurDeferredIncomeTaxesConsistOfFollowingDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/SignificantComponentsOfOurDeferredIncomeTaxesConsistOfFollowingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsInventory": { "auth_ref": [ "r382", "r383" ], "calculation": { "http://nanophase.com/role/SignificantComponentsOfOurDeferredIncomeTaxesConsistOfFollowingDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.", "label": "Inventory and other allowances" } } }, "localname": "DeferredTaxAssetsInventory", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/SignificantComponentsOfOurDeferredIncomeTaxesConsistOfFollowingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r377" ], "calculation": { "http://nanophase.com/role/SignificantComponentsOfOurDeferredIncomeTaxesConsistOfFollowingDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred income taxes" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/SignificantComponentsOfOurDeferredIncomeTaxesConsistOfFollowingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r382", "r383" ], "calculation": { "http://nanophase.com/role/SignificantComponentsOfOurDeferredIncomeTaxesConsistOfFollowingDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Net operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/SignificantComponentsOfOurDeferredIncomeTaxesConsistOfFollowingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": { "auth_ref": [], "calculation": { "http://nanophase.com/role/SignificantComponentsOfOurDeferredIncomeTaxesConsistOfFollowingDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.", "label": "Excess (tax) book depreciation" } } }, "localname": "DeferredTaxAssetsPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/SignificantComponentsOfOurDeferredIncomeTaxesConsistOfFollowingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": { "auth_ref": [ "r380", "r382", "r383" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.", "label": "Deferred Tax Assets, Tax Credit Carryforwards" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r382", "r383" ], "calculation": { "http://nanophase.com/role/SignificantComponentsOfOurDeferredIncomeTaxesConsistOfFollowingDetails": { "order": 6.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "Share-based compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/SignificantComponentsOfOurDeferredIncomeTaxesConsistOfFollowingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther": { "auth_ref": [ "r382", "r383" ], "calculation": { "http://nanophase.com/role/SignificantComponentsOfOurDeferredIncomeTaxesConsistOfFollowingDetails": { "order": 7.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves and accruals, classified as other.", "label": "Other accrued costs" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/SignificantComponentsOfOurDeferredIncomeTaxesConsistOfFollowingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r376" ], "calculation": { "http://nanophase.com/role/SignificantComponentsOfOurDeferredIncomeTaxesConsistOfFollowingDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Less:\u00a0\u00a0Valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/SignificantComponentsOfOurDeferredIncomeTaxesConsistOfFollowingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilities": { "auth_ref": [ "r368", "r377" ], "calculation": { "http://nanophase.com/role/SignificantComponentsOfOurDeferredIncomeTaxesConsistOfFollowingDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.", "label": "Deferred Tax Liabilities, Net", "negatedLabel": "Total deferred tax liabilities" } } }, "localname": "DeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/SignificantComponentsOfOurDeferredIncomeTaxesConsistOfFollowingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred tax liabilities:" } } }, "localname": "DeferredTaxLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/SignificantComponentsOfOurDeferredIncomeTaxesConsistOfFollowingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxLiabilitiesFinancingArrangements": { "auth_ref": [ "r382", "r383" ], "calculation": { "http://nanophase.com/role/SignificantComponentsOfOurDeferredIncomeTaxesConsistOfFollowingDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from financing arrangements.", "label": "Deferred Tax Liabilities, Financing Arrangements", "negatedLabel": "Excess tax basis convertible debt" } } }, "localname": "DeferredTaxLiabilitiesFinancingArrangements", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/SignificantComponentsOfOurDeferredIncomeTaxesConsistOfFollowingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanCostRecognized": { "auth_ref": [ "r323" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost for defined contribution plan.", "label": "Defined Contribution Plan, Cost" } } }, "localname": "DefinedContributionPlanCostRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/KProfit-sharingPlanDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.", "label": "Percentage of employee's matching contribution" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionPercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/KProfit-sharingPlanDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage employer matches of the employee's percentage contribution matched.", "label": "Employer's matching contribution percentage" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/KProfit-sharingPlanDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r92", "r204" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/EquipmentAndLeaseholdImprovementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r92", "r165" ], "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r304" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "The revenues for 2021 and 2020 by category are as follows:" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Stock Options and Stock Grants" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/StockOptionsAndStockGrants" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DueToRelatedPartiesCurrent": { "auth_ref": [ "r44", "r111", "r224", "r226", "r227", "r231", "r232", "r233", "r441" ], "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "Line of credit, related party" } } }, "localname": "DueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": { "auth_ref": [ "r111", "r224", "r226", "r227", "r231", "r232", "r233", "r441", "r474", "r492" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.", "label": "Due to Related Parties" } } }, "localname": "DueToRelatedPartiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ScheduleOfRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesNoncurrent": { "auth_ref": [ "r54", "r111", "r224", "r226", "r227", "r231", "r232", "r233", "r441" ], "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Portion of the carrying amount as of the balance sheet date of obligations due all related parties that is payable after one year or beyond the normal operating cycle if longer.", "label": "Long-term convertible loan, related party" } } }, "localname": "DueToRelatedPartiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r77", "r121", "r122", "r123", "r124", "r125", "r129", "r131", "r136", "r137", "r138", "r141", "r142", "r401", "r402", "r478", "r494" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Net income per share-basic", "verboseLabel": "Net income per share \u2013 basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperations", "http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basic earnings per common share:" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r77", "r121", "r122", "r123", "r124", "r125", "r131", "r136", "r137", "r138", "r141", "r142", "r401", "r402", "r478", "r494" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Net income per share-diluted", "verboseLabel": "Net income per share \u2013 diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperations", "http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Diluted earnings per common share:" } } }, "localname": "EarningsPerShareDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r139", "r140" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsDomestic": { "auth_ref": [ "r370", "r389" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to domestic income tax settlement.", "label": "Tax rate reconciliation and settlement" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxSettlementsDomestic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r49" ], "calculation": { "http://nanophase.com/role/AccruedExpensesConsistOfFollowingDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued payroll and related expenses" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/AccruedExpensesConsistOfFollowingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r352" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Remaining weighted average-period, expense recognition (years)" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/WeFollowAscTopic718Share-basedPaymentsInWhichCompensationExpenseIsRecognizedOnlyForShare-basedPaymentsExpectedToVest.Details" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r351" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/AdditionalDisclosuresForOptionsGrantedForAllYearsPresentedDetails", "http://nanophase.com/role/AggregateIntrinsicValueInTableAboveIsBasedOnOurClosingStockPriceOf4.40OnLastBusinessDayForYearEndedDecember312021.Details", "http://nanophase.com/role/WeFollowAscTopic718Share-basedPaymentsInWhichCompensationExpenseIsRecognizedOnlyForShare-basedPaymentsExpectedToVest.Details" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense": { "auth_ref": [ "r362" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of plan compensation cost recognized during the period.", "label": "Remaining unrecognized compensation expense" } } }, "localname": "EmployeeStockOwnershipPlanESOPCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/WeFollowAscTopic718Share-basedPaymentsInWhichCompensationExpenseIsRecognizedOnlyForShare-basedPaymentsExpectedToVest.Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue from External Customer [Line Items]" } } }, "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/RevenuesFor2021And2020ByCategoryAreAsFollowsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r70", "r71", "r72", "r116", "r117", "r118", "r120", "r126", "r128", "r144", "r197", "r284", "r289", "r355", "r356", "r357", "r385", "r386", "r400", "r411", "r412", "r413", "r414", "r415", "r416", "r504", "r505", "r506", "r550" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r404", "r405" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeaseInterestExpense": { "auth_ref": [ "r426", "r431", "r439" ], "calculation": { "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails": { "order": 2.0, "parentTag": "nanx_LeaseCostsFinance", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense on finance lease liability.", "label": "Interest on finance lease liabilities" } } }, "localname": "FinanceLeaseInterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiability": { "auth_ref": [ "r425", "r438" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "Finance Leases, Total minimum payments required:" } } }, "localname": "FinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfDecember312021AreAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r425" ], "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Current portion of finance lease obligations" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r425" ], "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Long-term portion of finance lease obligations" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "auth_ref": [ "r438" ], "calculation": { "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfDecember312021AreAsFollowsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Payment, Due", "totalLabel": "Finance Lease, Liability, Payment, Due" } } }, "localname": "FinanceLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfDecember312021AreAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r438" ], "calculation": { "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfDecember312021AreAsFollowsDetails": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Leases, Year 1" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfDecember312021AreAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r438" ], "calculation": { "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfDecember312021AreAsFollowsDetails": { "order": 3.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Leases, Year 3" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfDecember312021AreAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r438" ], "calculation": { "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfDecember312021AreAsFollowsDetails": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Leases, Year 2" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfDecember312021AreAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r438" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Finance Lease, Liability, Undiscounted Excess Amount" } } }, "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfDecember312021AreAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r428", "r435" ], "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease, Principal Payments", "negatedLabel": "Principal payment on finance leases" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "auth_ref": [ "r426", "r431", "r439" ], "calculation": { "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails": { "order": 1.0, "parentTag": "nanx_LeaseCostsFinance", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.", "label": "Amortization of finance lease assets" } } }, "localname": "FinanceLeaseRightOfUseAssetAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r436", "r439" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for finance lease calculated at point in time.", "label": "Weighted-average discount rate-finance leases" } } }, "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/SupplementalCashFlowInformationRelatedToLeasesIsAsFollowsForYearsEndedDecember312021And2020Details" ], "xbrltype": "percentItemType" }, "us-gaap_FinancingReceivablePercentPastDue1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of financing receivable balance that is past due.", "label": "Percentage of prepayments" } } }, "localname": "FinancingReceivablePercentPastDue1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/EquipmentAndLeaseholdImprovementsConsistOfFollowingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r78", "r108", "r167", "r170", "r172", "r175", "r178", "r196", "r221", "r222", "r223", "r226", "r227", "r228", "r229", "r230", "r232", "r233", "r409" ], "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r203", "r208" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Long Lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r75", "r167", "r170", "r172", "r175", "r178", "r468", "r476", "r480", "r495" ], "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Income before provision for income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes." } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r109", "r371", "r373", "r379", "r387", "r390", "r392", "r393", "r394" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r110", "r127", "r128", "r166", "r369", "r388", "r391", "r496" ], "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 }, "http://nanophase.com/role/ReconciliationOfIncomeTaxExpenseToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312021And2020IsAsFollowsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Provision for income taxes", "totalLabel": "TOTAL" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperations", "http://nanophase.com/role/ReconciliationOfIncomeTaxExpenseToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312021And2020IsAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r69", "r366", "r367", "r373", "r374", "r378", "r384" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "verboseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r370" ], "calculation": { "http://nanophase.com/role/ReconciliationOfIncomeTaxExpenseToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312021And2020IsAsFollowsDetails": { "order": 10.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.", "label": "Change in valuation allowance" } } }, "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ReconciliationOfIncomeTaxExpenseToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312021And2020IsAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": { "auth_ref": [ "r365", "r370" ], "calculation": { "http://nanophase.com/role/ReconciliationOfIncomeTaxExpenseToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312021And2020IsAsFollowsDetails": { "order": 7.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.", "label": "Tax basis in excess of book Convertible Debt" } } }, "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ReconciliationOfIncomeTaxExpenseToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312021And2020IsAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r370" ], "calculation": { "http://nanophase.com/role/ReconciliationOfIncomeTaxExpenseToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312021And2020IsAsFollowsDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Income tax credit at statutory rates" } } }, "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ReconciliationOfIncomeTaxExpenseToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312021And2020IsAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense": { "auth_ref": [ "r370" ], "calculation": { "http://nanophase.com/role/ReconciliationOfIncomeTaxExpenseToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312021And2020IsAsFollowsDetails": { "order": 4.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to noncontrolling interest income (loss) exempt from income taxes.", "label": "Effective Income Tax Rate Reconciliation, Noncontrolling Interest Income (Loss), Amount", "negatedLabel": "Permanent Tax Deduction Stock Options Exercised" } } }, "localname": "IncomeTaxReconciliationMinorityInterestIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ReconciliationOfIncomeTaxExpenseToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312021And2020IsAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpense": { "auth_ref": [ "r370" ], "calculation": { "http://nanophase.com/role/ReconciliationOfIncomeTaxExpenseToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312021And2020IsAsFollowsDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.", "label": "Nondeductible expenses" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ReconciliationOfIncomeTaxExpenseToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312021And2020IsAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": { "auth_ref": [ "r370" ], "calculation": { "http://nanophase.com/role/ReconciliationOfIncomeTaxExpenseToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312021And2020IsAsFollowsDetails": { "order": 8.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.", "label": "Expiration of Stock Options" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ReconciliationOfIncomeTaxExpenseToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312021And2020IsAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationOtherAdjustments": { "auth_ref": [ "r370" ], "calculation": { "http://nanophase.com/role/ReconciliationOfIncomeTaxExpenseToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312021And2020IsAsFollowsDetails": { "order": 9.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount", "verboseLabel": "Other" } } }, "localname": "IncomeTaxReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ReconciliationOfIncomeTaxExpenseToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312021And2020IsAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r370" ], "calculation": { "http://nanophase.com/role/ReconciliationOfIncomeTaxExpenseToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312021And2020IsAsFollowsDetails": { "order": 5.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).", "label": "State income tax, net of federal benefits" } } }, "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ReconciliationOfIncomeTaxExpenseToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312021And2020IsAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationTaxExemptIncome": { "auth_ref": [ "r370" ], "calculation": { "http://nanophase.com/role/ReconciliationOfIncomeTaxExpenseToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312021And2020IsAsFollowsDetails": { "order": 3.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income (loss) exempt from income taxes.", "label": "Effective Income Tax Rate Reconciliation, Tax Exempt Income, Amount", "negatedLabel": "Tax Exempt Income - PPP Loan" } } }, "localname": "IncomeTaxReconciliationTaxExemptIncome", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ReconciliationOfIncomeTaxExpenseToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312021And2020IsAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r91" ], "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "verboseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r91" ], "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Trade accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r91" ], "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "verboseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "auth_ref": [ "r91" ], "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Deferred Revenue" } } }, "localname": "IncreaseDecreaseInDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r91" ], "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in assets and liabilities related to operations:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet": { "auth_ref": [], "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in noncurrent operating assets after deduction of noncurrent operating liabilities classified as other.", "label": "Increase (Decrease) in Other Noncurrent Assets and Liabilities, Net", "negatedLabel": "Other long-term assets and liabilities" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r91" ], "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r132", "r133", "r134", "r138" ], "calculation": { "http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Weighted average additional shares assuming conversion of in-the-money stock options to common shares", "verboseLabel": "Options included in computation of earnings per share" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails", "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_InformationTechnologyAndDataProcessing": { "auth_ref": [ "r81" ], "calculation": { "http://nanophase.com/role/ReconciliationOfIncomeTaxExpenseToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312021And2020IsAsFollowsDetails": { "order": 6.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expenses incurred in the period for information technology and data processing products and services.", "label": "Expiration of NOL & Credits" } } }, "localname": "InformationTechnologyAndDataProcessing", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ReconciliationOfIncomeTaxExpenseToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312021And2020IsAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r73", "r164", "r417", "r420", "r479" ], "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperations", "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseRelatedParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense incurred on a debt or other obligation to related party.", "label": "Interest expense, related parties" } } }, "localname": "InterestExpenseRelatedParty", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ScheduleOfRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaid": { "auth_ref": [ "r96" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.", "label": "Interest paid via stock issuance, convertible loan, related party" } } }, "localname": "InterestPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r86", "r89", "r96" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest paid" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrent": { "auth_ref": [ "r8", "r9", "r49" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued interest expense, related parties" } } }, "localname": "InterestPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ScheduleOfRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r202" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventories" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/Inventories" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r59" ], "calculation": { "http://nanophase.com/role/InventoriesConsistOfFollowingDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/InventoriesConsistOfFollowingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryGross": { "auth_ref": [ "r61" ], "calculation": { "http://nanophase.com/role/InventoriesConsistOfFollowingDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Inventory, Gross", "totalLabel": "Inventories, gross" } } }, "localname": "InventoryGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/InventoriesConsistOfFollowingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r3", "r61", "r445" ], "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://nanophase.com/role/InventoriesConsistOfFollowingDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventories, net", "totalLabel": "Inventories, net" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets", "http://nanophase.com/role/InventoriesConsistOfFollowingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r10", "r62", "r102", "r143", "r199", "r200", "r202", "r453" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "verboseLabel": "Inventories" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterials": { "auth_ref": [ "r60" ], "calculation": { "http://nanophase.com/role/InventoriesConsistOfFollowingDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Raw materials" } } }, "localname": "InventoryRawMaterials", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/InventoriesConsistOfFollowingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryValuationReserves": { "auth_ref": [ "r61", "r201" ], "calculation": { "http://nanophase.com/role/InventoriesConsistOfFollowingDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of valuation reserve for inventory.", "label": "Inventory Valuation Reserves", "negatedLabel": "Allowance for excess quantities" } } }, "localname": "InventoryValuationReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/InventoriesConsistOfFollowingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r437", "r439" ], "calculation": { "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Total lease cost:" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Components of lease cost" } } }, "localname": "LeaseCostAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r437" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Quantitative information regarding the Company\u2019s leases is as follows:" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/LeaseCommitmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r205" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/EquipmentAndLeaseholdImprovementsConsistOfFollowingDetails", "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_LeasesOfLesseeDisclosureTextBlock": { "auth_ref": [ "r423" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.", "label": "Lease Commitments" } } }, "localname": "LeasesOfLesseeDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/LeaseCommitments" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeFinanceLeaseRemainingLeaseTerm": { "auth_ref": [ "r430" ], "lang": { "en-us": { "role": { "documentation": "Remaining lease term of finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Weighted-average remaining lease term-finance leases (in years)" } } }, "localname": "LesseeFinanceLeaseRemainingLeaseTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/SupplementalCashFlowInformationRelatedToLeasesIsAsFollowsForYearsEndedDecember312021And2020Details" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r438" ], "calculation": { "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfDecember312021AreAsFollowsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Lessee, Operating Lease, Liability, to be Paid" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfDecember312021AreAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r438" ], "calculation": { "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfDecember312021AreAsFollowsDetails": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Operating Leases, thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfDecember312021AreAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r438" ], "calculation": { "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfDecember312021AreAsFollowsDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Operating Leases, Year 1" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfDecember312021AreAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r438" ], "calculation": { "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfDecember312021AreAsFollowsDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Operating Leases, Year 5" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfDecember312021AreAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r438" ], "calculation": { "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfDecember312021AreAsFollowsDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Operating Leases, Year 4" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfDecember312021AreAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r438" ], "calculation": { "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfDecember312021AreAsFollowsDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Operating Leases, Year 3" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfDecember312021AreAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r438" ], "calculation": { "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfDecember312021AreAsFollowsDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Operating Leases, Year 2" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfDecember312021AreAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r438" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfDecember312021AreAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": { "auth_ref": [ "r430" ], "lang": { "en-us": { "role": { "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Weighted-average remaining lease term-operating leases (in years)" } } }, "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/SupplementalCashFlowInformationRelatedToLeasesIsAsFollowsForYearsEndedDecember312021And2020Details" ], "xbrltype": "durationItemType" }, "us-gaap_LetterOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).", "label": "Letter of Credit [Member]" } } }, "localname": "LetterOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r31", "r108", "r196", "r409", "r445", "r473", "r489" ], "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and shareholder\u2019s equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r50", "r108", "r196", "r221", "r222", "r223", "r226", "r227", "r228", "r229", "r230", "r232", "r233", "r397", "r398", "r399", "r409", "r443", "r444", "r445" ], "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r11", "r12", "r13", "r21", "r22", "r108", "r196", "r221", "r222", "r223", "r226", "r227", "r228", "r229", "r230", "r232", "r233", "r397", "r398", "r399", "r409", "r443", "r444" ], "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Liabilities, Noncurrent", "totalLabel": "Total long-term liabilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityBorrowingCapacityDescription": { "auth_ref": [ "r18", "r20" ], "lang": { "en-us": { "role": { "documentation": "Description of the credit facility's borrowing capacity including discussion of how the borrowing capacity is determined (for example, borrowing capacity based on the amount of current assets).", "label": "Line of Credit Facility, Borrowing Capacity, Description" } } }, "localname": "LineOfCreditFacilityBorrowingCapacityDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.", "label": "Line of Credit Facility, Commitment Fee Percentage" } } }, "localname": "LineOfCreditFacilityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": { "auth_ref": [ "r46" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.", "label": "Available" } } }, "localname": "LineOfCreditFacilityCurrentBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityDescription": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "Description of the terms of a credit facility arrangement. Terms typically include interest rate, collateral required, guarantees required, repayment requirements, and restrictions on use of assets and activities of the entity.", "label": "Line of credit facility, description" } } }, "localname": "LineOfCreditFacilityDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityExpirationDate1": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "Date the credit facility terminates, in YYYY-MM-DD format.", "label": "Line of Credit Facility, Expiration Date" } } }, "localname": "LineOfCreditFacilityExpirationDate1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "xbrltype": "dateItemType" }, "us-gaap_LineOfCreditFacilityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Line of Credit Facility [Line Items]" } } }, "localname": "LineOfCreditFacilityLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ScheduleOfRelatedPartiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r46" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Outsanding balance" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityTable": { "auth_ref": [ "r46", "r107" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.", "label": "Line of Credit Facility [Table]" } } }, "localname": "LineOfCreditFacilityTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ScheduleOfRelatedPartiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LinesOfCreditCurrent": { "auth_ref": [ "r19", "r470" ], "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Line of credit, bank" } } }, "localname": "LinesOfCreditCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r21", "r248", "r262", "r264", "r265", "r471", "r486" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r48" ], "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Current portion of long-term debt, related party" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r53" ], "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "PPP Loan (SBA)" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r53" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails", "http://nanophase.com/role/ScheduleOfRelatedPartiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r53", "r220" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails", "http://nanophase.com/role/ScheduleOfRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MachineryAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery and Equipment [Member]" } } }, "localname": "MachineryAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/EquipmentAndLeaseholdImprovementsConsistOfFollowingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r145", "r158" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Description of Business" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/DescriptionOfBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r88" ], "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash (used in) provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r88" ], "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r88", "r90", "r93" ], "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r67", "r68", "r72", "r76", "r93", "r108", "r119", "r121", "r122", "r123", "r124", "r127", "r128", "r135", "r167", "r170", "r172", "r175", "r178", "r196", "r221", "r222", "r223", "r226", "r227", "r228", "r229", "r230", "r232", "r233", "r402", "r409", "r477", "r493" ], "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://nanophase.com/role/ConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net income", "totalLabel": "Net income", "verboseLabel": "Net Income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows", "http://nanophase.com/role/ConsolidatedStatementsOfOperations", "http://nanophase.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Numerator: (in Thousands)" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonUsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Countries excluding the United States of America (US).", "label": "Non-US [Member]" } } }, "localname": "NonUsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_OfficeEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.", "label": "Office Equipment [Member]" } } }, "localname": "OfficeEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/EquipmentAndLeaseholdImprovementsConsistOfFollowingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expense:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r167", "r170", "r172", "r175", "r178" ], "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Income from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r432", "r439" ], "calculation": { "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r427" ], "calculation": { "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "totalLabel": "Total operating lease costs" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r425" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Leases, Total minimum payments required:" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfDecember312021AreAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r425" ], "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Current portion of operating lease obligations" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets", "http://nanophase.com/role/LeaseCommitmentsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r425" ], "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Long-term portion of operating lease obligations" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets", "http://nanophase.com/role/LeaseCommitmentsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r429", "r435" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating cash outflow from operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/SupplementalCashFlowInformationRelatedToLeasesIsAsFollowsForYearsEndedDecember312021And2020Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r424" ], "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating leases, right of use" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets", "http://nanophase.com/role/LeaseCommitmentsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r436", "r439" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Weighted-average discount rate-operating leases" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/SupplementalCashFlowInformationRelatedToLeasesIsAsFollowsForYearsEndedDecember312021And2020Details" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r380" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "verboseLabel": "Net operating loss carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwardsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Loss Carryforwards [Line Items]" } } }, "localname": "OperatingLossCarryforwardsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwardsTable": { "auth_ref": [ "r381" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.", "label": "Operating Loss Carryforwards [Table]" } } }, "localname": "OperatingLossCarryforwardsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r7", "r8", "r9", "r49" ], "calculation": { "http://nanophase.com/role/AccruedExpensesConsistOfFollowingDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/AccruedExpensesConsistOfFollowingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r43" ], "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other assets, net" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember": { "auth_ref": [ "r205" ], "lang": { "en-us": { "role": { "documentation": "All other long term capitalized assets related to property plant and equipment not otherwise previously categorized.", "label": "Other Capitalized Property Plant and Equipment [Member]" } } }, "localname": "OtherCapitalizedPropertyPlantAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_OtherIncome": { "auth_ref": [ "r497" ], "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue and income classified as other.", "label": "Other income, net" } } }, "localname": "OtherIncome", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities": { "auth_ref": [ "r87" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability exceeding amount recognized at acquisition date. Includes, but is not limited to, measurement period adjustment and less amount paid soon after acquisition date.", "label": "Lease liabilities arising from obtaining right-of-use assets" } } }, "localname": "PaymentForContingentConsiderationLiabilityOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/SupplementalCashFlowInformationRelatedToLeasesIsAsFollowsForYearsEndedDecember312021And2020Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r82" ], "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Acquisition of equipment and leasehold improvements" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r310", "r311", "r312", "r313", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r326" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for retirement benefits.", "label": "401(k) Profit-Sharing Plan" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/KProfit-sharingPlan" ], "xbrltype": "textBlockItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r330", "r353" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/CapitalStockDetailsNarrative", "http://nanophase.com/role/StockOptionsAndStockGrantsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/CapitalStockDetailsNarrative", "http://nanophase.com/role/StockOptionsAndStockGrantsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r24", "r269" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, authorized", "verboseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/CapitalStockDetailsNarrative", "http://nanophase.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r24", "r269" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r24", "r445" ], "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock, $.01 par value, 24,088 shares authorized, and no shares issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r5", "r37", "r38" ], "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLinesOfCredit": { "auth_ref": [ "r84", "r107" ], "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Proceeds from line of credit, bank" } } }, "localname": "ProceedsFromLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRelatedPartyDebt": { "auth_ref": [ "r84" ], "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.", "label": "Proceeds from line of credit, Beachcorp LLC" } } }, "localname": "ProceedsFromRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r83", "r354" ], "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from exercise of stock options", "verboseLabel": "Cash received" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/AggregateIntrinsicValueInTableAboveIsBasedOnOurClosingStockPriceOf4.40OnLastBusinessDayForYearEndedDecember312021.Details", "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductAndServiceOtherMember": { "auth_ref": [ "r306" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.", "label": "Product and Service, Other [Member]" } } }, "localname": "ProductAndServiceOtherMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperations", "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r306" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionDetailsNarrative", "http://nanophase.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r42", "r207" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/EquipmentAndLeaseholdImprovementsConsistOfFollowingDetails", "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r209", "r515", "r516", "r517" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Equipment and Leasehold Improvements" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/EquipmentAndLeaseholdImprovements" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r41", "r205" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property plant and equipment,gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/EquipmentAndLeaseholdImprovementsConsistOfFollowingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/EquipmentAndLeaseholdImprovementsConsistOfFollowingDetails", "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r15", "r16", "r207", "r445", "r481", "r490" ], "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Equipment and leasehold improvements, net", "verboseLabel": "Property, Plant and Equipment, Net, Total" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets", "http://nanophase.com/role/EquipmentAndLeaseholdImprovementsConsistOfFollowingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r40", "r207", "r515", "r516" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "verboseLabel": "Equipment and Leasehold Improvements" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r15", "r207" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Equipment and leasehold improvements consist of the following:" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/EquipmentAndLeaseholdImprovementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r15", "r205" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/EquipmentAndLeaseholdImprovementsConsistOfFollowingDetails", "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Equipment leasehold improvements and leased assets useful life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r314", "r440", "r441" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r314", "r440", "r441", "r442" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ScheduleOfRelatedPartiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r314" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party." } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ScheduleOfRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r314", "r440", "r442", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RepaymentsOfLinesOfCredit": { "auth_ref": [ "r85", "r107" ], "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Repayments of Lines of Credit", "negatedLabel": "Payments to the line of credit, bank" } } }, "localname": "RepaymentsOfLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfRelatedPartyDebt": { "auth_ref": [ "r85" ], "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.", "label": "Repayments of Related Party Debt", "negatedLabel": "Payments to line of credit, Beachcorp LLC" } } }, "localname": "RepaymentsOfRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r364", "r454", "r529" ], "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development expense" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expenses" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r28", "r289", "r358", "r445", "r488", "r507", "r508" ], "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r116", "r117", "r118", "r120", "r126", "r128", "r197", "r355", "r356", "r357", "r385", "r386", "r400", "r504", "r506" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r162", "r163", "r169", "r173", "r174", "r180", "r181", "r184", "r303", "r304", "r455" ], "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Total revenue", "verboseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperations", "http://nanophase.com/role/RevenuesFor2021And2020ByCategoryAreAsFollowsDetails", "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r103", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r309" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "verboseLabel": "Deferred Revenue" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r103", "r104" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Product Revenue" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r74", "r108", "r162", "r163", "r169", "r173", "r174", "r180", "r181", "r184", "r196", "r221", "r222", "r223", "r226", "r227", "r228", "r229", "r230", "r232", "r233", "r409", "r480" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenues from External Customers and Long-Lived Assets [Line Items]" } } }, "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RisksAndUncertaintiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Risks and Uncertainties [Abstract]" } } }, "localname": "RisksAndUncertaintiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r152", "r184" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/WeHadFiveSignificantCustomersForYearEndedDecember312021.Details" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Accrued expenses consist of the following:" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/AccruedExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfChangeInAssetRetirementObligationTableTextBlock": { "auth_ref": [ "r214" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in carrying amount of a liability for asset retirement obligations, for changes such as new obligations, changes in estimates of existing obligations, spending on existing obligations, property dispositions, and foreign currency translation.", "label": "Activity in the asset retirement obligation account for the years ended December 31, is as follows:" } } }, "localname": "ScheduleOfChangeInAssetRetirementObligationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r377" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Significant components of our deferred income taxes consist of the following:" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r138" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows:" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r370" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "A reconciliation of income tax expense to the amount computed by applying the Federal income tax rate to loss before provision for income taxes as of December 31, 2021 and 2020 is as follows:" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": { "auth_ref": [ "r180" ], "lang": { "en-us": { "role": { "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information.", "label": "Revenue from External Customers by Products and Services [Table]" } } }, "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/RevenuesFor2021And2020ByCategoryAreAsFollowsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r10", "r34", "r35", "r36" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Inventories consist of the following:" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/InventoriesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.", "label": "Notes and lines of credit consist of the following:" } } }, "localname": "ScheduleOfLineOfCreditFacilitiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r42", "r207" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/EquipmentAndLeaseholdImprovementsConsistOfFollowingDetails", "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.", "label": "Schedule of Related Parties" } } }, "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": { "auth_ref": [ "r74", "r183" ], "lang": { "en-us": { "role": { "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r330", "r353" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/AdditionalDisclosuresForOptionsGrantedForAllYearsPresentedDetails", "http://nanophase.com/role/AggregateIntrinsicValueInTableAboveIsBasedOnOurClosingStockPriceOf4.40OnLastBusinessDayForYearEndedDecember312021.Details", "http://nanophase.com/role/CapitalStockDetailsNarrative", "http://nanophase.com/role/StockOptionsAndStockGrantsDetailsNarrative", "http://nanophase.com/role/WeFollowAscTopic718Share-basedPaymentsInWhichCompensationExpenseIsRecognizedOnlyForShare-basedPaymentsExpectedToVest.Details" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r334", "r340", "r343" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Schedule of option activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/StockOptionsAndStockGrantsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": { "auth_ref": [ "r346" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of assumptions used to calculate Black-Scholes option pricing model for options granted" } } }, "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/StockOptionsAndStockGrantsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "auth_ref": [ "r150", "r152", "r153", "r154", "r406", "r408" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "We had five significant customers for the year ended December 31, 2021." } } }, "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/SignificantCustomersAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r159", "r160", "r161", "r167", "r168", "r172", "r176", "r177", "r178", "r179", "r180", "r183", "r184", "r185" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Business Segmentation and Geographical Distribution" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/BusinessSegmentationAndGeographicalDistribution" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r80" ], "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, general and administrative expense" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r91" ], "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r331" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Vesting period (years) of shares granted in period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/AdditionalDisclosuresForOptionsGrantedForAllYearsPresentedDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r349" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ScheduleOfAssumptionsUsedToCalculateBlack-scholesOptionPricingModelForOptionsGrantedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Weighted-average risk-free interest rates" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ScheduleOfAssumptionsUsedToCalculateBlack-scholesOptionPricingModelForOptionsGrantedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": { "auth_ref": [ "r348" ], "lang": { "en-us": { "role": { "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.", "label": "Weighted-average expected stock price volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ScheduleOfAssumptionsUsedToCalculateBlack-scholesOptionPricingModelForOptionsGrantedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/AdditionalDisclosuresForOptionsGrantedForAllYearsPresentedDetails", "http://nanophase.com/role/AggregateIntrinsicValueInTableAboveIsBasedOnOurClosingStockPriceOf4.40OnLastBusinessDayForYearEndedDecember312021.Details", "http://nanophase.com/role/CapitalStockDetailsNarrative", "http://nanophase.com/role/StockOptionsAndStockGrantsDetailsNarrative", "http://nanophase.com/role/WeFollowAscTopic718Share-basedPaymentsInWhichCompensationExpenseIsRecognizedOnlyForShare-basedPaymentsExpectedToVest.Details" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r353" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Shares for grants" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r337" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "periodEndLabel": "Shares Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r337" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "periodEndLabel": "Shares Exercisable, (per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r342" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Total intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/AggregateIntrinsicValueInTableAboveIsBasedOnOurClosingStockPriceOf4.40OnLastBusinessDayForYearEndedDecember312021.Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r339" ], "lang": { "en-us": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period", "negatedLabel": "Forfeited or expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r339" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Forfeited or expired (per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r341" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Weighted-average fair value of the options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ScheduleOfAssumptionsUsedToCalculateBlack-scholesOptionPricingModelForOptionsGrantedDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r353" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Shares Outstanding (Intrinsic value)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r336", "r353" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Shares Outstanding, Beginning", "periodStartLabel": "Shares Outstanding, Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r335" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Shares Outstanding Ending, (per share)", "periodStartLabel": "Shares Outstanding Beginning, (per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock": { "auth_ref": [ "r345" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for exercisable or convertible options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "We follow ASC Topic 718, Share-Based Payments, in which compensation expense is recognized only for share-based payments expected to vest." } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/StockOptionsAndStockGrantsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r328", "r333" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/AdditionalDisclosuresForOptionsGrantedForAllYearsPresentedDetails", "http://nanophase.com/role/AggregateIntrinsicValueInTableAboveIsBasedOnOurClosingStockPriceOf4.40OnLastBusinessDayForYearEndedDecember312021.Details", "http://nanophase.com/role/WeFollowAscTopic718Share-basedPaymentsInWhichCompensationExpenseIsRecognizedOnlyForShare-basedPaymentsExpectedToVest.Details" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Exercised (per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Granted (per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r332" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Shares based compensation payment award expiration period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/StockOptionsAndStockGrantsDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r347", "r359" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Weighted-average expected life (years) of the option" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ScheduleOfAssumptionsUsedToCalculateBlack-scholesOptionPricingModelForOptionsGrantedDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r353" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Shares Exercisable (Intrinsic value)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r353" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Shares Exercisable (years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r344" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Shares Outstanding (years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance at ending (in shares)", "periodStartLabel": "Balance at beginning (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermBorrowings": { "auth_ref": [ "r17", "r445", "r470", "r485" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.", "label": "Short-term Debt" } } }, "localname": "ShortTermBorrowings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r47" ], "lang": { "en-us": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short-term Debt, Type [Axis]" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r44" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShortTermLeaseCost": { "auth_ref": [ "r433", "r439" ], "calculation": { "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails": { "order": 3.0, "parentTag": "us-gaap_OperatingLeaseExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.", "label": "Short-term lease cost" } } }, "localname": "ShortTermLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r101", "r115" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r58", "r70", "r71", "r72", "r116", "r117", "r118", "r120", "r126", "r128", "r144", "r197", "r284", "r289", "r355", "r356", "r357", "r385", "r386", "r400", "r411", "r412", "r413", "r414", "r415", "r416", "r504", "r505", "r506", "r550" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/AccountsReceivableBalancesForTheseFiveCustomersWereApproximatelyDetails", "http://nanophase.com/role/ConsolidatedStatementsOfOperations", "http://nanophase.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r116", "r117", "r118", "r144", "r455" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/AccountsReceivableBalancesForTheseFiveCustomersWereApproximatelyDetails", "http://nanophase.com/role/ConsolidatedStatementsOfOperations", "http://nanophase.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r57", "r252", "r284", "r285", "r289" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Exercise of conversion rights convertible loan, related party (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r24", "r25", "r284", "r289" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Issuances of shares and stock option exercises (in shares)", "verboseLabel": "Stock Issued During Period, Shares, New Issues" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r24", "r25", "r284", "r289", "r338" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Stock option exercises (in shares)", "negatedLabel": "Exercised", "verboseLabel": "Shares exercised" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/AggregateIntrinsicValueInTableAboveIsBasedOnOurClosingStockPriceOf4.40OnLastBusinessDayForYearEndedDecember312021.Details", "http://nanophase.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://nanophase.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r58", "r284", "r289" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Exercise of conversion rights \u2013 convertible loan, related party" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r24", "r25", "r284", "r289" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Issuances of shares and stock option exercises" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r58", "r284", "r289" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock option exercises" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockOptionPlanExpense": { "auth_ref": [ "r92" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for option under share-based payment arrangement.", "label": "Share-based compensation expense" } } }, "localname": "StockOptionPlanExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/WeFollowAscTopic718Share-basedPaymentsInWhichCompensationExpenseIsRecognizedOnlyForShare-basedPaymentsExpectedToVest.Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r25", "r29", "r30", "r108", "r194", "r196", "r409", "r445" ], "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Total stockholders\u2019 equity", "periodEndLabel": "Balance at ending", "periodStartLabel": "Balance at beginning" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets", "http://nanophase.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r106", "r270", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r289", "r290" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Capital Stock" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/CapitalStock" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_SupplyCommitmentArrangementMember": { "auth_ref": [ "r23", "r472", "r487" ], "lang": { "en-us": { "role": { "documentation": "This item is intended to be populated, by the entity, with Members identifying each supply commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate." } } }, "localname": "SupplyCommitmentArrangementMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/SignificantCustomersAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SupplyCommitmentAxis": { "auth_ref": [ "r23", "r472", "r487" ], "lang": { "en-us": { "role": { "documentation": "Information by arrangements in which the entity has committed resources to supply goods or services to a customer.", "label": "Supply Commitment [Axis]" } } }, "localname": "SupplyCommitmentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/SignificantCustomersAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SupplyCommitmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Supply Commitment [Line Items]" } } }, "localname": "SupplyCommitmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/SignificantCustomersAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SupplyCommitmentMember": { "auth_ref": [ "r23", "r472", "r487" ], "lang": { "en-us": { "role": { "documentation": "Supply arrangement in which the entity has agreed to commit resources to supply goods or services to a customer. Excludes long-term commitments.", "label": "Supply Commitment [Member]" } } }, "localname": "SupplyCommitmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/SignificantCustomersAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SupplyCommitmentTable": { "auth_ref": [ "r23", "r472", "r487" ], "lang": { "en-us": { "role": { "documentation": "Summarization of information required or determined to be disclosed about arrangements in which the entity has committed resources to supply goods or services to a customer. May include identification of the goods or services to be furnished, identity of the purchasing party, pricing, effects on pricing for failing to deliver the [minimum] quantities required to be furnished, cancellation rights, and termination provisions.", "label": "Supply Commitment [Table]" } } }, "localname": "SupplyCommitmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/SignificantCustomersAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardValuationAllowance": { "auth_ref": [ "r376" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from tax credit carryforwards for which it is more likely than not that a tax benefit will not be realized.", "label": "Net operating loss carryforwards" } } }, "localname": "TaxCreditCarryforwardValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxPeriodAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information about the period subject to enacted tax laws.", "label": "Tax Period [Axis]" } } }, "localname": "TaxPeriodAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/IncomeTaxesDetailsNarrative", "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_TaxPeriodDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identified tax period." } } }, "localname": "TaxPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/IncomeTaxesDetailsNarrative", "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_TaxYear2012Member": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "Identified as tax year 2012.", "label": "Tax Year 2012 [Member]" } } }, "localname": "TaxYear2012Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "auth_ref": [ "r188", "r189", "r190", "r191", "r193", "r195" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for accounts receivable.", "label": "Trade Accounts Receivable" } } }, "localname": "TradeAndOtherAccountsReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r395" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r146", "r147", "r148", "r149", "r155", "r156", "r157" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates and Risks and Uncertainties" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceByDeferredTaxAssetAxis": { "auth_ref": [ "r376" ], "lang": { "en-us": { "role": { "documentation": "Information by type of deferred tax consequences attributable to deductible temporary differences.", "label": "Valuation Allowance by Deferred Tax Asset [Axis]" } } }, "localname": "ValuationAllowanceByDeferredTaxAssetAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r377" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "Increase (decrease) in valuation allowance" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r434", "r439" ], "calculation": { "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable lease cost" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r130", "r138" ], "calculation": { "http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted average number of diluted common shares outstanding", "totalLabel": "Weighted average number of diluted common shares outstanding" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperations", "http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r129", "r138" ], "calculation": { "http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted average number of basic common shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperations", "http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Denominator:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails" ], "xbrltype": "stringItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r115": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1707-109256" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1757-109256" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1500-109256" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r158": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r185": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r202": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742" }, "r209": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "410", "URI": "http://asc.fasb.org/extlink&oid=6392676&loc=d3e7480-110848" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "410", "URI": "http://asc.fasb.org/extlink&oid=6392692&loc=d3e7535-110849" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "410", "URI": "http://asc.fasb.org/extlink&oid=6392692&loc=d3e7535-110849" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "410", "URI": "http://asc.fasb.org/extlink&oid=6392692&loc=d3e7535-110849" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "410", "URI": "http://asc.fasb.org/extlink&oid=6393242&loc=d3e13201-110859" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r217": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r219": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(25))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r268": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130534-203044" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r309": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(l)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(o)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(p)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r326": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)-(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109244661&loc=d3e17540-113929" }, "r363": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32059-109318" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r394": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r423": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "840", "URI": "http://asc.fasb.org/topic&trid=2208923" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(17))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(3),(4))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(c)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.17)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.4)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r530": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r531": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r532": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r533": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r534": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r535": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r536": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r537": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r538": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r539": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.23)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r540": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r541": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r542": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r543": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r544": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r545": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r546": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r547": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r548": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r549": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.6)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(ee)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" } }, "version": "2.1" } ZIP 82 0001387131-22-004477-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001387131-22-004477-xbrl.zip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end